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Abstract 
       Chronic inflammation and increases in oxidative stress are observed in normal 
ageing and age related diseases, these are characterised by increases in aberrant 
NF-κB activation, expression of inflammatory genes and circulating cytokines. 
Dietary polyphenols found in fruits and vegetables, have been examined for 
potential antioxidant and anti-inflammatory effects in in vitro/vivo studies.  
        29 (poly)phenols were screened for their anti-inflammatory effects in Jurkat 
T-cells following 48h treatment. At 1μM, a physiologically relevant dose, 
resveratrol (RES) decreased IL2 release by 42% ± 7% and IL8 by 32% ± 8% 
compared with DMSO treated control (p<0.05). Cells were also stimulated with 
PMA/PHA to induce cytokine release at the 24h time-point, 1μM isorhamnetin 
(ISO) reduced cytokine release, IL2 by 50% ± 4%, IL8 by 58% ± 6% and TNFα by 
63% ± 7%, and curcumin (CUR) reduced IL2 by 43% ± 14%, IL8 by 30% ± 7% and 
TNFα by 22% ± 5 compared with PMA/PHA treated control (p<0.05). These 3 
compounds; CUR, ISO and RES, were investigated further using a proteomic 
approach. Several proteins were modified in the glutathione metabolism pathway 
with all treatments significantly (sig.) increasing glutathione reductase (GSR), an 
enzyme which converts oxidized to reduced glutathione. CUR increased GSR by 
1.2 fold, ISO 1.2 fold and RES 1.1 fold (p<0.003). ISO also caused sig. increases in 
other redox related proteins thioredoxin and peroxiredoxins. These data were 
validated with sig. increases in GSR gene expression with CUR and ISO at 24h, 
along with sig. increases in Nrf2 activation, CUR (1.5 fold) and ISO (1.9 fold).  
       These modulations to inflammatory and redox markers in the Jurkat cell 
model were replicated in another cell line, THP-1 monocytes. A sig. reduction in 
cytokine release was observed with 30µM ISO for both IL8 and TNFα compared 
with the DMSO, correlating with the reduction observed in the Jurkat cells. Nrf2 
was also sig. activated between 3 and 48h, however no sig. effect on the 
expression of GSR was observed. This suggests that ISO may have similar effects 
on inflammation but differed in terms of redox related proteins between the two 
cell types. CUR, ISO and RES sig. lowered cytokine release in both unstimulated 
and stimulated T-cells, and proteomics identified sig. increases in GSR. For CUR 
and ISO this increase was validated using western blot and qPCR analysis, with 
sig. increases in Nrf2 activation bring observed. The reduction in cytokine release 
was replicated in THP-1 following ISO treatment, along with increases in Nrf2 
activation, but no changes in glutathione proteins were observed. These data 
support the potential use of these compounds in enhancing cellular antioxidant 
potential and the use of the compounds as part of a healthy ageing diet.  
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INTRODUCTION 
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1.1 Ageing  
 
1.1.1 An increased ageing population leading to a higher incidence of 
chronic diseases. 
The number of people aged over 60 is anticipated to increase globally from 605 
million to 2 billion by 2050 (WHO)1. Improvements in health care have meant 
people are living longer but the incidence of chronic diseases associated with age 
such as cardiovascular disease, cancer and Alzheimer’s disease are also increasing. 
The burden the health services supporting the ageing community and treating 
chronic diseases is therefore becoming a problem. The increasing numbers of 
elderly people seeking treatments is estimated to cost the UK between £1 billion2 
and £1.4 billion3 each year. The focus now is on finding ways to improve the 
quality of life of the ageing population, by promoting healthy ageing and making 
sure these extra years are healthy years. It is thought that diets rich in 
antioxidants could help increase lifespan, improve health and prevent disease 
progression in an ageing population4, 5, 6. 
 
1.1.2 The role of inflammation and immune system dysregulation 
associated with ageing. 
As we age the adaptive and innate immune systems show multiple dysregulations 
resulting in a chronic systemic pro-inflammatory state, known as inflammaging, 
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first characterised by C. Franceschi in 20007. Inflammaging is defined by aberrant 
NF-κB activation, increases in the gene expression of inflammatory markers, and 
an elevation in circulating inflammatory cytokines. Along with increases in 
inflammatory markers, increases in baseline oxidative stress and reactive oxygen 
species (ROS)8 are also observed. ROS acts as signal for inflammation, resulting in 
the upregulation of pro-inflammatory cytokines, such as tumour necrosis factor 
(TNFα)9. ROS not only act as signals for inflammation but also contribute to the 
damage with ageing that occurs via oxidation to vital cellular components such as 
DNA, proteins and lipids, this leads to a build-up of oxidative damage.  Over time 
this build-up of oxidative damage and the inability to repair the damage with age 
is described as the “free radical theory of ageing”. It was first proposed by 
Harman in 1956, that molecules with unpaired electrons are highly reactive and 
cause accumulative damage, leading to the loss of function in ageing and age-
related diseases10. Initially the theory was focused on superoxide free radicals but 
over time this has included other reactive species such as hydrogen peroxide and 
peroxynitrite, Harman also later included the role of the mitochondria in 
oxidative damage, as a further source free radicals11. These changes in the 
immune system can leads to increases in oxidative stress and inflammation which 
contribute to the progression of age-related diseases12. Finding ways to lower 
inflammation and oxidative stress in the immune system could be beneficial to 
health of the ageing population and help treat and prevent certain disease. 
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1.2 Immune system. 
The immune system consists of a number of cell types, termed white blood cells 
and function to protect the body from foreign antigens, tissue injury and 
infectious diseases. There are several different white blood cells, which all 
originate from hematopoietic stem cells in the bone marrow. There are two main 
lineages of white blood cells, the myeloid leukocytes and the lymphocytes. The 
myeloid leukocytes are defined by the presence of granules in the cytoplasm, 
neutrophils, monocytes, and basophils are all types of myeloid leukocytes. The 
lymphocytes lineage contains B-lymphocytes, T-lymphocytes and natural killer 
cells which are mainly found in the lymphatic system. Immature T-lymphocytes 
are produced in the bone marrow and mature in the thymus. Naïve T-
lymphocytes are activated by antigen presenting cells, e.g. by macrophages or 
B—lymphocytes, these naïve cells are termed Th0 cells. TH0 cells can differentiate 
into a number of subtypes, the main ones e.g. Th1, Th2, and Th17 
differentiatedepending on the antigen presenting cell. Macrophages induce TH0 
cells to differentiate into Th1 cells, which are induced by interleukin 12 (IL12) 
production, B-lymphocytes cause differentiation into Th2 cells by induction of 
interleukin 4 (IL4) and Th17 cells are generated following infection and by either 
antigen presenting cells, by the presence of interleukin 6 (IL6) and transforming 
growth factor beta (TGFβ).T-lymphocytes are the main cytokine producing cells in 
the immune system. 
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1.2.1  Jurkat cells as a model for inflammation. 
T-lymphocytes are among the most affected cells associated with the decline in 
the immune system with ageing13. This is associated with decreases in the 
number of circulating T cells; along with impairments in T cell function such as 
activation, differentiation and proliferation. Dysfunction starts with impaired T-
cell receptor (TCR) failing to activate T cells, this impairs the TCRs signalling 
pathway fails to activate the T cell, there have been shown multiple impairments 
in signalling pathways within T cells with age14. Prolonged activation of pathways 
such as NF-κB, which can be caused by stress and cytokines leads to the 
upregulation of pro-inflammatory cytokines, increasing circulating inflammatory 
markers which all contribute to the pro-inflammatory state observed with ageing. 
Jurkat cells are an immortalized line of T-lymphocyte commonly used for 
the in vitro study of T-cell signalling and cytokine secretion. In this thesis these 
cells will be used to evaluate the effects dietary polyphenols have in modulating 
markers of inflammation and oxidative stress. The Jurkat cells produce a number 
of different cytokines which can be evaluated and compared with those cytokines 
modulated with age, other advantages of using the Jurkat cells is that these cells 
are an immortalised cell line, which meant that large number of comparisons 
could be made. This allowed the evaluation of a number of different polyphenols, 
doses and stimulations, which would not have been possible in primary 
lymphocyte cells. These T-lymphocytes were first isolated from a 14 year old boy 
with leukemia, over the years there have become various Jurkat T cell lines 
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developed; the most common is E6.1. These cells expresses high levels of mature 
TCR, low levels of cluster of differentiation 4 (CD4), and no cluster of 
differentiation 8 (CD8) or major histocompatibility complex (MHC) class II15. T-
lymphocytes that present the surface molecules CD4 are known as T helper cells 
and can be sub-divided. These sub groups include Th1 and Th2 which can be 
characterised by the inflammatory markers (cytokines) they secrete. In this thesis, 
Jurkat cells were treated with polyphenols for 48h in order to measure changes to 
cytokine release following treatment. This time point was chosen to allow 
treatments to have an effect on gene expression and protein production, to allow 
the analysis of cytokine release at the 48h time-point. Also, cells were treated 
with the stimulus PMA/PHA which induces cytokine release in the Jurkat cells. 
Previous studies showing cytokine signalling pathways such as AP-1 and NF-κB are 
activated following treatment with PMA, with their activity peaking at the 24hr 
time-point16. These transcription factors activate cytokine production, with their 
activation peaking at 24hr, this lead to the time point 48hr to be chosen to allow 
for gene transcription and translation of the cytokines. 
1.2.2 Cytokines, inflammatory markers. 
Cytokines are small proteins (5-20kDa) secreted by a variety of cells in order to 
signal and communicate between cells with the function of regulation of 
inflammation, differentiation and proliferation. For immune cells cytokines are 
essential for cell mediated immunity and allergic responses, with T-lymphocytes 
being a major source of cytokine release. There are more than 50 secreted factors 
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termed cytokines17, which can be grouped into different classes: interleukins, 
tumour necrosis factors (TNF), interferons (IFN), colony stimulating factors (CSF), 
transforming growth factors (TGF), and chemokines18.  
1.2.3 T-lymphocyte classes: T helper cells (Th1/Th2). 
T-lymphocytes are classified by the surface molecules they present with two main 
categories, the CD8 presenting cells known as cytotoxic T cells and CD4 
presenting T cells are known as T helper cells. A previously discussed T helper 
cells can be sub-divided into Th1 and Th2 and are distinguished by the different 
cytokines they secrete. 
1.2.4 Cytokine profiles of Th1/Th2 cells. 
The two subsets of T helper cells (Th1/Th2) produces different types of cytokines, 
Th1-type cytokines mainly produce pro-inflammatory cytokines whereas Th2-type 
cytokines tend to produce more anti-inflammatory cytokines (Fig. 1.1)19,20. Th1 
cells produce more cytokines such as interleukin 2, 6, and 12, interferon γ and 
tumour necrosis factor α, these are considered pro-inflammatory cytokines, 
whereas Th2 cells produce interleukin 4, 5, 10 and transforming growth factor 
beta which are anti-inflammatory cytokines. These proteins are important 
markers that are essential for signalling during inflammation, a number of these 
markers have been linked through epidemiology studies to ageing and age-
related diseases. The most common of these markers are interleukin 6 (IL6) and 
tumour necrosis factor alpha (TNFα)21.  
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1.2.5 Cytokines modulated with age. 
IL6 and TNFα are produced by immune cells but can be produced by other cells 
such as skeletal muscle, vascular endothelial cells and neural tissues22. In healthy 
individuals an increase was observed with circulating level of pro-inflammatory 
cytokines: TNFα (p = 0.003), IL1β (p = 0.027) and IL6 (p = 0.0001) in those aged > 
60 years compared with those < 30 years old23. Ageing and disease are associated 
with increases in pro-inflammatory cytokines, increases in circulating levels of 
TNFα have been reported to significantly increase over time and can effect 
disease progression. In patients diagnosed with septic shock those aged <50 had 
TNFα levels of 417 pg/ml, in the serum which was sig. lower than those aged > 50 
was 706 pg/ml24. Both show an increase in cytokine release which is what you 
wouyld expect in septic shock patients, however there was a greater cytokine 
response to septic shock in the elderly. Further examples of cytokines release 
modulated with age can be found in Chapter 3 introduction (3.1.3). 
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Figure 1.1 – Differential secretion of pro- and anti-inflammatory cytokines by T-
lymphocyte sub-groups Th1 and Th2. T-helper cells are sub-divided into Th1 
(red) and Th2 (green) cells and are classified by the cytokines they secrete. Th1 
cells mainly secrete pro-inflammatory cytokines interleukin 2 (IL2), interleukin 6 
(IL6), interleukin 12 (IL12), interferon gamma (IFNγ), and tumour necrosis factor 
alpha (TNFα). Th2 cells mainly secrete anti-inflammatory cytokines interleukin 4 
(IL4), interleukin 5 (IL5), interleukin 10 (IL10), and transforming growth factor 
beta (TGFβ). [Cytokine protein structures obtained from the protein data bank25, 
figure modified from Beverley, P.C.L. 200726].  
 
 
1.2.6 T-lymphocyte cytokine induction using phorbol esters such as PMA 
stimulation. 
Jurkat cells secrete large amounts of the cytokine interleukin 2 (IL2) a cytokine 
important for T cell differentiation. Production of IL2 can be induced in these cells 
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following stimulation with phorbol esters such as phorbol 12-myristate 13-
acetate (PMA), along with the lectin phytohaemaglutinin (PHA)27. PMA is a 
phorbol ester and PHA a lectin which work together to activate T-lymphocytes, 
through the protein kinase c (PKC) pathway, which stimulates cytokine release in 
particularly interleukin 228. Stimulating the cells will allow the investigation into 
whether or not the (poly)phenols were having a protective effect, when the cells 
were stimulated, mimicking an immune response. At baseline Jurkats produce 
low levels of cytokines, by inducing cytokines with PMA/PHA, a higher 
concentration of cytokines will be released, providing greater accuracy when 
measuring changes to cytokine release. 
 
1.2.7 T-lymphocyte affected by ageing. 
IL2 is an important signalling mechanism that is essential for T-lymphocyte 
activation and differentiation29. During ageing interleukin expression is disrupted, 
leading to a shift in the proportion of Th1/Th2 cytokine secreting cells, with more 
cells committed to the Th1 subtype, which secrete more proinflammatory 
cytokines30. Hoffmann et al 2005, showed that CD4+ T-cell cytokine production 
was significantly increased with age. IL2 production increased from 12.1% in 18-
34 year olds to 62.8% in >50 years, in isolated cells stimulated with PMA and 
ionomycin (% cytokine positive cells). TNFα also increased from 27.28% in 18-34 
year olds to 47.81% in >50 year olds31. Increases in pro-inflammatory cytokines 
interleukin 6 and TGFβ were also observed in heathy older people; with IL6 
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significantly increasing from 0.69 pg/ml in people aged 32-59, to 3.16 pg/ml in 
people aged 86-94, TGFβ also significantly increased from 141.5 pg/ml (32-59 
years) to 399.9 pg/ml (86-94 years)32. Changes in cytokine release are regulated 
by a number of pathways, in T lymphocytes cytokine release can be activated 
either through the AP-1, NF-κB or NFAT signalling pathways33. Activation of the 
TCR, for example by a foreign antigen leads to the activation of transcription 
factor activator protein 1 (AP-1) through the MAPK cascade, nuclear factor kappa 
B (NF-κB) through the PKCθ pathway and nuclear factor of activated T-cells (NFAT) 
through influxes in intracellular calcium. Activating these transcription factors 
leads to the induction of cytokine gene expression such as IL2, IL8 and IFNγ, 
which is a Th1 cytokine profile in lymphocytes339, 34. These increases in circulating 
pro-inflammatory cytokines have been associated with disease, for example 
atherosclerosis, has been shown to be associated with increases in MCP-1, IL8 
and TNFα35. Treatment of these inflammatory diseases using cytokine inhibitors is 
being widely researched, with anti-TNFα inhibitors now being used in the 
treatment of diseases such as rheumatoid arthritis 36 , inflammatory bowel 
disease37, 38 and asthma39. By modulating these inflammatory pathways, the pro-
inflammatory profile observed with ageing can be lowered and potentially 
improve the health of the elderly. 
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1.2.8 THP-1 monocytes as a model for inflammation. 
THP-1 are a human leukaemia monocytic cell line, which are used to study 
monocyte and macrophage modulations, functions, and signalling mechanism.  
Monocytes are a type of white blood cells contributing to the innate immune 
system and making up approximately 5% of all leukocytes in the human body40. 
Monocytes maturate in the bone marrow, circulate in the blood and migrate into 
tissues where they function as macrophages. In cell culture THP-1 monocytes can 
be differentiated into macrophages by induction using the phorbol ester, PMA 
(12-myristate 13-acetate)41. THP-1 monocytes are characterised by the presence 
of Fc and C3b receptors, the production of IL1 and lysozymes along with 
phagocytic activity42. In this study, the Jurkat T-lymphocytes were the main cell 
line used, for the inflammatory profile of the cells and contributions to the 
inflamm-ageing phenotype. THP-1 monocytes will be used to replicate 
modulations to inflammation and redox found in the Jurkat cell model. 
Monocytes were chosen as they were another immune cell effected with age but 
also had a similar cytokine profile such as IL1, IL6, and TNFα which comparisons 
could be made to the Jurkat cells43; cytokine production can be induced in this 
cell type through the addition of the endotoxin lipopolysaccharide (LPS) from the 
Gram-negative bacteria such as E. coli44. The modulations to cytokines release will 
be evaluated in both cell types following interventions with polyphenols. Just like 
with the T-lymphocytes, monocytes are affected during ageing, with sub-sets of 
monocytic cells being increased, resulting in the increase secretion of pro-
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inflammatory cytokines such as monocyte chemoattractant protein-1 (MCP-1)45. 
Evaluating the effects polyphenols have on reducing the pro- inflammatory 
profile observed with ageing, could potentials aid to protect and reduce age-
related diseases by added polyphenols as part of a healthy ageing diet. 
 
1.3 Oxidative stress 
1.3.1 Free radicals: molecules contributing to oxidative stress. 
Along with the increases in pro-inflammatory cytokines, an increase in oxidative 
stress by increased activation of free radicals has also been observed with 
ageing46. Free radicals are defined as molecules possessing an unpaired electron, 
which makes these molecules short-lived and highly reactive. There are many 
types of free radicals including hydroxyl radicals (OH•), superoxide (O• −2), nitric 
oxide (NO•) and lipid peroxyl radical (LOO•). Free radical generation mainly occurs 
in the mitochondria as part of energy generation (ATP), through the electron 
transport chain 47 . Processes such as inflammation 48 , phagocytosis 49  and 
exercise50 also generate free radicals as part of their processes and are required 
for normal function within the cell. However, dysfunction in free radical 
formation can be caused when production is uncontrolled and build up leads to 
excess in the cell, resulting in oxidative stress. There are a number of different 
proteins that are responsible for the removal of free radicals, forming the 
antioxidant defence.   
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1.3.2 Reactive oxygen species. 
Reactive oxygen species (ROS) are small reactive molecules containing oxygen 
such as superoxide and peroxides. In the cell ROS are generated during cellular 
metabolism, during times of environmental stress such as heat or UV, and by 
ionizing radiation. Exogenous ROS can be produced in the body by external 
factors such as radiation and smoke, these factors can cause water to lose an 
electron and form reactive molecules such as hydroxyls, hydrogen peroxide and 
superoxide. Endogenous ROS are produced within the cell through different 
processes, such as ATP production in the mitochondria via the electron transport 
chain, they can produce ROS such as superoxide and hydrogen peroxide55. These 
small molecules when in excess can cause cellular damage and when 
accumulated in the cell cause oxidative stress. However, small concentrations of 
ROS are essential for cell signalling and maintaining homeostasis. Nitric oxide51, 
superoxide52 and hydrogen peroxide53 have all been shown to act as intercellular 
messengers, regulating cell signalling and function. Antunes and Cadenas54, 
showed that a concentration of 0.7µM hydrogen peroxide (H2O2) resulted in a 
proliferative state in Jurkat cells, however higher concentration of 1-3µM H2O2 
caused apoptosis and >3µM H2O2 resulted in necrosis. Therefore free radical 
concentrations are tightly controlled and maintained, regulated by antioxidant 
enzymes that neutralise the radicals. If left uncontrolled build-up of radicals can 
lead to damage to numerous cellular components such as DNA, lipids and 
proteins resulting in cellular death and potential disease. The antioxidant defence 
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system protects the cell for excess ROS and regulates the levels with the use of 
non-enzymatic molecules such as glutathione and vitamins A, C, and E, along with 
enzymatic proteins such as glutathione peroxidase, catalase and superoxide 
dismutase.  These mechanisms help keep levels of ROS in a non-toxic level, 
however in certain circumstances these mechanisms are overwhelmed and 
cannot maintain this level, leading to build up and oxidative stress.  
 
1.3.3 Antioxidants maintaining redox homeostasis. 
In order for cells to maintain a steady state and protect against increases in 
oxidative stress, antioxidant enzymes are used to regulate and eliminate toxic 
free radicals and reactive oxygen species, which in excess cause damage to the 
cells. Intracellular antioxidant enzymes include superoxide dismutase, catalase 
and glutathione peroxidase, which work together to neutralise and remove ROS, 
to protect the cell from oxidative stress.    
 
1.3.4 Superoxide dismutase and catalase. 
Superoxide dismutase (SOD) and catalase (CAT) act as endogenous cellular 
defences against free radicals, with SOD converting superoxide (O2•) into 
molecular oxygen and hydrogen peroxide and CAT converting hydrogen peroxide 
to molecular oxygen and water (Fig. 1.2). 
41 
 
 
 
      
Fig 1.2 – Co-operative activities of manganese superoxide dismutase (MnSOD) 
and catalase in neutralising superoxide. Conversion of reactive oxygen species 
(O2
•) generated through the respiratory chain within the mitochondria, into 
hydrogen peroxide (H2O2) via superoxide dismutase (SOD). H2O2 is then 
converted to water and molecular oxygen by the enzyme catalase (CAT)55. 
 
Since superoxide is unstable and cannot diffuse though cellular 
membranes there are different isoforms of SOD depending on the cellular 
compartment they are located. Copper/zinc superoxide dismutase (Cu,Zn-SOD) is 
found in the cytoplasm and intermembrane space of the mitochondria, whereas 
manganese superoxide dismutase (Mn-SOD) is located in the mitochondrial 
matrix. The SOD enzyme has several cofactor binding sites, where metals bind to 
the active sites of the enzyme; these include copper, zinc, manganese, iron 
(eukaryotic) and nickel (prokaryotic)56,57, 58 hence the different names. The SOD 
enzyme removes superoxide by adding or removing an electron either generating 
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molecular oxygen (O2) or hydrogen peroxide (H2O2) depending on the ion state of 
the metal cofactor.     
Cu2+ -SOD + O2
-  Cu+ -SOD + O2 
Cu+-SOD + O2
- + 2H+  Cu2+ -SOD + H2O2 
  
 From this reaction the resulting H2O2 can then be neutralised by the 
enzyme catalase, an ubiquitous protein containing four heme (Fe3+) that catalyse 
the dismutation of hydrogen peroxide to water and molecular oxygen. 
 
2 H2O2       + catalase       2 H2O   +    O2        + catalase 
 
 Catalase is found throughout the cell, with high concentrations found in 
the mitochondria and peroxisomes, it also has one of the highest turnovers of 
enzymes with 6 million m lecules of H2O2 converted to water and oxygen per 
min59. Catalase has also been identified as an important growth-promoting factor 
in a number of inflammatory cells including B and T cells, leukaemia cells as well 
as fibroblast60. 
 
1.3.5 Oxidative stress and T cell activation. 
Superoxide and hydrogen peroxide are generated during T cell activation and the 
inflammatory response; they act as secondary messengers required in signal 
transduction needed for T cell function and proliferation. However, accumulation 
of reactive oxygen species (ROS) can lead to apoptosis and necrosis. In T cells, 
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ROS can activate pathways such as JAK/STAT and (PI3K)/AKT61. Regulatory T cells 
require ROS to trigger inflammatory responses; both over- and under-production 
of ROS have been implicated in inflammatory diseases, such as psoriatic 
dermatitis62. Therefore, maintaining appropriate levels of ROS is important for 
normal function; with the use of antioxidant enzymes such as SOD and catalase 
help maintain this balance and control of ROS. Research has been conducted 
investigating the use of SOD as an antioxidant therapy in the treatment of 
inflammatory diseases such as skin disorders, pulmonary diseases and arthritis63. 
Overexpression of Cu,Zn-SOD in mice has been shown to have a protective effect 
against myocardial ischemia and reperfusion injury64, so there is potential for SOD 
to be used as a therapeutic treatment in  inflammatory conditions, where 
inflammation cannot be maintained and regulated under normal mechanisms. 
 
1.3.6 Glutathione antioxidant system. 
 
Glutathione (GSH) is an important antioxidant responsible for maintaining the 
redox homeostasis of the cell by neutralising free radicals; it is one of the most 
abundant intracellular thiols. It acts as an antioxidant, using thiol groups as 
reducing agents, reducing disulphide bonds on cellular proteins to cysteines, 
during this process glutathione is oxidised (GSSG). Glutathione is recycled in the 
cell and with the help of glutathione reductase GSSG can be converted back to 
GSH, with the addition of NADPH, see Figure 1.3.  
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Similar to catalase, glutathione peroxidase (GPx) enzymes can reduce 
hydrogen peroxide into water, and also reduce lipid hydroperoxides to alcohols.  
Peroxidases have actives sites which either contain heme cofactors, redox-active 
cysteines or selenocysteines residues which catalyse these reactions. Glutathione 
peroxidases catalyse the reaction below, hydrogen peroxide (H2O2) oxidises a 
selenocysteine residue of the GPx, and this oxidation is then conversed back with 
the use of reduced glutathione (GSH) molecules, resulting in the formation of 
oxidised glutathione (GSSG) ad water. 
                                2GSH + H2O2  GSSG + 2H2O 
There are different isoforms with at least 8 different GPxs. GPx1 is the 
most common, found in the cytoplasm and prefers the substrate hydrogen 
peroxide, whereas GPx4 prefers lipid hydroperoxides. GPx2 and 3 are 
extracellular found in the intestines (GPx2) and plasma (GPx3) 65 , 66 . Two 
glutathione molecules are required for the reduction of hydrogen peroxide into 
water, with the generation of oxidised glutathione, which now contains a 
disulphide bond connecting the two glutathione molecules. The oxidised 
glutathione can then be converted back to reduced glutathione, completing the 
recycling system. 
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Figure 1.3 - Glutathione recycling mechanism. Hydrogen peroxide (H2O2) is 
removed from the cell by an antioxidant enzyme glutathione peroxidase (GPx) 
with the use of reduced glutathione (GSH). A disulphide bond is generated 
between two GSH molecules to created oxidised glutathione (GSSG). GSSG can 
be recycled in this system back to GSH with the enzyme glutathione reductase 
(GSR) and NADPH67. 
 
The synthesis of glutathione is controlled by two enzymes glutamate 
cysteine ligase (GCLC), followed by glutathione synthase (GSS).  Firstly, GCLC joins 
glutamate and L-cysteine to produce gamma-L-glutamyl-L-cysteine (γ-EC), 
followed by GSS which combines the γ-EC with glycine to make reduced 
glutathione. GCLC is the rate-limiting enzyme in this pathway and controls the 
concentrations of glutathione within the cell. Diet and fasting can affect the 
46 
 
 
 
production of glutathione due to limiting the intake of cysteine68 and amino 
acids69 therefore inhibiting the production of glutathione and impairing the cell 
ability to maintain redox homeostasis. 
 
1.3.7 Glutathione modulations with advancing age. 
During ageing, levels of glutathione have been shown to decline in human 
plasma70; this process is thought to occur through a number of different 
mechanisms.  There is a decrease in GSH, through significant lowered rates of 
glutathione synthesis71 and increase in GSSG, leading to imbalance. Theories 
include the loss of glucose-6-phosphate dehydrogenase activity, this enzyme is 
vital for maintaining levels of NADPH which is essential for glutathione reductase 
to remove oxidised gluathione72. For example, glutathione peroxidase activity has 
also been shown to decrease with age, GPx activity significantly declines by 2.9 
µmol/min/L for each additional year after the age of 6573.  
Glutathione is not only utilised by glutathione peroxidase, it is a cofactor 
for a number of different processes such as glutathione S-transferases (GSTs), 
which catalyse the conjugation of GSH to xenobiotic substrates 74 , other 
peroxidases such as peroxiredoxins 675 and transhydrogenases, which reduced 
oxidised moieties from DNA and proteins, such as glutathione-insulin 
transhydrogenase76. 
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1.3.8 Thioredoxin and peroxiredoxin antioxidant system. 
Thioredoxins (TXN) is a small, 12kDa oxidoreductase enzyme which facilitates the 
reduction of other proteins by cysteine thiol-disulfide exchange. TXN has a similar 
structure to glutaredoxin, peroxiredoxins, and glutathione peroxidase, which is 
reflected in their functions as thiol-dependant antioxidants77. TXN acts as an 
electron donor to thiol-dependent peroxidases such as peroxiredoxins, in order to 
remove reactive oxygen. TXN is also believed to have functions in DNA and 
protein repair by acting as a reducing substrate for ribonucleotide reductase 
(RNR), an enzyme involved in DNA repair and replication78.TXN1 is found in the 
cytoplasm and nucleus whereas TXN2 is found in the mitochondria. TXN2 only has 
2 cysteines, whereas TXN1 has 3 additional cysteine residues which are thought 
to be regulated by posttranslational modifications79. The two forms of TXN have 
different interaction and functions; TXN2 interacts with methionine sulfoxide 
reductase (MSR), an antioxidant enzyme restoring the oxidised methionine 
sulfoxide to methionine80, also peroxiredoxin 3 in scavenging of H2O2
81. TXN1 in 
the cytoplasm and nucleus also interacts with MSR, along with peroxiredoxins 1 
and 2. TXN2 also interacts with RNR to protect the cell from DNA damage and 
plays a role in redox signalling. Thioredoxin reductase regulates thioredoxin and 
catalyses the reduction of thioredoxin, when thioredoxin reductase is inactivated, 
it triggers the activation of the antioxidant transcription factor Nrf2. Other redox-
related transcription factors such as NF-κB, and signalling factors ASK1 are also 
activated82, 83. Overexpression of TXN in mice has been shown to be induce 
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resistance to inflammation and these mice had their average lifespan increased to 
135% longer than the controls84. Therefore, thioredoxins are important proteins 
influencing inflammation and ageing. 
Peroxiredoxins are a family of peroxidases that mainly reduce hydrogen 
peroxide and alkyl hydroperoxides to water and alcohol85. They are classified 
depended on the number of conserved cysteine residues the peroxiredoxins 
(PRDX) have either 1-Cys or 2-Cys. There are 6 different PRDXs found in mammals; 
PRDX1, PRDX2, PRDX3, PRDX4 and PRDX5 are 2-Cys enzymes and use thioredoxin 
in their catalytic activity, whereas PRDX6 is a 1-Cys enzyme which does not use 
thioredoxin but catalytic activity is linked to glutathionylation 86  and 
phospholipase A2
87. All PRDXs have the same basic catalytic function in which 
active cysteines are oxidised to a sulfenic acid (R-SOH) by peroxide substrate88. 
 
PRDX(red) + H2O2  PRDX(ox) + 2H2O 
PRDX(ox) + TXN(red)  PRDX(red) + TXN(ox) 
 
Each PRDX has specific roles in regulation and signalling. PRDX1 knockout 
mice have been shown to have decreased lifespan by up to 15% compared with 
controls89, overexpression of PRDX6 in mice protects against allergic airway 
inflammation by reducing levels of ROS90 and recently oxidised PRDX1 and 2 have 
been shown to be released from the cell on stimulus with inflammatory 
molecules such as lipopolysaccharide and TNFα. This stimulates the induction of 
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inflammatory cytokines and highlights a novel pathway in redox-dependant 
signalling mechanism in inflammation for human embryonic kidney cells and 
monocytic cells91.  
 
1.4 Ageing has been associated with dysregulation in redox homeostasis, 
increased oxidative stress and damage. 
During ageing the ability to maintain these antioxidant proteins and protect the 
cells against free radicals becomes impaired. Excessive production of free 
radicals92,93, the inability to regulate antioxidant gene expression94,95 and protein 
dysfunction leads to a build-up in oxidative stress96. This leads to damage to vital 
cellular components such as DNA, proteins and lipids. Protein oxidation can effect 
signal transduction, the stability of the proteins, degradation and activity there 
proteins may become inactive, degraded or not produced due to increased 
oxidative stress with ageing97. 
 
1.5 Dietary (poly)phenols. 
 
1.5.1 Natural antioxidants generated by plants. 
Polyphenols are naturally occurring compounds, found in a variety of food 
sources such as fruits, vegetables, beverages, herbs and spices. These compounds 
are produced in plants in order to defend themselves against oxidative damage 
by ultraviolet radiation and pathogens98. Plants synthesis polyphenols by the 
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deamination of phenylalanine via the shikimic acid pathway followed various 
processes depending on the compounds being produced99. These compounds are 
produced as part of the plants defence mechanisms, protecting from biotic and 
abiotic stress factors and synthesis has been shown by activating wound-
inducible polyphenol oxidases (an enzyme involved during synthesis) in tomato 
plants100.  
Polyphenols are compounds possessing an aromatic ring, including one 
(phenolic) or multiple (polyphenol) hydroxyl groups; in addition they can contain 
various functional groups including methyl, glycosides and sulphates. Polyphenols 
are split into categories based on the number of phenolic rings, structural 
elements binding the rings and functional groups. There are two main groups 
flavonoids and non-flavonoids, both have multiple sub-groups such as 
anthocyanins, flavones, and isoflavones (flavonoids) and phenolic acids, benzoic 
aldehydes, stilbenes (non-flavonoids)101. There have been over 8000 phenolic 
compounds identified, with almost half of those consisting of flavonoids102, 103, 104. 
This study chose (poly)phenols that possessed a variety of these properties, from 
different food sources and a range of metabolites, to include a broad range of 
compounds. 
1.5.2 Dietary polyphenols as antioxidants. 
Dietary (poly)phenols have been extensively studied for their antioxidant and 
anti-inflammatory effects both in in vitro and in vivo studies. Studies suggest the 
consumption of foods high in dietary polyphenols offer protection against the 
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progression of diseases such as heart disease, cancer and osteoporosis105. 
Polyphenols have been reported to be strong antioxidants which can scavenge 
reactive oxygen species and aid cellular processes to protect against increased 
levels of oxidative stress. This antioxidant capability is believed to occur via the 
donation of hydrogen, to neutralise free radicals106.  
 
R• + PP-OH  R-H + PPO•                       PP = Polyphenol       R• = Free radicals 
PPO• + PPO•  PPO-OPP            
                
The antioxidant potential of these compounds depends on the number of 
hydroxyl groups and their structure. This can be measured experimentally using 
the Folin-Ciocalteu regent, the Trolox equivalent antioxidant capacity or oxygen 
radical absorbance capacity (ORAC). Ninfali et al 2004 identified the antioxidant 
capacity of a number of different vegetables and spices using the ORAC method, 
curcumin (spice) had the greatest ORAC value with 76,800 ± 7500 µmoleTE/100g, 
marjoram (herb) 27,297 ± 2611 µmolTE/100g and artichokes (vegetable) 6552 ± 
650 µmolTE/100g 107 . The complexity of these compounds and antioxidant 
capacity is only one component that needs to be considered when evaluating the 
potential benefits of these compounds. The levels in which these foods are 
consumed need to be taken into consideration, as herbs and spices may have 
higher antioxidant capacities but will not be eaten in large quantities unlike fruits 
and vegetables. 
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1.5.3 Polyphenols and their bioavailability. 
Concentrations of these polyphenols found in the plasma vary depend on the 
concentration found in the food source, metabolism once within the body and 
their bioavailability (absorption and uptake into the circulatory system). Pérez-
Jiménez et al 2010 investigated 502 polyphenols from 452 foods, to rank the 100 
richest sources of dietary polyphenols108. The highest ranking foods included 
various spices and herbs (15000mg per 100g in cloves), cocoa, dark coloured 
berries, and also beverages such as wine (10mg per 100ml). Following 
consumption the polyphenols can be absorbed in the small intestine, colon, and 
liver, and the polyphenols can be extensively metabolised by gut microflora and 
in the tissues109. The human gut consists of a complex mixture of microorganisms, 
termed microflora and are essential for maintaining human health, aiding in 
metabolism, nutrition and immune function110.  Polyphenols are varied and 
complex in structure, once they enter the digestion system these compounds are 
metabolised, into smaller and potentially more bioactive compounds111. The 
structure of the polyphenols can greatly affect absorption and concentrations 
found in plasma. Bioavailability can be evaluated with the lipophilicity value (log 
Kow); it can predict the absorption, metabolism, excretion and toxicity of a 
compound112. Polyphenols are very sensitive to environmental factors affecting 
their antioxidant ability such as heat, light, water solubility, and pH, which will 
affect their metabolism and elimination rate. Therefore finding ways to deliver 
the polyphenols to the body in a way that can increase the bioavailability, 
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maintain the antioxidant structure and that is palatable to the user. For example 
curcumin, has a low aqueous solubility and low bioavailability (meaning it is 
poorly absorbed by the gut). Studies have been looking at nanoparticles to 
increase curcumins antioxidant potential within the body113,114. 
 
1.5.4 Polyphenols are extensively metabolised following ingestion in the 
stomach, intestines and by gut microflora. 
Once within the body polyphenols undergo a number of biological changes 
through metabolism in tissues and by colonic microflora115. When polyphenols 
reach the colon they are metabolised into phenolic acids by the colonic 
microflora such as Eubacterium ramulus, Bacteroides sp. and Enterococcus 
casseliflavus116. Quercetin is metabolised in the small intestine and 93% of 
quercetin found in the plasma is modified to quercetin 3-sulfate, quercetin 3-
glucuronide, and 3-methylquercetin 3-glucuronide117. Following consumption of 
green tea more than 50% of EGCG passes to the large intestines118, where 
metabolism by colonic microflora occurs, forming epigallocatechin and pyrogallol. 
Epigallocatechin is then further metabolised into a number of different products 
including methyl-(-)epigallocatechin and (-)-epigallocatechin-3-O-glucuronide (Fig. 
1.4). These metabolites have different antioxidant properties than their parent 
compounds. Structural changes to polyphenols as a result of metabolism have 
been shown to alter their antioxidant potential118. 
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Figure 1.4 - Green tea flavan-3-ols metabolism and breakdown products 
following consumption. (–)-epicatechin, (–)-epigallocatechin and (–)-
epigallocatechin-3-O-gallate (blue) are found in the large intestine, these 
structures are then broken down by colonic microflora (red). Further 
metabolites found in the urine after green tea consumption (green) which 
aren’t identified after metabolism via gut microflora, therefore catabolites 
enter the circulatory and undergo further metabolism before being excreted in 
urine. (Figure from Del Rio et al, 2010).119 
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 Within the gut, polyphenols are not just metabolised by the microflora, 
studies have shown that polyphenols also influence what gut microflora are 
present in the gut. Tzounis et al120 showed that the green tea metabolite 
(+)catechin significantly inhibited the growth of Clostridium histolyticum and 
increased E. coli and Clostridium coccoides-Eubacterium rectale growth, in an in 
vitro study using batch-culture model to represent the human large intestine. 
Therefore there is a two way interaction between the polyphenol intake and the 
gut microflora present in the gut.  
 However metabolism of polyphenols doesn’t solely occur in the gut. 
Polyphenols can pass the cell membrane and enter the cell, where phase II 
enzymes metabolise the polyphenols. The mechanism, rate and concentration of 
polyphenol absorption depend on the cell type and the polyphenol involved. 
There has been a large amount of work using Caco-2 cells to investigate 
polyphenol intake by cells, Caco-2 cells are human epithelial colorectal cells used 
to represent the small intestine. It has been shown that polyphenols can be taken 
up by Caco-2 cells by transporters such as SGLT1, MRP2, and P-glycoproteins. This 
was observed by Teng et al121, using polyphenols apigenin, resveratrol, emodin, 
and chrysophanol by using competitive inhibitors of these transporters. They 
showed that emodin and chrysophanol uptake was inhibited when transporter 
SGLT1 was inhibited, whereas apigenin and resveratrol was not. Therefore 
showing different polyphenols have different methods of uptake into the cell. 
Once within the cell they also showed metabolism of the polyphenols by phase II 
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enzymes over an hour time period. For emodin and chrysophanol the main 
metabolites were glucuronides. Polyphenol uptake has also been observed for T 
lymphocytes, with quercetin accumulation found in the mitochondria of T-
lymphocytes by passive diffusion122.  It is thought that quercetin accumulation in 
the mitochondria is to protect the mitochondria from ROS. 
 
1.5.5 Phenolic acids and polyphenols ((poly)phenols) chosen for study in 
this thesis. 
 
A variety of compounds were chosen for this study, covering a broad range of 
complex polyphenols, with numerous functional groups and multiple metabolites 
phenolic acids. As previously seen in Fig. 1.4 complex polyphenols such as (–)-
epigallocatechin-3-O-gallate (EGCG) can be broken down by gut microflora into 
small phenolics such as pyrogallol and catechol. A number of these catabolites 
enter the blood stream and are metabolised further into varies phenolics such as 
4-hydrobenzoic acid, 3-(3’-hydroxyphenyl)-3-hydroxypropionic acid, and hippuric 
acid. Figure 1.5 shows all the (poly)phenol compounds and their structures 
chosen for this thesis cytokine release investigation. The term (poly)phenol will 
be used when discussing both polyphenols and phenolic acids. The panel includes 
both complex polyphenols which have been well studied in the literature, such as 
EGCG, curcumin, quercetin, and resveratrol. Compounds with structural 
analogues of one another such as quercetin, 3-O-methylquercetin and 
isorhamnetin, which include additional functional groups e.g. methoxy group 
(OCH3). There is less literature on the smaller phenolic acids and their effect on 
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inflammatory markers. 19 phenolic acids were included in the panel, this included 
metabolites of the polyphenols used. For example, curcumin is metabolised into 
ferulic acid and dihydroferulic acid, pelargonidin 3-O-glucoside is metabolised 
into 4-hydroxybenzoic acid and quercetin metabolised into isorhamnetin, ferulic 
acid, dihydrocaffeic acid, 5-(3’-hydroxyphenyl)propionic acid, vanillic acid and 
protocatechuic acid.  
 
          ______________________________________________________________ 
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Figure 1.5 – Panel of (poly)phenol compounds chosen for cytokine release 
investigation. (Poly)phenol name(s) including structure are ordered in size, with 
the larges polyphenols at the top and the smaller phenolic acids at the bottom. 
 
 
1.5.6 Polyphenols, inflammation and oxidative stress. 
It is believed dietary polyphenols can modulate inflammation and oxidative stress 
by scavenging ROS, activating or inhibiting signalling pathways and upregulating 
the gene expression of antioxidant proteins. In the present study twenty-nine 
different polyphenols and phenolic acids (termed (poly)phenols when discussing 
both) were used, varying in structure and functional group and also from a variety 
of different food sources. Full details of each compound used can be found in 
appendix 1.  
It is important to understand the mechanism behind polyphenols mechanism of 
action, since a better understanding of these compounds will allow more 
targeted interventions to be derived, since free radicals, oxidation and 
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inflammation are key to numerous disease states.  Figure 1.6, shows a basic 
schematic view of how polyphenols are thought to act. 
 
 
Figure 1.6 - Simplified schematic of potential polyphenol mechanism of action. 
Polyphenols are thought to inhibit levels of reactive oxygen species (ROS), 
modulation of antioxidant enzymes gene expression through the transcription 
factor Nrf2 and modulating and inhibiting IKB kinases, in the NF-κB pathways, 
which down regulates the  expression of pro-inflammatory cytokines. Modified 
from Accomando el al (2010)123. 
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Protective mechanisms include the scavenging and detoxification of ROS, blocking 
the production of ROS, as well as influencing cellular antioxidant enzymes and 
pathways 124 .  Polyphenols can activate antioxidant pathways through the 
activation of Nrf2, which leads to the upregulation of antioxidant genes such as 
glutathione reductase, which increases the intracellular concentrations of the 
antioxidant GSH. Polyphenols are also thought to modulate inflammatory 
markers by decreasing the production of pro-inflammatory cytokines; this is 
achieved by inhibiting the NF-κB pathway. In this study, polyphenols were 
evaluated for changes in cytokine production and by proteomics to determine 
how these polyphenols are modulating cytokine release, with the aim to better 
understand which proteins and pathways are being modulated by polyphenols. 
 
1.5.7 Polyphenols used in the treatment of diseases. 
Polyphenols are already in use in the treatment of several conditions. Curcumin, a 
spice from turmeric is being trialled in the treatment of rheumatoid arthritis; 
patients receiving curcumin (500 mg) and diclofenac sodium (50 mg) alone or 
their combination, a significant improvement was noticed in the disease activity 
score and a reduction in swelling and tenderness in the joints when compared 
with current treatment methods (diclofenac sodium) for the disease in humans125. 
These effects with curcumin on arthritis have previously been observed in mouse 
models, were curcumin has been shown to decrease the expression of pro-
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inflammatory cytokines such as IL-1beta and TNF-alpha in the ankle joints, and 
expression of IgG2a inn the serum. Showing curcumin can lower the 
inflammatory response in collagen-induced arthritis in mice by feeding curcumin 
every day for 2 weeks126.  Mixtures of polyphenols have been shown to be 
beneficial in men with prostate cancer, a treatment of pomegranate, green tea, 
broccoli, and turmeric for 6 months showed a favourable effect on prostate 
specific antigens when compared with the placebo group 127 . Even though 
beneficial effects have been observed with these polyphenol treatments, the 
underlying mechanism of how these compounds work are poorly understood and 
research is still ongoing to fully evaluate their involvement in modulating cellular 
processes. This study aims to screen numerous (poly)phenols for the ability to 
lower pro-inflammatory markers, then to investigate further those compounds 
with the greatest effects, using proteomics to understand their mechanism of 
action. 
 
1.6 Aims of this thesis. 
The aims of the work that contributes to this thesis were: 
 
 Screen (poly)phenols and phenolic acids to determine which are likely to 
be anti-inflammatory. A panel of 29 (poly)phenols were investigated to 
examine effects on interleukin 2, interleukin 8 and tumour necrosis factor 
alpha release in both unstimulated and PMA/PHA stimulated Jurkat cells.         
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 (Poly)phenols identified from this cytokine panel as significantly reducing 
markers of inflammation will be further investigated using proteomic 
approaches. Label free, liquid-chromatography tandem mass spectrometry 
will be used to identify changes to protein concentrations following 
treatment with polyphenols.  
  Validation of the changes in protein release observed via the proteomics 
analysis and identification of a proposed mechanism of action through 
network and pathway analysis. 
 To confirm changes to cytokine release and oxidative stress proteins in an 
alternative cell type, THP-1 monocytes using the compound that showed 
the greatest modulation in the previous aims.        
 
1.7 Hypothesis 
 
This study hypothesises that polyphenols will significantly reduce cytokine release, 
and increase antioxidants markers to reduce oxidative stress in Jurkat and THP-1 
cells when compared with the control.  
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1 Materials. 
 
Abcam (Cambridge, England, UK): 
Anti-phosphorylated-Nrf2 antibody, anti-keap1 antibody, anti-TATA binding 
protein (TBP) antibody, anti-glutathione reductase, anti-catalase, anti-
thioredoxin, anti-peroxiredoxin-2, anti-vinculin, anti-Histone H3. 
 
 Active motif (La Hulpe, Belgium): 
TransAm Nrf2 activation kit. 
 
Bio-Rad (Richmond, California, USA): 
Bio-Plex Pro™ Assays, blotting grade non-fat milk, 4x Laemmli sample loading 
buffer. 
 
Chemicals VWR BDH Prolabo (Lutterworth, Leicestershire, UK): 
(Ethylenedinitrilo)tetraacetic acid disodium salt (Na2EDTA), potassium hydroxide 
pellets, sodium hydroxide pellets. 
 
Cell signalling technology, Inc (Danvers, MA, USA) 
Anti-rabbit antibody, anti-ERK1/2, anti-phosphoERK1/2. 
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GE Healthcare Life Sciences 
Amersham ECL full-range rainbow molecular weight marker, nitrocellulose 
blotting membrane. 
 
Life Technologies (Paisley, Strathclyde, UK): 
Gibco Foetal bovine serum (FBS), Gibco 1M 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), Gibco RPMI – 1640 (1X) phenol free media 
containing glutamine, without HEPES, Applied Biosystems High capacity cDNA 
reverse transcription kit, Applied Biosystems TaqMan universal PCR master mix. 
TaqMan gene assays – glutathione reductase, glutathione synthetase, glutathione 
peroxidase, glutamate-cysteine ligase, TATA-binding protein and beta-2 
microglobulin. 
 
Lonza (Basel, Switzerland): 
L-glutamine. 
 
Millipore (Watford, UK): 
Milliplex Map kit (11-plex) – human cytokine/chemokine magnetic bead panel. 
 
National Diagnostics (Atlanta, Georgia, USA): 
ProtoGel 30%, ProtoGel Stacking buffer, 4x Resolving Buffer, 10x running buffer, 
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N,N,N′,N′-Tetramethylethylenediamine  (TEMED). 
 
PAA Laboratories (Pasching, Austria): 
Foetal bovine serum gold (heat inactivated). 
 
Public health England (PHE) culture collection (Salisbury, England, UK): 
Jurkat E6.1 T lymphocytes, THP-1 monocytes. 
 
Promega (Madison, Wisconsin, USA): 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt (MTS) cell proliferation assay. 
 
Roche Life science (Dubai, UAE): 
Glutathione reductase. 
 
Santa Cruz biotechnology, Inc (Dallas, Texas, USA): 
Anti-Nrf2 antibody. 
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Sigma-Aldrich (Poole, Dorset, UK): 
2-vinylpyradine, 5,5’-dithiobis(2-nitro-benzoic acid)(DTNB), 5-sulfasalicylic acid, 6-
amino n hexanoic acid,ammonium persulfate (APS), anti-mouse antibody, anti-rat 
antibody, bicinchonic acid solution, β-glycerophosphate, β -Nicotinamide adenine 
dinucleotide phosphate, reduced tetra(cyclohexylammonium) salt  (NADPH), 
Bradford reagent, diamide, copper(II) sulphate solution, curcumin, dimethyl 
sulfoxide (DMSO), dithiothreitol, Dulbecco's phosphate-buffered saline (DPBS), E. 
coli B4 lipopolysaccharide (LPS), glutathione reduced (GSH) and oxidised (GSSG),  
glycerol, hepes-KOH, isorhamnetin, ochratoxin A, magnesium chloride, methanol, 
p-nitrophenyl phosphate, phorbol 12-myristoyl 13-acetate (PMA), 
phytohaemagglutinin (PHA), phenylmethulsulfonyl fluoride, phosphatase 
inhibitor cocktail, proteases inhibitor cocktail, BSA protein standard, resveratrol, 
RPMI-1640 medium Dutch modification with 1gm/L sodium bicarbonate and 20 
mM HEPES, sodium dodecyl sulphate (SDS), sodium fluoride, sodium 
metavandate, sodium molybdate, sodium chloride, sodium phosphate dibasic 
(Na2HPO4), tert-butylhydroquinone, tris, trypan blue, tween 20. 
 
Thermo Scientific (Rockford, Illinois, USA): 
Super Signal West Dura Chemiluminescent Substrate (ECL). 
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2.2 Methods. 
 
2.2.1 Jurkat cell culture. 
Human Jurkat T-lymphocytes (ATCC, UK) were cultured in RPMI-1640 
supplemented with 10% (v/v) fetal bovine serum and 2mM L-glutamine. Cells 
were cultured in an incubator at 5% (v/v) CO2, 20% O2 (v/v) and 37
oC. Growing 
cultures were maintaining between 4-6x105cells/ml128. 
 
2.2.2 THP-1 cell culture. 
Human monocytic leukaemia cell line (ATCC, UK) were initially cultured in phenol 
free RPMI-1640 already supplemented with 2mM L-glutamine with 20% (v/v) 
fetal bovine serum, 100µg/ml Penicillin-Streptomycin, and 2mM. Cells were 
cultured in an incubator at 5% (v/v) CO2, 20% O2 (v/v) and 37
oC. Growing cultures 
were maintaining between 4-6x105cells/ml. When cells reached exponential 
growth the fetal bovine serum was lowered to 10% (v/v) in media129. 
 
2.2.3 Thawing frozen cells and maintaining cell culture. 
Frozen aliquots of Jurkat E6.1 or THP-1 cells were thawed from liquid nitrogen 
storage rapidly in a water bath at 37oC. Aliquots were added to a 25 cm2 culture 
flask with 5 ml of medium prewarmed to 37oC. Cells were continually cultured at 
5% (v/v) CO2 and 37
oC, maintaining cultures between 3-9x100,000 cell/ml. A 
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sample was taken for counting, using the Trypan Blue exclusion method. Cells 
were then centrifuged at 224 x g for 5 min, old media was discarded and replaced 
with fresh media to appropriate volume for maintain growing culture. 
 
2.2.4 Cells counting.  
 
2.2.4.1 Trypan Blue exclusion. 
Cell number was determined via Trypan Blue exclusion either using a 
hemeocytometer or automatic cell counter (TC-20, BioRad, California, USA). 
Typan blue is a diazo dye which is only taken up by dead cells, allowing the dye to 
cross the cell membrane, distinguishing between live and dead cells.  
 
2.2.4.2 MTS (tetrazolium dye) cell proliferation assay. 
Other cell counting methods included the MTS cell proliferation assay, allowing 
multiple cell counts to be taken, by comparing unknown cell samples to a known 
cell standard curve. The MTS assay was used during the polyphenol screening due 
to the large number of treatments being performed (29 polyphenols, 2 doses, 
with and without stimulation), therefore Trypan Blue exclusion was not possible 
for this many samples.  MTS assay measures cell viability by assessing cell 
metabolic activity, NAD(P)H-dependent cellular oxidoreductase enzymes reduce 
the tetrazolium dye to the insoluble formazan, which can be measured 
spectrophotometrically between wavelengths 490-500nm 
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A standard curve was made using the Jurkat cells ranging from 2.0×106 to 1×104 
cells per ml (determined by Trypan Blue exclusion) (Fig. 2.1).  100µl of unknown 
cell samples and standards were transferred to a 96 well plate, in duplicate, 
followed by 20µl MTS (tetrazolium dyes) reagents. Plate was incubated for 1.5 h 
at 5% (v/v) CO2 and at 37
oC, absorbance then measured at 490 nm. The standard 
curve was used to calculate the unknown cell samples from the absorbance.  
 
 
Figure 2.1 – Jurkat standard curve used to determine the cell number following 
the intervention with (poly)phenol using the MTS method. Absorbance taken at 
490nm measuring standards ranging from 2x106 to 1x104 cell/ml (standards in 
duplicate). Standard curves were produced for each experiment. 
 
 
 
 
R² = 0.9974 
0
0.1
0.2
0.3
0.4
0.5
0.6
0 500000 1000000 1500000 2000000 2500000
A
b
so
rb
an
ce
 a
t 
4
9
0
n
m
 
Cells per ml 
71 
 
 
 
2.2.5 (Poly)phenols. 
All (poly)phenols were initially dissolved in dimethyl sulfoxide (DMSO) at 5mM. 
However, later experiments using just a few polyphenols, higher stock 
concentrations were produced using 30mM stocks.  Catechol, phloroglucinol, 
pyrogallol, hippuric acid, 4-hydroxybenzoic acid, protocatechuic acid, 
4'Hydroxyphenyllacetic acid, vanillic acid, 4’-hydroxymandelic acid, 3-(3'-
hydroxyphenyl)propionic acid, 3-(3'-hydroxyphenyl)propionic acid, 3-(4'-
hydroxyphenyl)lactic acid, caffeic acid, ferulic acid, isoferulic acid, tyrosol, 
dihydroferulic acid, 4’-hydroxyhippuric acid, feruloylglycine, isoferuloylglycine, 
resveratrol*, chlorogenic acid, curcumin*, quercetinσ, 3-O-methylquercetin*, 
isorhamnetin*, epigallocatechin gallate (EGCG)*, kuromanin*, callistephin 
chloride*, and punicalagin*, stored at -20OC. Phenolic acids and polyphenols 
(termed (poly)phenols when referring to both) were examined and provided by 
Professor Alan Crozier (School of Chemistry, University of Glasgow) unless 
otherwise stated with * (Sigma-Aldrich).  
See appendix 1 for information on individual (poly)phenols including structures, 
molecular weights, foods compounds  where they are present and concentrations 
reported in plasma. 
 
2.2.6 Preparation of stimulations PMA, PHA and LPS. 
Compounds were used to induce cytokine release in the cells; this allowed 
measurements of the protective effect polyphenols had against the stimulations. 
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At baseline Jurkat and THP-1 cells produce low levels of cytokines, therefore 
evaluating cytokine reduction may prove problematic, therefore coupling the 
experiments with stimulation provided greater accuracy to the assays. PMA / PHA 
treatments used 5 mg / ml phorbol 12-myristoyl 13-acetate (PMA) stock; final 
concentration 25 ng / ml. Phytohaemagglutinin (PHA) a 5 mg / ml stock; final 
concentration 5 µg / ml for 24h induces cytokine release in Jurkat cells16. The 
PMA/PHA stimulation couldn’t be used in the THP-1 cells, as PMA is used in the 
differentiation of THP-1 monocytes to macrophages, therefore does not have the 
same effect. Lipopolysaccharide (LPS) was used, as it has been well studies in the 
induction of cytokines in the THP-1 cell line, there are differences in the 
treatment times and the pathways they induce, however there is a cross over in 
the cytokines that are induced by the two treatments, allowing the comparisons 
between the two cell lines. LPS stock made up 1 mg / ml treated with 1µg / ml 
LPS and treated for 4h in the THP-1 cells .   
 
2.2.7 Cell treatments for multiplex analysis. 
 
2.2.7.1 Jurkat cell treatments for cytokine measurements. 
Cells were seeded at 2×106 cells / ml in 48 well plates and incubated overnight. 
Cells were then treated with DMSO (1μM equivalent = 0.02% v/v, 30μM 
equivalent = 0.6% v/v), 1 or 30μM (poly)phenols (5mM polyphenol stock) and 
incubated at 5% CO2 and 37
oC for 48 h. At the 24 h time point cells were treated 
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with 25 ng/ml PMA and 5 µg/ml PHA. Following incubation cells were 
resuspended by gently pipetting up and down, 100μl cell suspension was taken 
for MTS assay. The remaining cell suspension was centrifuged at 224 × g for 5 min 
and the medium was removed and stored at -80OC for future analysis.  
 
2.2.7.2 THP-1 monocyte cell treatments for cytokine measurements. 
Cells were seeded at 1×106 cells/ ml in 48 well plates. Cells were treated with 
dimethyl sulfoxide (DMSO) (0.1% of total media volume) 1, 10 or 30μM 
isorhamnetin (from 1, 10 and 30mM stock) and incubated at 5% CO2, at 37
oC for 
48 h. Cells were treated with 1µg/ml LPS which was added 4 h prior to the end 
point. Following incubation cells resuspended by pipetting and 100μl was 
removed for MTS assay. The remaining cell suspension was centrifuged at 224 × g 
for 5 min and the media was removed and stored at -80OC for future analysis. 
 
2.2.8 Multiplex assay.  
 
2.2.8.1 Multiplex assay (1) Jurkat. 
Multiplex bead analysis was used to measure cytokines IL2, IL8, and TNFα 
secreted into the medium obtained following polyphenol treatment by Jurkat T-
lymphocytes. Reagents were supplied by Bio-Rad, Heracules, USA unless 
otherwise stated; the method is illustrated in figure 2.2.  
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 A 96-well filter plate (Millipore, Massachusetts, USA) was pre-washed with 
assay buffer and removed by vacuum filtration with a pressure of 1-3mmHg. 
Added to the filter membrane are beads mixed with red and infrared 
fluorophores which are conjugated with antibodies for IL2, IL8, and TNFα on the 
surface of the beads, the plate was then washed twice in wash buffer by vacuum 
aspiration. Standards were made using Bio-Plex Pro™ human cytokine standards 
(Bio-Rad, Hertfordshire, UK), with a 1:4 serial dilution and were loaded onto the 
plate along with the samples (undiluted). These were incubated for 1 h under 
constant agitation at room temperature, protecting the plate from light; this 
allows the protein of interest to bind to the beads. The plate was washed 3 times 
in wash buffer using vacuum aspiration before adding a complementary 
biotinylated detection antibody. The plate was incubated for a further 1h under 
constant agitation at room temperature, again protecting from the light. 
Following incubation, 3 more washes were performed using vacuum aspiration 
and streptavidin-phycoerythrin fluorophore was added, allowing measurement of 
biotin bound streptavidin-phycoerythrin conjugates. The plate was agitated for a 
further 10 min at room temperature and protected from light. Three final washes 
using vacuum to remove liquid, the plate base was blotted dry and samples were 
resuspended in 150µl assay buffer. Plate was then agitated for 30s prior to 
analysis using Bio-Plex 200 platform (Bio-Rad, Heracules, USA), software was set 
to record 50 beads per analyte (The Bio-Plex uses lasers to read the colour code 
of each bead and analyte, e.g. 50 x IL2 beads, 50 x IL8 beads and 50 x TNFα beads 
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were analysed before moving to next sample on the 96 well plate). This process 
allows the quantification of multiple molecules within each sample.  
See appendix 2, for data on the reproducibility of the assay and 
correlations between experiments performed on different days. 
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Figure 2.2 – Bio-Plex Pro assay, a flow diagram summarising the steps required 
for multiple cytokine detection using a multiplex assay (summarised from Bio-
Plex Pro assay kit, BIORAD).  
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2.2.8.2 Multiplex (2) THP-1. 
Multiplex bead analysis was used to measure the cytokine content of G-CSF, GM-
CSF, GRO, IL1β, IL6, IL8, IL10, IL12p40, IL12p70, MCP-1, and TNFα in the medium 
obtained following polyphenol treatment on the THP-1 cells. Reagents were 
supplied by Mulliplex, Watford, UK, unless otherwise stated. The experiment was 
similar to BioRad multiplex analysis, with differences in length of incubation, 
automated plate washing and detection platforms used (detailed below). 
 Wash buffer was added to a 96 well plate, sealed and agitated for 10min 
at room temperature.  Standards were made human cytokine standards stating at 
10,000 pg/ml with 1 in 5 dilution, these were loaded on the plate in duplicate 
along with 2 quality controls (QC), at a low and high concentration, along with the 
samples. Assay buffer was added to the sample wells and culture media to the 
standard and QC wells. The 11 antibody-beads were sonicated in a water bath 
and vortex for 1 min, to resuspend beads before being diluted and added to the 
plate. The plate was sealed and incubated overnight at 4oC with agitation. 
 Following overnight incubation, the plate was washed twice with wash 
buffer using a magnetic plate washer (BioTek ELx40, setting supplied in manual), 
detection antibody was added and incubated at room temperature for 1h with 
agitation. Streptavidin-Phycoerythrin was added and left to incubate for 30 min at 
room temperature with agitation. The plate was then washed twice with wash 
buffer, followed by sheath fluid (delivery fluid for the Bioplex platform). The plate 
analysis was undertaken using Qiagen liquiChip, Luminex xMap technology, 
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Bioplex Manager, which uses lasers to measure and quantify the colour of 
individual beads.  
 
2.2.9 Multiplex data analysis. 
 
Raw data generated following multiplex analysis by the bioplex reader, software 
calculates unknown cytokine samples by using the know cytokine standard curve. 
Data for unknown samples was given as pg/ml for the chosen cytokines (e.g. IL2, 
IL8, TNFα). Initial checks to the data were made to insure a suitable standard 
curve was generated and that samples fell within the ranges of the standard 
curve. The data was then normalised to cell number, which was obtained by MTS 
assay (2.2.4.2) for each polyphenol treatment. The data was then presented as a 
percentage change from the DMSO treated control. Due to the large amounts of 
treatments, polyphenols comparisons were conducted in sets of 4 or 5 and 
statistical analysis was conducted for each separate experiment. Set 1 = 
Epigallocatechin gallate (EGCG), kuromanin, callistephin chloride, and punicalagin. 
Set 2 = Phloroglucinol, catechol, protocatechuic acid and 4-hydroxybenzoic acid. 
Set 3 = 4'Hydroxyphenyllacetic acid, 4’-hydroxymandelic acid, 3-(3'-
hydroxyphenyl)propionic acid and 3-(4'-hydroxyphenyl)lactic acid. Set 4 = Caffeic 
acid, Ferulic acid, Isoferulic acid and isoferuloylglycine. Set 5= Hippuric acid, 4’-
hydroxyhippuric acid, tyrosol and chlorogenic acid. Set 6 = Dihydroferulic acid, 
feruloylglycine, quercetin and 3-O-methylquercetin. Set 7 = Curcumin, 
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isorhamnetin, pyrogallol, resveratrol, and vanillic acid. Statistical analysis was 
performed on normalised raw data, with an ANOVA and Dunnett’s post-hoc test 
which compares multiple treatments against the DMSO treated control. The raw 
data expressed in pg/ml minus the DMSO control for each cytokine can be found 
in Appendix 1 (Table 8.2-8.5). 
 
2.2.10 Jurkat cell treatments for glutathione measurements. 
 
Cells were seeded at 2×106 cells / ml in 6 well plates. Cells were treated with 
dimethyl sulfoxide (DMSO), 1 or 30μM (poly)phenol. Cells were then incubated at 
5% CO2 and at 37
 OC for 48 h. At the 24 h time point cells were treated with 25 
ng/ml phorbol 12-myristoyl 13-acetate (PMA) and 5 µg/ml phytohaemagglutinin 
(PHA). Following incubation 100 μl was taken in duplicate for MTS assay and the 
remaining cell suspension was centrifuged at 224 × g for 5 min. The cell pellet was 
washed in Dulbecco's phosphate-buffered saline (DPBS) and was centrifuged at 
224 × g for 5 min. The pellet was resuspended in 100 μl extraction buffer 
(containing sodium phosphate dibasic, sodium EDTA and sulfosalicyclic acid 
hydrate, pH 7.5), then the samples were sonicated 3 x 5 s on ice and centrifuged 
at 20817 × g for 10 min at 4 OC. The supernatant was used for glutathione assay, 
measuring total and oxidised glutathione. 
 
80 
 
 
 
2.2.11 Glutathione enzymatic recycling assay. 
The glutathione recyling assay was used to measure intracellular concentrations 
of total and oxidised glutathione, following treatment of Jurkat cells with 
(poly)phenols. This method, illustrated in figure 2.3, uses glutathione reductase 
(ROCHE: Life Sciences, Dubai, UAE) and β-nicotinamide adenine dinucleotide 
phosphate (NADPH) to convert oxididsed (GSSG) to reduced glutathione (GSH), 
utilising the reduction of 5,5’dithiobis(2-nitro-benzoic acid) (DTNB) by GSH, 
forming reduced DTNB which is yellow in colour and can be measure 
spectrophotometrically at 412nm. The resulting GSSG molecule re-enters the 
system and the recycling process occurs, kinetic measurements are taken during 
the exponential phase of the reaction. Using known standards of GSH (10.4 to 
0.08µM) and GSSG (2.6-0.02µM) a standard curve can be used to quantify 
unknown amounts of total amount of glutathione (GSH and GSSG) in the Jurkat 
samples. Quantification of GSSG can be measured by masking GSH by pre-
incubating samples with 2-vinylpyridine (2-VP). 2-VP does not interfere with 
glutathione reductase therefore the enzymatic recycling can be done as before 
but will only be measure GSSG levels in the sample. Oxidised glutathione can be 
taken away from the total glutathione concentration, giving the levels of reduced 
glutathione present in the samples. 
For total glutathione measurements: 20µl of standards and samples 
(diluted 1 in 10 in extraction buffer) (buffered used are described in table 2.1) 
were added to a 96 well plate followed by 200µl of assay buffer (made up of the 
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NADPH solution, DTNB solution, glutathione reductase added just before 
absorbance was taken). Absorbance was read at 412 nm using a kinetic 
programme, taking absorbance readings every 15s for 10 mins, a standard curve 
was generated from the exponential phase of the reaction.  For oxidised 
glutathione measurements: 2-vinylpyridine was added to the standards and 
samples (at 1 in 100 dilutions) and incubated for 1h at room temperature, in 
order to mask GSH, meaning only GSSG will be present in the sample. Standards 
and samples were transferred to a 96 well plate, followed by the assay buffer and 
absorbance taken at 412nm, the same as previously described for total 
glutathione measurements.  
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Figure 2.3 – Principles behind the glutathione enzymatic recycling assay. Total 
glutathione measured using β-nicotinamide adenine dinucleotide phosphate 
(NADPH) and glutathione reductase to convert oxididsed glutathione (GSSG) to 
reduced gluathione (GSH), which is then recycled back to GSSG, along with the 
redcution of 5,5’dithiobis(2-nitro-benzoic acid) (DTNB) which can be measured 
using a spectrophotometer at 412nm. GSSG can be measured independent of 
GSH by pre-incubation with 2-vinylpyridine (2-VP) for 1 h, which masks GSH. 
Recycling assay can then be performed allowing the measurement of GSSG only. 
(Modified from Moeller, R. and Mason, A.Z.130). 
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Preparation of glutathione recycling assay buffers 
Stock buffer 143mM sodium phosphate dibasic, 124mM sodium EDTA, in 
distilled water (pH 7.5). 
NADPH solution 335.8µM (β-Nicotinamide adenine dinucleotide phosphate, 
reduced tetra(cyclohexylammonium) salt) in stock buffer. 
DTNB solution 6mM 5,5’-dithiobis(2-nitro-benzoic acid) in stock buffer. 
Extraction buffer 45.8mM (5-sulfosalicylic acid hydrate) in stock buffer. 
Oxidised glutathione 2.6 µM oxidised glutathione in extraction buffer. 
Reduced glutathione 10.4 µM reduced glutathione in extraction buffer. 
Assay buffer 7:1 ratio of NADPH:DTNB solutions. With 1 in 90 dilution of 
glutathione reductase enzyme added just prior to absorbance 
reading. 
 
Table 2.1 – Table detailing the preparation of buffers required for the 
glutathione recycling assay. Stock buffer is used to make NADPH solution, DTNB 
solution and extraction buffer, along with oxidised and reduced glutathione 
which are dissolved in extraction buffer. Assay buffer is comprises of a mixture 
of NADPH and DTNB solutions, with the addition of the glutathione reductase 
enzyme. 
 
 
The concentration of oxidised and reduced glutathione can be 
represented as a redox potential (mV) calculated using the Nernst equation 
below.  
𝑬𝒉 = 𝑬𝟎 +
𝑹𝑻
𝒏𝑭
𝑰𝒏 (
[𝑮𝑺𝑺𝑮]
[𝑮𝑺𝑯]𝟐
) 
Eh = redox potential GSH/GSSG (mV), E0 = standard potential (-264 mV), R = gas 
constant (8.314 j/oKmol), T = absolute temperature of analytical measurement 
(25oC = 298oK), n = number of electrons transferred (n=2), F = Faraday’s constant 
(96,485 coulomb/mol). 
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 In humans the intracellular GSH/GSSG redox potential is estimated to 
range from -260 mV to -230mV for dividing cells131, in the Jurkat cells the resting 
redox state was found to be -228mV (Fig. 2). Changes in glutathione with 
(poly)phenol treatment were compared to a DMSO treated control. No 
differences in the glutathione redox potentials were observed between untreated 
cells and DMSO treated cells, significant oxidation was observed with PMA/PHA 
treatment from -229 mV with DMSO to -211 mV with PMA + DMSO (Fig. 2.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 - Glutathione redox potential of Jurkat cells comparing untreated 
cells (UTC) with cells treated with DMSO for 24 h (dose matched to amounts 
used in (poly)phenol treatments). Cells were also treated with PMA/PHA and 
with the addition of DMSO for 24 h. Redox potential ± SEM (n = 4). 
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2.2.12 Glutathione oxidation by diamide and 50µM curcumin. 
 
As a positive control for a treatment to oxidative glutathione, cells were 
stimulated with diamide, which is a strong oxidising agent to induce the 
formation of oxidised glutathione. Figure 2.5 shows a significant increase in the 
concentration of oxidised glutathione following 15 minute treatment with 1mM 
diamide, other time points were examined at 5, 30 and 60 min (data not shown) 
but only the 15 min showed a significant increase. A high dose of curcumin (50µM) 
for 10 min was also used to give rise to a significant increase in oxidised 
glutathione, a greater induction of GSSG was observed with curcumin than with 
the diamide treatment (fig. 2.5B). Satisfied that the gluathione assay was capable  of 
measure changes in reduced and oxidised glutathione in the Jurkat cell model. 
 
Figure 2.5 – Positive control for oxidised glutrathione mesurements for glutathione 
recycling assay. A) Intracellular concentrations of oxidised glutathione in Jurkat cells 
following treatment with 1mM diamide for 15min. B) Intracellular concentrations of 
oxidised glutathione in Jurkat cells following treatment with 50µM curcumin for 10min. 
[mean ± SEM, n = 4, p < 0.05]. 
 
 
A 
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2.2.13 Protein quantification using spectroscopic analysis. 
 
2.2.13.1 Bradford assay. 
Standards were prepared from bovine serum albumin stock solution with a 1 in 2 
serial dilution starting at 1000µg/ml in water. Samples and standards were 
transferred to a 96 well plate, 200µl Bradford Ultra reagent (Expedeon, 
Cambridgeshire, UK) was added and absorbance was read at 595nm using a 
spectrophotometer. 
 
2.2.13.2 BCA assay. 
 Standards were prepared in the same way as for the Bradford assay, both 
standards and samples were transferred to 96 well plate. Copper(II)sulphate was 
added 1 in 50 to bicinchoninic acid, vortex and 200µl added to the plate, followed 
by 30 minutes incubation at 37oC, with absorbance being read at 562nm in a 
spectrophotometer. The BCA assay is based on two reactions, the first reaction is 
the reduction of Cu2+ ions (copper(II)sulfate) by peptide bonds in the proteins, the 
amount of protein present is direction proportional to the concentration of 
reduced Cu+, this is a temperature dependent reaction, hence the incubation step 
at 37oC. The second reaction two molecules of the bicinchoninic acid bind to each 
Cu+ ion, resulting in the colour change from green to purple, which can be 
measured spectrophotometrically at 562nm. 
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The different protein assays were used depended on the concentration of protein 
in sample and whether the cell lysis buffers contained protein interfering 
substances, such as SDS, phenol red, reducing or oxidising agents. 
 
 
2.2.14 Nuclear and cytoplasmic extractions in Jurkat cells. 
To measure the nuclear translocation of the activated transcription factor Nrf2, 
nuclear and cytoplasmic extracts were required from the Jurkat cells. Three 
methods were evaluated: the subcellular fractionation as described by Dimauro 
et al 2012132, ‘nuclear protein extraction without the use of detergents’ by Sigma 
Aldrich133, and ‘preparation of nuclear extracts’ by Active Motif134. The Active 
Motif method was the most accurate and consistent for nuclear and cytoplasmic 
extracts with Jurkat T lymphocytes using western blotting to evaluate. 
Cells were seeded at 2x106/ml in 6 well plates, incubate cells at 37OC, 5% 
(v/v) CO2, treated with (poly)phenol of interested with an equivalent DMSO 
treated control for 48h. Cells were washed 3x in ice cold DPBS and resuspended 
in 1ml on 5% PIB in DPBS solution, samples were kept on ice throughout. (Buffers 
described in table below – Table 2.2) 
 
 
 
 
88 
 
 
 
 
 
Samples were centrifuged at 224 x g for 5 min, the supernatant discarded 
and resuspended in HB buffer, the cells were left to swell on ice for 15 min. 5μl of 
10% Nonidet P40 substitute (0.5% (v/v) final concentration) was added and 
vortexed vigorously for 10 sec. The resulting homogenate was then centrifuged at 
4OC, 20817 x g for 30 sec, the supernatant removed and retained (cytoplasmic 
fraction). Phosphatase and protease inhibitor cocktail were added 1 in 100, to 
prevent dephosphorylation and proteolytic degradation during cell lysis and 
stored at -80 OC for future analysis. The resulting pellet was resuspended in 50μl 1% 
(w/v) SDS (also containing protease/phosphatase inhibitor cocktail 1 in 100), 
samples were sonicated on ice 3 x 5s , then centrifuged at 4OC for 10 min at 
14,000 x g. The supernatant (nuclear fraction) was retained and stored at -80OC. 
Protein was quantified using BCA assay. 
 
Table 2.2 - Nuclear/Cytoplasm extract buffers 
PIB (phosphatase inhibitor 
buffer) 
125 mM  NaF Sodium Fluoride  
250 mM β-glycerophosphate 
250 mM p-nitrophenyl phosphate (PNPP) 
25 mM NaVO3 – Sodium metavandate 
In distilled water. 
HP (hypertonic buffer) 20mM Hepes, pH 7.5 
5mM NaF  Sodium Fluoride 
10μM Na2MO4 – Sodium molybdate 
0.1mM EDTA Ethylenedicmmetetracetate 
acid. 
In distilled water. 
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2.2.15 SDS-PAGE and western blotting. 
Protein samples were prepared for western blot analysis by diluting with distilled 
water to contain appropriate amount of protein (ranging from 7.5 and 30µg of 
protein), with an appropriate amount of  4x Laemmli sample loading buffer 
(BioRad, Richmond, USA) (Tris-HC, glycerol, LDS, 1 in 20 dilution of 2-
mercaptoethanol, pH6.8). The 2-mercaptoethanol provides a negative charge to 
the proteins, the loading buffer make the protein sample denser, and allows 
visualisation of the samples when in the gel, which are important features 
required when separating protein by electrophoresis. Samples were boiled at 
100OC for 5 min to denature the proteins, and allowed to cool before adding to 
the gel. 
 
2.2.15.1 Gel preparation 
Reagents from National Diagnostics (Atlanta, USA) were used unless otherwise 
stated. 
A 12% (w/v) resolving gel was made my mixing 30% (w/v) Protogel, 4x resolving 
buffer, distilled water, 10% w/v ammonium persulfate (APS) (Sigma Aldrich, Poole, 
UK) and N,N,N′,N′-Tetramethylethylenediamine (TEMED) (Sigma Aldrich, Poole, 
UK) pH to 8.8. The Protogel and resolving contains SDS which provided a negative 
charge to the proteins, polyacrylamide which forms a matrix of pores upon 
polymerization by APS and TEMED. The mixture was allowed to polymerize for 
approximately 20min, with a thin layer of distilled water was placed on top of the 
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gel while it polymerised, to prevent the gel from drying out and prove a smooth 
edge. Once set the water was removed and a 4% (w/v) stacking gel is placed on 
top, this mixture contained 30% (w/v) Protogel and stacking buffer, pH 6.8. The 
lower percentage obtained with the stacking gel allowed large pores to be 
generated, which means the proteins move easily through the gel when a current 
was applied, and allowed the proteins to compact together before entering the 
resolving gel, were protein separation occurs. A comb was inserted between the 
glass plates, in order to generate the wells for protein samples to be loaded. Once 
the gel has set, the comb was removed and apparatus contain the gels was 
placed into the electrophoresis chamber. The upper and lower chambers were 
filled with a 1x running buffer, which contained 25 mM Tris, 190 mM glycine, 0.1 
% (w/v) SDS, and water, pH 8.3 which is stored at 4OC till required.  Samples were 
loaded into the wells along with a molecular weight ladder, which was used to 
check protein separation and distinguish between different molecular weights. 
Current was set to 20mA, until the dye front reaches the interface between the 
stacking and resolving gels, then the amps are increased to 60mA and max volts. 
When the dye front reaches the bottom of the gel, the current is stopped and the 
gels removed and prepared for protein transfer. 
 
2.2.15.2 Protein transfer using the semi-dry method 
Transfer buffers are prepared as described in table below, Table  2.3.  
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 Anode I buffer 0.3M Tris in 20% methanol. 
pH to 10.4 
Anode II buffer  12mM Tris in 20% methanol. 
pH to 10.4 
Cathode buffer 40mM 6-amino n hexanoic acid in 20% methanol. 
pH to 7.6 
1x Tris buffered saline 
solution (TBS) 
20mM Tris and 150mM sodium chloride (NaCl)  
pH to 7.6 
TBS-Tween (TBST) 1x TBS with 0.005% Tween 20 
pH to 7.6 
 
Table 2.3 –Buffers for protein transfer during western blotting.  Preparation of 
protein transfer buffers anode I, anode II and cathode buffers and western 
blotting buffers TBS, and TBST. 
 
 
 
Filter paper was cut to the size of the gel, soaked in appropriate transfer 
buffer and layered as shown below in fig. 2.6. The gel (with the stacking gel 
removed) was sandwiched between filter paper soaked in Anode I and II and 
Cathode Buffer, with a nitrocellulose membrane below the gel and was soaked in 
Anode II.  The nitrocellulose membrane is a matrix used to transfer proteins from 
the gel on to a medium which can be used in immunoblotting. 
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Figure 2.6 – Preparation of gel to allow protein transfer. 6 x filter papers (FP) 
soaked in Anode I Buffer, with 3 x FP soaked in Anode II on top. Nitrocellulose 
membrane soaked in Anode II sits below the gel, 9 x FP soaked in Cathode 
Buffer sit on top.   
 
 
A roller was used to smooth out the filter papers and remove any air 
bubbles, the gel and filter papers were sandwiched between two metal plates 
and a current applied top to bottom, 100mA for each gel for 1 h 15 min. This 
allowed transfer of the proteins from the gel to the nitrocellulose membrane. 
Following the transfer the membrane was removed and approx. 10ml of Ponceau 
S stain was applied to the membrane see figure 2.7. This allows visualization of 
the proteins to check for successful transfer to the membrane from the gel, even 
loading of the protein samples into the gel, and cutting of the membrane at 
different molecular weights to allow the membrane to be analysed for different 
proteins using antibodies. 
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Figure 2.7 - Ponceau S stain applied to nitrocellulose membrane to allow 
reversible visualisation of proteins. The stain contains a sodium salt, diazo dye, 
which has a red colour.  Stain can be removed using TBS-tween, which allows 
subsequent immunological detection.  
 
2.2.15.3 Immunoblotting 
Once Ponceau S stain has been removed by washes of TBS-T, the membrane was 
blocked in 5% (w/v) milk for 1 h. The milk was then removed and membrane 
washed 3x TBST every 10 min, followed by the primary antibody of choice diluted 
in 3% (w/v) milk, see table below (Table 2.4) for antibodies used and appropriate 
dilutions. The membrane was incubated with the primary antibody overnight on a 
rocker at 4OC. This allows the optimal binding of the antibody to the protein of 
interest. 
Following incubation the primary antibodies was removed (for some 
antibody these can be kept, stored at -20OC and reused) and washed 3 x TBST 
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every 10 min. The secondary antibody which is conjugated to horseradish 
peroxidase (HRP), was then added, either anti-mouse or anti-rabbit depending on 
the animal the primary antibody was raised. The secondary antibody was diluted 
as shown in table 4 in 3% (w/v) milk and incubated for 1 h on a rocker at room 
temperature. Following incubation the secondary antibody was removed and 
membrane washed 3x TBST every 10 min.  
 
ANTIBODIES Animal MW Dilution Code 
Primary antibody 
Anti-Nrf2 (C-20) Rabbit 61kDa 1:500 Santa Cruz 
biotechnology – sc-
722  
Anti-Phospho 
Nrf2 
Rabbit Predicted: 68kDa 
Observed: 90kDa 
1:1000 Abcam – ab76026 
Anti-Keap1 Rabbit 70kDa 1:1000 Abcam – ab66620 
Anti-GSR Rabbit 58kDa 1:1000 Abcam – ab16801 
Anti-TXN Rabbit 12kDa 1:2000 Abcam – ab86255 
Anti-TXNRD1 Rabbit 55kDa 1:1000 Abcam – ab16840  
Anti-Catalase Rabbit 60kDa 1:2000 Abcam – ab16731 
Anti-PRDX2 Rabbit 22kDa 1:500 Abcam – ab59539 
Anti-Vinculin Mouse 117kDa 1:1000 Abcam – ab18058 
Anti-Histone H3 Rabbit 17kDa 1:5000 Abcam – ab1791 
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Table 2.4 – Primary and secondary antibodies used in the immunoblotting for 
proteins: nuclear factor (erythroid-dervived 2_-like 2 (Nrf2), phosphorylated 
Nrf2, Kelch-like ECH-associated protein 1 (Keap1), glutathione reductase (GSR), 
thioredoxin (TXN), thioredoxin reductase 1 (TXNRD1), catalase, peroxiredoxins 
2 (PRDX2), vinculin, and histone H3. Table includes the species source of the 
antibody, the molecular weight, along with the dilution and reference code for 
the primary and secondary antibodies used.  
 
 
2.2.15.4 Analysis and normalisation of immunoblotting images. 
The membrane was visualised with the addition of an enhanced 
chemiluminescense  ECL reagent (Thermo Scientific, Illinois, USA) using a 
ChemiDoc XRS system (BioRad, Herts, UK) and analysed using software Quanity 
One, ChemiDoc XRS. The chemiluminescense reacts with the HRP-conjugated 
secondary antibody and emits light, which can be visualised and then quantified 
using software such as Quanity One or Image J. Densitometry values for proteins 
of interest were normalised to a protein loading control vinculin (cytoplasmic 
control) or Histone H3 (nuclear control) or normalised to the Ponceau S stain.  
Vinculin was used as a cytoplasmic control and histone H3 was used as a nuclear 
control, under some circumstances the Ponceau S stain was used, correcting to 
total protein in well. Normalisation allows a more accurate representation of 
Secondary antibody 
Anti-Mouse IgG Goat  1:50000 Sigma – A2554 
Anti-Rabbit IgG Goat  1:8000 Cell signalling - 
7074 
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increases or decreases in protein expression is due to the treatments and not due 
to the amount loaded in the wells.  When viewing the bands, membranes are 
exposed for different time periods to obtain the optimal balance between 
chemiluminescence signal and background, preventing under- and over-exposure. 
 
 
2.2.16 Nrf2 DNA binding assay. 
 
All reagents were supplied by Active Motif (La Hulpe, Belgium) unless otherwise 
stated.  
Cell pellets were resuspended in complete cell lysis buffer (containing DTT 
and protease inhibitor cocktail), samples were sonicated, and then centrifuged at 
14,000 xg at 4OC for 10 min, and the supernatant was stored at -80OC. The 
protein concentration was determined by Bradford assay, 20µg was then used to 
perform the assay. 
The 96 well plate provided in the kit has been coated with immobilised 
oligonucleotide containing the ARE consensus binding site (5’-
GTCACAGTGACTCAGCAGAATCTG-3’). The active form of Nrf2 will bind to this 
sequence. The plate is prepared by adding binding buffer to the wells required. A 
positive control is added which is provided by the kit, along with blanks and 
samples, the plate was then incubated for 1h at room temperature, with mild 
agitation. Plate was then washed 3x with wash buffer and Nrf2 antibody was 
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added (1:1,000 dilution) for 1h at room temperature with no agitation. Again the 
plate was washed 3x with wash buffer before adding the HRP-conjugated 
antibody (1:1,000 dilution) for 1h at room temperature with no agitation. 
Following this incubation the plate was washed 4x with wash buffer and a 
developing solution was added and allowed to develop for ~20 min at room 
temperature, protected from the light. A blue colour develops over this time and 
the stop solution was then added, the blue colour turns yellow. The absorbance 
can now be read at 450nm (with ref wavelength at 655nm).  
 
2.2.17 Cell treatments for proteomics analysis. 
Cells were seeded at 2×106 cells/ ml in 6 well plates,  treated with dimethyl 
sulfoxide (DMSO) (1μM equivalent = 0.02% DMSO), or 1µM (poly)phenol and  
10/30µM (poly)phenol and incubated at 5% CO2 and at 37
oC for 48 h. Following 
incubation cell number was determined using trypan blue exclusion with 
automatic cell counter. Samples were centrifuged at 224 × g for 5 min and 
washed 4 times with DPBS. Pellets were frozen and stored in -20 oC (n = 5).  
 
Experiments planning: 
Initial experiments conducted with DMSO, 1µM curcumin and resveratrol. A low 
number of proteins were identified, therefore follow up experiment included 
DMSO, 10µM curcumin and 30µM resveratrol. After reanalysing data, 
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isorhamnetin was also investigated using DMSO, 1 and 30µM isorhamnetin. For 
all experiments 5 replicates were used. 
 
2.2.18 Liquid Chromatography Mass Spectrometry (LC-MS) of proteins. 
 
LC-MS analysis of Jurkat cells following polyphenol challenge was conducted by 
Dr Deborah Simpson, Centre for Proteomics at University of Liverpool.  
 
2.2.18.1 Sample digestion. 
Cell pellets (8-11 million cells) were re-suspended in ice-cold 25mM ammonium 
bicarbonate (0.75mL) and each sample sonicated for three 10s pulses at 30% 
amplitude followed by a 50s rest period. 0.75µl of Benzonase nuclease was added 
and samples were held on ice. A protein assay was carried out and all sample 
dilutions were in the linear range of the standard curve (50-fold dilution). 
A volume of cell lysate equivalent to 50µg of protein was added to a 0.5mL low-
bind tubes and the volume of made up to 80µl with 25mM ammonium 
bicarbonate. 5µl of 1%(w/v) Rapigest (a surfactant which facilitates digestion) was 
added and the samples placed in a heating block and held at 80C for 10min. 
Dithiothreitol (5µl of a 60mM solution in 25mM ambic was added and samples 
held at 60C for 10min (reduction of disulphide bridges). Iodoacetamide 5µl 
(178mM in 25mM ammonium bicarbonate) was added and samples incubated in 
the dark for 30min at room temperature (alkylation of cysteines facilitating MS 
99 
 
 
 
analysis). Trypsin (5µl of 0.2µg/µl in 50mM acetic acid) added and samples 
incubated overnight at 37C. 
Day 2. 1µl of Trifluoroacetic acid (TFA) (hydrolysis of Rapigest surfactant) was 
added and samples were incubated at 37C for 45min. Centrifugation of samples 
at 17,300 x g for 30min and clarified digests transferred to fresh low-bind tubes. 
Centrifugation as above and 10µl of sample transferred to ‘total recovery 
autosample vials’ for LC-MS analysis. 
 
2.2.18.2 High resolution LC-MS/MS analysis. 
1µl of digest (500ng protein equivalent) was injected on-column and 
chromatographed over a 2h gradient using a method whereby following a survey 
scan at 70,000 resolution the top 10 most abundant peptide ions are fragmented 
and measured at high resolution (35,000) in the Orbitrap analyser to a mass 
accuracy of 0.01Da. 
 
2.2.18.3 LC separation. 
All peptide separations were carried out using an Ultimate 3000 nano system 
(Dionex/Thermo Fisher Scientific). For each analysis the sample was loaded onto 
a trap column (Acclaim PepMap 100, 2cm x 75µm inner diameter, C18, 3µm, 
100Å) at 5µl/min with an aqueous solution containing 0.1%(v/v) TFA and 2%(v/v) 
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acetonitrile. After 3 min, the trap column was set in-line with an analytical 
column (Easy-Spray PepMap® RSLC 15cm x 75µm inner diameter, C18, 2µm, 100Å) 
(Dionex). Peptide elution was performed by applying a mixture of solvents A and 
B. Solvent A was HPLC grade water with 0.1%(v/v) formic acid, and solvent B was 
HPLC grade acetonitrile 80%(v/v) with 0.1%(v/v) formic acid. Separations were 
performed by applying a linear gradient of 3.8% to 50% solvent B over 95 min at 
300nL/min followed by a washing step (5 min at 99% solvent B) and an 
equilibration step (15 min at 3.8% solvent B).  
 
2.2.18.4 Q Exactive set-up. 
The Q Exactive instrument was operated in data dependent positive (ESI+) mode 
to automatically switch between full scan MS and MS/MS acquisition. Survey full 
scan MS spectra (m/z 300-2000) were acquired in the Orbitrap with 70,000 
resolution (m/z 200) after accumulation of ions to 1x106 target value based on 
predictive automatic gain control (AGC) values from the previous full scan. 
Dynamic exclusion was set to 20s. The 10 most intense multiply charged ions (z ≥ 
2) were sequentially isolated and fragmented in the octopole collision cell by 
higher energy collisional dissociation (HCD) with a fixed injection time of 120ms 
and 35,000 resolution. Typical mass spectrometric conditions were as follows: 
spray voltage, 1.9kV, no sheath or auxillary gas flow; heated capillary 
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temperature, 250C; normalised HCD collision energy 30%. The MS/MS ion 
selection threshold was set to 1 x 104 counts and a 2 m/z isolation width was set. 
 
2.2.18.5 Database search and Protein identification. 
Raw data files were uploaded into Proteome Discoverer 1.3 and searched against 
the human UniProt database using the Mascot search engine (version 2.4.1). A 
precursor ion tolerance of 10ppm and a fragment ion tolerance of 0.01Da were 
used with carbamidomethyl cysteine set as a fixed modification and oxidation of 
methionine as a variable modification. The false discovery rate (FDR) against a 
decoy database was 1-5%.  
PCA plots generated to correlate the spread of data and identify 
significant groups of proteins (Appendix 3) 
 
 
2.2.19 RNA isolation and quantification of Jurkat cell samples. 
The extraction and purification of ribonucleic acids (RNA) from the Jurkat cells 
was conducted for future quantitative polymerase chain reaction (qPCR) analysis. 
There are several methods of extracting RNA, but all procedures follow the same 
basic principles of disrupting the cell membranes to release RNA into solution, 
separate RNA from protein, DNA and other contaminants, and effectively inhibit 
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nuclease activity which would otherwise degrade the RNA. In this study RNA was 
extracted using Qiagen RNeasy Mini kits.  
Jurkat cells were seeded at 1x106 cells/ml in 24 well plates, incubate cells 
at 37OC, 5% (v/v) CO2, treated with (poly)phenol of interested with equivalent 
DMSO control for 3, 9, 24, and 48h. Cells were washed 3x in ice cold DPBS and 
resuspended in 350µl of RLT buffer from Qiagen RNeasy Mini kits, then an equal 
volume of 70% (v/v) ethanol was added, immediately transferred to RNeasy Mini 
spin column, centrifuge for 15 s at 8,000 x g, discarding the flow-through. Buffer 
RW1 buffer was then added to the column and centrifuged for 15 s at 8,000 x g, 
discarding the flow-through. Buffer RPE is added to the column and centrifuged 
for 15 s at 8,000 x g, discarding the flow-through. Buffer RPE was added and spun 
for 2 min at 8,000 x g. Transfer spin column to a new collection tube and 
centrifuge for 1 min at full speed to dry the membrane.  Again transfer spin 
column to new collection tube, add 50µl of RNase-free water to the spin column 
membrane and centrifuge for 1 min at 8,000 x g. Isolated RNA is then stored at -
80OC before RNA quantification and CDNA generation. 
RNA quantification and purity was determined using either Bioanalyser or 
Nanodrop. Bioanalyser is a chip assay which separates ribosomal proteins via 
electrophoresis, dyes molecules added to the samples intercalate with the RNA 
which allows detection by laser-induced fluorescence. Software compared 
unknown samples to a known RNA ladder, determining RNA peaks and sample 
concentration (Example, Fig. 2.8). The NanoDrop measures nucleic acid 
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concentration using spectrophometric analysis, using small amounts of sample 
0.5 - 2µl of sample. The concentration of RNA can be determined along with 
purity of the sample, by assessing the ratio of absorbance at 260/280 for protein 
contamination, a ratio of ~2 is accepted as pure for RNA. The 260/280 
absorbance ratio is also assess other molecule contamination such as phenol, a 
ratio between 2.0-2.2 is considered pure for RNA (Example, Fig. 2.9).  
 
 
Figure 2.8 – Bioanalyser example report. An RNA 6000 Nano-ladder standard is 
run on every chip used as a reference for data analysis. The RNA 6000 Nano-
ladder contains six RNA fragments ranging in size from 0.2 to 6 kb (0.2 kb, 0.5 kb, 
1.0 kb, 2.0 kb, 4.0 kb, and 6.0 kb) at a total concentration of 150 ng/µl. 
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Figure 2.9 – Example RNA quantification using NanoDrop 2000 instrument. 
Absorbance spectrum is taken of the sample and a curve generated. Purity of 
the sample can be determined by the 260/280 ratio for (DNA) and 260/230 ratio 
(Protein) which in pure samples should be approximately 2. The concentration 
on RNA is also determined (ng/µl). 
 
2.2.20 Quantitative polymerase chain reaction (qPCR) to determine mRNA 
of proteins involved in glutathione metabolism. 
 
Complementary DNA was prepared from the extracted RNA samples by reverse 
transcription using high-capacity cDNA reverse transcription kit (Applied 
Biosystems). A master mix made up of reverse transcriptase (RTase), random 
primers, and nucleotide bases (dNTP) was prepared as shown in Table 2.5. The 
master mix contains all the elements required to converted the extracted RNA 
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into complementary DNA (cDNA), using the enzyme reverse transcriptase. 
Transcription is initiated by random primers and nucleotide triphosphates are 
presence in excess to allow full transcription of RNA. 
 
Table 2.5 – cDNA master mix preparation. To reverse transcription buffer and 
water, nucleotide triphosphate (dNTP), random primers and reverse 
transcriptase (MultiScribe RTase) were added together to make a master mix 
used in the generation into CDNA from RNA. 
 
 
To 10µl of the master mix, 10µl of 30 ng RNA sample was added (diluted 
using RNA free water), samples were gentle mixed following a short centrifuge, 
then incubated for 10min at 25OC, this allows the primers to anneal to the RNA.  
The samples were transferred to on a Hybaid Omn-E thermal cycler were the 
samples were heated to 37OC for 120 min, allowing reverse transcription to take 
place, then 85OC for 5 min, which terminates the reaction. The sample was then 
cooled to 4OC, before being stored at -20OC till ready for qPCR analysis. 
Component Volume x1 (µl) 
10x RT buffer 2 
25x dNTP mix 0.8 
10x RT random primers 2 
MultiScribe RTase  1 
H2O 4.2 
Total per reaction 10 
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Following cDNA synthesis, cDNA samples were loaded to a 96-well plate 
along with a TaqMan universal master mix, prepared as seen in table 2.6. This 
master mix contained commercially available primers, TaqMan® gene expression 
assays. In this study 6 different gene expression assays were used (Table 2.7). 
These included primers for the genes glutathione reductase, glutathione 
synthetase, glutathione peroxidase 1 and glutamate-cysteine ligase, along with 
two control genes TATA-binding protein and beta-2 microglobin which were 
added separately to the cDNA samples.  
The 96 well PCR plate was placed in the thermal cycler (BioRad CFX 
connect real-time system) using TaqMan protocol, which heated the sample to 
95OC for 10 min, then proceeds to 50x cycles of 95OC for 15s and 60OC for 60s, CT 
values are generated. This cycling process allows amplification of DNA, heating 
the sample to 95OC separates the DNA standards, lowering the temperature to 60 
OC allows the primers to bind to the gene of interest and DNA polymerase to copy 
the DNA. Multiple rounds of heating and cooling allow amplification of the DNA, 
along with the fluorescence probe (TaqMan) which is incorporated into the DNA. 
Therefore as the number of gene of interest copies increase, so does the amount 
of fluorescence, which is measured by the instrument over time.  
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Table 2.6 – Preparation of TaqMan master mix used in the quantitative PCR 
reaction. 
  
 Gene 20x TaqMan® Gene Expression Assays 
GSR Glutathione reductase Hs00167317_m1 
GCLC Glutamate-cysteine ligase Hs00155249_m1 
GSS Glutathione synthase Hs00609286_m1   
GPX1 Glutathione peroxidise 1 Hs00829989_gH   
TBP TATA binding protein Hs00427620_m1 
B2M Beta-2-microglobulin  Hs00984230_m1 
Table 2.7 – Gene primers used in the quantitative PCR reaction. All TaqMan 
genes were obtained from Life Technologies.  
 
2.2.21 Analysis and normalisation of qPCR data. 
Quantification used the comparative CT (ΔΔCT) method for calculating relative 
quantitation of gene expression. Ct values generated by the treatment samples 
(polyphenol treatments) were compared with control samples (DMSO). Before the fold 
Component Volume x1 (µl) 
20x TaqMan® gene expression assay 1 
2x TaqMan® gene expression master mix 10 
cDNA template  2 
RNase-free water  7 
Total per reaction 20 
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change form DMSO was determined values were normalised to an appropriate 
endogenous housekeeping gene (see 2.2.22) which was TBP, which was evaluated at 3, 9, 
24 and 48h. Figure 2.10 shows changes in CT values of TBP over time with the three 
different treatments and DMSO treated control. At times 3 and 48h there was almost 
identical readings for DMSO and polyphenols treatment with TBP, there was slight 
variation at the 9 and 24h time point but T-test showed these were not significant 
(p<0.05). B2M was also tried in this experiment but TBP was more consistent over time 
in Jurkat cells and was therefore used as the normalising control for the qPCR 
experiments.      
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Figure 2.10 – Changes in CT values of normalising gene TBP over time (3, 9, 24 
and 48h) following treatment with curcumin (A), isorhamnetin (B) and 
resveratrol (C) in Jurkat T lymphocytes compared with the DMSO treated 
control (n=3).   
 
 
2.2.22 Evaluating suitable housekeeping genes for qPCR and 
immunoblotting  analysis. 
 
Proteomics identified a number of the regularly used normalising controls were 
modulated following treatment with the three polyphenols curcumin, 
isorhamnetin and resveratrol. Therefore a list of commonly used qPCR controls 
were obtained, and cross referenced with the proteomics data and literature 
searches to identify qPCR controls previously used in Jurkat cells (Table 2.8). The 
table shows in the first column proteins identified as being modulated by the 
polyphenols treatments used in this study, the second column then identifies any 
pf the remaining proteins previously used as housekeeping genes in other 
20
22
24
26
28
30
0 10 20 30 40 50
C
t 
va
lu
e
 
Time (h) 
C) Resveratrol 
control
treatment
110 
 
 
 
studies. These data was also useful when identifying housekeeping genes for 
western blot analysis. TBP (TATA binding protein) and B2M (β2 microglobulin) 
were used as housekeeping genes for qPCR. 
 
Table 2.8 – Determining suitable housekeeping genes for qPCR analysis. 
Commonly used qPCR controls (Applied Biosciences), cross referenced with 
proteins identified through proteomics to be significantly altered with 
polyphenol treatment and literature searches testing qPCR controls in Jurkat 
cells. 
 
 
2.2.23 Statistical analysis.  
 
2.2.23.1 Statistical analysis of cytokine data. Values are most commonly 
represented as mean ± standard error of the mean (SEM), although 
percentage change and fold change are occasionally presented. 
 Proteomics Jurkat  Proteomics Jurkat 
18S   135 MT-ATP6   
ABL1   PES1   
ACTB   PGK1   
B2M   135 POLR2A   
CASC3   POP4   
CDKN1A   PP1A   
CDKN1B   PSMC4   
EIF2B1   PUM1   
ELF1   RPL30   
GADD45A   RPL37A   
GAPDH   RPLPO   
GUSB   RPS17   
HMBS   TBP   135 
HPRT1   TFRC   
IP08   UBC   
MRPL19   YWHAZ   
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Comparisons between the means of the samples were done using 
SPSS (IBM SPSS statistics 20, New York, USA), and a Student’s two-
tailed independent samples t-test’s were used to identify significant 
differences between the means. During the polyphenol cytokine 
screening process, Jurkat T cells were treated with numerous 
polyphenols and cytokine release measured. With these multiple 
measurements a one-way ANOVA was used with Dunnett’s post-hoc 
test comparing treatment data to control DMSO treated cell data. 
Significance was set at p < 0.05.  
 
2.2.23.2 Statistical analysis of LC-MS data. Progenesis software was used to 
determine the significance of the changes to protein expression of the 
three treatments curcumin, isorhamnetin and resveratrol compared 
with DMSO treated control; this was done using an ANOVA, with a p-
value set to ≤ 0.05. Also due to proteomics identifying large quantities 
of proteins being modulated by the treatments, the q-value was also 
expressed. The q-value is a false discovery rate adjusted p-
value.  Proteins that were identified to have significant changes in 
expression were investigated further using a number of different 
programs (see table 2.9). UniProt was used to determine protein 
function, GeneCards to convert protein accession number to gene ID, 
DAVID bioinformatics and Reactome was used to link individual 
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proteins into a network. Ingenuity uses data from literature to connect 
proteins in the data set, placing them in signalling pathways and 
showing the effects when certain compounds are added to the system. 
 
 
Table 2.9 – Programs used to identify function, pathways, clustering of the proteins 
identified using proteomics. 
Program Website Date accessed 
UniProt http://www.uniprot.org/ 6/01/14 
The GeneCards Human http://www.genecards.org/  6/01/14 
DAVID Bioinformatics Resources 6.7 http://david.abcc.ncifcrf.gov/  6/01/14 
STRING 9.05 http://string-db.org/ 6/01/14 
PANTHER Classification System http://www.pantherdb.org/ 6/01/14 
Reactome http://www.reactome.org/  10/11/14 
Ingenuity (Pathway analysis) http://www.ingenuity.com/  10/02/15 
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CHAPTER 3 
 
 
INVESTIGATION OF A (POLY)PHENOL PANEL TO 
IDENTIFY MOLECULES THAT MODULATE 
INFLAMMATION IN JURKAT T LYMPHOCYTE CELLS. 
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3.1 INTRODUCTION 
 
 
 
3.1.1 Cytokine production and regulation in T lymphocytes. 
 
 
Cytokines are inflammatory molecules secreted by a variety of cell types, 
these small proteins facilitating signalling both between neighbouring cells and 
acting on the originating cell. The main function of cytokines is to coordinate the 
immune response, with pro-inflammatory and anti-inflammatory cytokines 
mediating these inflammatory mechanisms. Responses vary between the 
cytokine being released and its target cell. In T-lymphocytes, cytokines are 
essential for activation, differentiation, and proliferation. However, T-
lymphocytes are not the only source of cytokine release; other immune cells 
including macrophages and B cells 136  also produce cytokines along with 
endothelial cells, muscle cells, and fibroblasts137,138,139. Cytokines may behave 
differently depending on the cell type they are produced in or acting upon.  
 
3.1.2 Effects of T lymphocyte dysregulation and ageing. 
 
T lymphocytes are one of the major producers of cytokines, prompting the 
focus of this study to use these cells as a model to observe changes in 
inflammatory markers. During the ageing process the number of T-lymphocytes 
declines, along with this decline an impaired function and dysregulation is also 
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observed 140 . Dysfunction in the immune system with age is described as 
‘immunesenescence’141.   
This normally tightly regulated system becomes dysregulated with age and 
increases in baseline pro-inflammatory cytokines are observed. Pro-inflammatory 
cytokines are produced in a number of responses such as an infection, 
recognising foreign pathogens, and damage to the cell, these responses are 
essential to protect the cell/body from damage. This process is highly regulated 
with pro-inflammatory cytokine induction and feedback mechanisms to quench 
this induction and restore the resting state of the cells, important to maintain 
homeostasis. However, during ageing disruptions to this feedback mechanism are 
observed with over and under production of particular cytokines, affecting the 
cells ability to respond appropriately.  Elevated levels of cytokines such as 
interleukin 6 (IL6), interleukin 8 (IL8), MCP-1, TNFα, and C - reactive protein (CRP) 
have been documented in the serum of elderly populations142.  
 
3.1.3 Interleukin 2 (IL2), interleukin 8 (IL8) and TNFα changes with age.  
 
 
IL2 is an essential cytokine for T lymphocyte activation and differentiation, 
during ageing IL2 is reduced due to the decline on the number of T cells. However 
this decline is only observed in the very elderly >90 years, in those aged between 
65-85 the levels of IL2 remained the same as those in the young category aged 
between 25-34 years, in healthy patients143. Increases in pro-inflammatory 
cytokine such as TNFα have been observed in the plasma of both healthy elderly 
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patients and those with age-related conditions such as type-2 diabetes144. IL8 is 
another pro-inflammatory cytokine observed to be elevated in a number of age-
related diseases, such as Alzheimer’s disease145. However, levels in healthy ageing 
have been shown to vary between the sexes and in vitro respond differently 
when an inflammatory stimulus is added. Clark and Peterson in 1994 observed 
difference in levels of IL8 between elderly male and female healthy subjects. 
Women had similar levels to the young control groups, with levels of 57.8 ± 2.1 
ng/ml in elderly women compared with 66.4 ± 5 ng/ml in the young control group. 
Men had significantly lower levels with 8.8 ± 2.1 ng/ml. However, even though 
they had lower base-line levels, upon stimulation with LPS, they had an 8-fold 
induction which was significantly increased when compared with stimulated 
control, women showed no change with stimulation146. 
 
3.1.4 Dietary (poly)phenols and benefits to health and age. 
 
  
Polyphenols are naturally occurring compounds which are found in a wide 
variety of sources including fruits, vegetables, spices, and beverages. These 
compounds are believed to have benefits to health such as lowering levels of free 
radicals, inducing protective antioxidant signaling pathways and reducing blood 
pressure147. Some of these compounds are already being trialed in the treatment 
for certain diseases, such as curcumin in patients with rheumatoid arthritis using 
a daily dose of 500mg capsule148.  
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Polyphenols structures are complex and varied, once polyphenols enter the 
body, they are metabolised either in the stomach or intestines. The complex 
polyphenols, which come directly from the food source, are modified or broken 
down into smaller phenolic acids. Some of the more complex polyphenols will 
make it to the blood stream in low concentrations, along with these the 
metabolites and phenolic acids will also be present in a higher concentration. In 
this study a variety of compounds was chosen to include in both a number of 
polyphenols and phenolic acids (both termed (poly)phenols). Two different 
concentrations were used, a low dose of 1μM which was considered more 
physiologically relevant and a higher dose of 30μM, to evaluate changes to 
markers of inflammations with these (poly)phenols .  This data was also published 
as part of a paper ‘Identification of (poly)phenol treatments that modulate the 
release of pro-inflammatory cytokines by human lymphocytes’ co-authored 
between myself and Christopher Ford149.  
 
 
3.2 AIMS. 
 
 
The aim of this study was to screen 29 different dietary (poly)phenols for 
their anti-inflammatory effects in Jurkat T-lymphocytes. This panel of compounds 
included complex polyphenols, with multiple functional groups, along with small 
phenolic acids which are metabolites of the polyphenols. The aim was to 
determine what effect these (poly)phenols would have on the cell viability in this 
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cell type and determine a suitable treatment dose. This immune cell model was 
used to evaluate the anti-inflammatory effects these (poly)phenols have on these 
cells by measuring cytokine release following 48 h treatment with the compounds.  
 
3.3 RESULTS. 
 
 
3.3.1 Evaluating cytokine detection in unstimulated and PMA/PHA 
stimulated cells using multiplex analysis. 
 
Jurkat T-lymphocytes were treated with PMA/PHA, a protein kinase C 
activator and a plant-derived lymphocyte mitogen for 24 h to induce an 
inflammatory response and cytokine release. Assessments were made to 
determine the cell viability with DMSO and PMA/PHA, figure 3.1 shows an ~ 45% 
reduction in cell viability with PMA/PHA. A panel of 13 cytokines were chosen as 
known cytokines secreted by Jurkat T-lymphocytes and multiplex analysis 
platform was used to measure the induction of cytokine release following 
stimulation. The PMA/PHA stimulated cells showed a large increase in the release 
in a number of cytokines compared with untreated cell and DMSO treated control 
treatments (Table 3.1). However, there was a large proportion of the cytokines 
that were undetectable in the untreated cells.  There was an induction of 
cytokine release with cytokines IL2 and IL8. IL2 was 14 ± 1 pg/ml in DMSO treated 
cells which increased to 6970 ± 304 pg/ml when stimulated with PMA/PHA. IL8 
was also expressed at relatively low levels with DMSO treated cells, 34 ± 2 pg/ml, 
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following induction with PMA/PHA this increased to 1613 ± 93 pg/ml. There was 
also an induction with TNFα in PMA/PHA cells reaching levels of 260 ± 12 pg/ml, 
prior to stimulation TNFα was undetectable in the DMSO control cells.  Therefore 
these three cytokines, IL2, IL8, and TNFα were chosen for further experiments 
due to their high sensitivity to induction by PMA/PHA treatment and the 
relatively well defined roles of each of these cytokines as pro-inflammatory 
physiological factors.  
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Cytokine measured in 
Jurkat 24 h conditioned 
medium 
Untreated 
control (pg/ml) 
DMSO vehicle 
control (pg/ml) 
24h PMA/PHA 
stimulated 
(pg/ml) 
Eotaxin-1 ND 2.85 ± 1.47 0.48 ± 0.56 
GM-CSF ND ND 5.81 ± 0.39* 
IFNγ ND ND ND 
IL1β ND ND ND 
IL2 13.45 ± 1.39 14.40 ± 1.41 6969.69 ± 303.95* 
IL4 21.55 ± 0.35 ND 1.86 ± 5.67 
IL6 ND ND ND 
IL7 0.3 ± 0.06 0.804 ± 0.66 3.52 ± 0.66 
IL8 35.25 ± 2.88 34.22 ± 2.32 1612.68 ± 92.71* 
IL12p70 ND ND ND 
IL13 ND ND 7.68 ± 1.52* 
MCP-1 ND ND ND 
TNFα ND ND 259.55 ± 12.36* 
Table 3.1 - Cytokines induced by PMA/PHA treatment of Jurkat CD4+ T-
lymphocytes. Data expressed as means ± SEM. ND indicates no detection. 
Abbreviations: Granulocyte macrophage-colony stimulating factor (GM-CSF), 
interleukin (IL), interferon (IFN), monocyte chemoattractant protein (MCP). 
Data expressed as mean ± SEM, * n=4, p<0.05149. 
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3.3.2 Modification to cytokine release and cell proliferation by Jurkat T-
lymphocytes. 
 
 
 
Cytokine release was measured following 48h treatment with the chosen 
phenolic compounds. There were 29 compounds in total, these consisted of small 
metabolites called phenolic acids, structurally they contain one phenolic ring 
(C6H5OH) and the panel also included larger more complex polyphenols,  
containing multiple phenol structures and functional groups (full compound 
details can be found in Appendix 1). A colormetric assay (MTS) was used to 
determine the cell viability, along with a multiplex assay to measure changes in 
cytokine release of interleukin 2 (IL2), interleukin 8 (IL8) and tumour necrosis 
factor alpha (TNFα). The data has been expressed as a percentage change from 
DMSO treated control. 
 
3.3.3 Assessment of cell viability following (poly)phenol treatments. 
 
 
 
Jurkat cells were treated for 48h with the chosen (poly)phenols. Figure 3.2, 
shows the effect treatments had on cell viability, at both 1 and 30µM 
concentrations of (poly)phenols. Only a couple of the treatments reduced the 
number of Jurkat cells and in all the cases that had reduced viability, this was with 
the 30μM concentration suggesting toxicity with the higher dose. The largest 
decrease is cell number was observed with 30μM curcumin decreased cell 
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number by 45% ± 3%, followed by 30μM catechol with 43% ± 5%, compared with 
DMSO treated control. However a number of the treatments did cause an 
increase in cell viability, the greatest increases was observed with 1μM 
kuromanin increasing cell number by 40% ± 8% compared with DMSO treated 
control.  
The effect PMA/PHA stimulation had on cell viability was also investigated. 
The Jurkat cells were treated with the (poly)phenol compounds for 48h the same 
as before but with the addition of PMA/PHA at the 24 h time point. PMA is a 
phorbol ester and PHA a lectin which work together to activate T lymphocytes, 
through the protein kinase c (PKC) pathway, stimulating cytokine release 
particularly interleukin 2150. This would allow investigation into whether or not 
the (poly)phenols were having a protective effect, when the cells were stimulated, 
mimicking an immune response. 
Stimulating cytokine release with PMA/PHA resulted in a decrease in cell 
number ~45% reduction compared with DMSO treated cells (see fig. 3.1). In 
stimulated cells there was much more cell death with the polyphenol compounds 
than observed with unstimulated cells (Figure 3.2 and 3.5); again this was mainly 
observed with the higher dosage. 30μM catechol (75% ± 3%), 30μM 
phloroglucinol (70% ± 2%), 1 and 30μM 4’hydroxybenzoic acid (36% ± 11, 68 ± 
2%), 30μM protocatechuic acid (56% ± 4), and 1 and 30μM 3-O-methylquercetin 
(68% ± 7%, 49% ± 8%), these compounds had the greatest decrease in cell 
viability. Only a few compounds had an increase in cell number when combined 
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with the stimulation, this was 30µM punicalagin and 30µM feruloylglycine. 
Feruloylglycine was the only (poly)phenol that had an increase in cell number in 
both the unstimulated and stimulated cells. 
 
 
Figure 3.1 - Cell viability following the addition of PMA/PHA stimulation by 
Jurkat T-lymphocytes. Jurkat cell number following 48h incubation with the two 
concentrations of DMSO used, with and with PMA/PHA stimulation at the 24h 
time point. 0.02% is equivalent to 1μM (poly)phenol and 0.6% is equivalent to 
30μM (poly)phenol. The data is expressed as mean ± SEM (n=6). * Shows 
significance p<0.05 PMA/PHA compared with equivalent DMSO dose 0.02%, # 
significance p<0.05 PMA/PHA compared with equivalent DMSO dose 0.6%. 
 
 
3.3.4 Cytokine release by Jurkat T lymphocyte cells following (poly)phenol 
treatment. 
 
Following the 48h treatment with the 29 different polyphenol compounds, 
cytokines secreted by the Jurkat cells into the culture media were measured using 
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a multiplex assay. From the pre-screening panel conducted, 3 cytokines could be 
measured in the Jurkat samples (table 3.1), interleukin 2 (IL2) and interleukin 8 
(IL8) in unstimulated cells and in the stimulated cells tumour necrosis factor alpha 
(TNFα) could be measured. Data is presented as a percentage change from DMSO 
treated control, raw data can be obtained in appendix 2, fig 8.5 - 8.8. 
 
3.3.5 Decreases in cytokine release by unstimulated cells. 
 
 
A large proportion of the treatments had an anti-inflammatory effect 
lowering cytokine release of both IL2 and IL8 in the Jurkat T lymphocytes, 
following the 48h treatments. The greatest decreases in IL2 were observed with 
30μM curcumin (99%  ± 2%), resveratrol (70% ± 6%), and isorhamnetin (61% ± 5%) 
figure 3.3, which were significantly decreased compared with DMSO treated 
control. These decreases were also observed for IL8 with 30μM isorhamnetin, 
lowering IL8 by 66 ± 4%, 1μM EGCG, callisephin chloride, and punicalagin also 
significantly lowered IL8 in the Jurkat cells compared with DMSO treated control 
(Fig. 3.4). The lower dose of 1μM polyphenols, also had significant reductions in 
cytokine release. The greatest effects in lowering cytokine release were observed 
with 1μM isoferuloylglycine (68% ± 2%) and ferulic acid (63% ± 3%) for interleukin 
8. Some of these anti-inflammatory effects were shown to be dose dependent for 
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example 1μM resveratrol lowered IL2 by 42% ± 7% and IL8 by 32% ± 6%, and 
30μM resveratrol lowered IL2 70% ± 6% and IL8 by 55% ± 5%.  
 
 
3.3.6 Increases in cytokine release by unstimulated cells. 
 
 
 
For the majority of the treatments a decrease in cytokine release was 
observed. The most dramatic increase in cytokine release was observed with 
pyrogallol, a metabolite of green tea. Both 1 and 30 μM pyrogallol significantly 
increased cytokine release of IL8 by 334 ± 50% and 1722 ± 74% (respectively) 
compared with the DMSO treated control. The increases were so large data had 
to be represented in a separate graph, figure 3.5A/B.  
 
3.3.7 Decreases in cytokine release by stimulated cells. 
 
 
 
The Jurkat cells were incubated with the (poly)phenols for 48h, with 
PMA/PHA stimulation at the 24h time-point, this was to induce cytokine release. 
With the PMA/PHA stimulation, the increase in cytokine release allowed the 
measurement of TNFα. With the addition of the stimulation it was predicted that 
the (poly)phenols would have a protective effect against the induction of cytokine 
release. There were three main (poly)phenols that stood out as particularly good 
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at lowering cytokine release in the stimulated cells. 30μM curcumin lowered IL2 
by 98% ± 0.2%, IL8 by 62% ± 4%, and TNFα 98% ± 2%, 30μM quercetin lowered 
IL2 by 84% ± 3% and TNFα by 89% ± 3%, and 3-O-methylquercetin lowered IL2 by 
84% ± 2% and TNFα by 92% ± 1% (Figures 3.7, 3.8, 3.9) 
 
 
3.3.8 Increases in cytokine release by stimulated cells. 
 
 
There were more increases in cytokine release with the (poly)phenols in 
the PMA/PHA stimulated cells than with the unstimulated cells. The largest 
increase in cytokine release was observed with 1μM 3-O-methylquercetin, a 
metabolite of quercetin, increased IL2 by 459 ± 38% and IL8 by 160 ± 7% (Fig. 3.7 
and 3.8). Others that increased IL2 were 30μM 4’hydroxybenzoic acid (193 ± 11%) 
and 1μM feruloylglycine (169 ± 31%) (Fig. 3.7). 30μM Catechol and phloroglucinol 
increased IL8 release by 254% ± 11% and 219% ± 33% (respectively) (Fig. 3.8). 
Both 1 and 30μM punicalagin increased TNFα release by 239% ± 14% and 508% ± 
18% (respectively), along with 30μM phloroglucinol (264% ±2 9%) and 
4’hydroxybenzoic acid (2895 ± 13%) (Fig. 3.9). 
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Figure 3.5 – A) Changes in interleukin 2 (IL2) and interleukin 8 (IL8) release with 1 and 
30μM pyrogallol in unstimulated cells, expressed as percentage change from DMSO 
vehicle control.  B) Changes in interleukin 2 (IL2), interleukin 8 (IL8) and tumour necrosis 
factor alpha (TNFα) release with 1 and 30μM pyrogallol in stimulated cells, expressed as 
percentage change from DMSO vehicle control. Data expressed as mean ± SEM (n=6) , 
One-way ANOVA with Dunnett’s post hoc test * p < 0.05 (statistics performed in sets of 4 
treatments, see 2.2.9). 
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3.3.9 The effect of (poly)phenol mixtures on cytokine release. 
As part of a balanced diet these dietary (poly)phenols would be found in 
combination with one another. For a more physiological representation of how these 
compounds are acting, mixtures of four different (poly)phenols were put together 
and added to the Jurkat cells for 48 h. These compounds are arranged in molecular 
weight order, with phenolic acids on the left, polyphenols on the right.  Figure 10A, 
shows changes to IL2 release with individual and mixed compounds. In 4/6 cases the 
mixtures of compounds showed greater anti-inflammatory effects than the 
compound individually, a greater effect occurred when these compounds were 
mixed together. In particular a mixture of EGCG, punicalagin, kuromanin, and 
callistephin chloride had the greatest anti-inflammatory effect ~60% reduction of IL2 
compared with DMSO treated control.  
In figure 3.10B, 2 out of the 6 mixture combinations had greater anti-
inflammatory than the individual compounds for IL8. This greatest effect was 
observed with a mixture of dihydroferulic acid, ferulic acid, isoferulic acid and 
isoferulylglycine with a 43% ± 5% reduction in IL8.   
The (poly)phenol mixes were made up to a total polyphenol content of 1μM, 
therefore each individual compound was 0.25μM. Using the data already produced, 
individual comparison were made using data from the 1μM treatment, ideally for a 
true representation of the synergistic effect a treatment of 0.25μM would be 
required. A greater synergistic effect maybe observed if a true dose comparison was 
used. 
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Figure 3.10 –Mixtures of 4 (poly)phenols (total 1μM phenolic content – 0.25 μM 
individual) alongside the individual (poly)phenols making up that mixture. A) 
shows changes to IL2 release by unstimulated Jurkat cells compared with DMSO 
treated control and B) shows changes to IL8 release by unstimulated Jurkat cells 
compared with DMSO treated control. Graphs represent a percentage change from 
DMSO treated control (0%) in unstimulated cells. (Poly)phenols arrange in 
molecular weight order. [Mean ± SEM, n=6. One-way ANOVA with Dunnett’s post 
hoc test * p < 0.05 (statistics performed in sets of 4 treatments, see 2.2.9)]. 
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Mix 1 = Phloroglucinol (Phlor), catechol (Cat), protocatechuic acid (Proto) and 4-
hydroxybenzoic acid (4-HBA). Mix 2 = Hippuric acid (Hipp), 4’-hydroxyhippuric acid (4HHA), 
tyrosol (Try) and chlorogenic acid (Chlor). Mix 3 = 4'Hydroxyphenyllacetic acid (HPLA), 4’-
hydroxymandelic acid (4-HMA), 3-(3'-hydroxyphenyl)propionic acid (3HPPA) and 3-(4'-
hydroxyphenyl)lactic acid (3HPLA). Mix 4 = Caffeic acid (Caff), Ferulic acid (Fer), Isoferulic 
acid (IF) and isoferuloylglycine (IFG). Mix 5= Dihydroferulic acid (DHFA), feruloylglycine (FG), 
quercetin (Q) and 3-O-methylquercetin (3OMQ). Mix 6 = Epigallocatechin gallate (EGCG), 
kuromanin (Kur), callistephin chloride (Call), and punicalagin (Pun). 
 
 
 
3.5 DISCUSSION. 
 
This project analysed multiple (poly)phenols for their effects on cell viability 
and modulations to cytokine release in Jurkat T lymphocytes. 
 
3.5.1 The effect of polyphenol on cell viability in Jurkat T lymphocytes. 
 
Overall cell viability was not significantly affected by the (poly)ohenol 
treatments, only in certain cases modulations were observed using the higher dose. 
Kuromanin (also known as cyaniding 3-O-glucoside) in particular increased cell 
proliferation by 40% ± 8%, kuromanin is found in a number of fruits including 
pomegranates, grapes, and cranberries. Consumption of cranberry polyphenols 
showed an increase in T cell production in healthy patients following 10 weeks of 
consumption151. Some treatments also inhibited cell proliferation including curcumin 
and catechol with a reduction of ~40%. Previous studied have investigated the 
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effects polyphenols have on cell viability, particularly in cancer cell lines. Being able 
to inhibit cell proliferation specifically in cancer cells is a promising prospect in 
cancer treatment. However, the current literature can be confusing and have 
opposing positions regarding cell proliferation, depending on dose or cell type being 
used. For example, Roe et al 2010 found EGCG to inhibit cell proliferation and induce 
apoptosis in human ovarian cell line152. However, Yoo et al 2010 found EGCG to 
increase cell proliferation in the brain cell in mice153. Depending on the cell type in 
question, in vitro or in vivo these compounds have different effects on cell 
proliferation. The Jurkat cell used in this study are from a cancer cell line, therefore 
the effect on cell viability may differ in primary T lymphocytes than what was 
observed in vitro. Also, cell viability for the screening study use the MTS assay, which 
measures viability based on the reduction of tetrazolium dye by the enzyme 
NAD(P)H-dependent oxidoreductase. This assay depends on the cellular metabolic 
activity due to the NAD(P)H, for this study the assumption has been made that the 
(poly)phenols haven’t effected cellular metabolic activity but this may not be the 
case. (Poly)phenols may have increased or decreased cellular metabolic activity 
therefore cell viability would not correlate with metabolic activity. There were 29 
(poly)phenols, 2 treatments doses of 1 and 30µM, an n number of 6, and 
unstimulated and PMA stimulated conditions, this equated to almost 700 data points 
not including experimental controls. Therefore the MTS assay allows multiple 
analysis and higher throughput compared with the traditional Trypan blue exclusion 
method. For the purpose of this study investigating the overall effect these 
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compounds had in order to determine a suitable treatment dose for further 
investigations. Once the field has been narrowed done to a few (poly)phenols then 
more in-depth analysis will be performed on the effect on cell number. 
 
3.5.2 Effects of low concentrations of (poly)phenols on cytokine release by 
Jurkat T lymphocytes. 
 
1µM was considered to be a more physiologically relevant dose to the levels 
found in the blood plasma, these results were separated from the other data and 
both IL2 and IL8 were represented together. Figure 3.11 shows the majority of the 
(poly)phenol treatments showed a reduction in cytokine release of both IL2 and IL8. 
Only catechol increased cytokine release at this dose and pyrollalol (which isn’t 
shown in this graph, see figure 3.5). Ferulic acid and isoferuloyglycine were the most 
anti-inflammatory compounds with over 60% reduction in IL8 release; interestingly 
IL2 did not have the same effect, with a reduction of less than 20%. EGCG and 
punicalagin also had a stronger reduction with IL8 than IL2; the majority of the other 
treatments lowered IL2 and IL8 to the same level. This suggests that ferulic acid and 
isoferuloyglycine may be acting differently than the other compounds, having 
varying and more specific effects on cytokine release.  
There appeared to be greater anti-inflammatory effects with the more 
complex the polyphenols become. The smaller phenolic acids (left hand-side figure 
3.11) seemed to have less reduction, ever pro-inflammatory characteristics when 
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compared with the polyphenols (right hand-side figure 3.11). Polyphenols are more 
complex and have a greater number of functional groups or modifications to the 
basic phenol ring. These functional groups maybe having a greater influence on 
cytokine release and signalling pathways than the phenolic acids investigated. 
Further work to evaluate a structure function relationship between the complexity of 
the compound and cytokine release will be investigated (see section 3.5.5/3.5.6).  
 
Figure 3.11 – Cytokine release of IL2 and IL8 with 1μM (poly)phenols. Graph shows 
effect of 1μM (poly)phenols as a percentage change from DMSO control (0%) in 
unstimulated cells for interleukin 2 (blue) and interleukin 8 (purple). (Poly)phenols 
arrange in molecular weight order. [Mean ± SEM, n=6. One-way ANOVA with 
Dunnett’s post hoc test * p < 0.05 (statistics performed in sets of 4 treatments, see 2.2.9)]. 
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3.5.3 Parent compounds and their metabolites comparing cytokine release. 
 
From the screening process, the most anti-inflammatory (poly)phenols 
screened were curcumin, resveratrol, quercetin, and isorhamnetin. These 
(poly)phenols are the parent compounds found in foods they tend to have low 
bioavailability and are metabolised by colonic microflora and also in the tissues. The 
polyphenols can be glucuronidated, sulphated and broken down into smaller 
phenolic acids.   Figure 3.12, shows quercetin being broken down into phenolic acids 
some of which were included in the study, phloroglucinol, protocatechuic acid, and 
3-(3’-hydroxyphenyl)propionic acid. The allowed the investigation of whether or not 
the phenolic acids have the same effects on cytokine release as the parent 
compounds.  
 
 
 
 
Figure 3.12 – Phenolic acid breakdown products of quercetin154.   
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  Quercetin and its methylated form isorhamnetin had similar effects in 
unstimulated cells, lowering both IL2 and IL8 release. However they had dramatically 
different effects in stimulated cells, with quercetin increasing and isorhamnetin 
lowering cytokine release. The smaller phenolic acids phloroglucinol, protocatechuic 
acid, and 3-(3’-hydroxyphenyl)propionic acid all lowered cytokine release in both 
unstimulated and stimulated cells, but less than the parent compound quercetin 
(See figure 3.13). 
Figure 3.14, shows curcumin, the active principle of the dietary spice turmeric, 
lowered cytokine release of IL2 by 43% ± 14%, IL8 by 30% ± 7% and TNFα 21% ± 4% 
in stimulated cells. The curcumin metabolites ferulic acid and dihydroferulic acid 
retained the anti-inflammatory effects observed with curcumin. Curcumin had less of 
an effect in unstimulated cells, whereas ferulic acid lowered IL8 by -63% ± 3%. 
Curcumin blocks Ca2+ mobilization in T cells, preventing activation of nuclear factor 
of activated T cells (NFAT) and also nuclear factor kappaB (NF-κB) via T cell 
receptor155. This may explain the decreases in both IL2 (expression regulated by 
NFAT) and IL8 release (expression regulated by NF-κB)156. 
Resveratrol is found in red wine resulted in a decrease in IL2 release by         
42 ± 7% and IL8 by 31% ± 3% in unstimulated cells (Fig. 3.15 ). The smaller phenolic 
acids vanillic acid and caffeic had similar effects especially in stimulated cells. Other 
studies have shown resveratrol to lower inflammation, with 5µM resveratrol 
suppress NF-κB activation induced by TNFα in Jurkat cells157. 
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Figure 3.13 – Quercetin and metabolites effects on inflammation. Effect of 
(poly)phenols on cytokine release from Jurkat cells (expressed as percentage 
change from DMSO carrier cells). Cells were treated with 1μM parent compound 
quercetin or metabolites, for 48h with and without PMA/PHA added at the 24h 
time point. 
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Figure 3.14 – Curcumin and metabolites effects on inflammation. Effect of 
(poly)phenols on cytokine release from Jurkat cells (expressed as percentage 
change from DMSO carrier cells). Cells were treated with 1μM parent compound 
curcumin or metabolites, for 48h with and without PMA/PHA added at the 24h 
time point. 
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Figure 3.15 – Resveratrol and metabolites effects on inflammation. Effect of 
(poly)phenols on cytokine release from Jurkat cells (expressed as percentage 
change from DMSO carrier cells). Cells were treated with 1μM parent compound 
resveratrol or metabolites and wine phenolic, for 48h with and without PMA/PHA 
added at the 24h time point. 
 
 
3.5.4 Lowering of cytokine release was amplified by the mixtures of 
(poly)phenol. 
 
The mixtures of the polyphenol the compounds aren’t necessarily found in 
the same food source. Compounds EGCG, kuromanin, callistephin chloride, and 
punicalagin had the greatest decrease in IL2 cytokine release when mixed together 
146 
 
 
 
(Fig. 3.10A); they are found in foods such as green tea, raspberries, and 
pomegranates. Although they aren’t found in the same food source, they are most 
likely eaten together as part of a balanced diet. Other research has observed 
synergistic effects when investigating (poly)phenols, Shen et al 2010 measured lower 
levels of TNFα gene expression in LPS treated mice which had consumed green tea 
polyphenols and 1-α-OH- vitamin D3, than each consumed individually158. These 
synergistic effects will allow lower doses to be used, to gain equal or greater 
inflammatory responses. 
 
3.5.5 Investigating a structure function relationship within the (poly)phenols. 
 
 The (poly)phenols used had a variety of molecular weights and functional 
groups, analysis of the data suggested there may be a structure-function relationship, 
with the more complex polyphenols having greater anti-inflammatory effects that 
the smaller phenolic acids. To evaluate if the bioavailability of the compounds was 
affecting the viability of the cells, the lipopholicity (Kow) was plotted against cell 
viability for all compounds (Figure 3.16). This graph indicated there may be a 
relationship between the bioavailability of the compounds and the viability of the 
cells; however certain functional groups will have greater effects than others. 
Therefore dividing the data into chemical classes such as methoxy groups, nitrogen 
containing groups, would give better representation of the cell viability effects, 
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however there were not enough compounds in each category for this analysis to be 
done. 
 
 
Figure 3.16 – Graph shows the lipophilic values of the (poly)phenol compounds 
(Kow) plotted against the cell viability following 48h with a 1µM (poly)phenol 
treatment.  
 
 
3.5.6 Methoxy (poly)phenols  identified to have greater effects on cytokine 
release.   
 
Greater number of hydroxyl groups and their positioning, have been shown 
to alter (poly)phenol antioxidant capabilities159. Methoxy groups are functional 
groups made up of a methyl group bound to oxygen (OCH3) and are of particular 
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interest as they are lipophilic compounds and are more easily absorbed by the cell 
across the phospholipid bilayer. Therefore methyl groups tend to have a greater 
bioavailability, crossing the cell membrane easier and potential having a greater 
effect within the cell, but the drawback is they have decreased antioxidant capacity 
compared with similar non-methoxy compounds. Compare similar (poly)phenols 
with and without methoxy groups and evaluating the effects these compounds had 
on cytokine release.  
Figure 3.17B, unstimulated cells the non-methoxy polyphenol protocatechuic 
acid had little effect on cytokine release at either dose. However, vanillic acid and its 
methoxy counter-part lowered both IL2 and IL8 at both 1 and 30μM. For the lower 
dose this was a 45 ± 3% reduction for IL2 and 42 ± 6% reduction for IL8. With over a 
40% reduction in cytokine release shows that the methoxy group is playing an 
important role in driving the anti-inflammatory response either by its greater 
presents in the cell or through other signalling pathways. Further investigation would 
be required to determine the mechanisms behind these effects.  
Similar effects were observed with the stimulated cells (Fig. 3.17C), with the 
protocatechuic acid having a pro-inflammatory effect increasing IL2 by 56 ± 9%, IL8 
by 89 ± 9% and TNFα by 50 ± 7%. However, with vanillic acid an anti-inflammatory 
effect was observed lowering IL2 by -26 ± 3%, IL8 by -40 ± 5% and TNFα by -46 ± 5%. 
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Figure 3.17 – A) Structural differences between protocatechuic acid and vanillic 
acid. B) Effect 1 and 30μM protocatechuic acid and vanillic acid had on cytokine 
release from Jurkat cells (expressed as percentage change from DMSO). Cells were 
treated for 48h with (C) and without PMA/PHA (B) added at the 24h time point. 
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 Vanillic acid was not the only methoxy compounds in the (poly)phenols 
screening, however it was the only compound with a non-methoxy structural 
counter-part to compare the result. Other compounds included ferulic acid, isoferulic 
acid, dihydroferulic acid, feruloylglycine, isorhamnetin and curcumin. We observed 
large reduction in IL2 with the curcumin treatments; this may be due to curcumin 
containing two methoxy groups (Fig. 3.18). 
 
Figure 3.18 – Example of other methoxy (poly)phenols included in the screening, 
isorhamnetin (1 methoxy group) and curcumin (2 methoxy groups). 
 
 
 Pterostilbene, is structurally similar to resveratrol but has two hydroxyl 
groups replaced with methoxy groups. Studies have compared these two compounds 
and have shown that pterostilbene had a positive effect on cellular stress and 
inflammation compared with resveratrol, which had no effect; conducted in mice 
exhibiting signs of Alzheimer’s disease160.  
Isorhamnetin Curcumin 
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3.5.7 Identifying (poly)phenols that significantly lowering the cytokine release 
of IL2, IL8 and TNFα in stimulated and unstimulated cells.  
Graphs 3.19 and 3.20 summaries only those (poly)phenols that significantly reduced 
cytokine release in the Jurkat cells when compared with DMSO treated control. By 
just looking at the significant ones, the aim was to focus down on just a couple of 
polyphenols to be used for further investigation. From figure 3.19, 30µM curcumin is 
shown to be the most significant polyphenol reducing IL2 cytokine release in 
unstimulated cells, followed by 30µM resveratrol and isorhamnetin. 1µM EGCG, 
Callisephin chloride and punicalagin also have a greater reduction in IL8, along with 
the phenolic acid 1µM isorferuloylglycine. 
  Figure 3.20, shows just the significant (poly)phenols that significantly reduced 
cytokine release in PMA stimulated cells. Again curcumin seems the most significant 
reducing IL2, IL8 and TNFα, along with both 1 and 30µM isorhamnetin significantly 
lowering all three cytokines. 30µM quercetin and 3-O-methylquercetin also had large 
decrease in both IL2 and TNFα. Resveratrol lowered both IL2 and TNFα with both 
doses 1 and 30µM. It was therefore chosen that curcumin, isorhamnetin and 
resveratrol would be the three (poly)phenols chosen for further investigation using 
proteomic approaches. Based on their effecting in lowering cytokines IL2, IL8 and 
TNFα, with both doses and in unstimulated and stimulated cells. 
To evaluate the changes in cytokine release observed with curcumin, 
isorhamnetin and resveratrol, these compounds were analysed further by evaluating 
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the changes in protein expression via label free proteomics. This will allow network 
and pathway analysis to be conducted to evaluate how these compounds may be 
causing the reduction in cytokine release observed in the Jurkat T-lymphocytes.  
 
 
Figure 3.19 – Graph showing just the (poly)phenols that had a significant reduction 
in cytokine release of IL2 and IL8 with both 1 and 30μM (poly)phenols in 
unstimulated cells. Shown as a percentage change from DMSO control (0%) in 
unstimulated cells for interleukin 2 (blue) and interleukin 8 (purple). [Mean ± SEM, 
n=6. One-way ANOVA with Dunnett’s post hoc test p < 0.05 (statistics performed in 
sets of 4 treatments, see 2.2.9)]. 
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Figure 3.20 – Graph showing just the (poly)phenols that had a significant reduction 
in cytokine release of IL2, IL8 and TNFα with both 1 and 30μM (poly)phenols in 
stimulated cells. Shown as a percentage change from DMSO control (0%) in 
unstimulated cells for interleukin 2 (blue), interleukin 8 (purple) and TNFα in green. 
[Mean ± SEM, n=6. One-way ANOVA with Dunnett’s post hoc test p < 0.05 
(statistics performed in sets of 4 treatments, see 2.2.9)]. 
 
 
 
 
-120
-100
-80
-60
-40
-20
0
P
e
rc
e
n
ta
ge
 c
h
an
ge
 f
ro
m
 D
M
SO
 c
o
n
tr
o
l (
%
) 
Anti-inflammatory in stimulated cells 
IL2
IL8
TNFα 
154 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
 
 
 
 
PROTEOMIC ANALYSIS OF CHANGES IN PROTEIN 
CONCENTRATION FOLLOWING TREATMENT OF 
JURKAT T-LYMPHOCYTES WITH POLYPHENOLS. 
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4.1 INTRODUCTION. 
 
4.1.1 Proteomic analysis evaluating the changes to proteins following 
polyphenol treatments. 
 
Chapter 3 identified polyphenols that significantly lowered markers of 
inflammation in Jurkat T lymphocytes in both unstimulated and PMA/PHA stimulated 
cells. In particular curcumin, isorhamnetin and resveratrol were among the 
compounds that significantly lowered cytokine release by Jurkat T-lymphoctes when 
stimulated with PMA/PHA (Table 4.1). In this investigation it was chosen to first 
investigate the effects in unstimulated cells, to observe the effects the polyphenols 
were having in a non-stressed situation, both unstimulated and stimulated cells 
shown significant reductions in cytokine release. Further investigation would be 
interesting to evaluated the change in protein expression with the PMA/PHA 
stimulus but was not covered in this study. In order to determine the mechanisms 
regulating the changes in cytokine release, quantitative proteomics was used. 
Previous proteomic analyses have examined changes in protein levels due to 
polyphenol treatment in a variety of cell types, however, these studies have tended 
to focus on extremely high doses of polyphenols to induce protein changes. For 
example, Díaz-Chávez et al 2013 used 250μM resveratrol in MCF-7 breast cancer 
cells for 48 h, while investigating the chemopreventive and anti-tumour effect of 
resveratrol161. Achieving this level of resveratrol in vivo is unlikely, since in rats 
administered an oral dose of 5 mg/kg resveratrol, levels in the plasma were 1.5µM, 
including resveratrol-conjugates and metabolites at 4h after consumption, with only 
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0.08µM of this being free resveratrol162. Higher doses in the plasma can be achieved, 
for example mice given 75 mg/ml resveratrol, achieved a level of 28.4µM in the 
plasma following 2 weeks of oral administration163.  
Therefore, in this study a lower dose of 1μM was used, to treat the cells 
together with a higher dose either 10 or 30μM (depending on the polyphenol), to 
examine changes to proteins abundance. As previously shown (poly)phenols can 
alter cytokine release by cells at both low and high concentrations, see Table 4.1. 
Label free, shotgun proteomics were used to identify proteins that were significantly 
modulated following treatment with curcumin, isorhamnetin, or resveratrol. Label-
free proteomics does not use stable isotopes that chemically binds to the proteins, 
but quantifies proteins on precursor signal intensity. The advantages of label-free 
proteomics means the whole proteome can be analysed and multiple states 
compared (DMSO and 1 and 30µM polyphenols)164,165.  
Treatment IL2 IL8 TNFα 
-PMA +PMA -PMA +PMA -PMA +PMA 
Cur 1µM -2 ± 6% -43 ± 14% * -7 ± 5% -30 ± 7% * - -21 ± 4% 
30 µM -99 ± 1% * -98 ± 0% * 242 ± 25% * -62 ± 4% * - -98 ± 0% * 
Iso 1µM -36 ± 9% * -50 ± 4% * -47 ± 3% -58 ± 6% * - -63 ± 7% * 
30 µM -61 ± 5% * -58 ± 5 % *  -66 ± 4% -59 ± 8% * - -85 ± 3% * 
Res 1µM -42 ± 7% * -34 ± 10% * -32 ± 8% -15 ± 5% - -18 ± 2% * 
30 µM -70 ± 6% * -54 ± 9% * -55 ± 5% -4 ± 6% - -77 ± 3% * 
 
Table 4.1 - Cytokine release following 48h treatment with polyphenols curcumin 
(Cur), isorhamnetin (Iso) and resveratrol (Res) by Jurkat T-lymphocytes. Percentage 
change of interleukin 2 (IL2), interleukin 8 (IL8), and tumour necrosis factor alpha 
(TNFα) release with 1 and 30μM polyphenol treatment with (+PMA) and without (-
PMA) PMA/PHA stimulation. Significant changes from DMSO treated control are 
highlighted in bold (*). [Data sumerised from Chapter 3, figure 3.3 – 3.9, mean 
percentage change from DMSO treated control (0%) ± SEM, n=6] . 
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4.1.2 Proteomics analysis: Label-free mass spectrometry technique. 
  
Previous proteomics studies evaluating changes to protein abundance due to 
polyphenols have tended to use two-dimensional gel electrophoresis to separate 
proteins and identify changes to protein expression following treatments. This 
technique has its benefits, but is limited by reproducibility and detection of larger or 
less soluble proteins. More recently liquid-chromatography tandem mass 
spectrometry (LC-MS/MS) has become a more widely used technique, increasing 
protein detection rate and greater reproducibility compared with 2D gel 
electrophoresis. LC-MS/MS was used in this study to observe global changes in 
protein expression due to the (poly)phenol interventions in Jurkat T-lymphocytes. 
Using this quantitative proteomics technique, changes compared with DMSO treated 
control can be used to detect changes to protein expression following the 
polyphenol treatments. This allows detailed network analysis to be performed to 
understand the mechanisms responsible for the change in inflammatory markers.  
 
4.1.3 Protein network analysis. 
 
In order to understand the significance behind changes to protein expression 
following polyphenol treatment, software can be used to identify the processes and 
pathways modulated by the treatments. Being able to link individual changes in 
proteins with mechanisms and pathways, will give a greater insight into how 
(poly)phenols are modulating processes in the cells, in particular those proteins 
associated with inflammation. Databases such as STRING, DAVID bioinformatics and 
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software such as Ingenuity® were used to cluster the proteins into functional groups 
and investigate potential mechanisms linking the effects due to the (poly)phenol 
treatments. 
 
4.2 AIMS. 
 
Following the initial screening process describe in Chapter 3, which 
investigated the effect of (poly)phenols on inflammatory markers, potential 
candidates were identified for further investigation. The aim of this study was to use 
a proteomic approach to investigate the overall changes to the levels of individual 
protein components following treatment with these chosen polyphenols (curcumin, 
isorhamnetin and resveratrol). In addition network analysis was used to evaluate 
changes in signalling pathways and identify a potential mechanism of action for the 
polyphenols.  
 
4.3 RESULTS.  
 
4.3.1 Proteomics analysis: number of proteins modulated following 
polyphenols treatments for 48 h in Jurkat T lymphocytes. 
 
Previous work has shown that (poly)phenols can modulate cytokine release 
by Jurkat T lymphocytes, and this led to investigation of the effects of the 
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(poly)phenols on modulating all proteins using shotgun LC-MS/MS proteomics 
(Methods section 2.2.18). A low (1µM) and a high (10 or 30 µM) dose of curcumin, 
isorhamnetin, and resveratrol were used to identify numerous changes to proteins, 
to allow network analysis and evaluate changes to signalling pathways and processes.  
Table 4.2, shows the number of proteins that were significantly modulated 
following the treatments with polyphenols compared to the DMSO treated control. 
The lower dose of 1µM showed fewer proteins modulated when compared with the 
higher dose. The low dose isorhamnetin showed the greatest number of protein 
changes (83) and resveratrol showed the greatest number at the higher dose (434) (p 
< 0.05). Further analysis between the number of induced and repressed proteins, 
categorised into function groups can be found in Appendix 5. Proteins were initial 
screened based on a p-value < 0.05 to show significant difference from DMSO 
control, however due to low fold changes observed the q-value has also been shown 
but was not used as an initial screening factor. The q-value is a false discovery rate 
(FDR) adjusted p-value, a q-value of 0.05 implies that 5% of significant tests will 
result in false positives, whereas a p-value of 0.05 implies that 5% of all tests will 
result in false positives. Q-value are more restrictive but more accuracy when 
evaluating small fold changes and give more confidences that the changes we have 
observed are actually significant. 
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Table 4.2 - Number of proteins found to have significant fold changes following 48h 
treatment with the three different (poly)phenols curcumin, resveratrol and 
isorhamnetin at a low (1µM) and high(10 or 30µM) concentration compared with 
DMSO control. Identified by label-free shotgun proteomics, n = 5,  p < 0.05.  
 
 
 
 
 
4.3.2 Proteins modified by all three (poly)phenol treatments at either one or 
both doses. 
 
Identifying proteins that were common to all three compounds will give an 
insight into the main proteins vital for the mechanism of action of (poly)phenols. 
There were 21 proteins common to all of the treatments, mainly observed at the 
higher doses (table 4.3). These were then split into those that had either induced or 
repressed expression (top half of the table) and those that had opposing effects 
Number of proteins  significantly modulated by (poly)phenol treatments by 
Jurkat T-cells 
 All Reduced Increased 
1 μM curcumin 21 7 14 
1 μM resveratrol 42 2 40 
1 μM Isorhamnetin 83 54 29 
 
10 μM curcumin 187 134 53 
30 μM resveratrol  434 265 169 
 30 μM Isorhamnetin  403 227 176 
161 
 
 
 
(bottom half). 12/21 proteins had the same effects with 8 proteins being repressed 
and 4 induced. Proteins such as cyclin-dependent kinase 1 which is important for cell 
cycle regulation were down regulated with all three treatments. Importin subunit 
alpha-1 (KPNA2) was also down regulated; importins transport proteins from the 
cytoplasm to the nucleus via nuclear localisation signal (NLS). Up regulated proteins 
include glutathione reductase (GSR), a key enzyme in maintaining redox homeostasis 
and also D-3-phosphoglycerate dehydrogenase (PHGDH) an enzyme which catalyses 
the formation of NADPH, was also significantly upregulated with all  three 
treatments (p < 0.03). 30µM isorhamnetin significantly decreased 
hydroxymethylglutaryl-CoA synthase 1.91 fold and ribonucleoside-diphosphate 
reductase large subunit 1.3 fold with both p- and q- values < 0.05. Glutathione 
reductase was increased   1.2 fold and phosphoserine aminotransferase 1.3 fold 
increase with 30µM isorhamnetin with both p- and q- values < 0.05. 
For all proteins significantly modified by the treatments curcumin, isorhamnetin 
and resveratrol see Appendix 4. 
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Common proteins identified by LC-MSMS following treatment with curcumin, isorhamnetin and 
resveratrol, all significant altered compared with DMSO control. 
Protein name GENE 
accession  
Protein 
accession 
Fold change 
curcumin  
Fold change 
resveratrol  
Fold change 
Isorhamnetin  
Thymidylate synthase  TYMS P04818 1.2 (10µM) ↓ 1.2 (30µM) ↓ 1.1 (30µM) ↓ 
p-value / q-value  0.007 / 0.353 0.002 / 0.038 0.023 / 0.139 
Cyclin-dependent kinase 
1  
CDK1 P06493 1.1 (10µM) ↓ 1.1 (30µM) ↓ 1.1 (1µM) ↓ 
p-value / q-value 0.035 / 0.494 0.014 / 0.076 0.009 / 0.106 
Lamina-associated 
polypeptide 2 
TMPO P42166 1.1 (10µM) ↓ 1.1 (30µM) ↓ 1.1 (1µM) ↓ 
p-value / q-value 0.002 / 0.257 0.008 / 0.063 0.039 / 0.987 
Importin subunit alpha-1  KPNA2 P52292 1.1 (10µM) ↓ 1.3 (30µM) ↓ 1.2 (30µM) ↓ 
p-value / q-value 0.038 / 0.494 0.000 / 0.008 0.019 / 0.129 
40S ribosomal protein 
S18  
RPS18 P62269 1.1 (10µM) ↓ 1.1 (30µM) ↓ 1.1 (30µM) ↓ 
p-value / q-value 0.016 / 0.405 0.030 / 0.109 0.005 / 0.083 
Hydroxymethylglutaryl-
CoA synthase  
 
HMGCS1 Q01581 
 
1.3 (10µM) ↓ 1.2 (30µM) ↓ 
1.1 (1µM) ↓ 
1.91 (30µM) ↓ 
p-value / q-value  
0.001 / 0.232 0.000 / 0.003 
0.039 / 0.987 
0.000 / 0.000 
Guanine nucleotide-
binding protein subunit 
beta-2-like 1  
GNB2L1 P63244 1.1 (10µM) ↓ 1.1 (30µM) ↓ 1.1 (30µM) ↓ 
p-value / q-value 0.031 / 0.75 0.010 / 0.068 0.009 / 0.102 
RNA-binding protein with 
serine-rich domain 1  
  RNPS1 Q15287 1.1 (10µM) ↓ 1.1 (30µM) ↓ 1.1 (30µM) ↓ 
p-value / q-value 0.028 / 0.460 0.005 / 0.048 0.047 / 0.182 
Alanine--tRNA ligase AARS P49588 1.1 (10µM) ↑ 1.2 (30µM) ↑ 1.1 (30µM) ↑ 
p-value / q-value 0.026 / 0.443 0.000 / 0.003 0.018 / 0.125 
D-3-phosphoglycerate 
dehydrogenase  
PHGDH O43175 1.1 (10µM) ↑ 1.1 (30µM) ↑ 1.1 (30µM) ↑ 
p-value / q-value 0.006 / 0.353 0.002 / 0.038 0.027 / 0.144 
Glutathione reductase GSR P00390 1.2 (10µM) ↑ 1.1 (30µM) ↑ 1.2 (30µM) ↑ 
p-value / q-value 0.000 / 0.232 0.003 / 0.040 0.001 / 0.043 
Phosphoserine 
aminotransferase  
PSAT1 Q9Y617 1.1 (10µM) ↑ 1.2 (30µM) ↑ 1.3 (30µM) ↑ 
p-value / q-value 0.017 / 0.405 0.001 / 0.028 0.000 / 0.018 
      
Calnexin  CANX P27824 1.1 (10µM) ↑ 1.1 (30µM) ↑ 1.1(30µM) ↓ 
p-value / q-value 0.029 / 0.432 0.001 / 0.022 0.021 / 0.133 
Carnitine O-
palmitoyltransferase 1  
 
CPT1A P50416 
 
1.1 (10µM) ↑ 1.1 (30µM) ↑ 
1.1(1µM) ↓ 
1.1(30µM) ↓ 
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p-value / q-value  
0.004 / 0.353 0.003 / 0.040 
0.025 / 0.987 
0.002 / 0.053 
Ribonucleoside-
diphosphate reductase 
large subunit  
RRM1 P23921 1.1 (10µM) ↓ 1.2 (30µM) ↑ 1.3 (30µM) ↓ 
p-value / q-value 0.001 / 0.232 0.000 / 0.003 0.000 / 0.022 
U1 small nuclear 
ribonucleoprotein A  
SNRPA P09012 1.1 (10µM) ↓ 1.2 (30µM) ↓ 1.1 (30µM) ↑ 
p-value / q-value 0.022 / 0.428 0.006 / 0.052 0.007 / 0.090 
Ribonucleoside-
diphosphate reductase 
subunit M2  
RRM2 P31350 1.3 (10µM) ↓ 1.6 (30µM) ↓ 1.6 (30µM) ↑ 
p-value / q-value 0.002 / 0.257 0.000 / 0.003 0.018 / 0.125 
Ena/VASP-like protein  EVL Q9UI08 1.1 (10µM) ↓ 1.1 (30µM) ↓ 1.2 (30µM) ↑ 
p-value / q-value 0.025 / 0.433 0.020 / 0.091 0.014 / 0.121 
Lymphoid enhancer-
binding factor 1  
LEF1 Q9UJU2 1.1 (10µM) ↓ 1.3 (30µM) ↓ 1.1 (30µM) ↑ 
p-value / q-value 0.040 / 0.494 0.000 / 0.006 0.007 / 0.090 
Hematological and 
neurological expressed 1 
protein  
HN1 Q9UK76 1.09 (10µM) ↓ 1.3 (30µM) ↓ 1.08 (30µM) ↑ 
p-value / q-value 0.038 / 0.494 0.000 / 0.003 0.035 / 0.160 
 
Table 4.3 - Quantitative proteomics identified proteins which are common to all 
three (poly)phenol treatments curcumin, isorhamnetin and resveratrol, at either 
one or both treatment doses. Green highlights proteins repressed and blue 
proteins induced by (poly)phenol treatment. All proteins significant altered 
compared with DMSO control,  n = 5,  p < 0.05. 
 
 
4.3.3 Redox-active centres and oxidoreductase activity. 
 
In addition to the increase in glutathione reductase with all three treatments, 
other proteins containing redox-active centres were also significantly modulated by 
the polyphenol treatments (Table 4.4). Peroxiredoxin 1 was induced by both 
isorhamnetin (1.1 fold) and curcumin (1.1 fold), peroxiredoxin 6 was induced by 
isorhamnetin (1.1 fold) and repressed by resveratrol (1.1 fold). Isorhamnetin also 
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induced peroxiredoxin 2 (1.1 fold), thioredoxin (1.2 fold), and thioredoxin reductase 
1 (1.2 fold). All these proteins are responsible in maintain redox homeostasis in the 
cell, suggesting polyphenols may be modulating redox as part of their mechanism of 
action.  
 
 
Table 4.4 – Proteins containing redox-active centres or oxidoreductase activity that 
were significantly modified by the polyphenol treatments. 
Gene 
Name 
Full name Fold change Treatment p-value / 
q-value 
DHCR24 Delta(24)-sterol reductase  1.2 1µM Isorhamnetin 0.013/0.987 
DHCR24 Delta(24)-sterol reductase  1.2 30µM Isorhamnetin 0.004/0.0072 
DHRC7 7-dehydrocholesterol reductase  1.1 30µM Resveratrol 0.005/0.051 
DHRC8 7-dehydrocholesterol reductase  1.2 30µM Isorhamnetin 0.001/0.047 
MT-CO2 Cytochrome c oxidase subunit 2   1.1 30µM Isorhamnetin 0.001/0.038 
MT-ATP6 ATP synthase subunit a  1.1 1µM Isorhamnetin 0.037/0.987 
MT-ATP6 ATP synthase subunit a  1.1 30µM Isorhamnetin 0.004/0.072 
IMPDH2 Inosine-5'-monophosphate 
dehydrogenase 2 
 1.1 10µM Curcumin 0.022/0.428 
IMPDH2 Inosine-5'-monophosphate 
dehydrogenase 3 
 1.1 30µM Isorhamnetin 0.033/0.155 
NDUFA9 NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex 
subunit 9 
 1.2 30µM Resveratrol 0.036/0.120 
NDUFS3 NADH dehydrogenase 
[ubiquinone] iron-sulfur protein 
3 
 1.1 30µM Isorhamnetin 0.008/0.098 
NDUFS8 NADH dehydrogenase 
[ubiquinone] iron-sulfur protein 
8 
 1.1 30µM Isorhamnetin 0.046/0.182 
NDUFV2 NADH dehydrogenase 
[ubiquinone] flavoprotein 2  
 1.2 30µM Isorhamnetin 0.025/0.142 
MT-ND4 NADH-ubiquinone 
oxidoreductase chain 4 
 1.2 30µM Isorhamnetin 0.034/0.158 
ACAD9 Acyl-CoA dehydrogenase family 
member 9  
 1.1 30µM Resveratrol 0.033/0.115 
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ACADS Short-chain specific acyl-CoA 
dehydrogenase 
 1.1 30µM Resveratrol 0.027/0.103 
ACADM Medium-chain specific acyl-CoA 
dehydrogenase 
 1.1 30µM Resveratrol 0.007/0.055 
ACADM Medium-chain specific acyl-CoA 
dehydrogenase  
 1.2 30µM Isorhamnetin 0.003/0.071 
ACADVL Very long-chain specific acyl-CoA 
dehydrogenase  
 1.3 30µM Resveratrol 0.000/0.003 
ALDH18A1 Delta-1-pyrroline-5-carboxylate 
synthase 
 1.1 10µM Curcumin 0.001/0.238 
ALDH18A1 Delta-1-pyrroline-5-carboxylate 
synthase 
 1.1 30µM Resveratrol 0.004/0.048 
AKR1A1 Alcohol dehydrogenase 
[NADP(+)]  
 1.1 30µM Isorhamnetin 0.042/0.173 
AKR1B1 Aldose reductase  1.2 30µM Isorhamnetin 0.007/0.090 
AKR7A2 Aflatoxin B1 aldehyde reductase 
member 2  
 1.0 30µM Resveratrol 0.030/0.109 
AKR7A2 Aflatoxin B1 aldehyde reductase 
member 2  
 1.1 30µM Isorhamnetin 0.018/0.125 
TXNDC12 Thioredoxin domain-containing 
protein 12 
 1.1 30µM Isorhamnetin 0.022/0.133 
BLVRB Flavin reductase (NADPH)   1.2 30µM Resveratrol 0.018/0.089 
CAT Catalase   1.1 30µM Resveratrol 0.003/0.046 
COX4I1 Cytochrome c oxidase subunit 4 
isoform 1  
 1.1 10µM Curcumin 0.006/0.353 
COX4I1 Cytochrome c oxidase subunit 4 
isoform 1  
 1.1 30µM Resveratrol 0.049/0.138 
COX5B Cytochrome c oxidase subunit 5B   1.1 30µM Isorhamnetin 0.007/0.090 
GLYR1 Putative oxidoreductase GLYR1  1.1 1µM Isorhamnetin 0.026/0.987 
DHRS7 Dehydrogenase/reductase SDR 
family member 7  
 1.1 30µM Resveratrol 0.008/0.063 
FDFT1 Squalene synthase   1.2 30µM Resveratrol 0.001/0.022 
FDFT1 Squalene synthase   1.8 30µM Isorhamnetin 0.000/0.000 
FASN Fatty acid synthase  1.1 30µM Resveratrol 0.000/0.018 
FASN Fatty acid synthase  1.2 30µM Isorhamnetin 0.004/0.071 
G6PD Glucose-6-phosphate 1-
dehydrogenase 
 1.1 30µM Isorhamnetin 0.012/0.117 
GLUD1 Glutamate dehydrogenase 1 / 2, 
mitochondrial  
 1.1 30µM Isorhamnetin 0.021/0.133 
GSR Glutathione reductase  1.2 10µM Curcumin 0.000/0.232 
GSR Glutathione reductase  1.1 30µM Resveratrol 0.003/0.040 
GSR Glutathione reductase  1.2 30µM Isorhamnetin 0.001/0.043 
GAPDH Glyceraldehyde-3-phosphate 
dehydrogenase 
 1.0 30µM Resveratrol 0.011/0.069 
HADH Hydroxyacyl-coenzyme A 
dehydrogenase  
 1.1 30µM Resveratrol 0.042/0.127 
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HADHA Trifunctional enzyme subunit 
alpha, mitochondrial 
 1.1 30µM Isorhamnetin 0.028/0.145 
HSD17B4 Peroxisomal multifunctional 
enzyme type 2  
 1.1 30µM Resveratrol 0.009/0.064 
HSD17B4 Peroxisomal multifunctional 
enzyme type 2  
 1.1 30µM Isorhamnetin 0.010/0.110 
IDH1 Isocitrate dehydrogenase [NADP] 
cytoplasmic  
 1.5 1µM Curcumin 0.016/0.997 
IDH2 Isocitrate dehydrogenase 
[NADP], mitochondrial  
 1.1 30µM Isorhamnetin 0.022/0.133 
IDH3B Isocitrate dehydrogenase [NAD] 
subunit beta, mitochondrial  
 1.1 30µM Isorhamnetin 0.009/0.182 
IVD Isovaleryl-CoA dehydrogenase, 
mitochondria 
 1.2 30µM Resveratrol 0.050/0.139 
LDHB L-lactate dehydrogenase B chain   1.1 30µM Resveratrol 0.013/0.075 
LDHB L-lactate dehydrogenase B chain   1.2 30µM Isorhamnetin 0.029/0.146 
MDH1 Malate dehydrogenase, 
cytoplasmic  
 1.1 30µM Isorhamnetin 0.018/0.125 
ME2 NAD-dependent malic enzyme, 
mitochondrial 
 1.1 10µM Curcumin 0.030/0.470 
ME2 NAD-dependent malic enzyme, 
mitochondrial 
 1.1 30µM Resveratrol 0.037/0.122 
MTHFD2 Bifunctional 
methylenetetrahydrofolate 
dehydrogenase/cyclohydrolase, 
mitochondrial  
 1.2 30µM Resveratrol 0.022/0.097 
OGDH 2-oxoglutarate dehydrogenase, 
mitochondrial 
 1.2 1µM Isorhamnetin 0.014/0.987 
OGDH 2-oxoglutarate dehydrogenase, 
mitochondrial 
 1.2 30µM Resveratrol 0.026/0.102 
PRDX1 Peroxiredoxin-1  1.1 10µM Curcumin 0.016/0.405 
PRDX1 Peroxiredoxin-1  1.1 30µM Isorhamnetin 0.041/0.171 
PRDX2 Peroxiredoxin-2  1.1 30µM Isorhamnetin 0.024/0.140 
PRDX6 Peroxiredoxin-6  1.1 30µM Resveratrol 0.006/0.053 
PRDX6 Peroxiredoxin-6  1.1 30µM Isorhamnetin 0.009/0.127 
PGD 6-phosphogluconate 
dehydrogenase, decarboxylating  
 1.1 30µM Isorhamnetin 0.016/0.125 
PHGDH D-3-phosphoglycerate 
dehydrogenase 
 1.1 10µM Curcumin 0.006/0.353 
PHGDH D-3-phosphoglycerate 
dehydrogenase 
 1.1 30µM Resveratrol 0.002/0.038 
PHGDH D-3-phosphoglycerate 
dehydrogenase 
 1.1 30µM Isorhamnetin 0.016/0.125 
PCYOX1 Prenylcysteine oxidase 1  1.1 10µM Curcumin 0.012/0.386 
PCYOX1 Prenylcysteine oxidase 1  1.3 30µM Resveratrol 0.001/0.025 
PCYOX1L Prenylcysteine oxidase-like   1.4 30µM Resveratrol 0.013/0.074 
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P4HA1 Prolyl 4-hydroxylase subunit 
alpha-1 
 1.2 30µM Resveratrol 0.041/0.125 
P4HA1 Prolyl 4-hydroxylase subunit 
alpha-1 
 1.3 30µM Isorhamnetin 0.004/0.071 
PDHA1 Pyruvate dehydrogenase E1 
component subunit alpha, 
somatic form, mitochondrial  
 1.1 30µM Resveratrol 0.030/0.109 
RDH11 Retinol dehydrogenase 11   1.2 30µM Resveratrol 0.026/0.102 
RRM1 Ribonucleoside-diphosphate 
reductase large subunit  
 1.1 10µM Curcumin 0.001/0.232 
RRM1 Ribonucleoside-diphosphate 
reductase large subunit  
 1.2 30µM Resveratrol 0.000/0.003 
RRM1 Ribonucleoside-diphosphate 
reductase large subunit  
 1.3 30µM Isorhamnetin 0.000/0.022 
RRM2 Ribonucleoside-diphosphate 
reductase subunit M2 
 1.3 10µM Curcumin 0.002/0.257 
RRM2 Ribonucleoside-diphosphate 
reductase subunit M2 
 1.6 30µM Resveratrol 0.000/0.003 
RRM2 Ribonucleoside-diphosphate 
reductase subunit M2 
 1.2 30µM Isorhamnetin 0.018/0.125 
SCCPDH Saccharopine dehydrogenase-like 
oxidoreductase 
 1.2 30µM Resveratrol 0.006/0.051 
SORD Sorbitol dehydrogenase  1.2 1µM Curcumin 0.040/0.997 
SDHA Succinate dehydrogenase 
[ubiquinone] flavoprotein 
subunit, mitochondrial  
 1.1 30µM Resveratrol 0.006/0.054 
TXNDC12 Thioredoxin domain-containing 
protein 12 
 1.1 30µM Isorhamnetin 0.022/0.122 
TXNRD1 Thioredoxin reductase 1, 
cytoplasmic 
 1.1 1µM Isorhamnetin 0.028/0.987 
TXNRD1 Thioredoxin reductase 1, 
cytoplasmic 
 1.2 30µM Isorhamnetin 0.000/0.022 
UQCRFS1 Cytochrome b-c1 complex 
subunit Rieske, mitochondrial  
 1.1 30µM Isorhamnetin 0.030/0.148 
 
Table 4.4 - Redox-related proteins (classified by David Bioinformatics) identified by 
LC-MS/MS proteomics. Significant fold changes occurring following treatment with 
the polyphenols compared with DMSO treated control. (n = 5, p < 0.05). 
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4.3.4 Oxidative phosphorylation 
 
Other pathways modified by the treatments were oxidative phosphorylation, 
with 27 proteins being identified. ATPase synthase, cytochome c oxidase, NADH 
dehydrogenase, and cytochrome b-c1 complex subunits are examples of some of the 
proteins significantly repressed by the treatments (p < 0.05) (see Appendix 4).   
 
 
 
4.3.5 Ribosome modification by the three polyphenol treatments. 
 
A number of ribosomal proteins were identified by proteomics screening with 
all three polyphenol treatments with both the 60S and 40S being repressed (table 
4.5). Ribosomal proteins catalyse the synthesis of new proteins, suggesting a down 
regulation of protein synthesis. Interestingly, all three treatments had the same 
effect lowering the ribosomal proteins (unlike the proteins identified with redox 
activity, in which some compounds had opposing effects), suggesting that effects in 
protein synthesis may be a general polyphenol effect, whereas redox-related 
changes were more compound specific. 
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Table 4.5 – Significant modulation to ribosomal proteins with all three polyphenol 
treatments. 
 
Gene 
name 
 
 
Full name 
 
Fold change 
 
Treatment 
p-value /  
q-value 
RPL3 60S ribosomal protein L3   1.1 30µM Isorhamnetin 0.012 / 0.118 
RPL4 60S ribosomal protein L4   1.0 10µM Curcumin 0.009 / 0.365 
RPL4 60S ribosomal protein L4   1.1 30µM Isorhamnetin 0.001 / 0.047 
RPL6 60S ribosomal protein L6   1.1 30µM Isorhamnetin 0.017 / 0.125 
RPL7 60S ribosomal protein L7   1.0 10µM Curcumin 0.017/0.405 
RPL7 60S ribosomal protein L7   1.0 30µM Resveratrol 0.031/ 0.110 
RPL7A 60S ribosomal protein L7a   1.1 30µM Isorhamnetin 0.050 / 0.186 
RPL9 60S ribosomal protein L9   1.1 1µM Isorhamnetin 0.046 / 0.987 
RPL10 60S ribosomal protein L10   1.1 30µM Resveratrol 0.044 / 0.130 
RPL10A 60S ribosomal protein L10a   1.1 30µM Resveratrol 0.014 / 0.076 
RPL11 60S ribosomal protein L11  1.1 30µM Isorhamnetin 0.032 / 0.153 
RPL12 60S ribosomal protein L12   1.1 10µM Curcumin 0.007 / 0.353 
RPL12 60S ribosomal protein L12   1.1 30µM Resveratrol 0.009 / 0.063 
RPL13 60S ribosomal protein L13   1.0 10µM Curcumin 0.039 / 0.494 
RPL13 60S ribosomal protein L13   1.1 30µM Resveratrol 0.004 / 0.048 
RPL13A 60S ribosomal protein L13a   1.1 30µM Isorhamnetin 0.012 / 0.112 
RPL14 60S ribosomal protein L14   1.2 30µM Isorhamnetin 0.018 / 0.125 
RPL15 60S ribosomal protein L15  1.1 30µM Isorhamnetin 0.001 / 0.051 
RPL17 60S ribosomal protein L17   1.1 30µM Isorhamnetin 0.028 / 0.146 
RPL18A 60S ribosomal protein L18a   1.1 30µM Isorhamnetin 0.047 / 0.184 
RPL24 60S ribosomal protein L24   1.1 30µM Isorhamnetin 0.049 / 0.186 
RPL27 60S ribosomal protein L27   1.1 30µM Isorhamnetin 0.022 / 0.186 
RPL27A 60S ribosomal protein L27a   1.1 30µM Isorhamnetin 0.013 / 0.120 
RPL28 60S ribosomal protein L28   1.1 30µM Resveratrol 0.025 / 0.101 
RPL30 60S ribosomal protein L30   1.1 30µM Isorhamnetin 0.014 / 0.120 
RPL36AL 60S ribosomal protein L36a-
like  
 1.1 30µM Resveratrol 0.033/0.114 
RPL38 60S ribosomal protein L38   1.1 30µM Isorhamnetin 0.035 / 0.186 
RPLP1 60S acidic ribosomal 
protein P1  
 1.1 30µM Resveratrol 0.005/0.048 
RPSA 40S ribosomal protein SA   1.1 30µM Resveratrol 0.005/0.048 
RPS2 40S ribosomal protein S2   1.1 30µM Resveratrol 0.045/0.131 
RPS21 40S ribosomal protein S21   1.1 30µM Resveratrol 0.026/0.102 
RPS23 40S ribosomal protein S23   1.0 30µM Resveratrol 0.026/0.102 
RPS23 40S ribosomal protein S23  1.1 30µM Isorhamnetin 0.002 / 0.058 
RPS27 40S ribosomal protein S27   1.1 30µM Isorhamnetin 0.023 / 0.128 
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RPS27A Ubiquitin-40S ribosomal 
protein S27a  
 1.1 30µM Isorhamnetin 0.010 / 0.107 
RPS3 40S ribosomal protein S3   1.1 30µM Isorhamnetin 0.010 / 0.109 
RPS3A 40S ribosomal protein S3a   1.1 30µM Resveratrol 0.006/0.054 
RPS3A 40S ribosomal protein S3a   1.1 30µM Isorhamnetin 0.019 / 0.128 
RPS5 40S ribosomal protein S5   1.1 30µM Isorhamnetin 0.032 / 0.153 
RPS6 40S ribosomal protein S6   1.1 30µM Isorhamnetin 0.003 / 0.192 
RPS8 40S ribosomal protein S8   1.1 30µM Isorhamnetin 0.003 / 0.071 
RPS9 40S ribosomal protein S9  1.0 30µM Resveratrol 0.049/0.138 
RPS9 40S ribosomal protein S9  1.1 1µM Isorhamnetin 0.004 / 0.987 
RPS9 40S ribosomal protein S9   1.2 30µM Isorhamnetin 0.001 / 0.038 
RPS28 40S ribosomal protein S28   1.1 1uM Isorhamnetin 0.030 / 0.987 
 
Ribosomal proteins (classified by David Bioinformatics) identified by proteomics. 
Significant fold changes occurring following treatment with the polyphenols 
compared with DMSO treated control. (n = 5, p < 0.05) 
 
 
4.3.6 RESVERATROL: proteins modulated following treatment with 
resveratrol.  
 
Progenesis analysis of the proteomics data identified 21 significant changes 
to protein abundance (7 proteins repressed and 14 induced), following treatment 
with 1μM resveratrol (see appendix 4 or figure 4.2). Midasin, a nuclear chaperone 
showed the greatest induction with a fold change of 2.7 (p < 0.04). Midasin is 
important for the maturation and nuclear export of pre-60S ribosome subunits. 
Other proteins of interest include ADRBK1 (GRK2), a G-protein coupled receptor 
kinase, which is activated by PKA and targets beta adrenergic receptor. GRK2 
expression is dependent on NF-κB transcriptional activity and has been shown to be 
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elevated in inflammation 166 . GRK2 was significantly repressed with the 1µM 
resveratrol treatment, but also with 30µM resveratrol and 10µM curcumin. Another 
protein of interest was transketolase, an enzyme part of the pentose phosphate 
pathway, which has also been linked to antioxidant defence pathways167, which was 
induced with all 1µM treatments (1.1 fold) and repressed with the 30µM treatment 
(1.1 fold). Along with these proteins there was a significant increase in 
serine/threonine-protein phosphatase PGAM5 by 1.3 fold. PGAM5 is a substrate for 
a KEAP1-dependent ubiquitin ligase complex, contributing to the repression of Nrf2 
gene expression168, and also acts as a mediator for programmed necrosis169. 
434 proteins were modulated following treatment with the higher dose of 
resveratrol, 265 proteins were significantly repressed and 169 induced. Four proteins 
also showed the increases with 1μM resveratrol treatment, these included beta-
adrenergic receptor kinase 1 (1.3 fold), Transketolase (1.1 fold), Ran GTPase-
activating protein 1 (1.1 fold), and annexin A7 (1.1 fold). Annexin A7 regulates 
calcium and phospholipid binding and also involved in exocytosis. This protein is 
thought to have a role in cancer, since in some tissue type annexin A7 acts as a 
tumour suppressor such as prostate cancer but in other tissues such as the liver and 
breast cancer, annexin A7 promotes tumour development170.      
Ingenuity software was used to identify proteins that were connected to each 
other, linking mechanisms and pathways altered by the 30µM resveratrol treatment. 
Figure 4.1, shows one of network generated from the software, identifying two 
clusters of up-regulated proteins (red) feeding into NF-κB complex and down-
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regulated proteins forming around alpha- and beta- tubulin. Another network that 
was identified as being significantly modified was phospholipase c signalling (Fig. 4.2). 
Phospholipase c signalling is important for hydrolysing 
phosphatidylinositoldiphosphate into diacylglycerol and inositoltriphosphate, leading 
to the release of intracellular calcium. And a number of proteins were down-
regulated in this signalling pathway, including integrin beta 1, RhoGEF and GRB2.  
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Figure 4.1 – Network analysis of proteins modulated following treatment of 30µM 
resveratrol by Jurkat T-lymphocytes. Ingenuity network analysis obtained using 
30µM resveratrol data set. Red = induced proteins, green = repressed proteins, 
solid lines = direct interactions, and dashed lines = indirect interactions (full key 
details can be found in Appendix 5). 
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Figure 4.2 - Ingenuity network analysis obtained using the 30µM resveratrol data 
set, identified phospholipase c signalling as a modified pathway. Red = induced 
proteins, green = repressed proteins, solid lines = direct interactions, and dashed 
lines = indirect interactions (full key details can be found in Appendix 5). 
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4.3.7 CURCUMIN: proteins modulated following treatment with curcumin.  
 
 
 Following treatment of cells with the low dose of curcumin, 42 proteins were 
significant modulated, with 2 proteins significantly repressed and 40 induced. 
Unconventional myosin-la (MYO1A) had the greatest fold change with a 3.6 
reduction (p < 0.05). This protein functions as an actin-based molecular motor 
directing the movement of organelles along the actin filaments.  
 
10μM curcumin significantly modulated changes in 187 proteins, 53 of these 
were induced and 134 repressed (Table 4.2, Appendix 4). None of these proteins 
were reproduced from the treatment with 1μM curcumin. However, beta-adrenergic 
receptor kinase 1 was supressed with 10μM curcumin and this protein was also 
suppressed with 1 and 30μM resveratrol.  
 Beta-adrenergic receptor kinase 1 (ADRBK1 or GRK2) was suppressed with 10μM 
curcumin (1.2 fold), and 1μM (1.2 fold) and 30μM (1.3 fold) resveratrol (p < 0.05). 
Ingenuity analysis also identified NF-κB as being associated with network modulation 
following 10µM curcumin treatment (Figure 4.3). This network centres around NF-κB 
and also the 20S proteasome, similar to resveratrol being clustered into induced and 
repressed groups.  
 As mentioned previously, the glutathione pathway was modulated by all three 
treatments. Glutathione reductase feeds directly into the NF-κB pathway showing in 
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the network analysis (Fig 4.1). For curcumin in particular, other redox proteins were 
identified including glutathione S-transferase P that was induced 1.1 fold (p < 0.02). 
Peroxiredoxin-1, another redox protein was induced 1.1 fold (p < 0.02). Ingenuity 
analysis also highlighted the Nrf2 pathway to be modulated following the curcumin 
treatment (Figure 4.4).  
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Figure 4.3 – network analysis of proteins modulated following 10µM treatment of 
curcumin. Ingenuity network analysis obtained using the 10µM curcumin data set. 
Red = induced proteins, green = repressed proteins, solid lines = direct interactions, 
and dashed lines = indirect interactions (full key details can be found in Appendix 
5). 
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Figure 4.4 – network analysis of proteins modulated following 10µM treatment of 
curcumin Ingenuity network analysis obtained using the 10µM curcumin data set 
identified Nrf2 signalling as a modified pathway. Red = induced proteins, green = 
repressed proteins, solid lines = direct interactions, and dashed lines = indirect 
interactions (full key details and zoomed in version can be found in Appendix 5). 
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4.3.8 ISORHAMNETIN: proteins modulated following treatment with 
isorhamnetin.  
 
 
83 proteins were modulated by the low dose of isorhamnetin, with 54 
repressed and 29 induced. Reactive oxygen species modulator 1 (ROMO) was 
repressed by isorhamnetin (1.1 fold); ROMO induces ROS production, which is 
important for cell proliferation but is thought to play a role in oxidative DNA damage. 
There was also a reduction in Glutathione S-transferase Mu 3 (GSTM3) which was 
also observed with the higher dose of isorhamnetin, this enzyme is involved in 
detoxification, but may also play a role in cell signalling171.  
 
Following treatment with 30µM isorhamnetin, 403 proteins were significantly 
modulated, 227 repressed and 176 induced (table 4.2, appendix 4). There were a 
number of proteins dose dependently affected, with 35 appearing in both the 1 and 
30µM treatment. This included proteins such as hydroxymethylglutaryl-CoA synthase 
(HMCS2) which decreased from 1.1 fold with 1µM to 1.9 fold with 30µM 
isorhamnetin (p < 0.04). HMCS2 is an enzyme with combines acetyl-CoA with 
acetoacetyl-CoA to form HMG-CoA, an important transferase for cholesterol 
biosynthesis.  Like the other two polyphenols network analysis isorhamnetin showed 
proteins clustering around the NF-κB transcription factor (Figure 4.5), showing 
modulation to the NF-κB signalling pathway to be a common mechanism for all three 
treatments. There was no direct interaction linked between all the polyphenols 
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treatments, however glutathione reductase was shown to have indirect links to NF-
κB between all the treatments. Suggesting redox regulation may be central to the 
changes in NF-κB signalling.  
A number of other redox proteins were also modulated following 
isorhamnetin treatment included thioredoxin (1.2 fold), thioredoxin reductase 1 (1.2 
fold), peroxiredoxin 1 (1.1 fold), peroxiredoxin 2 (1.1 fold), and peroxiredoxin 6 (1.1 
fold) (p < 0.05). Ingenuity analysis also identified the Nrf2 signalling pathway to be 
modulated, similar to that of curcumin (Figure 4.6). Thus it appears that all three 
polyphenol treatments were modulating redox proteins and for curcumin and 
isorhamnetin the Nrf2 signalling pathway appears to be central to that.  
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Figure 4.5 – network analysis of proteins modulated following 30µM treatment of 
isorhamnetin. Ingenuity network analysis obtained using the 30µM isorhamnetin 
data set. Red = induced proteins, green = repressed proteins, solid lines = direct 
interactions, and dashed lines = indirect interactions (full key details can be found 
in Appendix 5). 
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Figure 4.6 – network analysis of proteins modulated following 30µM treatment of 
isorhamentin Ingenuity network analysis using 30µM isorhamnetin data set, 
identifying Nrf2 signalling as a modified pathway. Red = induced proteins, green = 
repressed proteins, solid lines = direct interactions, and dashed lines = indirect 
interactions (full key details and zoomed in version can be found in Appendix 5). 
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4.5 DISCUSSION. 
 
From the screening study conducted in Chapter 3, investigating the anti-
inflammatory effects of numerous (poly)phenols, curcumin, isorhamnetin and 
resveratrol were identified as having the greatest effects modulating inflammatory 
markers. These compounds were chosen to investigate further using a proteomic 
approach, treated the Jurkat cells with a low dose (1µM) and a high (10 or 30µM) of 
the chosen (poly)phenols (10µM was used for the curcumin treatment, as 30µM 
caused significant cell death in the Jurkat cells). By using quantitative proteomics, a 
number of proteins were found to be significantly modulated following treatments 
with curcumin, isorhamnetin and resveratrol. Analysis was conducted to identify 
common proteins and pathways between all the polyphenol treatments. Some of the 
pathways modulated by the treatments included glutathione homeostasis, oxidative 
phosphorylation and ribosomal protein expression.  
 
 
 
4.5.1 Network analysis of polyphenol proteomics identified NF-κB to be a 
central modulated factor. 
 
 
Though Ingenuity network analysis, the transcription factor NF-κB was found 
to be central to all three polyphenol treatments. NF-κB is a well-defined transcription 
factor for regulating the expression of cytokines, in Jurkat cells NF-κB along with AP-1 
are mainly responsible for T-cell activation and the induction of pro-inflammatory 
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cytokines such as TNFα and IL6172. Other proteins were also identified that interact 
with NF-κB, such as GRK2. GRK2 is a G-coupled receptor kinase central in signal 
transduction cascades; its roles include endocytosis and chemokine signalling, 
modulating inflammation through the NF-κB pathway (Fig. 4.7). GRK2 was repressed 
by 1 and 30µM resveratrol and 10µM curcumin treatments, which would result in an 
inhibition of inflammation through NF-κB. GRK2 is upregulated in patients with 
chronic heart failure173, 174, along with elevated levels of GRK2 detected in the 
lymphocytes of patients suffering with heart failure175.  Research is being conducted 
with GRK2 inhibitors as potential therapeutic treatments176. 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 – GRK2 signalling in response to ROS leading to activation of NF-κB, 
leading to the induction of inflammatory markers. (Modified from Corbi, G et al 
2013177). 
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4.5.2 Unconventional Myosin -1a reduction with curcumin. 
 
 
Unconventional myosin-la (MYO1A) had the greatest fold change out of all 
the three treatments with a 3.6 reduction (p < 0.05). This protein functions as an 
actin-based molecular motor directing the movement of organelles along the actin 
filaments. However there isn’t much literature regarding the role of unconventional 
myosin and T-lymphocytes, abundance of MYO1A has been demonstrated in CD4 
and CD8 T-cells, and has been shown to play a role in nuclear transcription, 
exocytosis, and vesicular trafficking178. Other unconventional myosin’s have been 
show to participate in immune cells functions such as positioning of receptors on the 
membrane, activation following binding with MHC molecules, directing the secretion 
of molecules via vesicles (Figure 4.8). MYO1C is involved in transcriptional regulation, 
it has been shown to associate with RNA polymerase I holoenzyme and ribosomal 
genes179. It is unclear what the role is of MYO1A in Jurkat cells, but possible lines of 
investigation is the reduction in MYO1A is associated with the reduction of cytokine 
release of IL2 observed with the curcumin, either through the release or possible 
transcriptional regulation.   
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Figure 4.8 – Roles of myosins in immune cells, functions and interactions with 
structures (Maravillas-Montero et al, 2011)178.   
 
 
 
4.5.3 Polyphenols and oxidative phosphorylation. 
 
 
As noted previously, a number of oxidative phosphorylation proteins were 
modulated, including ATPase synthase, cytochome c oxidase, NADH dehydrogenase, 
and cytochrome b-c1 complex subunits.  A recent paper by van Dijk S J et al180 
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showed the expression of genes involved in oxidative phosphorylation were down-
regulated in subjects with a Mediterranean diet (low in saturated fats and high in 
fruits and vegetables) and for some of the proteins identified in this study, the gene 
expression was also found to be altered in the Mediterranean diet study. These 
proteins included V-type proton ATPase subunit H, and subunit A, NADH 
dehydrogenase [ubiquinone] iron-sulfur protein 8, cytochrome c oxidase subunit 4 
isoform 1, and cytochrome b-c1 complex subunit 7. This shows the potential for 
these dietary polyphenols to lower levels of oxidative phosphorylation.  
 
 
4.5.4 Modulation of redox homeostasis with the polyphenol treatments.   
 
Glutathione reductase was a common protein modulated by all three 
polyphenol treatments and is an important regulator of redox homeostasis in the cell.  
Glutathione reductase maintains the levels of reduced glutathione in the cytosol and 
was induced by the treatments. Glutathione reductase catalyses the reduction of 
oxidised glutathione (GSSG) to reduced glutathione (GSH), and is therefore vital in 
maintaining the redox homeostasis of the cell, responding to oxidative stress. 
Previous research has shown increases in glutathione reductase with polyphenols, 
for example mice fed a diet containing 2% (v/v) curcumin for 30 days showed 
increased glutathione reductase activity by 179% in the liver and 134% in the 
kidneys181, along with increased activity in other redox-related proteins including 
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glutathione peroxidase, glucose-6-phosphate dehydrogenase and catalase. 
Proteomics analysis also identified some of these redox-related proteins in this study.  
These redox-related proteins identified including glutathione transferases, 
thioredoxin, and peroxiredoxins. Network analysis revealed a number of proteins 
involved in glutathione metabolism pathway (Table 4.6). Isorhamnetin had the 
greatest effect on this pathway compared with the other treatments, with at least 6 
other redox proteins being identified (Figure 4.8, Table 4.6). This included 6-
phosphogluconate dehydrogenase (PGD) and Glucose-6-phosphate 1-dehydrogenase 
(G6PD) which were both increased by 30µM isorhamnetin and have reducing 
capabilities to convert NADP+ to NADPH. For glutathione reductase to be able to 
convert GSSG to GSH, NADPH is required for this reaction.  Isocitrate dehydrogenase 
also converts NADP+ to NADPH; this enzyme was increased by the 1µM curcumin 
treatment although a reduction was observed with the 30µM isorhamnetin 
treatment. This may be explained by the fact that isorhamnetin has already 
increased NADPH production via PGD or G6PD, therefore IDH1 was not stimulated, 
or another possibility may be the location of these enzymes. IDH1 is found in the 
cytoplasm as well as in peroxisomes, an organelle specialising in oxidative reactions. 
It could be that this protein is localising in different regions of the cell upon 
stimulation with the treatments, accounting for the opposing effects observed with 
the different treatments. Studies have shown that curcumin can activate 
mitochondrial isocitrate dehydrogenase in colon cancer cell line, possibly by 
modifying the sulphydryl groups on the enzyme182.  
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Glutathione S-transferases were also modulated following the polyphenol 
treatments; these proteins catalyse the conjugation of GSH with various exogenous 
and endogenous hydrophobic electrophiles. Glutathione S-transferases serve to 
detoxify the cellular environment, but also have signalling capabilities. Glutathione S-
transferase P (GSTP1) was induced by both 10µM curcumin and 30µM isorhamnetin, 
this category of glutathione S-transferases seem to have a number of signalling 
properties. GSTPs can bind to JNK, preventing its activation, which would lead to 
apoptosis; it also acts as a negative regulator of I-κB kinase/NF-κB signalling, stress –
activated MAPK cascade and TNFα production. Curcumin has been shown to 
increase the gene expression of GSTP1 in humans liver cells following treatment with 
20µM for 8h183. Quercetin which is structurally similar to isorhamnetin has also been 
shown to increase the GST activity in rat liver, when fed a 2g/kg diet enriched with 
quercetin and catechin184.  
Finally, another protein feeding into the glutathione metabolism pathway is 
spermidine synthase, which contributes to the biosynthesis of spermidine. 
Spermidine is a polyamine which aids in the survival of the cell by maintaining 
membrane potential and regulating gene expression through chromatin regulation. 
This protein was induced by the 30µM isorhamnetin treatment; Isorhamnetin had a 
number of effects on this pathway, predominantly having a positive effect on the 
increase in reduced glutathione, protecting the cell from oxidative stress.    
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GSR Glutathione reductase  ↑ cur, iso, res 
TXNDC12 Thioredoxin domain-containing protein 12  ↓ iso 
IDH1 Isocitrate dehydrogenase [NADP]   ↓ iso ↑ cur 
PGD 6-phosphogluconate dehydrogenase, decarboxylating  ↑ iso 
G6PD Glucose-6-phosphate 1-dehydrogenase  ↑ iso 
GSTK1 Glutathione S-transferase kappa 1  ↑ res 
GSTM3 Glutathione S-transferase Mu 3  ↓ iso 
GSTP1 Glutathione S-transferase P ↑ cur, iso 
SRM Spermidine synthase  ↑ iso 
Table 4.6 – Key for glutathione metabolism pathway diagram on following page 
and a summary of treatment effects. Cur = curcumin, Iso = isorhamnetin, and Res = 
resveratrol.      
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The network analysis also identified the Nrf2 signalling pathway to be 
modulated with both curcumin and isorhamnetin (Figures 4.4 and 4.6).  Nrf2 is a key 
regulator of the glutathione antioxidant pathway and feeds into the changes 
observed in the other redox proteins. As Nrf2 is a transcription factor which is 
responsible for the activation of antioxidant gene expression such as glutathione 
reductase, glutathione peroxidase, glutathione transferase, thioredoxin, 
peroxiredoxin, glucose-6-phosphate dehydrogenase and NAD(P)H quinone 
oxidoreductase 1185. Polyphenols have previously been shown to modulate Nrf2 
activation and for example, isorhamnetin protects against oxidative stress by 
activating Nrf2 in liver cells186. With all these changes in redox proteins, investigating 
Nrf2 activation by these compounds is the next step in understanding the 
mechanisms of action of polyphenols and to explore in detail the changes to 
glutathione pathways (Figure 4.9, Table 4.6).  
Due to the small fold changes observed and some high q-values with a 
number of the proteins identified; these statistical changes with the treatments 
should be taken with caution. Therefore further analysis into the changes in 
glutathione proteins will be examined more in-depth with other methods.  
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CHAPTER 5 
 
 
 
ANALYSIS OF GLUTATHIONE MODIFICATION BY 
POLYPHENOL TREATMENT OF JURKAT T-LYMPHOCYTES. 
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5.1 INTRODUCTION 
 
 
5.1.1 Ageing and elevated levels of oxidative stress. 
Ageing has been associated with dysregulation of the immune system 
characterised by chronic inflammation187, increases in baseline oxidative stress, and 
elevated levels of reactive oxygen species188. The main source of ROS generation is in 
the mitochondria, as part of the electron transport chain189. These molecules are 
important for cellular signalling190, however, aberrant ROS production has been 
observed with ageing, results in the accumulation of oxidative damage to vital 
cellular components like DNA, proteins and lipids191, molecules important for cell 
survival. A number of proteins are responsible for maintaining the redox 
homeostasis of the cell, using antioxidant enzymes such as superoxide dismutase 
(O2
- to H2O2), catalase and glutathione peroxidase (H2O2 to H2O)
192.  Imbalances 
between antioxidant capabilities and oxidant production of the cell will lead to 
oxidative stress and in the elderly may aid the progression of age-related diseases 
such as arthritis193, diabetes194 and Alzheimer’s195. 
 
5.1.2 Antioxidant proteins maintaining redox homeostasis in the cell. 
Antioxidant proteins and enzymes are the major cellular protection against 
oxidants, maintaining the redox status of the cell. These antioxidant proteins help 
remove harmful oxidants by converting them into molecules such as H2O. The major 
antioxidant enzymes include superoxide dismutase (SOD), catalase, glutathione 
peroxidase, thioredoxin and peroxiredoxins. In Chapter 4, proteomics identified a 
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number of these redox proteins induced by the polyphenol treatments. Catalase was 
induced by the 30µM resveratrol treatment, 10µM curcumin increased 
peroxiredoxin-1 and 30µM increased thioredoxin in the Jurkat T lymphocytes 
compared with DMSO treated control. Glutathione reductase was a common redox 
protein induced by all three polyphenol treatments. Suggesting that glutathione 
homeostasis is a central to component to the polyphenols mechanism of action. 
 
5.1.3 Polyphenols regulating cellular redox mechanisms. 
 
(Poly)phenols have been shown to regulate cellular redox mechanisms, in 
particular the glutathione system in previous studies. Resveratrol has been shown to 
significantly increase the glutathione content of rat astrocytes treated for 24 h with 
25 and 50 μM resveratrol compared with untreated controls196. Resveratrol has also 
been shown to increase the protein expression of glutamate cysteine ligase, 
glutathione peroxidase-1 and glutathione reductase in human coronary artery 
endothelial cells197. Supplementing the diet of mice with curcumin (2%, w/v) for 30 
days significantly increased the activity of glutathione reductase, glutathione 
peroxidase, glucose-6-phosphate dehydrogenase and catalase in both the liver and 
the kidneys198. In cerebellar granule neurons (CGNs) from rats, curcumin also 
significantly increased the activity of glutathione reductase (1.4 fold), glutathione S-
transferase (2.3 fold), and superoxide dismutase (5.2 fold) with 24h treatments with 
curcumin and additional observed a significant increase in the levels of GSH by 14.3 
fold, with 30µM curcumin199. This study also noted that curcumin could activate 
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nuclear factor (erythroid-derived 2)-like 2 (Nrf2) translocation to the nucleus of the 
CGNs cells, allowing the activation of antioxidant gene expression. 
In this chapter, the ability of polyphenols to modulate antioxidant proteins 
such as glutathione reductase, along with the gene expression of glutathione 
peroxidase, glutathione synthetase and glutamate-cysteine ligase will be assessed. 
Intracellular levels of GSH will also be measured and changes to Nrf2 transcriptional 
activation will be studied.  
 
5.2 AIMS 
The aim was to investigate the changes to the glutathione pathway 
previously identified by proteomics to be modulated by all three treatments  
(Chapter 4) and to validate the data produced by quantitative proteomics by other 
methods of protein and gene expression analysis. It was also intended to explore the 
signalling pathway regulating antioxidant gene expression by evaluating changes to 
the transcription factor Nrf2.  
 
5.3 RESULTS.  
 
 
5.3.1 Glutathione reductase protein expression with polyphenol treatments 
over time. 
Glutathione reductase was one of the proteins identified through proteomics to be 
significantly modulated by all three of the (poly)phenols, with curcumin increased by 
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1.2 fold, resveratrol by 1.1 fold and isorhamnetin by 1.2 fold (p < 0.05). Western blot 
analyses were used to examine changes to glutathione reductase following 48 h 
treatment with 10μM curcumin, 30μM isorhamnetin and 30μM resveratrol (Table 
4.3). No significant changes were observed with the three treatments at 48 h 
following treatment (Fig. 5.1A).  
The initial western blot analysis showed no significant differences between 
the three (poly)phenol treatments with 3 replicates. This experiment was repeated, 
focusing on the isorhamnetin treatment and increasing the number of replicates to 6, 
but again no significant changes were observed with isorhamnetin treatment (Fig. 
5.1B). Therefore, further investigations at other time-points were trailed to see if 
significant increases could be observed with the polyphenol treatments.  A 
significant increase in glutathione reductase following treatment with isorhamnetin, 
curcumin and resveratrol (Fig. 5.2) at the 24 h time-point was observed using 
western blot analysis.  
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Figure 5.1 – Glutathione reductase protein expression after 48 h treatment with 
curcumin, isorhamnetin and resveratrol (representative blots). A) Changes in 
glutathione reductase (GSR) in Jurkat cells following 48 h treatment with 10μM 
curcumin (Cur) and 30μM isorhamnetin (Iso) and resveratrol (Res) using anti-GSR 
(58kDa) compared with DMSO (D) treated control. Data normalised to vinculin 
(n=3). B) Changes in glutathione reductase (GSR) in Jurkat cells following 48 h 
treatment with 30μM isorhamnetin (Iso) using anti-GSR (58kDa) compared with 
DMSO (D) treated control. Data normalised to vinculin (n=6). 
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Figure 5.2 – Glutathione reductase protein content following 24 h treatment with 
isorhamnetin, curcumin and resveratrol (representative blots). Western blot 
analysis of changes in GSR in Jurkat cells following 24 h treatment with 10μM 
curcumin and 30μM isorhamnetin and resveratrol compared with DMSO treated 
control. Data normalised to Ponceau stain (n=3, * p < 0.05). 
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5.4.2 Analysis of glutathione reductase, glutathione synthetase, glutathione 
peroxidase, and glutamate—cysteine ligase gene expression. 
 
Since changes to protein levels of glutathione reductase were not seen at the 
48 h time-point but were detected at the 24 h time-point, a time-course experiment 
was conducted, this evaluated the gene expression of glutathione reductase, along 
with the other glutathione homeostasis proteins, glutathione synthetase and 
glutamate—cysteine ligase (that are enzymes involved in the biosynthesis of 
glutathione, and also glutathione peroxidase, which catalyses the reaction of GSH 
with hydrogen peroxide). 
 
 
* 
* 
* 
* 
0
0.5
1
1.5
2
2.5
3
0 5 10 15 20 25 30 35 40 45 50
Fo
ld
 c
h
an
ge
 f
ro
m
 D
M
SO
 t
re
at
e
d
 c
o
n
tr
o
l 
A) Glutathione reductase (GSR) 
Curcumin Isorhamnetin Resveratrol
201 
 
 
 
 
 
 
 
* 
* * 
* 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
0 5 10 15 20 25 30 35 40 45 50
Fo
ld
 c
h
an
ge
 f
ro
m
 D
M
SO
 t
re
at
e
d
 c
o
n
tr
o
l 
B) Glutathione peroxidase (GPx1) 
Curcumin Isorhamnetin Resveratrol
* 
* 
* 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
0 5 10 15 20 25 30 35 40 45 50
Fo
ld
 c
h
an
ge
 f
ro
m
 D
M
SO
 t
re
at
e
d
 c
o
n
tr
o
l 
C) Glutathione synthetase (GSS) 
Curcumin Isorhamnetin Resveratrol
202 
 
 
 
                                   
Figure 5.3 – Time-course of treatments with curcumin, isorhamnetin and 
resveratrol on the gene expression of GSR, GPx1, GSS, and GCLC. Analysis of gene 
expression of glutathione reductase (GSR), glutathione peroxidase 1 (GPx1), 
glutathione synthetase (GSS) and glutamate-cysteine ligase (GCLC) following 
treatment with 10µM curcumin, 30µM isorhamnetin and resveratrol treatment 
over a time-course of 3, 9, 24, and 48 h in Jurkat T-lymphocytes. Data are 
expressed as fold change from DMSO treated control (1), data normalised to TATA 
binding protein (TBP). [Mean ± SEM, n = 3, * p-value < 0.05] 
 
 
 Significant increases in glutathione reductase mRNA were observed 
following isorhamnetin and curcumin treatment showed a doubling at 24h time-
point (Fig. 5.3A). Significant increases in GCLC mRNA (Fig. 5.3D) were also observed 
at the 24h time-point with isorhamnetin and significant decreases in GSS mRNA (Fig. 
5.3C) were observed at the 9h time-point following all the polyphenols treatments. 
Significant reductions in GPx1 mRNA (Fig. 5.3B) were observed at the 9h time-point 
with isorhamnetin and curcumin and again at 48h with resveratrol and isorhamnetin. 
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5.4.3 Glutathione modulation by (poly)phenols. 
 
 
 
The significant increase in glutathione reductase protein concentration and 
gene expression, together with increases in glutamate-cysteine ligase mRNA with 
isorhamnetin treatment, suggested an effect of the polyphenols on cellular 
glutathione at the 24h time point.  Jurkat T-lymphocytes were treated with various 
concentrations of the (poly)phenols for 48 h and intracellular levels of glutathione 
were measured using a spectrophotometric kinetic assay, as described in Methods 
section 2.2.10.  
Figure 5.4A, shows a significant increase in the intracellular concentration of 
reduced glutathione following treatment with 10µM curcumin. This effect was not 
observed with the 30µM isorhamnetin or 30µM resveratrol treatments and both 
significantly reduced the cellular concentration of reduced glutathione (Fig 5.4B and 
C). Figure 5.5, shows levels of oxidised glutathione following 48h polyphenol 
treatment, a significant increase in GSSG was observed with 10µM curcumin and no 
significant changes were observed with 30µM isorhamnetin and resveratrol 
treatments. Levels of oxidised glutathione made up a maximum of 4.85% of trh total 
glutathione present. 
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Figure 5.4 – Concentrations of intracellular reduced glutathione (GSH) in 
nmol/million cells from Jurkat cells treated with A) 1 and 10µM curcumin, B)  1 and 
30µM isorhamnetin and C)  1 and 30µM resveratrol for 48 h, compared  with 
DMSO treated control, [Mean ± SEM, n = 4, T-test * p < 0.05]. 
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Figure 5.5 – Concentrations of intracellular oxidised glutathione (GSSG) in 
nmol/million cells from Jurkat cells treated with A) 1 and 10µM curcumin, B)  1 and 
30µM isorhamnetin and C)  1 and 30µM resveratrol for 48 h, compared  with 
DMSO treated control, [Mean ± SEM, n = 4, T-test * p < 0.05]. 
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5.4.4 Curcumin and isorhamnetin increase Nrf2 activation. 
 
 
 
 
A DNA binding assay was used to directly measure in vitro protein-DNA 
interaction, using dsDNA able to bind the transcription factor Nrf2 (Methods 2.2.15). 
Jurkat cells were treated for 48 h with a low or high doses of (poly)phenols and a 
positive control of tert-butylhydroquinone (t-BHQ).  Both curcumin and isorhamnetin 
significantly increased Nrf2 activation compared with DMSO vehicle control (Fig. 5.6). 
There is a steady increase is Nrf2 activation with isorhamnetin, whereas 1 and 10 µM 
curcumin increase Nrf2 activation to the same degree. Resveratrol had no significant 
effects on Nrf2 activation.  
A time-course experiment of Nrf2 activation showed significant Nrf2 
activation from 3h to 48h with isorhamnetin. Curcumin also showed a significant fold 
change in Nrf2 activation at both 9h and 48 h compared with the DMSO treated 
control (Fig. 5.7).  
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Figure 5.6 – DNA binding assay for Nrf2 activation in Jurkat cell samples following 
treatment with curcumin, resveratrol, and isorhamnetin for 48 hr. Positive control 
– Nrf2 protein provided by kit, DMSO vehicle control, tert-butylhydroquinone (t-
BHQ) positive control added to cell in culture. (Mean ± SEM, n=5, * p < 0.05). 
 
Figure 5.7 – DNA binding assay for Nrf2 activation in Jurkat cell samples following 
treatment with 10µM curcumin, 30µM resveratrol, and 30µM isorhamnetin for 1, 3, 
9, 24, and 48 h. Data presented as a fold change from DMSO treated control valued 
at 1. (Mean ± SEM, n=5, * p < 0.05). 
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5.3.5 Immunoblotting for Nrf2, and phosphorylated Nrf2 with isorhamnetin 
treatment. 
 
 
Isorhamnetin had the greatest effects in Nrf2 activation assessed using the DNA 
binding assay. Figure 5.8A, shows an increase in protein expression of both Nrf2 and 
phosphorylated Nrf2. Significant increases were noted at the 24h time-point for Nrf2 
following treatment with isorhamnetin compared with DMSO treated control (Fig. 
5.8B). The ratio of phosphorylated Nrf2 to Nrf2 is 1.3:1 (1h), 0.9:1 (3h), 1:1 (9h) and 
0.6:1 (48h). 
    
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 – A) Western blot for Phosphorylated- Nrf2 and Nrf2 following 
treatment with isorhamnetin for 1, 3, 9, and 24h in Jurkat T-lymphocytes. B) 
Densitometry analysis of Nrf2 following 24h treatment with isorhamnetin 
normalised to vinculin and compared with DMSO treated control. (n=3, * p < 0.05). 
       
 
 
5.3.6 Inhibition of nuclear translocation of Nrf2 by the use of Ochratoxin A. 
 
 
To determine how these changes to redox proteins might be linked to the 
changes in cytokine release already observed in Chapter 3. Experiments were 
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undertaken to inhibit Nrf2 and measure cytokine release following treatment with 
isorhamnetin. Ochratoxin A (OTA) was used to inhibit the translocation of Nrf2 into 
the nucleus200. Figure 5.9, shows Jurkat cell viability with time following increasing 
doses of OTA from 1 to 30µM.  
 
 
 
Figure 5.9 – Jurkat cell viability following treatment with 1, 2.5, 5, 10 and 30µM 
Ochratoxin A over a 72h time period. (n=3). 
 
 
Nuclear and cytoplasmic extracts were also taken at the 72h time-point and 
western blotting used to measure the abundance of Nrf2. Figure 5.10A, shows 
western blot analysis of experiment using 1 and 2.5µM OTA at 72h. There was a 
trend to an increase in Nrf2 in the cytoplasm and decrease in the nucleus with 2.5µM 
OTA treatment (Fig. 5.10B and C). Further studies were undertaken at shorter time-
point (24h, 30min pre-treatment and addition OTA at 12h time-point) and showed 
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significant inhibitions of Nrf2 translocation to the nucleus with 5µM OTA (Fig. 5.11A). 
Figure 5.11B, shows a slight reduction in the Nrf2 content in the nucleus with 5µM 
OTA treatment after 30min, although this inhibition was not statistically significant 
compared with the DMSO treated control. 
 
 
 
 
 
 
 
                                             
                                            
                                          
 
 
 
Figure 5.10 – Jurkat treatment with 1 and 2.5µM Ochratoxin A for 72 h, nuclear and 
cytoplasmic extracts taken for western blot analysis. A) Nrf2 concentration in 
nuclear and cytoplasmic extracts, vinculin content with cytoplasm protein control 
and TBP as the nuclear protein control in comparison with DMSO treated control 
(n=2). B) Densitometry of Nrf2 in the cytoplams normalised to vinculin. C) 
Densitometry of Nrf2 in the nucleus normalised to TBP. 
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Figure 5.11 – Inhibition of Nrf2 translocation into the nucleus by 5µM OTA 
treatment in Jurkat T lymphocytes. A) Nrf2 protein concentration in nuclear 
extracts following 24 h treatment with 5 µM OTA (Pre-treatment with 5µM OTA for 
30 min and at the 12h time-point) [15µg protein loaded, n = 4, data normailsed to 
nuclear control histone H3, * p < 0.05]. B) Nrf2 protein concentration in nuclear 
extracts following 30 min treatment with 5 µM OTA  [30µg protein loaded, n = 3, 
data normailsed to nuclear control histone H3]. 
 
 
 
 
5.5 DISCUSSION.   
 
 
From the previous work reported in Chapter 4 using quantitative proteomics, 
glutathione reductase was identified as a protein significantly induced by all three 
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polyphenols treatments. Curcumin increased glutathione reductase by 1.2 fold, 
isorhamnetin by 1.2 fold and resveratrol by 1.1 fold. Even though the increases were 
statistically significant the fold changes were relatively low and therefore 
confirmation of these changes in glutathione reductase were required using other 
methods.  
 
5.4.1 Polyphenols significantly increased the gene expression and protein 
levels of glutathione reductase in Jurkat T lymphocytes. 
 
Western blot analysis revealed no significant changes in glutathione 
reductase protein expression following 48h treatment with any of the polyphenols. 
Since the fold changes in glutathione reductase (identified by proteomics) were small 
either western blot analysis was not sensitive enough to detect these changes, or the 
two methods are measuring different aspects of GSR. Proteomics methods detect 
peptides rather than the whole protein as is the case with western blot analysis. 
Therefore, this may account for the lack of significant changes observed with the 
polyphenol treatments at 48h. However, further analysis at the 24h time-point did 
show increases in glutathione reductase protein content for all three treatments, 
isorhamnetin induced the greatest increase with 1.3 fold induction; resveratrol had a 
1.1 fold and curcumin a 1.03 fold increase. These data suggest that even though 
proteomics identified glutathione reductase to be induced at the 48h time-point, 
there was a greater induction at the 24 h time-point. A further time-course 
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experiment would help evaluate when the peak changes in glutathione reductase 
occurs with the three different polyphenol treatments. 
 
5.4.2 Increases in expression of genes involved in glutathione production. 
 
 
Figure 5.12 – Glutathione synthesis and regulation pathway. Reduced glutathione 
is generated by two enzymes glutamate-cysteine ligase (GCLC) and glutathione 
synthase (GSS). GCLC is the first, rate limiting enzyme in the synthesis of 
glutathione, it utilises L-glutamate (Glu) and L-cysteine (Cys) to produce gamma-L-
glutamyl-L-cysteine (γ-EC).  Glutathione synthetase combines γ-EC and glycine (Gly) 
to make reduced glutathione (GSH). Reduced glutathione is vital in maintaining 
redox homeostasis by the removal of oxidants such as hydrogen peroxide (H2O2) by 
glutathione peroxidase (GPx1). Two GSH molecules are required for the 
conversation of H2O2 into water (H2O), glutathione is oxidised in the process 
(GSSG). For glutathione recycling to occur, glutathione reductase (GSR) converts 
GSSG back to GSH with the use of nicotinamide adenine dinucleotide phosphate 
(NADPH). (Figure modified from Liu et al, 2015)201 
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A time-course experiment was conducted to evaluate the gene expression of 
enzymes involved in glutathione synthesis and glutathione recycling. Figure 5.12, 
illustrates the enzymes involved in glutathione recycling, with glutathione peroxidase 
(GPx1) acting to neutralise oxidants which would potentially be damaging to the cell, 
causing reduced glutathione (GSH) to be oxidised during the process to GSSG. 
Glutathione reductase then converts GSSG back to GSH with the use of NADPH. 
Glutathione reductase protein concentration was shown to be increase by all three 
treatments at 48h with proteomics and 24h using western blot analysis. Significant 
increases were also observed in GSR gene expression with both curcumin and 
isorhamnetin, with a doubling in mRNA content at the 24h time-point compared 
with the DMSO treated control. With gene expression peaking at the 24h time-point, 
this suggests that GSR protein expression maybe peaking between the 24 and 48 h 
time-points, thus the analysis conducted may have missed the greatest increase.   
The reported relationship between glutathione reductase and polyphenols is 
confused, with numerous studies showing that polyphenols induce protein or gene 
expression of GSR197, 198, 199; however there is also evidence to support polyphenols 
inhibiting GSR activity. Elliott et al in 1992 investigated the inhibition of GSR with 14 
different chemically related flavonoids202. For example, quercetin had an I50 value of 
280, of which is much greater than the levels used in this study. Adding to the 
complexity, slight changes in polyphenol structure have been reported to 
dramatically affect the level of inhibition and addition of antioxidant enzymes such 
as superoxide dismutase and catalase have been reported to reverse the inhibition. 
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Isorhamnetin (structurally similar to quercetin) has not been studied for inhibitory 
effects on GSR, and this would be an important experiment to perform, to 
understand how the increases in GSR gene and protein expression and relate to GSR 
activity. 
Along with the increases in GSR, significant increases in GCLC gene expression 
were also observed with isorhamnetin treatment at the 24h time-point; this is the 
rate-limiting enzyme in the formation of glutathione and was associated with a 
decrease in glutathione peroxidase gene expression at the 9 h time-point. For 
isorhamnetin, an increase in GCLC would predict an  increase in GSH, an increase in 
GSR converting GSSG back to GSH and a lowering in GPx1 potentially  generating less 
GSSG, would suggest an overall increase in the intracellular concentration of GSH 
should occur. However, when measuring GSH levels, curcumin was the only 
compound that induced a significant increase in GSH, with an increase from 716 to 
3151 nmol/million cells compared with the DMSO treated control, there was also a 
significant increase in GSSG with curcumin, increasing from 20 to 85 nmol/million 
cells. However, this increase was less than 5% of the total glutathione measured. 
Isorhamnetin and resveratrol both caused a significant reduction in the levels of GSH 
produced, compared with DMSO treated control. There may be a number of 
explanations why levels of glutathione were lowered with the resveratrol and 
isorhamnetin treatments. It could be related to the time in which the measurements 
were taken since by 48h any changes in glutathione may be reversed or other redox 
proteins identified through the proteomics, to be increased with the isorhamnetin 
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treatment (Glutathione transferases203 and peroxiredoxins 6204) may have used the 
increased amounts of glutathione.  
 
5.4.3 Nrf2 activation induced by curcumin and isorhamnetin. 
 
Increases in redox-proteins are regulated by the transcription factor, nuclear 
factor erythroid 2-reated factor 2 (Nrf2). Nrf2 is a master regulator of a number of 
different antioxidant genes, such as thioredoxin, NADPH production and glutathione 
production and regeneration205.  In this study Nrf2 activation was significantly 
increased by isorhamnetin at 3, 9, 24 and 48h after treatment and with 1 and 10µM 
curcumin at 48h treatment compared with the DMSO treated control. Figure 5.13, 
shows the fold change in Nrf2 over time, along with the changes in two antioxidant 
genes (glutathione reductase (GSR) and glutamate-cysteine ligase (GCLC)) known to 
be regulated by Nrf2 for each individual polyphenol treatment. For resveratrol, no 
changes were observed in Nrf2 activation and this was mirrored in the level of 
changes in expression of GSR and GCLC. Curcumin and isorhamnetin both increase 
Nrf2 activation but the patterns of activation over time were different. Curcumin 
increased Nrf2 by 2.5 fold at 9 h, with a lag in GSR gene expression until 24h. For 
isorhamnetin there was an increase in Nrf2 activation, starting at 1h, increasing till 
9h and again there was a lag in GSR gene expression until an increase at 24h. In 
contrast to the pattern seen with curcumin; both GSR and GCLC showed the same 
expression pattern with isorhamnetin treatment. The two compounds that activated 
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Nrf2 both caused an ~doubling of activation at the 9h time-point, but had different 
response times and effects on gene expression of 2 antioxidant proteins. This 
suggests even though they both activate Nrf2, other factors affect antioxidant gene 
expression differ between the two compounds. 
.  
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Figure 5.13 – Summary of fold changes for Nrf2, GSR and GCLC. Fold changes in 
Nrf2, glutathione reductase (GSR) and glutamate-cysteine ligase (GCLC) over time 
with the three different polyphenol treatments A) isorhamnetin B) resveratrol and 
C) Curcumin compared with DMSO treated control (1). (Data represented from fig. 
5.3A, 5.3D and 5.6). 
 
 
Preliminary work was undertaken to attempt to inhibit Nrf2 activation in 
Jurtkat T lymphocytes, in order to determine if the activation in Nrf2 is driving the 
changes observed in cytokine release, as shown by polyphenols. Ochratoxin A (OTA), 
is a toxin produced by fungi and has been shown to inhibit Nrf2 translocation200, 200, 
206. This study has shown that 5µM OTA can significantly inhibit the translocation of 
Nrf2 into the nucleus for 24h (30 min pre-treatment and again at 12h time-point). 
However, even though the study showed OTA to inhibit Nrf2, the process is not ideal 
with the toxicity of OTA. Future work could experiment with siRNA which may prove 
less toxic, which could be used together with isorhamnetin for 24h to measure the 
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resulting cytokine release. This will identify if the reduction in cytokine release 
observed with isorhamnetin is mediated by activation of Nrf2 or the two are acting 
through different pathways. This work will bridge the findings in Chapter 3 on 
inflammation, with the observation in this Chapter on changes to redox proteins by 
polyphenols. To fully appreciate these changes, further work was conducted in 
another cell type, investigating if isorhamnetin could modify redox and inflammation 
mechanisms in THP-1 monocytes. 
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CHAPTER 6 
 
 
VALIDATION OF THE EFFECTS OF ISORHAMNETIN 
ON CYTOKINES AND GLUTATIONE IN AN 
ALTERNATIVE CELL TYPE, THP-1 CELLS. 
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6.1 INTRODUCTION. 
 
The study conducted in Chapter 3 identified polyphenol compounds that 
significantly lowered markers of inflammation in Jurkat T lymphocytes. The 
compounds identified which had the greatest effects on lowering cytokine release in 
these cells were curcumin, isorhamnetin and resveratrol. Proteomic analysis was 
then used to investigate overall changes in protein abundance following 48h 
treatment with these polyphenols, as shown in Chapter 4. This revealed that the 
polyphenol treatment was significantly modulating redox proteins content, in 
particular glutathione reductase, which was induced by all three polyphenols. 
Treatment of cells with isorhamnetin also significantly increased thioredoxin, 
thioredoxin reductase, peroxiredoxin 1, 2, and 6, content in the Jurkat T lymphocytes. 
These redox modulations with isorhamnetin were investigated further in Chapter 5, 
were significant increases to Nrf2 activation were observed. Together with increases 
in glutamate—cysteine ligase gene expression and increases in glutathione 
reductase protein and gene expression compared with the DMSO treated control.   
It was observed that isorhamnetin (structure shown in Figure 6.1) showed the 
greatest number of modulations in both redox proteins and cytokine release in 
Jurkat T lymphocytes; therefore this compound was used to determine if the effects 
could be replicated in other cell types. Another immune cell line was chosen, a 
human monocyte cell line (THP-1), as these are also cytokine producing cells and 
thus providing the investigation of inflammatory markers following treatment with 
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isorhamnetin. THP-1 cells are able to produce a variety of cytokines, including IL8 
and TNFα, both of which are also detectable in the Jurkat T lymphocytes207,208.  Other 
cytokine markers include IL1β, IL6, IL10209  and MCP-1210  which are detectable 
following stimulation of THP-1 cells with lipopolysaccharide (LPS). PMA/PHA which 
was used previously to induce cytokine release in the Jurkat cells in Chapter 3, could 
not be used in these circumstances due to PMA inducing THP-1 monocyte 
differentiation into macrophages, therefor LPS was used to stimulate the THP-1 cells. 
It has been well studies in the induction of cytokines in the THP-1 cell line, there are 
differences in the treatment times and the pathways they induce, however there is a 
cross over in the cytokines that are induced by the two treatments, allowing the 
comparisons between the two cell lines.  
 
Figure 6.1 – Structure of isorhamnetin, an O-methylated flavonol.  
 
Due to the different cell line being used, more cytokines were expressed than 
in the Jurkat cell line. Notably MCP-1, IL1β, IL6 and IL10 could be detected in THP-1, 
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along with IL8 and TNFα in the Jurkat cells. MCP-1 is a member of the C-C chemokine 
family and is a chemotactic factor for monocytes and is induced by oxidative stress, 
cytokines or growth factors. Elevated MCP-1 and its receptors have been shown to 
play a role in the development of atherosclerosis211. EGCG has been shown to 
supress TNFα induced MCP-1 gene expression in HUVEC cells in a dose-dependent 
manner212. IL6 is a interleukin which can act as both and anti- and pro- inflammatory 
cytokine, secreted by both T- cells and macrophages. It plays an important role in 
fighting infection and tissue damage. Its anti-inflammatory effects are mediated 
though its inhibitory effects on TNFα and IL-1 activation of IL-10. IL6 has been shown 
to contribute to a number of age-related diseases such as atherosclerosis, 
Alzheimer’s and rheumatoid arthritis213. IL10 is an anti-inflammatory cytokine, it 
works by down regulating the expression of h1 cytokines, MHC class II antigens and 
co-stimulatory molecules on macrophages. IL-10 can also block NF-κB activity, which 
is the main transcription factor of pro-inflammatory cytokine expression. Resveratrol 
has been shown to increase IL-10, and a down regulation of pro-inflammtory 
cytokines IL-1β, TNFα and IL6 following induction by LPS in brain cells214.   
THP-1 cells have previously been used to investigate the anti-inflammatory 
effects of dietary polyphenols. Drummond et al in 2013 demonstrated that 25µM 
quercetin (an analogue of isorhamnetin) significantly reduced TNFα release in THP-1 
macrophages following 48h treatment with LPS stimulation at the 24 h time-point215. 
Other studies have shown that polyphenols lower cytokine release in this cell type, 
both resveratrol (2.5, 5, 10µM) and curcumin (10, 20µM) significantly inhibited steric 
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acid-mediated induction of the pro-inflammatory mediators TNFα and IL1β in the 
THP-1 cells216. Treatment of cells with isorhamnetin has been shown to significantly 
increase nuclear translocation of Nrf2 and increased heme oxygenase 1 (HO-1) 
protein expression in the presence of oxidized low-density lipoprotein ox-LDL which 
induced cell apoptosis in THP-1 macrophages217.     
 
6.2 AIMS. 
Following the identification of polyphenols that reduced markers of inflammation in 
Chapter 3, and further analysis with proteomics in Chapter 4, isorhamnetin was 
identified to modulate to both redox proteins and inflammatory markers. The aim of 
the work in this Chapter was to determine if isorhamnetin had the same effect in 
another cell type, human monocytes THP-1. This will allow the comparison between 
the two cell models, and hence the more general applicability of the data. 
 
6.3 RESULTS.  
 
 
6.3.1 Optimisation of THP-1 monocytes culture with the addition of 
isorhamnetin. 
 
A significant increase in cell number was observed with 10µM isorhamnetin 
in unstimulated THP-1 cells (Fig. 6.2A). Cells that were stimulated with LPS showed 
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no significant changes to cell number following treatment with isorhamnetin (Fig. 
6.2B).  
 
 
 
Figure 6.2. A) THP-1 cell number following treatment with 1, 10, and 30µM 
isorhamnetin for 48 h (unstimulated cells). B) THP-1 cell number following 
treatment with 1, 10, and 30µM isorhamnetin for 48 h, with a 4 h 1µg/ml LPS 
(+DMSO) stimulation at the end [Mean ± SEM, n = 6, * p < 0.05].  
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6.3.2 Multiplex analysis of cytokine release in stimulated and unstimulated 
THP-1 cells. 
The cytokines investigated were chosen as they related to the previous data 
from the Jurkat cells (Chapter 3), along with additional cytokines known to be 
produced by these cells. The 11 cytokines used were G-CSF, GM-CSF, GRO, IL1β, IL6, 
IL8, IL10, IL12(p40), IL12(p70), MCP-1, and TNFα. The cells were either unstimulated 
to measure the effect of isorhamnetin alone or stimulated with lipopolysaccharides 
(LPS) to induce cytokine release. This method was similar to that used with the Jurkat 
T-lymphocyte experiment; however the same stimulus could not be used, since 
PMA/PHA does not have the same effect on THP-1 cells. LPS was chosen since it is 
extensively studied to induce cytokine release in this cell type. 
 Three out of the eleven cytokine measured had levels which were 
undetectable by the multiplex analysis; G-CSF, GM-CSF and IL12p40. Only two of the 
cytokines could be measured in both the unstimulated and stimulated cells, these 
were MCP-1 and TNFα. A significant dose dependant reduction was observed with 
MCP-1 in unstimulated cells (Fig. 6.3A); this effect was also replicated in the LPS 
stimulated cells following treatment with 10 and 30µM isorhamnetin. Both 
unstimulated and LPS stimulated THP-1 cells significantly reduced MCP-1 release 
compared with DMSO or LPS treated control (Fig. 6.3B). A reduction from 135 ± 4 
pg/ml with DMSO to 67 ± 2 pg/ml with 30µM isorhamnetin in unstimulated cells and 
265 ± 6 pg/ml (DMSO) lowered to 182 ± 5 pg/ml (30µM Isorhamnetin) in LPS 
stimulated cells. No significant effects was observed on TNFα in unstimulated cells 
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(Fig. 6.3C), however a significant reduction was observed in the LPS stimulated cells 
with the 30µM treatment of isorhamnetin (10223 ± 51 pg/ml), compared with LPS 
treated control (10428 ± 70 pg/ml) (Fig. 6.3D). 
 
Figure 6.3 – Multiplex analysis of MCP-1 and TNFα following treatment of THP-1 
cells with 1, 10, and 30µM isorhamnetin for 48 h. A) MCP-1 release following 
treatment with isorhamnetin in unstimulated cells. B) MCP-1 release following 
treatment with isorhamnetin in unstimulated cells. C) TNFα release following 
treatment with isorhamnetin for 48 h with 4 h stimulation by LPS [Mean ± SEM, n = 
5, * p < 0.05]. 
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Figure 6.4 – Multiplex analysis of IL1β, IL6, IL8, IL10, IL12(p70) and GRO following 
treatment with 1, 10, and 30µM isorhamnetin for 48 h with 4 h stimulation with  
LPS in THP-1 monocytes. A) IL1β B) IL6 C) IL8 D) IL10 E) IL12(p70) F) GRO [Mean ± 
SEM, n = 5, * p < 0.05]. 
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 Significant changes were observed in IL1β, IL6, IL8, IL10 and GRO release in 
the cells stimulated with LPS compared with the LPS treated control. Figure 6.4(A, B, 
and D) shows a significant reductions in IL1β, IL6, and IL10 with the 1µM 
isorhamnetin treatment, figures 6.4 (C and F) also significant reductions in IL8 (8521 
± 449 LPS to 6309 ± 395 pg/ml isorhamnetin) and GRO (1720 ± 64 LPS to 1514 ± 41 
pg/ml isorhamnetin) with the 30µM isorhamnetin treatment compared with the LPS 
treated control. There was also a significant increase in IL10 with the 30µM 
isorhamnetin treatment, an increase from the LPS treated cells from 48 ± 4 pg/ml to 
125 ± 24 pg/ml with isorhamnetin, a 2.5 fold increase (Fig. 6.4D). No significant 
effects were observed with IL12 (p70) (Fig. 6.4F).   
 
 
 
6.3.3 Gene expression analysis of glutathione reductase, glutathione synthase, 
glutathione peroxidase and glutamate—cysteine ligase. 
 
 
A significant increase in glutathione peroxidase 1 (GPx1) mRNA was observed 
at the 3 hour time-point, however no other significant changes were observed in 
glutathione reductase (GSR), glutathione synthase (GSS) or glutamate-cysteine ligase 
(GCLC) over the time-course of treatment with 30µM isorhamnetin, compared with 
DMSO treated control (Fig. 6.5). 
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Figure 6.5 – qPCR using primers for glutathione reductase (GSH), glutathione 
synthase (GSS), glutathione peroxidase (GPX1) and  glutamate—cysteine ligase 
(GCLC) following 30µM isorhamnetin treatment over a time-course of 3, 9, 24, and 
48 h in THP-1 cells. [Mean ± SEM, n = 3, * p < 0.05] 
 
 
 
6.3.4 Nrf2 activation with isorhamnetin treatment in unstimulated and 
stimulated THP-1 cells. 
 
 
A significant increase in Nrf2 activation was observed in unstimulated cells 
following treatment with 30µM isorhamnetin treatment compared with DMSO 
treated control (Fig. 6.6A) and also in LPS stimulated cells (Fig. 6.6B), compared with 
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LPS treated control. 10µM had no effect on Nrf2 DNA binding; however, 1µM 
isorhamnetin showed a significant lowering of Nrf2 activation in unstimulated cells.  
 
 
Figure 6.6 – DNA binding assay measuring Nrf2 activation in THP-1 monocyte cell 
samples following treatment with 1, 10, 30µM isorhamnetin for 48 h, without LPS 
treatment (A) and with 1µg/ml LPS stimulation for 4h (B). Positive control, Nrf2 
protein provided by kit. (Mean ± SEM, n=5, * p < 0.05). 
 
A 
B 
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The time course effects of 1 and 30µM isorhamnetin showed a significantly 
increase starting at 3h and peaking at 48h, with 30µM isorhamnetin treatment, 
compared with DMSO treated control. Treatment of cells with 1µM isorhamnetin 
only showed a significant increase in Nrf2 activation at the 48h time-point (Fig. 6.7). 
 
 
Figure 6.7 – DNA binding assay measuring Nrf2 activation in THP-1 monocyte cell 
samples following treatment with 1 and 30µM isorhamnetin for 3, 9, 24, and 48 h. 
(Mean ± SEM, n=5, * p < 0.05). 
 
 
 
6.4 DISCUSSION.  
 
 
To evaluate the general applicability of the changes in isorhamnetin 
treatment had on markers of inflammation and redox modulation which were 
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previously reported in the Jurkat cell (Chapters 3, 4 and 5), the experiments were 
repeated using human monocytes THP-1 cells.  
 
6.4.1 Modulations to cytokine release following treatment of THP-1 cells with 
isorhamnetin for 48h. 
 
A significant reduction in IL8 and TNFα (Fig. 6.4C and 6.3D) were observed in the 
THP-1 cells following 48h treatment with isorhamnetin compared with LPS treated 
controls, which correlates with the reduction observed previously in the Jurkat cells 
(Chapter 3, fig. 3.8 and 3.9). Other studies have shown that other polyphenols can 
lower IL8 release in LPS stimulated THP-1 cells, for example resveratrol dose 
dependently inhibited LPS-induced IL8 production and release in THP-1 cells218. Data 
showed that there were other reductions in cytokines release included MCP-1, IL1β, 
IL6, and GRO, with a significant increase in IL10 also observed with 30µM 
isorhamnetin. IL10 is an anti-inflammatory cytokine, its main role is in repressing 
excessive immune responses and protecting against tissue damage. Dysregulation, 
lowers the levels of IL10 and contributes to inflammatory diseases such as 
inflammatory bowel disease, liver inflammation and psoriasis219.  Studies have 
shown that other polyphenols can increase the expression of IL10, Wong et al in 
2010, showed a significant increases in IL10 gene expression at physiologically 
relevant doses of 2 and 10 µM EGCG following 72h treatment in Jurkat T 
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lymphocytes220. Polyphenols that can increase anti-inflammatory cytokines and 
lower pro-inflammatory cytokines, have the potential ability to restore the 
imbalance observed in ageing, were there is a greater proportion of circulating pro-
inflammatory cytokines in the system.  
 
Mapping the cytokine interactions using Ingenuity software allowed a visual 
representation of the connections made between the cytokines identified (Figure 
6.8). This diagram shows theoretical interactions between the treatments used, 
protein expression and signalling based on data found in literature research.  The 
data base holds a number of different chemicals and molecules, which can be used 
to predict the interactions this has on proteins or in this case cytokine expression. 
However there was no literature based references that connected the compound 
isorhamnetin with the cytokines; but there were connections for the LPS used to 
stimulate the cells. This allowed the mapping of LPS stimulus and cytokine 
interactions with THP-1 cells. 7 out of the 8 cytokines detected using the multiplex 
analysis, were identified as having indirect links LPS stimulation in the software. As 
previous Ingenuity analysis identified NF-κB to be a central factor in the mechanism 
of action of polyphenols in the Jurkat cells, LPS and NF-κB were added to the scheme. 
By adding these factors, the interactions with the cytokines can be observed within 
the scheme. Direct interactions were identified for IL6, IL8 (CXCL8) and TNFα with 
NF-κB, all three cytokines showed a reduction in cytokine release, as was also shown 
in the Jurkat T lymphocytes. This diagram was used to give an overall picture of the 
235 
 
 
 
cytokine interactions and how these cytokines are affected by LPS and isorhamnetin 
and their involvement with the transcription factor NF-κB.  
 
 
Figure 6.8. IPA cytokine network analysis, modulation occurred with isorhamnetin 
treatment (blue). Connections made between LPS (orange) and also connections to 
NF-κB (purple) with the cytokines, which is a possible mechanism of action of 
isorhamnetin. Red (induction) and green (reduction) in cytokine release following 
48h treatment with isorhamnetin. The eight cytokines which had detectable 
changes following the isorhamnetin (Blue) and LPS treatment (orange). 
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6.4.2 Activation of Nrf2 with isorhamnetin, but not induction of glutathione 
genes. 
 
 As with the Jurkat cells, a significant activation of Nrf2 was observed with 
isorhamnetin treatment. This increased over time from 3 to 48 h, but this activation 
of Nrf2 had no effect on the expression of the antioxidant genes. Quantitative PCR 
showed no significant changes to the mRNA for glutathione reductase, glutathione 
synthase and glutamate cysteine ligase following isorhamnetin treatment. There was 
a significant increase in the glutathione peroxidase mRNA at the 3 h time-point. This 
is unlike data from Jurkat T lymphocytes were a significant increase in glutathione 
reductase and glutamate-cysteine ligase gene expression was observed at the 24 h 
time-point.  
These data show some overlapping areas where isorhamnetin had the same 
effect in both the Jurkat and THP-1 cell lines in terms of inflammation and cytokine 
release, but differing effects in terms of the redox-related protein expression. 
Further work investigating glutathione reductase protein expression and 
concentrations of intracellular glutathione is needed to evaluate comparisons 
between the Jurkat T lymphocytes and THP-1 monocytes connecting redox 
modulations and what functional effect these changes have in cells.  
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CHAPTER 7 
 
 
OVERALL DISCUSSION.  
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7.1 SUMMARY OF MAIN FINDINGS. 
 
The initial aims of this work described in this thesis were: 
 
 To screen a variety of dietary (poly)phenols for their effects on cell viability 
and changes to cytokine release in Jurkat T-lymphocytes. These compounds 
included complex polyphenols and smaller metabolites phenolic acids. The 
aim was to determine a treatment dose and evaluate the anti-inflammatory 
properties of the compounds. 
 (Poly)phenols identified from the screening to have the greatest anti-
inflammatory effect, will be examine further with quantitative proteomics. 
This will allow changes in protein concentrations to be observed following 
treatment with the chosen (poly)phenols (curcumin, isorhamnetin and 
resveratrol). Network analysis will be conducted to evaluate changes to 
signalling pathways. 
 Evaluation of changes to glutathione reductase, which was previously 
identified through proteomics to be modulated by all three treatments. 
Validation of these changes through protein and gene expression analysis and 
further analysis of the antioxidant signalling pathway by the transcription 
factor Nrf2. 
 Further analysis of these changes to inflammatory cytokine release and 
modulations to redox homeostasis observed with Jurkat T-lymphocytes, were 
evaluated in another cell type (THP-1 monocytes) with the polyphenol which 
showed the greatest changes, which was isorhamnetin. 
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The data obtained have shown: 
 
 Sixteen of the twenty-nine polyphenol treatments screened produced 
statistically significant reductions in the release of cytokines by Jurkat T-
lymphocytes following 48h of treatment. The most anti-inflammatory 
polyphenols screened were curcumin, resveratrol and isorhamnetin. At 1μM, 
a physiologically relevant dose for polyphenols, resveratrol decreased IL2 by 
42% ± 7% and IL8 by 32% ± 8% compared with vehicle control (p<0.05). For 
cells stimulated with PMA/PHA to induce cytokine release, 1μM isorhamnetin 
reduced IL2 by 50% ± 4%, IL8 by 58% ± 6% and TNFα by 63% ± 7%, and 
curcumin reduced  IL2 by 43% ± 14%, IL8 by 30% ± 7% and TNFα by 22% ± 
5 (p<0.05). 
 Proteomics identified several proteins in the glutathione metabolism pathway that 
were modified by polyphenol the polyphenol treatments. Significant increases in 
the enzyme glutathione reductase were observed with curcumin (1.2 fold), 
isorhamnetin (1.2 fold) and resveratrol (1.1 fold) (p<0.003) following 48 h of 
treatment. Isorhamnetin in particular also showed significant increases in 
other redox related proteins including thioredoxin and peroxiredoxins; these 
were confirmed with protein and gene expression analysis. A DNA-binding 
assay showed increases in Nrf2 activation, a transcription factor for 
antioxidant proteins, curcumin increased this by 1.5 fold and isorhamnetin 1.9 
fold. 
 While evaluating the anti-inflammatory and redox modulating effect of 
isorhamnetin in an alternative cell type (THP-1 monocytes), significant 
decreases in cytokine release were observed for IL8, MCP-1 and TNFα in LPS 
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stimulated cells. Increases in Nrf2 activation were also observed but no 
significant changes to antioxidant gene expression were seen. 
 
7.2 Experimental set-up and limitations. 
 
 
29 (poly)phenol compounds were chosen to examine the anti-inflammatory 
effects in Jurkat T-cells. Jurkat cells were chosen as T-lymphocytes are one of a 
number of cells which are greatly affected by ageing and are a large source of 
cytokine production. Jurkat cells are an immortalised T-lymphocyte cell line, which 
was chosen over a primary cell line due to the number of comparisons wanted for 
the screening of the (poly)phenols. This would not have been possible in primary 
lines, as secondary cell lines provide continual cell growth and the numbers needed 
for the treatments required. THP-1 monocytes were also chosen to complement the 
work seen in the Jurkat cells, another immune cell line which also produces large 
quantities of cytokines. Another area of interest may be with muscle cell or 
endothelial cells which also produce cytokines but are not as closely related as the 
lymphocytes and monocytes, it would be interesting to see if the same effects are 
observed in these cell lines as well. 
The 29 compounds were picked to include complex polyphenols with 
multiple phenol rings and functional groups, along with smaller phenolic acids which 
would correlate with metabolic breakdown products of the larger complex 
polyphenols. With a wide range of (poly)phenols to choose from and  a limited 
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number of compounds  can be evaluated at any one time. One area of (poly)phenol 
metabolism which wasn’t cover in this study was evaluating the anti-inflammatory 
effects was to look at those compounds that are conjugation to phenolic groups 
via glucuronidation and/or sulfation. This would be an interesting area to study as a 
number of these polyphenols are conjugated with these groups. Another limitation 
of the study was measuring the cell number following treatment with the 
(poly)phenols using the MTS assay, as previously discussed in Chapter 3, the MTS 
measures cell viability based on the metabolic activity of the cell, and this may vary 
with the treatments. Later experiments, narrowing down the (poly)phenol field to 
just 3 compounds meant more accurate forms of cell viability could be conducted via 
Trypan Blue exclusion. 
Cells were treated for 48 hrs with the chosen (poly)phenols, which was 
chosen to allow time for gene and protein expression. Significant reductions in 
cytokine release were observed at the 48h time-point and this format was carried 
forward when investigating proteomic changes. For future work it may be interesting 
to look at earlier time-points as (poly)phenols can have instant effects of proteins 
and other proteins have quicker expression times. In this study, shorted time frames 
were used such as 1, 3, 9, 24 and 48h for transcription factor activation but this 
could have been used on a number of different proteins that were shown to have 
been modulated following the treatments, as significant increase in mRNA 
expression occurred at the 24h time-point. Also the two stimulations used were 
PMA/PHA and LPS, the stimulations used were to induce a cytokine response in the 
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cells. PMA/PHA was added at the 24h time-point and LPS at 4h time-point (prior to 
end); the difference in time was due to the activations pathways and toxicity of the 
two treatments. The time-points allowed for a protective effect of the (poly)phenols 
prior to the stimulation being added. The need for two different stimuli was based 
on the fact that PMA/PHA, which was used in the original Jurkat cell treatments 
couldn’t be used in the THP-1 cells. As PMA in THP-1 cells had a different effect of 
differentiating THP-1 monocytes into macrophages. 
Label-free proteomics was chosen over other proteomic methods, as it 
wasn’t know what proteins to expect, therefore evaluating all changes to proteins 
would give an insight into the pathways being modulated by the treatments. Future 
work using label proteomics would give greater accuracy into certain pathways, such 
as changes to oxidations. 1 and 30µM treatments were used in the proteomics in 
unstimulated cells. Due to the cost and time these were the only experiments 
conducted, however future work to include more doses would give a better dose-
depended response to protein modulation, also to include the stimulus, as this might 
have provided large fold changes and given more confidence to the changes 
observed in the unstimulated experiments. 
Other limitations to the study include culturing the cells at 20% O2, this is 
common practise in in vitro studies, however no necessarily appropriate. Incubators 
are normally supplemented with 20% O2 and 5% CO2, atmospheric levels; however, 
very few cells actually encounter that concentration. In vivo the arterial blood 
experiences levels > 12% and tissue cells between 3-5% O2
221. It has been shown that 
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culturing primary T-cells at atmospheric oxygen significantly alters intracellular redox 
states by decreasing intracellular glutathione and increasing oxidised glutathione222. 
This effect was observed in this study, with increases in GSH with isorhamnetin and 
resveratrol treatments, when changes to glutathione reductase and other redox 
proteins would suggest an increase in GSH. Therefore conducting these experiments 
again at a lower oxygen concentration would be interesting to see if the levels of 
GSH increase with the polyphenol treatments. 
 
 
7.3 Cytokine release from Jurkat T lymphocytes was significantly repressed by 
the treatment with polyphenols. 
 
Ageing has been shown to be associated with chronic inflammation with 
increases in interleukin 6 (IL6)223,224  and tumour necrosis factor alpha (TNFα) 
observed being observed225,226. Lowering cytokine release could be beneficial in age 
related disease such as atherosclerosis, type 2 diabetes, and Alzheimer’s, and 
increased levels of TNFα have been shown to be associated with the pathogenesis of 
these diseases227.  
 It is believed that dietary interventions could have a potential benefit in 
overcoming age-related degeneration of the immune system and aid healthy ageing. 
Human’s diets were once high in plant based food and humans arguably may have 
evolved to rely on the intake of an optimal high level of polyphenol/ antioxidants. 
However modern diets tend to contain less polyphenols/antioxidants, which may be 
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insufficient to maintain an optimal oxidation/antioxidant balance. With increases in 
baseline oxidative stress associated with ageing and with the number of people 60 
years or over doubling since 1980228 (World Health Organisation), it appears to be 
important to increase dietary antioxidant intake. As dietary antioxidants can reduce 
oxidation and slow the progression of age-related diseases, it may potentially be 
possible to tailor a diet to contain foods with the greatest anti-inflammatory and 
antioxidant benefits. The aim of this work was to determine potential phenolic 
compounds that will reduce the pro-inflammatory and oxidative state observed with 
ageing.  
The most anti-inflammatory polyphenols screened were curcumin, 
resveratrol and isorhamnetin. Curcumin was the most anti-inflammatory polyphenol 
screened, with 30µM treatments lowering cytokine release in unstimulated cells. For 
cells stimulated with PMA/PHA, 30µM curcumin decreased IL2 from 6802 ± 698 
pg/ml (DMSO) to 145 ± 16.6 pg/ml, IL8 from 1133 ± 160 pg/ml (DMSO) to 433 ± 41 
pg/ml and TNFα from 188 ± 31 pg/ml (DMSO) to 3.2 ± 0.2 pg/ml. Curcumin is a 
component of the dietary spice turmeric and traditionally has been used in herbal 
remedies. It has a number of beneficial properties and been shown to influence 
many signalling pathways. Curcumin has been reported to blocks Ca2+ mobilization in 
T cells, this prevents the activation of nuclear factor of activated T cells (NFAT) along 
with nuclear factor kappaB (NF-κB) via T cell receptor229. This may explain the 
significant decreases in both IL2 (expression regulated by NFAT) and IL8 release 
(expression regulated by NF-κB) observed with the curcumin treatment230.  
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Other anti-inflammatory compounds identified were quercetin and its 
metabolite isorhamnetin which significantly loweried cytokine release compared 
with DMSO treated control.  30µM quercetin decreased TNFα by 89% ± 2% and 
30µM isorhamnetin decreased IL2 from 6802 ± 698 pg/ml (DMSO) to 2854 ± 366 
pg/ml, IL8 from 1133 ± 160 pg/ml (DMSO) to 468 ± 90 pg/ml and TNFα from 188 ± 31 
pg/ml (DMSO) to 29 ± 6 pg/ml in stimulated cells. Boesch-Saadatmandi et al 2007 
showed that 10µM quercetin and isorhamnetin significantly decreased mRNA and 
protein levels of TNFα in mouse macrophage-like cell line following stimulation with 
lipopolysaccharide231. They also showed a significantly lowering of plasma levels of 
TNFα from mice fed a quercetin supplement for 6 weeks. Another compound that 
significant decreased cytokine release was resveratrol, with both 1 and 30µM 
resveratrol reducing IL2 release from 14.4 ± 1 pg/ml (DMSO) to 8.3 ± 1 pg/ml from 
1µM resveratrol and 9 ± 0.8 pg/ml (DMSO) to 2.7 ± 0.6 pg/ml with 30µM resveratrol 
in unstimulated cells. Resveratrol is commonly found in the skin of grapes and has 
already been reported to have effects at lowering inflammation232. In other studies 
using Jurkat T lymphocyte cells, 5µM resveratrol was shown to suppress NF-κB 
activation induced by TNFα233.    
Not all the phenolic compounds screened had an anti-inflammatory effects. 
Both 1 and 30µM pyrogallol increased IL8 release from 34 ± 2 pg/ml (DMSO) to 149 ± 
19 pg/ml with 1µM pyrogallol and 10 ± 0.7 pg/ml (DMSO) to 176 ± 7 pg/ml with 30 
µM pyroallol in unstimulated cells. Pyrogallol is a metabolite of the green tea 
polyphenol epigallocatechin gallate (EGCG), in this study 30µM EGCG caused a slight 
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increase IL2 release from 37 ± 4 pg/ml (DMSO) to 41 ± 3 pg/ml in unstimulated cells 
although this was not statistically significant.  Pyrogallol has been shown to be a ROS 
generator and this may be cause of the dramatic increases in cytokines produced. 
When investigating pyrogallol’s effect on glutathione, it was shown to increase total 
and reduced glutathione and reduced the redox potential from -237.6 mV ± 2 mV 
with DMSO to -241.2 mV ± 2 mV with 30µM pyrogallol (data not shown). In 
agreement with the results shown here, Han et al. observed GSH levels to be 
increased in calf pulmonary artery endothelial cells treated with lower doses of 
pyrogallol (10-50µM)236. Pyrogallol has been shown to be a ROS generator and 
induces cell death in a number of cell lines including As4.1 juxtaglomerular cells234 
and HeLa cells235. This could explain why high doses of pyrogallol deplete GSH, due 
to increased ROS whereas lower doses do not236. In this experiment pyrogallol did 
not significantly alter cell number in the Jurkat cells. At lower concentrations of 
pyrogallol, the observed increases in total and reduced glutathione may be a 
protective effect against the increase in ROS production.  
 
 
7.4 Significant increases in the abundance of redox proteins with polyphenol 
treatments that were identified through quantitative proteomics.  
 
Proteomics was used to identify changes to protein abundance following 
treatment with the three chosen polyphenols, curcumin, isorhamnetin and 
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resveratrol. 30µM resveratrol showed the greatest number of changes with 434 
proteins being modulated. This study aimed to identify common mechanism and 
pathways modulated by the polyphenols treatments.  Network analysis identified 
proteins involved in redox regulation, oxidative phosphorylation and ribosomal 
modifications as pathways significantly modified by all three treatments. Ribosomal 
proteins (60S and 40S) were significantly suppressed by the polyphenols; ribosomal 
proteins catalyse the synthesis of new proteins, suggesting a down regulation of 
protein synthesis. Cocoa polyphenols have been shown to block p90 kDa ribosomal 
protein S6 kinase (RSK), which directly activates the S6 component of the 40S 
ribosomal subunit in JB6 mice 237 . 40S ribosomal protein S6 was significantly 
repressed 1.1 fold by 30µM isorhamnetin. This ribosomal protein S6 becomes 
phosphorylated on several serine residues by RSK proteins and it is thought 
activation of individual ribosomal proteins regulates translation (Figure 7.1)238. In the 
case of the cocoa polyphenols suppressing RSK, TNFα-induced NF-κB and AP-1 
activation was reduced along with inhibiting the TNFα-induced VEGF expression and 
this was proposed to contribute to the chemo-protective ability of these compounds.    
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Figure 7.1 - RSK (p70 kDa ribosomal protein S6 kinase) a mediator for cell survival, 
protecting the cell from apoptosis. RSK is a modulator of ribosomal proteins, 
effecting protein synthesis, along with cell cycle progression and survival239.  
 
 
 
Other pathways modulated by the polyphenols included oxidative 
phosphorylation which was significantly repressed. These included proteins such as 
cytochrome c oxidase, NADH dehydrogenase and ATPase synthase, in which studies 
have shown that suppression as these proteins, is beneficial to reduce the build-up 
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of free radicals associated with age. In patients with Alzheimer’s disease (AD) 
differential expression has been observed with oxidative phosphorylation genes 
overexpression of 8-hydroxyguanosine and cytochrome oxidase, leading to oxidative 
damage and defects to mitochondrial DNA240.  
 
  Ingenuity network analysis examined common mechanism of action via 
network analysis of the proteomics data. No inflammatory networks were 
specifically identified, but the top networks identified using Ingenuity software all 
centred around the NF-κB pathway, a major transcription factor in the regulation of 
inflammation241,242. Investigations into polyphenols and the NF-κB pathway have 
reported that certain polyphenols can inhibit the phosphorylation or ubiquitination 
of IκB preventing degradation and the sub-sequential translocation of NF-κB into the 
nucleus243. Also, polyphenols can inhibit the interactions NF-κB has with its target 
DNA, therefore preventing the gene expression of pro-inflammatory cytokines243 243,  
244. Interestingly, glutathione reductase was a common interaction linking the NF-κB 
pathway to the observed effects of all three polyphenol treatments. Glutathione 
reductase is as an enzyme important in maintaining the redox homeostasis of the 
cell by converting oxidised glutathione (GSSG) to reduced glutathione (GSH). The link 
between inflammation and redox is well studied and polyphenols have been show to 
modulate both. Curcumin for example has been shown to inhibit both hydrogen 
peroxide and TNFα induced activation of NF-κB, AP-1 and the release of IL8, along 
with increases in levels of GSH and gene expression of GCLC in alveolar epithelial 
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cells245. With glutathione reductase being found as a common protein modulated by 
all three treatments, the next step was to validate the changes observed with the 
proteomics and investigate further the changes to glutathione reaeration and 
regulation. 
 
 
 
7.5 Induction of redox proteins confirmed using protein and gene analysis, 
together with induction of the antioxidant transcription factor Nrf2. 
 
 
To confirm the increases in glutathione reductase (GSR) observed with 
quantitative proteomics in Chapter 4, western blot analysis was performed. 
Significant increases in GSR were confirmed at the 24h time-point with all 
treatments, curcumin with a 1.03 fold increase, resveratrol with 1.1 fold and 
isorhamnetin had the greatest increase with 1.3 fold induction compared with the 
DMSO treated control. A time-course experiment was conducted to evaluate the 
gene expression of GSR, along with other genes involved in glutathione production 
and regeneration. This included glutathione peroxidase (GPx1), an enzyme that 
scavenges and inactivates hydrogen and lipid peroxidases, protecting the cells from 
oxidative damage, glutathione synthetase (GSS) and glutamate-cysteine ligase 
(GCLC), both enzymes involved in the formation of glutathione, with GCLC being the 
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rate-limiting enzyme. Significant increases in GSR mRNA expression were observed 
with both curcumin and isorhamnetin, with a doubling of gene expression at the 24h 
time-point. No increase was observed with resveratrol treatment compared with 
DMSO treated control. Both GPx1 and GSS showed a decrease in mRNA expression 
at the 9h time-point with the polyphenols. Only isorhamnetin showed a significant 
(2.3 fold) increase in GCLC gene expression at the 24 h time-point compared with 
DMSO treated control. With increases in GSR, converting GSSG back to GSH, GCLC 
generating more GSH and GPx1 decreased, this suggests an increase in the 
intracellular concentration of GSH may occur. This was the case for curcumin  were 
GSH levels increased from 716 ± 45 (DMSO) to 3151 ± 436 nmol/million cells with 
10µM curcumin, but was not seen with isorhamnetin and resveratrol, where both 
observed a significant reduction in GSH. An explanation may arise from the time-
course experiment which showed different expression patterns. For isorhamnetin 
GSR mRNA expression steadily increased between 9 and 24h, whereas curcumin was 
increased at 9h but sharply increased at the 24h time-point, and resveratrol showed 
no significant changes to GSR over the time-points studied. It could be that for 
resveratrol and isorhamnetin 48h was not a time-point when GSH was most 
abundant. Further time-points would need to be investigated to determine this. 
Another explanation is that GSH is utilised by other redox proteins for example 
glutathione transferase 246  and certain peroxiredoxins 247 , 248 , which were both 
significantly upregulated by the isorhamnetin treatment.  
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To evaluate the mechanisms underlying these increases in activation of the 
transcription factor, nuclear factor (erythroid-derived 2)-like 2 (Nrf2) was measured. 
Nrf2 is a master regulator of antioxidant responses, activating the gene expression of 
genes such as glutathione reductase (GSR), glutathione transferases (GSTs), 
Thioredoxin (TXN), thioredoxin reductase (TXNRD), Peroxiredoxins (PRDXs), Glucose-
6-phosphate 1-dehydrogenase (G6PD), heme-oxygenase 1 (HO-1) and many 
others249. These genes regulate processes such as glutathione synthesis, NADPH 
production and quinone detoxificantion. The data showed that Nrf2 was significantly 
activated by both curcumin and isorhamnetin at the 48h time point, compared with 
DMSO treated control using a Nrf2 DNA binding assay. No significant increase was 
observed with resveratrol at the 48h time-point. These data are consistent with the 
changes observed with GSR and GCLC gene expression, as these genes were 
upregulated by curcumin and isorhamnetin, but not by resveratrol.  A time course of 
Nrf2 activation was conducted and isorhamnetin showed significant activation, 
initiating at 3h and continued at, 9, 24 and 48h, curcumin was significantly induced 
at the 9 and 48h time-points. This shows differential activation of Nrf2 with the two 
compounds. Isorhamnetin appears to be having the greatest effects on Nrf2 
activation and also antioxidant gene expression, with increases in glutathione 
reductase gene and protein expression, along with increases in other redox proteins. 
Pathway analysis was conducted to link all the changes observed with isorhamnetin 
contributes to this compound’s antioxidant and anti-inflammatory properties.   
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7.6 Proposed mechanism of the antioxidant action of isorhamnetin. 
 
Isorhamnetin was found to have had the greatest effect on modulation 
proteins in the Jurkat cell model system, with 403 proteins identified through 
proteomics. A number of proteins identified contribute to maintaining the redox 
homeostasis of the cell. These include glutathione reductase, thioredoxin and 
peroxiredoxins. Further analysis confirmed changes to glutathione reductase, along 
with the induction of antioxidant gene expression and Nrf2 activation. A proposed 
mechanism of action was generated, linking together these proteins which were 
modulated by 30µM isorhamnetin treatment (Fig. 7.2).  
This mechanism centres on Nrf2 activation, which was demonstrated to be 
increased following the isorhamnetin treatment, not only at the 48h but also at 3, 9, 
and 24 h. This contributes to the upregulation of antioxidant genes such as 
glutathione reductase and glutamate-cysteine ligase which was also shown to be 
upregulated with isorhamnetin. Nrf2 is also responsible for the regulation of other 
antioxidant genes such as glutathione transferase, thioredoxin, thioredoxin 
reductase, peroxiredoxins 1, and for NADPH production, iron sequestration and 
quinone detoxification256. 
  Along with Nrf2 there are other cellular components involved in the 
regulation of antioxidant genes, they are Kelch-like ECH-associated protein 1 
(Keap1), and also the antioxidant response elements (ARE). Keap1 is responsible for 
retaining Nrf2 in the cytoplasm and targets Nrf2 or degradation. Polyphenols have 
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been shown to inhibit Keap1 and allow nuclear translocation of Nrf2; quercetin has 
been shown to increase the mRNA expression of Nrf2 and protein and also reduce 
levels of Keap1 in human HepG2 cells250. Dietary polyphenols may also modulate 
antioxidant gene expression through the signalling pathways ERK, p38 and JNK251, 260. 
These pathways are complex, depending on the cell type and activator; the 
responses can vary from cell proliferation, differentiation, gene expression and 
apoptosis. Preliminary additional data have shown phosphorylated ERK1/2 is 
significantly induced at the 24h time-point with isorhamnetin treatment using 
western blot analysis (data not shown).   
The quantitative protein analysis identified a number of redox proteins that 
were induced following treatment with isorhamnetin, including glutathione 
reductase, thioredoxin, peroxiredoxins 1, 2, and 6, Glucose-6-phosphate 1-
dehydrogenase, Prostaglandin-H2 D-isomerase, and glutathione transferases. Due to 
the relatively small changes observed western blot was used to confirm the data, 
GSR induction was observed at the 24h time-point but not at 48h and induction of 
GSR mRNA was observed. Induction of thioredoxin and peroxiredoxins 2 were also 
confirmed at the 48h time-point using western blot analysis (data not shown).  
Thioredoxin (TRX) is a small, 12 kDa protein acting as an oxioreductase 
enzyme containing a dithiol-disulfide active site and facilitates the reduction of 
proteins by cysteine thiol-disulfide exchange. Thioredoxin reductase (TRDX1) 
regenerates oxidized TRX to its reduced form utilising NADPH252. Both thioredoxin 
and thioredoxin reductase 1 were both induced by isorhamnetin treatment. 
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Peroxiredoxins (PRDX) work closely with thioredoxin, as PRDX uses TRX as a 
reductant after reducing hydrogen peroxide253. PRDX 1, 2, 3, and 6 were modulated 
by treatment with isorhamnetin. PRDX1 and 2 reduce peroxidases with reducing 
agents provided by the thioredoxin system, unlike PRDX6 which has glutathione 
peroxidase activity 254 . PRDX3 was the only peroxiredoxin reduced by the 
isorhamnetin treatment, and has been shown to acts synergistically with MAP3K13 
to regulate the activation of NF-κB; inhibition of NF-κB would correlate with the 
reduction in cytokine release observed255. Another important redox protein is 
catalase, which reduces hydrogen peroxide to water and oxygen using Fe in the 
catalytic site, overexpression of this protein in the mitochondria of mice has been 
shown to increase lifespan256.  Although changes in catalase were not identified by 
proteomics for isorhamnetin treatment, it was identified for resveratrol treatment. 
Subsequent data of western blotting analysis has shown showed a significant 
increase in catalase with all three polyphenol treatments at the 48 h time-point (data 
not shown). 
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Figure 7.2 – Proposed mechanism of action for the antioxidant and anti-
inflammatory effects of Isorhamnetin.   
Key – Nrf2 (nuclear factor (erythroid-derived 2)-like 2), ERK (Extracellular signal-
regulated kinases 1/2), PRDX (peroxiredoxin), TXN (Thioredoxin), TXNRD1 
(thioredoxin reductase 1), FAD (flavin adenine dinucleotide), GSR (glutatSAhione 
reductase), GPX (glutathione peroxidase), TXNDC12 (Thioredoxin domain-
containing protein 12), G6PD (Glucose-6-phosphate 1-dehydrogenase), PGD 
(Prostaglandin-H2 D-isomerase), NADPH (Nicotinamide adenine dinucleotide 
phosphate reduced), GSH (reduced glutathione), GSSG (oxidised glutathione), 
GSTM3 (Glutathione S-transferase M3), GSTP1 (Glutathione S-transferase P), CAT 
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(Catalase), ASK1 (Apoptosis signal-regulating kinase 1), JNK (c-Jun N-terminal 
kinases), MKK (Mitogen-activated protein kinase kinase), p38 MAPK (p38 mitogen-
activated protein kinase), NF-κB (nuclear factor kappa B), IL2 (interleukin 2), IL8 
(interleukin 8), TNFα (Tumour necrosis factor alpha). Arrows indicate activation 
whereas flat-headed arrows denote inhibitor effects. [Initial pathway was 
generated by KEGG pathway database257, additions were added from literature 
searches258,259,260,261,262]. 
 
 
 As discussed previously there were a number of changes to glutathione 
production and regulation. Increases in GCLC (the rate limiting enzyme in glutathione 
production) and a decrease in glutathione peroxidases (generating oxidised 
glutathione) were observed with isorhamnetin. Proteomics also identified proteins 
involved in NADPH production, G6PD (Glucose-6-phosphate 1-dehydrogenase), PGD 
(Prostaglandin-H2 D-isomerase), which provide the NADPH molecules required for 
the enzymatic activity of glutathione reductase and also the thioredoxin263 and 
peroxiredoxin 6 system 264.  
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 This mechanism proposed (Fig. 7.2) indicated that isorhamnetin treatment 
leads to the induction of Nrf2 activation, activation of antioxidant genes and altered 
redox regulation. This is thought to contribute to NF-κB inhibition, inhibition of pro-
inflammatory cytokines and results in the lowering in cytokine release observed with 
isorhamnetin. To fully evaluate this hypothesis, experimental inhibition of Nrf2 will 
be required followed by measurements of the effects on cytokine release. 
Preliminary work has been conducting using the mycotoxin Ochratoxin A to inhibit 
Nrf2 in the Jurkat T lymphocyte cells but this was inconclusive. It has been previously 
shown that Nrf2 knockout mice are more sensitive to inflammatory disease265 and 
carcinogenesis266. It therefore appears that this pathway plays a major role in health 
and modulations to the pathway may be beneficial in health and disease. 
 
7.7 Cytokine release was significantly reduced by isorhamnetin in THP-1 cells, 
but changes to glutathione homeostasis were not. 
 
To evaluate these changes to inflammation and redox modulation in the Jurkat cell 
with isorhamnetin, the experiments conducted were repeated in an alternative cell 
type, human monocytes THP-1 cells.  A significant reduction in IL8 and TNFα, 
correlates with the Jurkat cells results, other cytokines also lowered included MCP-1, 
IL1β, IL6, and GRO. IL10 was also induced with 30µM isorhamnetin treatment in THP-
1 cells, IL10 is an anti-inflammatory cytokine and is a positive effect on the cell. 
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Significant activation of Nrf2 was observed, increasing over time from 3h to 48 h; but 
this activation of Nrf2 didn’t result in an increase in antioxidant genes. Quantitative 
PCR showed no significant changes to the gene expression of glutathione reductase, 
glutathione peroxidase, glutathione synthase and glutamate cysteine ligase following 
isorhamnetin treatment. This shows that there are some overlapping areas with 
were isorhamnetin is having the same effect in both the Jurkat and THP-1 cell lines, 
but differences in terms of the redox related protein expression.  
 
7.8 Summary. 
 
Ageing has been associated with increases in baseline oxidative stress along with 
chronic inflammation. This study has shown that dietary polyphenols have the 
potential to modulate pathways involved in inflammation and redox homeostasis, 
which could benefit the elderly and could potentially prevent age-related diseases.  
Isorhamnetin, a compound found in onions significantly lowered the release of 
inflammatory markers by over 50%, for cytokines IL2, IL8 and TNF in stimulated cells. 
Isorhamnetin also induced activation of the antioxidant transcription factor Nrf2, 
which was followed by an induction of antioxidant proteins including glutathione 
reductase, catalase, peroxiredoxins and thioredoxin. These modulations support the 
potential use of isorhamnetin and other compounds evaluated in this study, in 
enhancing cellular antioxidant potential. The incorporation of these types of 
compounds into a healthy ageing diet could help prevent disease and maintain a 
healthy lifestyle.  
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8.1 APPENDIX 1 
(Poly)phenol data sheets including chemical name, abbreviation, chemical formula, 
molar mass, structure, food sources of the (poly)phenol and concentrations found in 
blood plasma (where data available). Data obtained from Phenol Explorer unless 
otherwise stated. 
 
 
Table 8.1 Polyphenol data: name, structure, molecular weightm food sources and 
concentractions in plasma. 
CATECHOL (CAT) 
 
 
Food sources: 
 
Food: Cocoa. 
Drink: Beers, 
coffee, Green tea 
(metabolite) 
Concentration in plasma: 
 
0.262 ± 0.107 µg/ml 5 day 
treatment of 100mg/m2 
i.v. for 1h each day in 
humans.267 
 
Formula: C6H6OH2 
Molar mass: 110.1 g/mol 
Log Kow = 0.88 
 
 
 
PHLOROGLUCINOL (PHL)  
 
 
Food sources: 
 
Concentration in plasma: 
 
~700 ng/ml was detercted 
in human plasma, 0.33h 
after administration of a 
single oral dose of 160mg 
of phloroglucinol268. 
Formula: C6H6 O3 
Molar mass: 126.11 g/mol 
Log Kow = 0.55 
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PYROGALLOL (PYR) 
 
Food sources: 
 
Drinks: Beers, 
cocoa, coffee, 
green tea 
(metabolite) 
 
Concentration in plasma: 
 
Formula: C6H6 O3 
Molar mass: 126.11 g/mol 
Log Kow = 0.97 
 
 
 
 
 
4-HYDROXYBENZOIC ACID (HBA) 
 
 
Food sources: 
 
Food: Cereals 
(Maize, oat, 
rice), fruit 
(Berries, 
grapefruit, 
dates), carrots, 
olives, olive oil 
Drink: Beers, 
Wines. 
Concentration in plasma: 
 
9.73 µmol/L after 24h 
(human – 40 g/day for 4 
weeks, cocoa power in 
skimmed milk)269 
Formula: C7H6O3 
Molar mass: 138.12 g/mol 
Log Kow = 1.58 
 
 
 
 
TYROSOL (TYR) 
 
Food sources: 
 
Food: Olives, 
olive oil, vinegar 
Drink: Beers, 
Wines, 
champagne. 
Concentration in plasma: 
 
31.710 ± 0.412 µg/ml 
purified from olive oil by-
product in (rat) plasma270.  
Formula: C8H10O2 
Molar mass: 138.16 g/mol 
Log Kow =  
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4’-HYDROXYPHENYLACETIC ACID (HPA) 
 
Food sources: 
 
Food: Cereals 
(Maize, oats), 
Olives, Olive oil 
Drinks: Beers, 
wine. 
Concentration in plasma: 
 
0.11 µmol/L after 24h 
(human – 40 g/day for 4 
weeks, cocoa power in 
skimmed milk)2692 
Formula: C8H8O3 
Molar mass: 152.15 g/mol 
Log Kow = 0.09 
 
 
3-(3'-HYDROXYPHENYL)PROPIONIC ACID (HPP) 
 
Food sources: 
 
Drinks: Red wine 
and red grape 
extract capsules 
Foods: Cocoa 
 
Concentration in plasma: 
 
0.23 µmol/L after 24h 
(human – 40 g/day for 4 
weeks, cocoa power in 
skimmed milk)2692 
Formula: C9H10O3 
Molar mass: 166.17 g/mol 
Log Kow = 0.77 
 
VANILLIC ACID (VAN) 
 
Food sources: 
 
Food: Cereal 
(rye, wheat, 
maize, oat, rice), 
fruit (dates, 
berries, 
grapefruit) 
Olives, olive oil, 
soy oil, Herbs 
(sage, thyme, 
rosemary, basil, 
oregano), 
almonds 
Drink: Beers, 
wine (red), rum, 
cognac, whisky, 
sherry 
Concentration in plasma: 
 
2.71 µmol/L after 24h 
(human – 40 g/day for 4 
weeks, cocoa power in 
skimmed milk)2692 
Formula: C8H8O4 
Molar mass: 168.15 g/mol 
Log Kow = 1.22 
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4-HYDROXYMANDELIC ACID (HMA) 
 
Food sources: 
 
Drinks: Red wine 
and red grape 
extract capsules 
Concentration in plasma: 
 
Formula: C8H8O4 
Molar mass: 168.15 g/mol 
Log Kow =  
 
 
 
 
HIPPURIC ACID (HIP) 
 
Food sources: 
 
Foods: Cocoa, 
grapes 
Drinks: Black tea 
(metabolite), 
wine (red) 
Concentration in plasma: 
 
11 nmol/ml in plasma from 
house painters271. 
Formula: C9H9NO3 
Molar mass: 179.17 g/mol 
Log Kow = 0.46 
 
 
 
CAFFEIC ACID (CAF) 
 
Food sources: 
 
Foods: Cereal, 
dates, 
lingonberry, 
blueberries, 
apples, oil, 
herbs, olives. 
Drinks: Beers, 
cider, wine (red), 
prune juice, 
coffee272 
Concentration in plasma: 
 
41.3 µmol/L after 8 days 
(rats 250µmol/day)273 
Formula: C9H8O4 
Molar mass: 180.16 g/mol 
Log Kow = 1.15 
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3-(4'-HYDROXYPHENYL)LACTIC ACID (HPL) 
 
Food sources: 
 
Concentration in plasma: 
 
118 +/- 45 ng/ml in the 
plasma of normal 
humans274. 
Formula: C9H10O4 
Molar mass: 182.17 g/mol 
Log Kow = 0.67 
 
 
 
FERULIC ACID (FER) 
 
Food sources: 
 
Foods: Cereal 
(rye, wheat, 
maize, oat, rice), 
chocolate, 
tomatoes, 
cabbage dried 
fruit, fruit 
(berries, 
grapefruit, 
apples), olives, 
olive oil,  soy oil, 
walnuts, herbs 
(sage, oregano, 
rosemary), 
turmeric 
(metabolite). 
Drink: Beers, 
wine, sherry, 
champagne, 
coffee, citrus 
juices2725 
 
. 
 
 
Concentration in plasma: 
 
0.21 µmol/L after 24h 
(human – 40 g/day for 4 
weeks, cocoa power in 
skimmed milk).269  
1.68 µmol/L after 30 min 
(rat –   single dose 5.15 
mg/kg body weight). 
Formula: C10H10O4 
Molar mass: 194.18 g/mol 
Log Kow = 1.51 
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ISOFERULIC ACID (IFA) 
 
Food sources: 
 
Foods: Vinegar. 
Concentration in plasma: 
 
4.5 µmol/L after 8 days (rat 
– 250 µmol/day 5-
caffeoylquinic acid) 
Formula: C10H10O4 
Molar mass: 194.18 g/mol 
Log Kow = 1.42 
 
 
DIHYDROFERULIC ACID (FER) 
 
Food sources: 
 
Food: turmeric 
(metabolite). 
Drink: coffee.  
Concentration in plasma: 
Formula: C10H12O4 
Molar mass: 196.07 g/mol 
Log Kow = 1.63 
 
 
 
 
 
4’-HYDROXYHIPPURIC ACID (HHA) 
 
Food sources: 
 
Food: Cocoa 
 
Concentration in plasma: 
 
0.11 µmol/L after 24h 
(human – 40 g/day for 4 
weeks, cocoa power in 
skimmed milk)2692 
Formula: C9H9NO4 
Molar mass: 195.0 g/mol 
Log Kow = 0.67 
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RESVERATROL (RES) 
 
Food sources:  
 
Food: Chocolate, 
lingonberry, 
redcurrent, 
cranberry, oil, 
pistachio. 
Drinks: Wine 
(red). 
Concentration in plasma: 
 
28.4µM following 2 weeks 
of oral administration of 
75 mg/ml resveratrol in 
mice275. 
Formula: C14H12O3 
Molar mass: 228.0 g/mol 
Log Kow = 3.1 
 
 
 
 
 
FERULOYLGLYCINE (FLG) 
 
Food sources: 
 
Drinks: Coffee, 
juice drinks 
Concentration in plasma: 
Formula: C12H13NO5 
Molar mass: 251.0 g/mol 
Log Kow = 0.31  
 
 
 
ISOFERULOYLGLYCINE (IFG) 
         
 
 
Food sources: 
 
Drinks: coffee 
Concentration in plasma: 
Formula: C14H12O3 
Molar mass: 228.0 g/mol 
Log Kow =  
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QUERCETIN (QUE) 
 
Food sources: 
 
Foods: Cereal, 
chocolate, apple, 
tomatoes, 
onions. 
Drinks: Beers, 
wine (red), black 
tea 
Concentration in plasma: 
 
3.95 µmol/L 3h after oral 
consumption of dry 
shallots (onions) in 
humans276. 
Formula: C15H10O7 
Molar mass: 302.0 g/mol 
Log Kow = 1.48 
 
3-O-METHYLQUERCETIN (3MQ) 
 
 
Food sources: 
 
Foods: Apples, 
onions 
Concentration in plasma: 
 
~1µM after 2h following 
ingestion of 200mg 
quercetin in humans277. 
Formula: C16H12O7 
Molar mass: 316.26 g/mol 
Log Kow = 1.65 
 
ISORHAMNETIN (ISO) 
 
Food sources: 
 
Foods: Onions 
(red/yellow) 
Drinks: Wine 
(red) 
Concentration in plasma: 
 
75ng/ml after 72h oral 
dose in rats278.  
 
(isorhamnetin/tamarixetin) 
183 ng/ml after 600mg/kg 
body weight in rats, 
increased 10 fold after 8 
days of Ginkgo extract 
(Chinese non-flowering 
plant)279. Formula: C16H12O7 
Molar mass: 316.26 g/mol 
Log Kow = 1.78 
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CHLOROGENIC ACID (CGA) 
 
Food sources: 
 
Foods: Dried 
fruit, carrots, 
broccoli, 
blueberries, 
apples. 
Drinks: Wine 
(rosé), tea 
(green/black), 
coffee, cider2725. 
Concentration in plasma: 
 
14.8 ± 11.7 µmol/L after 
3hfollowing the 
consumption of 0.2g 
decaffeinated green coffee 
in humans280. 
Formula: C16H18O9 
Molar mass: 354.31 g/mol 
Log Kow = -1.01 
 
CURCUMIN (CUR) 
 
Food sources: 
 
Foods: Turmeric, 
curry powder 
Concentration in plasma: 
 
11ng/L after 1h 
consumption of 3.6g 
curcumin daily for 29 days 
in humans281. 
2.3 µg/ml (10g) and 
1.7µg/ml (12g) after 72h 
consumption of curcumin 
in humans282. 
Formula: C21H20O6 
Molar mass: 368.38 g/mol 
Log Kow = 3.29 
 
CYANIDIN-3-O-GLUCOSIDE (CYA) 
 
 
 
Food sources: 
 
Foods: Olives, 
lettuce, 
marionberry  
Drinks: Wine 
(red), black 
grape, raspberry, 
strawberry, 
blackcurrent, 
blackberry, 
pomegranate 
juice 
Concentration in plasma: 
 
0.31 µmol/L after single 
dose of0.9mmol/kg body 
weight in rats. 
 
43nmol/L oral consumtion 
of marionberries in pigs283. 
 
Formula: C21H21O11 
Molar mass: 449.0 g/mol 
Log Kow = 0.77 
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(-)-EPIGALLOCATECHIN-3-O-GALLATE (EGCGI) 
 
Food sources: 
 
Foods: Kiwi, 
pecan, hazelnut, 
avocado 
Drinks: Tea 
(green, black, 
camomile, 
oolong) 
Concentration in plasma: 
~4µM 90 min after oral 
ingestion of green tea 
extract in humans. ~8µM 
30min post injection of 
EGCG 
 
Formula: C22H18O11 
Molar mass: 458.37 g/mol 
Log Kow = 2.56 
PERARGONIDIN-3-O-GLUCOSIDE (PEL) 
 
Food sources: 
 
Food: 
strawberries284 
Concentration in plasma: 
 
274 nmol/L after 1h 
consumption of 
strawberries in humans284. 
Formula: C21H21O10 
Molar mass: 468.84 g/mol 
Log Kow = 1.25 
PUNICALAGIN (PUN) 
 
Food sources: 
 
Drinks: 
Pomegranate 
juice 
Concentration in plasma: 
30µg/ml following 
consumption of 1.2g 
punicalagin  for 37 days in 
rats285. 
Formula: C48H28O30 
Molar mass: 1084.0 g/mol 
Log Kow = -2.33 
 
 
Structures and data from EMBL-EBI (www.ebi.ac.uk, accessed 14.8.13) or Phenol-Explorer 
(www.phenol-explorer.eu, accessed June 2015) 
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8.2 APPENDIX 2 
Due to the number of (poly)phenols used in the study, experiments were conducted 
on different days. Graphs were plotted with individual cell numbers or cytokine data 
both on the same day and also between days to assess the variability between 
experiments. 
 
Figure 8.1 – Variability between cell number both within an experiment and also 
between experiments conducted on different days. Cell viability with 1µM DMSO 
in A) unstimulated B) stimulated cells and with 30µM DMSO C) unstimulated and D) 
stimulated cells. 
 
A B 
C D 
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Figure 8.2 – Variability between IL2 and IL8 in unstimulated cells both within an 
experiment and also between experiments conducted on different days. Variability 
in untreated cells A) IL2 B) IL8 release, in 1µM DMSO treated cells C) IL2 D) IL8 and 
in 30µM DMSO treated cells E) IL2 and F) IL8.  
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Figure 8.3 – Variability between IL2 and IL8 in PMA/PHA stimulated cells both 
within an experiment and also between experiments conducted on different days. 
Variability in untreated cells A) IL2 B) IL8 release, in 1µM DMSO treated cells C) IL2 
D) IL8 and in 30µM DMSO treated cells E) IL2 and F) IL8. 
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Figure 8.4 – Variability between TNFα in PMA/PHA stimulated cells both within an 
experiment and also between experiments conducted on different days. Variability 
in A) untreated cells B) 1µM DMSO treated cells C) 30µM DMSO treated cells. 
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Polyphenol cytokine raw data. 
 
Table 8.2. Luminex data for cells treated with 29 different polyphenols at both 1 and 30µM 
for 48h (unstimulated cells). Mean of the raw data minus DMSO treated control (pg/ml) 
along with standard error of the mean (SEM).  
 
IL2 
(pg/ml) SEM 
IL8 
(pg/ml) SEM 
1µM Catechol 2.4 2.0 23.9 31.0 
30µM Catechol -42.8 8.1 19.1 4.0 
1µM Phloroglcinol -2.4 0.8 -22.4 8.8 
30µM Phloroglcinol -18.2 4.0 4.3 1.4 
1µM Pyrogallol 1.4 1.1 114.3 17.2 
30µM Pyrogallol -1.6 0.6 166.1 7.1 
1µM Hippuric acid -0.4 1.2 -1.5 3.1 
30µM Hippuric acid -0.7 1.1 -1.9 0.9 
1µM 4'hydroxybenzoic acid -0.8 0.9 -3.3 14.7 
30µM 4'hydroxybenzoic acid -10.5 11.1 2.4 6.0 
1µM Protocatechuic acid -1.0 1.3 4.0 22.4 
30µM Protocatechuic acid -3.7 14.8 5.5 5.8 
1µM 4'Hydroxyphenyllacetic acid -3.3 1.0 -14.2 5.8 
30µM 4'Hydroxyphenyllacetic acid -3.2 1.2 0.0 1.5 
1µM Vanillic acid -6.5 0.5 -14.4 1.9 
30µM Vanillic acid -2.9 0.5 -4.5 1.7 
1µM 4'Hydroxymandelic acid -6.7 1.7 -28.1 5.2 
30µM 4'Hydroxymandelic acid -3.4 1.1 -8.3 1.7 
1µM 3-(3'-hydroxyphenyl)propionic acid -6.5 1.0 -17.4 4.5 
30µM 3-(3'-hydroxyphenyl)propionic acid -2.3 0.6 -5.6 2.2 
1µM 3-(4'-hydroxyphenyl)lactic acid -4.4 2.0 -23.3 4.8 
30µM 3-(4'-hydroxyphenyl)lactic acid -4.2 1.4 0.8 1.6 
1µM Caffeic acid -1.5 1.9 -2.6 4.2 
30µM Caffeic acid -0.3 1.0 -2.2 2.1 
1µM Ferulic acid -2.1 0.6 -51.5 2.0 
30µM Ferulic acid -1.7 0.5 37.4 2.5 
1µM Isoferulic acid -3.3 0.5 -11.7 4.4 
30µM Isoferulic acid -0.5 0.5 -5.0 1.5 
1µM Trysol -4.1 1.0 -9.7 1.7 
30µM Trysol -6.7 1.0 -7.5 0.6 
1µM Dihydroferulic acid -1.4 0.3 -2.9 1.0 
30µM Dihydroferulic acid -4.4 0.2 -2.1 0.5 
1µM 4'-hydroxyhippuric acid -2.6 0.8 -13.6 2.3 
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30µM 4'-hydroxyhippuric acid -2.8 1.0 -3.3 0.7 
1µM Feruloglycine -1.8 0.4 -3.4 1.3 
30µM Feruloglycine -4.6 0.6 -1.8 0.9 
1µM Isoferuloylglycine -2.4 1.1 -55.6 1.7 
30µM Isoferuloylglycine -2.0 0.3 39.3 4.7 
1µM Resveratrol -6.1 1.0 -10.9 2.6 
30µM Resveratrol -6.2 0.6 -5.3 0.5 
1µM 5-O-caffeolyquinic acid -4.0 1.0 -11.6 0.6 
30µM 5-O-caffeolyquinic acid -5.8 0.7 -7.5 0.9 
1µM Curcumin -0.3 0.8 -2.3 1.7 
30µM Curcumin -8.8 0.1 23.4 2.4 
1µM Quercetin -2.1 0.5 -3.9 0.9 
30µM Quercetin -6.1 0.6 -2.4 0.9 
1µM 3-O-methylquercetin 4.8 0.8 -1.3 0.9 
30µM 3-O-methylquercetin -5.0 0.6 -3.6 0.6 
1µM Isohamnetin -5.2 1.3 -15.9 0.9 
30µM Isohamnetin -5.4 0.5 -6.4 0.4 
1µM EGCG -0.8 0.3 -100.8 20.4 
30µM EGCG -3.9 0.5 3.8 2.8 
1µM Kuromanin -3.6 0.2 -70.1 23.9 
30µM Kuromanin -5.1 0.3 5.1 8.0 
1µM Callistephin chloride -3.5 0.6 -105.9 6.7 
30µM Callistephin chloride -4.1 0.6 7.5 5.2 
1µM Punicalagin -1.0 1.1 -94.1 10.5 
30µM Punicalagin 0.3 0.7 -15.3 2.3 
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Table 8.3. Luminex data for cells treated with mixtures of 4 different polyphenol 
compounds at both 1 and 30µM for 48h (unstimulated cells). Mean of the raw data minus 
DMSO treated control (pg/ml) along with standard error of the mean (SEM). 
 
IL2 
(pg/ml) SEM 
IL8 
(pg/ml) SEM 
1µM Mix EGCG, Pun, Call, Kur -4.7 0.3 -99.9 16.2 
30µM Mix EGCG, Pun, Call, Kur -2.8 0.5 -8.3 4.3 
1µM Mix Phlor, Cat, Proto,4-HBA -0.4 0.7 5.4 16.0 
30µM Mix Phlor, Cat, Proto,4-HBA -20.9 11.3 16.0 9.5 
1µM Mix 4-HPLA, 4-HMA, 3HPPA, 
3HPLA -7.5 1.1 -28.5 5.5 
30µM Mix 4-HPLA, 4-HMA, 3HPPA, 
3HPLA -7.7 0.6 -9.7 0.7 
1µM Mix (Caff, Fer, IF, IFG) -4.4 0.9 -16.2 4.3 
30µM Mix (Caff, Fer, IF, IFG) -2.0 0.5 -5.3 1.2 
1µM Mix (Hipp, 4HHA, Try, 5OCQA) -3.0 0.8 -6.9 1.9 
30µM Mix (Hipp, 4HHA, Try, 5OCQA) -6.0 0.9 -4.8 1.4 
1µM Mix(DHFA, FG, Q, 3OMQ) -3.6 0.7 -6.5 0.9 
30µM Mix(DHFA, FG, Q, 3OMQ) -5.2 0.6 -4.3 0.5 
 
 
Mix 1 = Epigallocatechin gallate (EGCG), kuromanin, callistephin chloride, and punicalagin. 
Mix 2 = Phloroglucinol, catechol, protocatechuic acid and 4-hydroxybenzoic acid. 
Mix 3 = 4'Hydroxyphenyllacetic acid, 4’-hydroxymandelic acid, 3-(3'-
hydroxyphenyl)propionic acid and 3-(4'-hydroxyphenyl)lactic acid. 
Mix 4 = Caffeic acid, Ferulic acid, Isoferulic acid and isoferuloylglycine. 
Mix 5= Hippuric acid, 4’-hydroxyhippuric acid, tyrosol and chlorogenic acid. 
Mix 6 = Dihydroferulic acid, feruloylglycine, quercetin and 3-O-methylquercetin. 
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Table 8.4. Luminex data for cells treated with 29 different polyphenols at both 1 and 30µM 
for 48h with PMA/PHA stimulation at the 24h time-point (stimulated cells). Mean of the 
raw data minus DMSO treated control (pg/ml) along with standard error of the mean 
(SEM). 
 
 
IL2 
(pg/ml) SEM 
IL8 
(pg/ml) SEM 
TNFα 
(pg/ml) SEM 
1µM Catechol -2056.5 1152.9 229.5 1005.2 -93.6 48.4 
30µM Catechol -2495.3 83.3 5015.3 211.9 -52.7 3.0 
1µM Phloroglcinol -1400.1 923.2 -1677.2 344.6 -20.1 7.1 
30µM Phloroglcinol 4106.7 489.3 4336.4 655.9 206.5 22.7 
1µM Pyrogallol -716.1 410.8 -199.5 115.6 -62.6 23.0 
30µM Pyrogallol -2601.4 467.6 337.2 74.4 -77.5 19.4 
1µM Hippuric acid 1580.9 596.8 -48.2 91.1 129.3 26.5 
30µM Hippuric acid 228.6 393.7 82.3 52.0 0.3 11.3 
1µM 4'hydroxybenzoic acid 5248.1 1111.1 1587.0 841.8 282.5 67.4 
30µM 4'hydroxybenzoic acid 6328.4 346.8 2667.6 162.1 187.8 25.3 
1µM Protocatechuic acid -1674.7 627.0 -280.5 696.0 -21.2 43.4 
30µM Protocatechuic acid 1823.3 283.6 1750.6 155.4 39.0 5.5 
1µM 4'Hydroxyphenyllacetic 
acid -1184.9 245.6 -347.0 238.0 8.5 14.3 
30µM 4'Hydroxyphenyllacetic 
acid 1030.2 629.5 822.4 276.0 22.9 11.6 
1µM Vanillic acid -1511.6 451.0 -417.8 128.7 -34.4 23.7 
30µM Vanillic acid -1769.4 210.2 -456.8 54.4 -85.6 9.4 
1µM 4'Hydroxymandelic acid 229.8 212.6 -8.3 265.6 8.8 6.4 
30µM 4'Hydroxymandelic acid 1071.5 532.9 110.0 155.1 10.3 10.6 
1µM 3-(3'-
hydroxyphenyl)propionic acid -389.4 415.2 -278.1 290.9 -3.2 3.9 
30µM 3-(3'-
hydroxyphenyl)propionic acid 1519.8 407.8 -3.9 180.7 16.8 5.5 
1µM 3-(4'-hydroxyphenyl)lactic 
acid -917.8 463.3 -959.8 226.0 -15.4 12.9 
30µM 3-(4'-
hydroxyphenyl)lactic acid -352.7 378.3 -356.1 249.3 -15.5 9.8 
1µM Caffeic acid -2617.5 401.0 -701.5 155.5 -50.4 15.1 
30µM Caffeic acid -1901.4 518.7 -365.3 139.1 -42.0 11.7 
1µM Ferulic acid -1366.5 281.6 -458.6 89.1 -34.0 18.8 
30µM Ferulic acid -1394.2 546.1 -571.4 144.4 -51.8 23.2 
1µM Isoferulic acid -13.6 581.9 -281.2 151.7 -2.0 21.8 
30µM Isoferulic acid -1677.9 468.6 -507.6 94.4 -59.5 14.1 
1µM Trysol -141.1 284.3 141.0 120.1 75.7 26.7 
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30µM Trysol -920.3 381.8 -23.5 77.0 21.5 22.0 
1µM Dihydroferulic acid -730.0 592.4 -353.6 105.3 -30.8 22.4 
30µM Dihydroferulic acid -3263.8 500.2 -433.9 41.3 -126.8 11.2 
1µM 4'-hydroxyhippuric acid -751.4 237.9 -192.8 90.7 34.8 16.5 
30µM 4'-hydroxyhippuric acid -687.1 381.5 92.9 79.0 12.2 13.1 
1µM Feruloglycine 8322.7 1500.0 825.1 279.0 265.6 50.4 
30µM Feruloglycine -296.1 939.5 56.2 147.8 -54.0 14.4 
1µM Isoferuloylglycine -2065.0 517.1 -606.6 144.0 -56.6 27.0 
30µM Isoferuloylglycine -3393.3 554.3 -918.7 98.4 -78.8 18.3 
1µM Resveratrol -1311.0 77.5 -216.5 75.6 -96.5 34.2 
30µM Resveratrol -4260.4 177.6 -50.7 68.0 -144.3 5.7 
1µM 5-O-caffeolyquinic acid -222.3 356.1 -94.3 112.7 43.3 16.6 
30µM 5-O-caffeolyquinic acid -1162.0 337.0 -189.6 79.4 -19.3 12.4 
1µM Curcumin -2169.0 404.3 -567.2 159.8 -81.2 31.3 
30µM Curcumin -6656.7 16.6 -699.9 40.8 -185.2 0.2 
1µM Quercetin 8268.4 1001.0 290.1 171.3 70.4 36.8 
30µM Quercetin -6844.8 238.1 -84.4 138.2 -202.6 3.3 
1µM 3-O-methylquercetin 24240.9 2178.8 1904.4 178.9 185.2 27.7 
30µM 3-O-methylquercetin -6820.9 123.8 -314.4 75.5 -208.8 1.9 
1µM Isohamnetin -3608.9 290.9 -860.7 90.4 -150.4 17.2 
30µM Isohamnetin -3947.5 365.8 -665.1 89.9 -159.4 5.1 
1µM EGCG -420.5 254.1 1014.2 490.7 22.3 6.6 
30µM EGCG -821.2 268.7 1459.4 251.2 16.7 8.2 
1µM Kuromanin -804.2 488.6 -428.8 588.3 31.2 6.2 
30µM Kuromanin -928.3 215.6 354.1 273.2 -1.6 2.7 
1µM Callistephin chloride -636.6 304.2 572.0 244.4 22.8 8.7 
30µM Callistephin chloride -884.2 132.5 221.7 93.7 -2.9 2.1 
1µM Punicalagin 595.6 231.3 1774.6 398.1 148.5 8.8 
30µM Punicalagin -456.5 275.9 147.2 226.5 170.9 6.2 
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Table 8.4. Luminex data for cells treated with mixtures of 4 different polyphenol 
compounds at both 1 and 30µM for 48h with PMA/PHA stimulation at the 24h time-point 
(stimulated cells). Mean of the raw data minus DMSO treated control (pg/ml) along with 
standard error of the mean (SEM). 
 
 
IL2 
(pg/ml) SEM 
IL8 
(pg/ml) SEM 
TNFα 
(pg/ml) SEM 
1µM Mix 1(EGCG, Pun, Call, Kur) -1121.3 681.0 107.5 1284.8 10.8 19.6 
30µM Mix 1 (EGCG, Pun, Call, Kur) -2518.5 202.0 -1630.5 122.2 6.5 1.6 
1µM Mix 2(Phlor, Cat, Proto,4-HBA) 1397.3 683.3 2208.6 531.1 73.2 35.9 
30µM Mix 2 (Phlor, Cat, Proto,4-
HBA) 1180.9 428.5 4990.8 493.4 -5.2 6.6 
1µM Mix 3 (4-HPLA, 4-HMA, 
3HPPA, 3HPLA) -1065.5 328.0 -692.1 225.2 -22.2 10.7 
30µM Mix 3 (4-HPLA, 4-HMA, 
3HPPA, 3HPLA) 602.6 387.5 217.2 223.6 -4.5 2.4 
1µM Mix 4 (Caff, Fer, IF, IFG) -2181.5 438.4 -633.0 100.9 -64.7 11.4 
30µM Mix 4 (Caff, Fer, IF, IFG) -980.4 498.3 -725.5 120.9 -37.6 12.9 
1µM Mix 5 (Hipp, 4HHA, Try, 
5OCQA) -666.9 385.5 -408.9 98.2 -55.1 20.6 
30µM Mix 5 (Hipp, 4HHA, Try, 
5OCQA) -1345.8 75.7 -330.6 52.5 -104.0 13.3 
1µM Mix 6 (DHFA, FG, Q, 3OMQ) 2689.1 673.0 -291.1 150.6 -60.3 12.9 
30µM Mix 6 (DHFA, FG, Q, 3OMQ) -4120.4 633.1 -215.1 140.9 -174.5 6.8 
 
Mix 1 = Epigallocatechin gallate (EGCG), kuromanin, callistephin chloride, and punicalagin. 
Mix 2 = Phloroglucinol, catechol, protocatechuic acid and 4-hydroxybenzoic acid. 
Mix 3 = 4'Hydroxyphenyllacetic acid, 4’-hydroxymandelic acid, 3-(3'-
hydroxyphenyl)propionic acid and 3-(4'-hydroxyphenyl)lactic acid. 
Mix 4 = Caffeic acid, Ferulic acid, Isoferulic acid and isoferuloylglycine. 
Mix 5= Hippuric acid, 4’-hydroxyhippuric acid, tyrosol and chlorogenic acid. 
Mix 6 = Dihydroferulic acid, feruloylglycine, quercetin and 3-O-methylquercetin. 
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8.3    APPENDIX 3 
Principal component analysis (PCA): PCA plots are used to determine how well the 
proteomics data has separated between control and treatment groups. 
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8.4    APPENDIX 4 
Table 8.6 – Significantly modulated proteins in Jurkat T lymphocytes after 1μM 
resveratrol identified by label-free LC-MS. 
Accessiona    Descriptionb Confidence 
scorec 
Fold 
change  
p-value q-value 
Q96HS1 Serine/threonine-protein 
phosphatase PGAM5, 
mitochondrial, PGAM5 
91.21 1.32 0.040 0.999 
Q86U38 Nucleolar protein 9, NOP9 136.99 1.27 0.006 0.999 
P25098 Beta-adrenergic receptor 
kinase 1, ADRBK1 
187.92 1.22 0.046 0.999 
Q9UDW1 Cytochrome b-c1 complex 
subunit 9, UQCR10 
113.05 1.20 0.013 0.999 
P62280 40S ribosomal protein S1, 
RPS11 
492.97 1.14 0.028 0.999 
Q5JTV8 Torsin-1A-interacting protein 
1, TOR1AIP1 
140.77 1.14 0.032 0.999 
P29401 Transketolase, TKT 1231.04 1.10 0.041 0.999 
Q13595 Transformer-2 protein 
homolog alpha, TRA2A 
151.78 1.10 0.037 0.999 
P28066 Proteasome subunit alpha 
type-5, PSMA5 
252 1.10 0.041 0.999 
P26639 Threonine--tRNA ligase, 
cytoplasmic, TARS 
431.43 1.12 0.046 0.999 
P46060 Ran GTPase-activating protein 
1, RANGAP1* 
486.43 1.17 0.024 0.999 
Q99613 Eukaryotic translation 
initiation factor 3 subunit C, 
EIF3C 
639.11 1.19 0.039 0.999 
O14744 Protein arginine N-
methyltransferase 5, PRMT5 
252.84 1.19 0.021 0.999 
Q9BRJ6 Uncharacterized protein, 54.59 1.21 0.018 0.999 
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a Accession number according to UniProt database. b Protein description with relative 
symbol. c Confidence score generated by Progenesis. * Proteins shared between 
both treatments (resveratrol and curcumin). Green reduction, red induction.  
 
1.0 – 1.49   
1.5 – 1.99   
2 – 2.49   
2.5 – 2.99   
3 – 3.49   
3.5 +   
 
* Protein common between resveratrol and 
curcumin treatment. 
 
C7orf50   
P20073 Annexin A7, ANXA7* 141.91 1.23 0.000 0.300 
P16989 Y-box-binding protein 3, CSDA 268.94 1.28 0.039 0.999 
P55039 Developmentally-regulated 
GTP-binding protein 2, DRG2* 
70.26 1.29 0.010 0.999 
O60664 Perilipin-3, PLIN3 241.46 1.31 0.017 0.999 
Q9NRN7 L-aminoadipate-semialdehyde 
dehydrogenase -
phosphopantetheinyl 
transferase, AASDHPPT 
74.55 1.38 0.048 0.999 
Q4V339 COBW domain-containing 
protein 6, CBWD6* 
35.08 1.85 0.028 0.999 
Q9NU22 Midasin, MDN1 67.54 2.65 0.036 0.999 
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Table 8.7 – Significantly modulated proteins in Jurkat T lymphocytes after 1μM 
curcumin identified by label-free LC-MS. 
Accessiona  Descriptionb Confidence 
score c 
Fold 
change  
p-value q-value 
Q9UBC5  Unconventional myosin-Ia, MYO1A 55.74 3.63 0.048 0.997 
Q6L8Q7 2',5'-phosphodiesterase 12, HNRPDL 53.82 1.33 0.019 0.997 
P57772 Selenocysteine-specific elongation 
factor, EEFSEC 
31.69 1.29 0.013 
0.997 
O75608 Acyl-protein thioesterase 1, LYPLA1 124.72 1.11 0.043 0.997 
P19338 Nucleolin, NCL 2004.18 1.12 0.003 0.997 
P36954 DNA-directed RNA polymerase II 
subunit RPB9, POLR2I 
83.56 1.12 0.33 
0.997 
Q9UBF2 Coatomer subunit gamma-2, COPG2 282.00 1.13 0.024 0.997 
O14979 Heterogeneous nuclear 
ribonucleoprotein D-like, HNRPDL 
374.30 1.13 0.021 
0.997 
Q99798 Aconitate hydratase, mitochondrial, 
ACO2 
697.28 1.14 0.037 
0.997 
Q9Y3D6 Mitochondrial fission 1 protein, FIS1 27.44 1.15 0.010 0.997 
Q14257 Reticulocalbin-2, RCN2 235.41 1.16 0.039 0.997 
Q10567 AP-1 complex subunit beta-1, Ap1B1 360.9 1.17 0.031 0.997 
Q07960 Rho GTPase-activating protein 1, 
ARHGAP1 
160.70 1.17 0.005 
0.997 
P46060 Ran GTPase-activating protein 1, 
RANGAP1* 
486.43 1.17 0.016 
0.997 
P48556 26S proteasome non-ATPase 
regulatory subunit 8, PSMD8 
149.62 1.18 0.041 
0.997 
O00148 ATP-dependent RNA helicase, 
DDX39A   
879.06 1.18 0.045 
0.997 
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P20073 Annexin A7, ANXA7*  141.91 1.19 0.035 0.997 
Q9BQ75 Protein CMSS1,  C3orf26 73.7 1.19 0.045 0.997 
Q00796 Sorbitol dehydrogenase, SORD 199.37 1.20 0.040 0.997 
P10644 cAMP-dependent protein kinase 
type I-alpha regulatory subunit, 
PRKAR1A 
185.21 1.21 0.037 
0.997 
Q16851 UTP--glucose-1-phosphate 
uridylyltransferase, UGP2 
181.55 1.23 0.030 
0.997 
P51784 Ubiquitin carboxyl-terminal 
hydrolase 11, USP11 
153.8 1.23 0.041 
0.997 
P09104 Gamma-enolase, ENO2 1052.23 1.24 0.046 0.997 
Q15363 Transmembrane emp24 domain-
containing protein 2, TMED2 
165.36 1.25 0.003 
0.997 
Q9UL25 Ras-related protein Rab-21, RAB21 116.79 1.26 0.008 0.997 
Q9BVP2 Guanine nucleotide-binding protein-
like 3, GNL3 
176.98 1.27 0.008 
0.997 
P55039 Developmentally-regulated GTP-
binding protein, DRG2* 
70.26 1.28 0.043 
0.997 
Q7KZ85 Transcription elongation factor 
SPT6, EEFSEC 
136.36 1.31 0.036 
0.997 
Q14807 Kinesin-like protein KIF22  34.55 1.31 0.035 0.997 
Q8IYB3 Serine/arginine repetitive matrix 
protein 1, SRRM1 
114.74 1.31 0.041 
0.997 
Q8IZ69 tRNA (uracil-5-)-methyltransferase 
homolog A, TRMT2A 
40.54 1.32 0.042 
0.997 
Q9NTX5 Ethylmalonyl-CoA decarboxylase, 
ECHDC1 
61.11 1.34 0.045 
0.997 
Q14011 Cold-inducible RNA-binding protein, 
CIRPDL 
48.91 1.34 0.018 
0.997 
Q9Y4P1 Cysteine protease ATG4B  64.94 1.40 0.042 0.997 
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a Accession number according to UniProt database. b Protein description with relative 
symbol. c Confidence score generated by Progenesis. * Proteins shared between 
both treatments (resveratrol and curcumin). Green reduction, red induction. 
 
 
Q96GC9 Vacuole membrane protein 1, VMP1 32.02 1.47 0.039 0.997 
Q9Y2Z4 Tyrosine--tRNA ligase, 
mitochondrial, YARS2 
29.61 1.51 0.003 
0.997 
O75874 Isocitrate dehydrogenase [NADP] 
cytoplasmic, IDH1 
124.87 1.51 0.016 
0.997 
Q9NXX6 Non-structural maintenance of 
chromosomes element 4 homolog 
A, NSMCE4A 
32.05 1.59 0.001 
0.997 
Q9BZE4 Nucleolar GTP-binding protein , 
GTPBP4 
92.43 1.74 0.014 
0.997 
Q9C0C9 Ubiquitin-conjugating enzyme E2 O, 
UBE20 
55.05 1.74 0.032 
0.997 
Q8TAT6 Nuclear protein localization protein 
4 homolog, NPLOC4 
91.12 1.76 0.002 
0.997 
Q4V339 COBW domain-containing protein 6 
(Cobalamin synthase W domain 
containing protein 6. Colbalamin = 
vitamin B12), CBWD6* 
35.08 1.99 0.010 
0.997 
1.0 – 1.49   
1.5 – 1.99   
2 – 2.49   
2.5 – 2.99   
3 – 3.49   
3.5 +   
 
* Protein common between resveratrol and 
curcumin treatment. 
299 
 
 
 
 
 
 
 
Table 8.8 – Significantly modulated proteins in Jurkat T lymphocytes after 30μM 
resveratrol identified by label-free LC-MS. 
 
Accession Description 
Confidence 
score 
Fold 
change p value 
q-value 
Q9Y5K8 V-type proton ATPase subunit D  34.03 1.91 0.031 0.111 
Q92917 
G patch domain and KOW motifs-
containing protein  34.95 1.60 0.028 0.106 
P16402 Histone H1.3  664.87 1.56 0.025 0.101 
Q01581 
Hydroxymethylglutaryl-CoA synthase, 
cytoplasmic  137.6 1.53 0.000 0.003 
P18065 
Insulin-like growth factor-binding 
protein 2  109.7 1.50 0.011 0.069 
Q9UG63 
ATP-binding cassette sub-family F 
member 2  93.35 1.47 0.012 0.070 
P16403; 
P22492; 
Q02539 Histone H1.2  768.82 1.44 0.002 0.035 
P04264; 
P19013; 
Q6KB66; 
Q7Z794 Keratin, type II cytoskeletal 1  517.39 1.43 0.019 0.090 
Q9P2K5 Myelin expression factor 2  41.24 1.41 0.036 0.120 
Q05086 Ubiquitin-protein ligase E3A  36.49 1.39 0.007 0.060 
P41567; 
Eukaryotic translation initiation factor 
254.95 1.34 0.001 0.022 
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O60739 1 
P62633 Cellular nucleic acid-binding protein  204.08 1.34 0.004 0.048 
Q13422 DNA-binding protein Ikaros  99.61 1.33 0.003 0.041 
A0A5B9 T-cell receptor beta-2 chain C region  48.89 1.31 0.007 0.060 
Q8WW12 
PEST proteolytic signal-containing 
nuclear protein  39.68 1.30 0.011 0.069 
P20290 Transcription factor BTF3  258.04 1.29 0.000 0.003 
P49366 Deoxyhypusine synthase  241.19 1.29 0.013 0.074 
Q9NRX4 14 kDa phosphohistidine phosphatase  81.18 1.29 0.002 0.038 
O43747 AP-1 complex subunit gamma-1  47.02 1.28 0.035 0.118 
Q9UEY8 Gamma-adducin  50.56 1.28 0.015 0.083 
P25098; 
P35626 Beta-adrenergic receptor kinase 1  379.78 1.28 0.002 0.035 
Q9Y6H1; 
Q5T1J5 
Coiled-coil-helix-coiled-coil-helix 
domain-containing protein 2, 
mitochondrial  116.57 1.27 0.003 0.046 
Q9UK76 
Hematological and neurological 
expressed 1 protein  157.04 1.27 0.000 0.003 
P98179 Putative RNA-binding protein 3  57.01 1.26 0.002 0.039 
P35613 Basigin  151.91 1.26 0.007 0.059 
P52292 Importin subunit alpha-1  285.55 1.25 0.000 0.008 
Q9UJU2; 
P36402 Lymphoid enhancer-binding factor 1  125.22 1.25 0.000 0.006 
O60880 SH2 domain-containing protein 1A  233.37 1.25 0.000 0.006 
Q86X55 
Histone-arginine methyltransferase 
CARM1  79.86 1.25 0.047 0.135 
Q9NZT2 Opioid growth factor receptor  30.45 1.24 0.036 0.120 
Q14444 Caprin-1  317.74 1.24 0.000 0.006 
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P02786 Transferrin receptor protein 1  751.33 1.24 0.000 0.003 
Q9NY27 
Serine/threonine-protein phosphatase 
4 regulatory subunit 2  151.06 1.23 0.002 0.035 
Q9NRL3 Striatin-4  33.58 1.23 0.003 0.046 
Q9UHD9 Ubiquilin-2  361.52 1.23 0.040 0.125 
Q7Z5R6 
Amyloid beta A4 precursor protein-
binding family B member 1-interacting 
protein  105.04 1.23 0.002 0.035 
A6NCE7; 
Q9H492 
Microtubule-associated proteins 1A/1B 
light chain 3 beta 2  32.86 1.23 0.000 0.015 
Q6IN85 
Serine/threonine-protein phosphatase 
4 regulatory subunit 3A  50.12 1.22 0.024 0.101 
O95671 
N-acetylserotonin O-
methyltransferase-like protein  49.68 1.22 0.014 0.076 
O15117 FYN-binding protein  194.45 1.22 0.005 0.048 
E9PAV3; 
Q9BZK3 
Nascent polypeptide-associated 
complex subunit alpha, muscle-specific 
form  357.92 1.22 0.000 0.011 
Q15397 
Pumilio domain-containing protein 
KIAA0020  73.06 1.22 0.005 0.051 
P62805 Histone H4  730.01 1.22 0.001 0.025 
P37268 Squalene synthase  570.67 1.22 0.001 0.022 
P30520 
Adenylosuccinate synthetase isozyme 
2  224.65 1.21 0.002 0.035 
Q9BZX2 Uridine-cytidine kinase 2  34.33 1.21 0.040 0.125 
Q86Y56 HEAT repeat-containing protein 2  35.29 1.21 0.023 0.098 
A8MWD9 
Small nuclear ribonucleoprotein G-like 
protein  62.19 1.20 0.034 0.116 
Q9NR30 Nucleolar RNA helicase 2  554.67 1.20 0.001 0.022 
Q9UBC2 
Epidermal growth factor receptor 
substrate 15-like 1  168.36 1.20 0.008 0.063 
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Q32MZ4; 
Q9Y608 
Leucine-rich repeat flightless-
interacting protein 1  481.3 1.19 0.001 0.028 
Q9H2J4 Phosducin-like protein 3  33.16 1.19 0.003 0.046 
Q96RU3 Formin-binding protein 1  585.89 1.19 0.000 0.011 
Q9BV44 THUMP domain-containing protein 3  51.83 1.19 0.046 0.132 
O75940 
Survival of motor neuron-related-
splicing factor 30  110.3 1.19 0.007 0.060 
Q9UKX7 Nuclear pore complex protein Nup50  362.63 1.19 0.001 0.031 
Q8N257 Histone H2B type 3-B  793.32 1.19 0.048 0.137 
Q99543 DnaJ homolog subfamily C member 2  40.25 1.19 0.041 0.126 
Q9Y5A9 
YTH domain-containing family protein 
2  33.93 1.19 0.019 0.090 
Q9UBU8 Mortality factor 4-like protein 1  95.95 1.18 0.004 0.048 
P13674 Prolyl 4-hydroxylase subunit alpha-1  369.15 1.18 0.041 0.125 
Q9BTE6 Alanyl-tRNA editing protein Aarsd1  145.39 1.18 0.018 0.088 
O75534 
Cold shock domain-containing protein 
E1  202.3 1.18 0.001 0.022 
Q16795 
NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 9, 
mitochondrial  35.16 1.18 0.036 0.120 
Q14978 
Nucleolar and coiled-body 
phosphoprotein 1  248.18 1.18 0.003 0.046 
Q8ND56 Protein LSM14 homolog A  60.15 1.17 0.034 0.115 
O75368 
SH3 domain-binding glutamic acid-rich-
like protein  316.99 1.17 0.001 0.022 
P09012 U1 small nuclear ribonucleoprotein A  272.05 1.17 0.006 0.052 
Q9H307 Pinin  337.09 1.17 0.017 0.087 
Q86UP2 Kinectin  187.47 1.16 0.007 0.060 
Q9UI30 tRNA methyltransferase 112 homolog  118.91 1.16 0.008 0.063 
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O43660 Pleiotropic regulator 1  175.44 1.16 0.013 0.074 
P07311 Acylphosphatase-1  82.06 1.16 0.004 0.048 
P49247 Ribose-5-phosphate isomerase  179.41 1.16 0.040 0.125 
Q9NY12 
H/ACA ribonucleoprotein complex 
subunit 1  133.13 1.15 0.011 0.070 
P04818 Thymidylate synthase  295.42 1.15 0.002 0.038 
Q8WU90 
Zinc finger CCCH domain-containing 
protein 15  126.94 1.15 0.030 0.109 
O14745 
Na(+)/H(+) exchange regulatory 
cofactor NHE-RF1  404.93 1.15 0.030 0.109 
Q9NZL9 
Methionine adenosyltransferase 2 
subunit beta  298.63 1.15 0.009 0.065 
Q5T8P6 RNA-binding protein 26  32.64 1.15 0.006 0.053 
P49006 MARCKS-related protein  367.08 1.15 0.016 0.085 
Q13895 Bystin  152.67 1.15 0.045 0.131 
O60869 
Endothelial differentiation-related 
factor 1  133.9 1.15 0.033 0.115 
P61077; 
P51668 Ubiquitin-conjugating enzyme E2 D3  124.88 1.15 0.005 0.048 
Q9Y295 
Developmentally-regulated GTP-
binding protein 1  316.25 1.15 0.010 0.068 
Q96CT7 
Coiled-coil domain-containing protein 
124  198.22 1.15 0.023 0.097 
Q9H845 
Acyl-CoA dehydrogenase family 
member 9, mitochondrial  49.36 1.15 0.033 0.115 
Q92522 Histone H1x  515.28 1.15 0.019 0.090 
Q9NX55 Huntingtin-interacting protein K  57.99 1.14 0.002 0.038 
Q6YP21 
Kynurenine--oxoglutarate 
transaminase 3  127.61 1.14 0.040 0.125 
P62495 
Eukaryotic peptide chain release factor 
subunit 1  431.99 1.14 0.000 0.016 
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Q9NZL4 Hsp70-binding protein 1  331.9 1.13 0.008 0.063 
Q15843 NEDD8  87.62 1.13 0.004 0.048 
Q9UN86 
Ras GTPase-activating protein-binding 
protein 2  161.75 1.13 0.025 0.101 
Q9H4E7 
Differentially expressed in FDCP 6 
homolog  151.95 1.13 0.040 0.125 
Q92974 
Rho guanine nucleotide exchange 
factor 2  980.94 1.13 0.000 0.003 
Q9Y4Z0 
U6 snRNA-associated Sm-like protein 
LSm4  75.4 1.13 0.042 0.126 
Q6PKG0; 
Q659C4 La-related protein 1  245.38 1.12 0.009 0.065 
P00813 Adenosine deaminase  562.55 1.12 0.002 0.035 
Q7Z6Z7 E3 ubiquitin-protein ligase HUWE1  138.15 1.12 0.011 0.069 
Q13243 Serine/arginine-rich splicing factor 5  284.11 1.12 0.009 0.065 
Q13347 
Eukaryotic translation initiation factor 
3 subunit I  466.6 1.12 0.013 0.074 
P51858 Hepatoma-derived growth factor  472.6 1.12 0.001 0.028 
Q9Y3F4 
Serine-threonine kinase receptor-
associated protein  497.38 1.12 0.001 0.024 
P06454 Prothymosin alpha  541.29 1.12 0.041 0.126 
P62993 
Growth factor receptor-bound protein 
2  415.34 1.12 0.019 0.090 
P30086 
Phosphatidylethanolamine-binding 
protein 1  544.57 1.12 0.019 0.090 
Q6FI81 Anamorsin  145.83 1.12 0.022 0.097 
O00170 AH receptor-interacting protein  291.69 1.12 0.001 0.028 
P13073 
Cytochrome c oxidase subunit 4 
isoform 1, mitochondrial  199.5 1.12 0.002 0.038 
O94900 
Thymocyte selection-associated high 
mobility group box protein TOX  92.22 1.12 0.009 0.066 
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Q6JBY9 CapZ-interacting protein  184.69 1.12 0.037 0.121 
Q9UEE9 Craniofacial development protein 1  100.06 1.12 0.028 0.108 
Q96AE4; 
Q6TDU7 
Far upstream element-binding protein 
1  768.47 1.12 0.005 0.048 
Q8WZA0 Protein LZIC  39.03 1.12 0.002 0.035 
Q08722 Leukocyte surface antigen CD47  81.28 1.11 0.017 0.087 
P06493 Cyclin-dependent kinase 1  357.46 1.11 0.014 0.076 
O00743 
Serine/threonine-protein phosphatase 
6 catalytic subunit  277.01 1.11 0.012 0.073 
P49903 Selenide, water dikinase 1  183.03 1.11 0.007 0.060 
Q969Q0 60S ribosomal protein L36a-like  133.76 1.11 0.033 0.114 
Q15287 
RNA-binding protein with serine-rich 
domain 1  104.21 1.11 0.005 0.048 
P63220 40S ribosomal protein S21  153.73 1.11 0.026 0.102 
Q93009 
Ubiquitin carboxyl-terminal hydrolase 
7  181.42 1.11 0.044 0.130 
Q14008 Cytoskeleton-associated protein 5  509.07 1.11 0.029 0.109 
P68402 
Platelet-activating factor 
acetylhydrolase IB subunit beta  113.42 1.11 0.013 0.074 
P68400; 
Q8NEV1 Casein kinase II subunit alpha  356.95 1.11 0.001 0.035 
P54886 
Delta-1-pyrroline-5-carboxylate 
synthase  306.09 1.11 0.004 0.048 
O15347; 
P0C6E5 High mobility group protein B3  200.88 1.11 0.024 0.099 
P62306 Small nuclear ribonucleoprotein F  148.54 1.11 0.038 0.122 
Q9BTD8 RNA-binding protein 42  166.61 1.11 0.031 0.109 
P31689 DnaJ homolog subfamily A member 1  420.34 1.11 0.006 0.055 
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P05556 Integrin beta-1  190.12 1.11 0.029 0.109 
P12814; 
O94979; 
P35609; 
Q08043 Alpha-actinin-1  1730.34 1.11 0.033 0.115 
O43396 Thioredoxin-like protein 1  315.19 1.11 0.005 0.051 
Q9UMX0; 
Q9NRR5 Ubiquilin-1  560.33 1.11 0.020 0.091 
O00410; 
O60518 Importin-5  919.06 1.11 0.021 0.095 
O75821 
Eukaryotic translation initiation factor 
3 subunit G  347.4 1.10 0.001 0.025 
O14980 Exportin-1  801.14 1.10 0.002 0.038 
P07195 L-lactate dehydrogenase B chain  1171.65 1.10 0.013 0.075 
O75347 Tubulin-specific chaperone A  320.88 1.10 0.038 0.124 
P49327 Fatty acid synthase  945.33 1.10 0.000 0.018 
O75791 GRB2-related adapter protein 2  271.69 1.10 0.030 0.109 
P54725 
UV excision repair protein RAD23 
homolog A  285.71 1.10 0.003 0.046 
P08559; 
P29803 
Pyruvate dehydrogenase E1 
component subunit alpha, somatic 
form, mitochondrial  87.04 1.10 0.030 0.109 
P13693 
Translationally-controlled tumor 
protein  238.44 1.10 0.017 0.087 
P16401 Histone H1.5  684.91 1.10 0.033 0.115 
P67936; 
P07951 Tropomyosin alpha-4 chain  955.83 1.10 0.017 0.088 
Q9BQA1 Methylosome protein 50  255.29 1.10 0.022 0.097 
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Q9UBQ5 
Eukaryotic translation initiation factor 
3 subunit K  117.86 1.10 0.020 0.091 
Q9UKV3 
Apoptotic chromatin condensation 
inducer in the nucleus  389.29 1.10 0.010 0.068 
P28062 Proteasome subunit beta type-8  377.13 1.10 0.029 0.109 
Q7L1Q6 
Basic leucine zipper and W2 domain-
containing protein 1  342.92 1.10 0.002 0.038 
O43504 Ragulator complex protein LAMTOR5  183.16 1.10 0.025 0.101 
P26583 High mobility group protein B2  642.03 1.10 0.011 0.069 
P34932 Heat shock 70 kDa protein 4  2122.67 1.10 0.032 0.112 
P62258 14-3-3 protein epsilon  929.19 1.09 0.019 0.090 
P14324 Farnesyl pyrophosphate synthase  342.1 1.09 0.005 0.051 
P17844 
Probable ATP-dependent RNA helicase 
DDX5  1180.49 1.09 0.000 0.007 
O95433 
Activator of 90 kDa heat shock protein 
ATPase homolog 1  598.35 1.09 0.002 0.035 
Q9Y266 Nuclear migration protein nudC  420.29 1.09 0.044 0.130 
P26196; 
Q8TCU6 
Probable ATP-dependent RNA helicase 
DDX6  465.06 1.09 0.009 0.063 
P61247 40S ribosomal protein S3a  903.43 1.09 0.006 0.054 
P11940; 
Q4VXU2; 
Q96DU9; 
Q9H361 Polyadenylate-binding protein 1  1090.82 1.09 0.004 0.048 
O95347 
Structural maintenance of 
chromosomes protein 2  252.71 1.09 0.008 0.063 
P07766 
T-cell surface glycoprotein CD3 epsilon 
chain  135.04 1.09 0.016 0.085 
P15880 40S ribosomal protein S2  627.29 1.09 0.045 0.131 
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Q14847 LIM and SH3 domain protein 1  406.09 1.09 0.045 0.131 
Q9UNX4 WD repeat-containing protein 3  236.19 1.09 0.018 0.088 
Q53GS9 
U4/U6.U5 tri-snRNP-associated protein 
2  221.7 1.09 0.023 0.098 
Q15269 Periodic tryptophan protein 2 homolog  301.88 1.09 0.011 0.069 
P08865 40S ribosomal protein SA  631.66 1.09 0.005 0.048 
Q14019 Coactosin-like protein  468.22 1.09 0.043 0.129 
Q14318 
Peptidyl-prolyl cis-trans isomerase 
FKBP8  361.26 1.09 0.019 0.090 
Q14498; 
Q86U06 RNA-binding protein 39  711.79 1.09 0.012 0.072 
P17174 
Aspartate aminotransferase, 
cytoplasmic  388.1 1.09 0.002 0.038 
P46060 Ran GTPase-activating protein 1  697.25 1.09 0.010 0.067 
Q8NC51 
Plasminogen activator inhibitor 1 RNA-
binding protein  493.03 1.08 0.025 0.101 
P13807 Glycogen [starch] synthase, muscle  204.91 1.08 0.003 0.045 
Q15691; 
Q9UPY8 
Microtubule-associated protein RP/EB 
family member 1  453.96 1.08 0.038 0.122 
B5ME19; 
Q8ND83 
Eukaryotic translation initiation factor 
3 subunit C-like protein  691.44 1.08 0.036 0.120 
Q9UI08 Ena/VASP-like protein  736.92 1.08 0.020 0.091 
P36405 ADP-ribosylation factor-like protein 3  198.43 1.08 0.039 0.124 
P04075; 
P05062 Fructose-bisphosphate aldolase A  1632.72 1.08 0.030 0.109 
O95865 
N(G),N(G)-dimethylarginine 
dimethylaminohydrolase 2  434.12 1.08 0.001 0.034 
P62942 
Peptidyl-prolyl cis-trans isomerase 
FKBP1A  312.02 1.08 0.047 0.134 
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P62269 40S ribosomal protein S18  492.85 1.08 0.030 0.109 
O43684 Mitotic checkpoint protein BUB3  333.72 1.08 0.015 0.080 
P62316 Small nuclear ribonucleoprotein Sm D2  256.88 1.08 0.044 0.130 
Q01130; 
Q9BRL6 Serine/arginine-rich splicing factor 2  417.47 1.08 0.002 0.038 
P22234 Multifunctional protein ADE2  1268.29 1.08 0.000 0.003 
P52907 
F-actin-capping protein subunit alpha-
1  686.35 1.08 0.022 0.097 
Q15046 Lysine--tRNA ligase  519.41 1.08 0.025 0.101 
P05386 60S acidic ribosomal protein P1  293.95 1.08 0.005 0.048 
Q14980 Nuclear mitotic apparatus protein 1  2382.65 1.08 0.005 0.051 
Q13435 Splicing factor 3B subunit 2  914.21 1.08 0.006 0.053 
P42166 
Lamina-associated polypeptide 2, 
isoform alpha  1091.49 1.08 0.008 0.063 
Q9BXJ9 
N-alpha-acetyltransferase 15, NatA 
auxiliary subunit  411.09 1.08 0.018 0.089 
P46779 60S ribosomal protein L28  268.52 1.08 0.025 0.101 
Q13123 Protein Red  142.18 1.08 0.034 0.115 
P36639 
7,8-dihydro-8-oxoguanine 
triphosphatase  264.86 1.08 0.010 0.068 
O43768; 
P56211 Alpha-endosulfine  158.37 1.07 0.036 0.119 
Q70J99 Protein unc-13 homolog D  282.89 1.07 0.002 0.035 
P63104 14-3-3 protein zeta/delta  1155.92 1.07 0.015 0.083 
O00299 Chloride intracellular channel protein 1  729.86 1.07 0.002 0.038 
P60228 
Eukaryotic translation initiation factor 
3 subunit E  413.98 1.07 0.037 0.122 
Q13151 
Heterogeneous nuclear 
ribonucleoprotein A0  626.79 1.07 0.011 0.069 
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Q14240 Eukaryotic initiation factor 4A-II  785.95 1.07 0.018 0.088 
P30153; 
P30154 
Serine/threonine-protein phosphatase 
2A 65 kDa regulatory subunit A alpha 
isoform  916.1 1.07 0.047 0.135 
P26373 60S ribosomal protein L13  440.18 1.07 0.004 0.048 
O00151 PDZ and LIM domain protein 1  413.36 1.07 0.015 0.080 
Q15181 Inorganic pyrophosphatase  823.4 1.07 0.008 0.062 
Q9UHD8 Septin-9  671.18 1.07 0.005 0.051 
Q01082; 
P11277 Spectrin beta chain, non-erythrocytic 1  4885.22 1.07 0.000 0.018 
P62826 GTP-binding nuclear protein Ran  473.02 1.07 0.001 0.025 
Q14152; 
Q15650 
Eukaryotic translation initiation factor 
3 subunit A  778.49 1.07 0.021 0.095 
P31948 Stress-induced-phosphoprotein 1  1552.32 1.06 0.026 0.102 
P63244 
Guanine nucleotide-binding protein 
subunit beta-2-like 1  1251.87 1.06 0.010 0.068 
O75533 Splicing factor 3B subunit 1  1447.45 1.06 0.011 0.069 
O75822 
Eukaryotic translation initiation factor 
3 subunit J  185.59 1.06 0.042 0.126 
Q16630 
Cleavage and polyadenylation 
specificity factor subunit 6  330.28 1.06 0.011 0.069 
P19338 Nucleolin  1725.72 1.06 0.018 0.088 
P29401 Transketolase  1572.82 1.06 0.002 0.036 
O76021 
Ribosomal L1 domain-containing 
protein 1  493.24 1.06 0.021 0.093 
O94776; 
Q9BTC8 Metastasis-associated protein MTA2  681.1 1.06 0.008 0.063 
Q15365 Poly(rC)-binding protein 1  781.54 1.06 0.022 0.097 
P30041 Peroxiredoxin-6  716.74 1.06 0.006 0.053 
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P37802 Transgelin-2  735.45 1.06 0.040 0.125 
Q07021 
Complement component 1 Q 
subcomponent-binding protein, 
mitochondrial  542.83 1.06 0.012 0.072 
P49368 T-complex protein 1 subunit gamma  1646.66 1.06 0.010 0.069 
P62318 Small nuclear ribonucleoprotein Sm D3  396.06 1.06 0.011 0.069 
Q9UHV9 Prefoldin subunit 2  238.84 1.06 0.017 0.087 
Q15019 Septin-2  572.78 1.06 0.023 0.097 
O15371 
Eukaryotic translation initiation factor 
3 subunit D  411.23 1.06 0.022 0.096 
O75083 WD repeat-containing protein 1  1553.05 1.06 0.018 0.089 
O43390 
Heterogeneous nuclear 
ribonucleoprotein R  1125.31 1.06 0.025 0.101 
Q9NX58 
Cell growth-regulating nucleolar 
protein  343.48 1.06 0.042 0.126 
O60711 Leupaxin  215.86 1.06 0.042 0.126 
P61978 
Heterogeneous nuclear 
ribonucleoprotein K  1488.79 1.06 0.034 0.116 
P27635; 
Q96L21 60S ribosomal protein L10  423.3 1.06 0.044 0.130 
P62906 60S ribosomal protein L10a  217.31 1.06 0.014 0.076 
P41091; 
Q2VIR3 
Eukaryotic translation initiation factor 
2 subunit 3  415.61 1.06 0.023 0.098 
P78371 T-complex protein 1 subunit beta  1948.05 1.05 0.004 0.048 
Q13177; 
O75914; 
Q13153 Serine/threonine-protein kinase PAK 2  797.73 1.05 0.030 0.109 
P30050 60S ribosomal protein L12  505.8 1.05 0.009 0.063 
Q15393 Splicing factor 3B subunit 3  1279.11 1.05 0.002 0.035 
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Q9P258 Protein RCC2  919.6 1.05 0.004 0.048 
P51610 Host cell factor 1  497.77 1.05 0.035 0.118 
P08621 
U1 small nuclear ribonucleoprotein 70 
kDa  455.1 1.05 0.024 0.100 
O14979 
Heterogeneous nuclear 
ribonucleoprotein D-like  416.28 1.05 0.025 0.101 
Q99733 Nucleosome assembly protein 1-like 4  580.16 1.05 0.044 0.130 
P55327 Tumor protein D52  382.04 1.05 0.004 0.048 
P04406; 
O14556 
Glyceraldehyde-3-phosphate 
dehydrogenase  1450.97 1.05 0.011 0.069 
P18124 60S ribosomal protein L7  594.63 1.05 0.031 0.110 
P46781 40S ribosomal protein S9  441.05 1.05 0.049 0.138 
P62266 40S ribosomal protein S23  280.91 1.05 0.026 0.102 
P50395 Rab GDP dissociation inhibitor beta  1487.24 1.05 0.022 0.097 
Q86V81 THO complex subunit 4  503.33 1.05 0.005 0.048 
P00492 
Hypoxanthine-guanine 
phosphoribosyltransferase  408.53 1.05 0.037 0.122 
P18669; 
P15259; 
Q8N0Y7 Phosphoglycerate mutase 1  1120.25 1.05 0.035 0.118 
Q13813; 
Q15643 
Spectrin alpha chain, non-erythrocytic 
1  5359.81 1.03 0.020 0.091 
P13639 Elongation factor 2  2127.27 1.03 0.008 0.063 
Q15459 Splicing factor 3A subunit 1  535.62 1.03 0.027 0.103 
Q99986 Serine/threonine-protein kinase VRK1  508.71 1.03 0.047 0.135 
P49736 DNA replication licensing factor MCM2  1351.22 1.02 0.021 0.093 
O43488; 
Aflatoxin B1 aldehyde reductase 
member 2  462.63 1.03 0.030 0.109 
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O95154; 
Q8NHP1 
P21281; 
P15313 
V-type proton ATPase subunit B, brain 
isoform  473.82 1.03 0.042 0.126 
P13489 Ribonuclease inhibitor  1077.08 1.03 0.040 0.125 
Q9Y4L1 Hypoxia up-regulated protein 1  1551.1 1.03 0.048 0.136 
Q01813 6-phosphofructokinase type C  1550.41 1.04 0.029 0.109 
Q9NQR4 Omega-amidase NIT2  357.97 1.04 0.040 0.125 
Q52LJ0 Protein FAM98B  289.38 1.04 0.019 0.090 
P49321 Nuclear autoantigenic sperm protein  1018.75 1.04 0.031 0.110 
P38606 
  
1.04 0.024 0.100 
P55084 
Trifunctional enzyme subunit beta, 
mitochondrial  420.82 1.04 0.048 0.137 
Q92973 Transportin-1  411.11 1.04 0.023 0.097 
P45880 
Voltage-dependent anion-selective 
channel protein 2  658.71 1.05 0.045 0.131 
Q14697 Neutral alpha-glucosidase AB  1909.17 1.05 0.030 0.109 
P36871 Phosphoglucomutase-1  608.02 1.05 0.005 0.051 
P27694 
Replication protein A 70 kDa DNA-
binding subunit  1027 1.05 0.019 0.090 
Q99460 
26S proteasome non-ATPase 
regulatory subunit 1  964.51 1.05 0.025 0.101 
Q8TEM1 
Nuclear pore membrane glycoprotein 
210  1066.6 1.05 0.005 0.051 
Q08211 ATP-dependent RNA helicase A  2489.66 1.05 0.009 0.065 
P11310 
Medium-chain specific acyl-CoA 
dehydrogenase, mitochondrial  701.71 1.05 0.007 0.055 
Q9HCE1 Putative helicase MOV-10  425.86 1.05 0.019 0.090 
Q8WWP7 GTPase IMAP family member 1  195.03 1.05 0.017 0.088 
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Q16836 
Hydroxyacyl-coenzyme A 
dehydrogenase, mitochondrial  213.73 1.06 0.042 0.127 
Q06210; 
O94808 
Glutamine--fructose-6-phosphate 
aminotransferase [isomerizing] 1  890.28 1.06 0.017 0.087 
P35606 Coatomer subunit beta'  1012.26 1.06 0.008 0.060 
P22307 Non-specific lipid-transfer protein  487.81 1.06 0.010 0.067 
P78527 
DNA-dependent protein kinase 
catalytic subunit  4240.54 1.06 0.004 0.048 
P23368 
NAD-dependent malic enzyme, 
mitochondrial  495.38 1.06 0.037 0.122 
P99999 Cytochrome c  204.25 1.06 0.049 0.138 
P27797 Calreticulin  941.73 1.06 0.020 0.091 
P45974 
Ubiquitin carboxyl-terminal hydrolase 
5  368.88 1.06 0.020 0.092 
P14625; 
Q58FF3 Endoplasmin  1591.23 1.06 0.018 0.088 
P04844 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 2  1263.95 1.07 0.004 0.048 
P30085 UMP-CMP kinase  368.12 1.07 0.010 0.069 
Q15942 Zyxin  141.74 1.07 0.034 0.115 
Q9H9B4; 
Q9BWM7 Sideroflexin-1  536.97 1.07 0.017 0.087 
P53618 Coatomer subunit beta  678.32 1.07 0.038 0.123 
P39748 Flap endonuclease 1  625.62 1.07 0.002 0.036 
P39656 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase 48 kDa 
subunit  493.31 1.07 0.004 0.048 
Q99798 Aconitate hydratase, mitochondrial  1341.41 1.07 0.000 0.011 
Q9BQ69 
O-acetyl-ADP-ribose deacetylase 
MACROD1  211.59 1.07 0.008 0.063 
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Q6DD88; 
Q8NHH9 Atlastin-3  549.03 1.07 0.024 0.099 
P07237 Protein disulfide-isomerase  1433.87 1.07 0.012 0.071 
P11216; 
P06737; 
P11217 Glycogen phosphorylase, brain form  588.14 1.08 0.004 0.048 
P11021; 
O95399 78 kDa glucose-regulated protein  1803.98 1.08 0.002 0.036 
P00390 Glutathione reductase, mitochondrial  591.49 1.08 0.003 0.040 
Q9BTV4 Transmembrane protein 43  220.02 1.08 0.025 0.101 
Q9Y5B9 FACT complex subunit SPT16  1138.09 1.08 0.015 0.082 
P08107; 
P48741 Heat shock 70 kDa protein 1A/1B  812.68 1.08 0.038 0.123 
P27824 Calnexin  921.13 1.08 0.001 0.022 
P46459 Vesicle-fusing ATPase  388.19 1.08 0.005 0.048 
Q9H3N1 
Thioredoxin-related transmembrane 
protein 1  207.26 1.08 0.031 0.110 
Q96CS3 FAS-associated factor 2  142.79 1.08 0.040 0.125 
Q8WXF1 Paraspeckle component 1  398.39 1.08 0.035 0.118 
Q9H4A4 Aminopeptidase B  259.08 1.08 0.011 0.069 
P12955 Xaa-Pro dipeptidase  204.66 1.08 0.040 0.125 
Q9Y5M8 
Signal recognition particle receptor 
subunit beta  188.62 1.09 0.041 0.126 
P24539 
ATP synthase F(0) complex subunit B1, 
mitochondrial  349.23 1.09 0.044 0.129 
Q02978 
Mitochondrial 2-oxoglutarate/malate 
carrier protein  417.62 1.09 0.019 0.090 
O14929 
Histone acetyltransferase type B 
389.28 1.09 0.016 0.083 
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catalytic subunit  
Q15435 
Protein phosphatase 1 regulatory 
subunit 7  298.92 1.09 0.029 0.109 
O75694 Nuclear pore complex protein Nup155  342.84 1.09 0.005 0.048 
Q9NPQ8 Synembryn-A  67.84 1.09 0.004 0.048 
O75915 PRA1 family protein 3  64.72 1.09 0.030 0.109 
Q9NYU2 
UDP-glucose:glycoprotein 
glucosyltransferase 1  459.23 1.09 0.028 0.106 
Q9Y2Q5 Ragulator complex protein LAMTOR2  79.84 1.09 0.046 0.133 
P17858 6-phosphofructokinase, liver type  762.02 1.10 0.013 0.075 
Q9Y2Q3 Glutathione S-transferase kappa 1  213.37 1.10 0.027 0.104 
P53007 
Tricarboxylate transport protein, 
mitochondrial  293.76 1.10 0.045 0.131 
O15173 
Membrane-associated progesterone 
receptor component 2  223.17 1.10 0.034 0.116 
Q15006 
ER membrane protein complex subunit 
2  160.14 1.10 0.040 0.125 
P28288 
ATP-binding cassette sub-family D 
member 3  200.35 1.10 0.009 0.065 
Q9UBM7 7-dehydrocholesterol reductase  268.1 1.10 0.005 0.051 
P51571 
Translocon-associated protein subunit 
delta  152.76 1.10 0.004 0.047 
P51659 
Peroxisomal multifunctional enzyme 
type 2  635.52 1.10 0.009 0.064 
Q96F07; 
Q7L576 
Cytoplasmic FMR1-interacting protein 
2  153.02 1.10 0.042 0.126 
Q6NUK1 
Calcium-binding mitochondrial carrier 
protein SCaMC-1  184.97 1.10 0.020 0.092 
P31040 
Succinate dehydrogenase [ubiquinone] 
flavoprotein subunit, mitochondrial  787.16 1.10 0.006 0.054 
P20073 Annexin A7  401.75 1.11 0.008 0.060 
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Q9BSJ8 Extended synaptotagmin-1  1047.19 1.11 0.006 0.053 
O43169 Cytochrome b5 type B  171.08 1.11 0.013 0.074 
P55145 
Mesencephalic astrocyte-derived 
neurotrophic factor  219.25 1.11 0.006 0.053 
P34913 Bifunctional epoxide hydrolase 2  158.27 1.11 0.011 0.069 
Q15005 Signal peptidase complex subunit 2  315.44 1.11 0.030 0.109 
Q00534 Cyclin-dependent kinase 6  453.5 1.11 0.006 0.053 
Q86YV0 RAS protein activator like-3  98.56 1.11 0.041 0.126 
P04040 Catalase  452.67 1.11 0.003 0.046 
P08134 Rho-related GTP-binding protein RhoC  400.33 1.12 0.006 0.053 
Q9NVP2 Histone chaperone ASF1B  94.35 1.12 0.018 0.088 
O00116 
Alkyldihydroxyacetonephosphate 
synthase, peroxisomal  217.32 1.12 0.027 0.103 
P62879 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-2  694.09 1.12 0.042 0.126 
P69905; 
P02008 Hemoglobin subunit alpha  319.91 1.12 0.001 0.022 
P53990 IST1 homolog  225.87 1.12 0.002 0.038 
P61619; 
Q9H9S3 
Protein transport protein Sec61 
subunit alpha isoform 1  386.38 1.12 0.010 0.068 
O43175 D-3-phosphoglycerate dehydrogenase  870.82 1.12 0.002 0.038 
Q9NTJ5 
Phosphatidylinositide phosphatase 
SAC1  512.85 1.12 0.006 0.051 
Q9Y678 Coatomer subunit gamma-1  535.67 1.12 0.003 0.046 
Q12769 Nuclear pore complex protein Nup160  212.95 1.12 0.047 0.134 
P48444 Coatomer subunit delta  455.06 1.12 0.002 0.036 
O43252 
Bifunctional 3'-phosphoadenosine 5'-
phosphosulfate synthase 1  332.4 1.13 0.001 0.025 
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P61009 Signal peptidase complex subunit 3  105.12 1.13 0.025 0.101 
Q9Y394 
Dehydrogenase/reductase SDR family 
member 7  334.92 1.13 0.008 0.063 
Q14790 Caspase-8  78.87 1.13 0.013 0.074 
Q13555; 
Q13554 
Calcium/calmodulin-dependent 
protein kinase type II subunit gamma  142.26 1.13 0.014 0.077 
P23258 Tubulin gamma-1 chain  141.13 1.13 0.040 0.125 
Q9UM00 
Transmembrane and coiled-coil 
domain-containing protein 1  90.32 1.13 0.012 0.070 
P48651 Phosphatidylserine synthase 1  108.56 1.13 0.012 0.070 
Q15436 Protein transport protein Sec23A  362.12 1.13 0.045 0.131 
P35610 Sterol O-acyltransferase 1  41.75 1.13 0.022 0.096 
P18858 DNA ligase 1  134.39 1.14 0.001 0.025 
O43852 Calumenin  247.71 1.14 0.029 0.109 
Q96P70 Importin-9  279.02 1.14 0.015 0.080 
Q9NPF4 
Probable tRNA N6-adenosine 
threonylcarbamoyltransferase  127.38 1.14 0.040 0.125 
Q16629 Serine/arginine-rich splicing factor 7  143.28 1.14 0.008 0.063 
P50416 
Carnitine O-palmitoyltransferase 1, 
liver isoform  663.42 1.14 0.003 0.040 
P40937 Replication factor C subunit 5  330.3 1.14 0.000 0.021 
P16219 
Short-chain specific acyl-CoA 
dehydrogenase, mitochondrial  136.02 1.14 0.027 0.103 
P35244 Replication protein A 14 kDa subunit  241.15 1.15 0.003 0.045 
P49588 Alanine--tRNA ligase, cytoplasmic  1261.62 1.15 0.000 0.003 
Q9H3U1 Protein unc-45 homolog A  79.69 1.15 0.017 0.086 
Q15437 Protein transport protein Sec23B  340.66 1.15 0.004 0.048 
Q9Y617 Phosphoserine aminotransferase  379.25 1.16 0.001 0.028 
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Q99805 
Transmembrane 9 superfamily 
member 2  50.51 1.16 0.040 0.125 
Q86WV1 
Src kinase-associated phosphoprotein 
1  74.51 1.16 0.043 0.129 
Q9NRP0 se complex subunit OSTC  58.9 1.16 0.035 0.118 
A6NDJ8 
Putative Rab-43-like protein 
ENSP00000330714  117.15 1.16 0.008 0.063 
Q8WY22 BRI3-binding protein  135.37 1.16 0.004 0.048 
P13995; 
Q9H903 
Bifunctional 
methylenetetrahydrofolate 
dehydrogenase/cyclohydrolase, 
mitochondrial  82.82 1.16 0.022 0.097 
P42765 3-ketoacyl-CoA thiolase, mitochondrial  151.54 1.16 0.033 0.114 
Q02218; 
Q9ULD0 
2-oxoglutarate dehydrogenase, 
mitochondrial  140.72 1.17 0.026 0.102 
P20645 
Cation-dependent mannose-6-
phosphate receptor  119.18 1.17 0.001 0.028 
Q9UNL2 
Translocon-associated protein subunit 
gamma  102.86 1.17 0.011 0.069 
Q8N766 
ER membrane protein complex subunit 
1  157.91 1.18 0.023 0.098 
Q13464 Rho-associated protein kinase 1  88.41 1.18 0.032 0.112 
Q8TC12 Retinol dehydrogenase 11  148.3 1.18 0.026 0.102 
Q9H3P7 Golgi resident protein GCP60  122.57 1.19 0.021 0.094 
Q8TBC4 
NEDD8-activating enzyme E1 catalytic 
subunit  56.31 1.19 0.030 0.109 
O15533 Tapasin  73.93 1.19 0.012 0.073 
Q9H061 Transmembrane protein 126A  44.52 1.19 0.040 0.125 
Q9Y2H1 
Serine/threonine-protein kinase 38-
like  75.01 1.20 0.021 0.093 
Q8NBX0 
Saccharopine dehydrogenase-like 
oxidoreductase  214.21 1.20 0.006 0.051 
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Q9Y2Y0 
ADP-ribosylation factor-like protein 2-
binding protein  50.44 1.20 0.033 0.115 
P23921 
Ribonucleoside-diphosphate reductase 
large subunit  505.12 1.21 0.000 0.003 
P30043 Flavin reductase (NADPH)  62.02 1.21 0.018 0.089 
Q96N66 Lysophospholipid acyltransferase 7  50.35 1.22 0.027 0.105 
P00747 Plasminogen  200.49 1.22 0.010 0.068 
Q8NFW8 N-acylneuraminate cytidylyltransferase  297.19 1.23 0.007 0.059 
O95400 
CD2 antigen cytoplasmic tail-binding 
protein 2  50.26 1.23 0.016 0.086 
P52732 Kinesin-like protein KIF11  249.33 1.23 0.003 0.044 
P26440 
Isovaleryl-CoA dehydrogenase, 
mitochondrial  45.62 1.23 0.050 0.139 
Q9Y5P6 
Mannose-1-phosphate 
guanyltransferase beta  30.85 1.24 0.019 0.090 
Q9NVI1 Fanconi anemia group I protein  103.5 1.25 0.000 0.003 
Q9BT22 
Chitobiosyldiphosphodolichol beta-
mannosyltransferase  124.21 1.25 0.004 0.048 
Q9NQS7 Inner centromere protein  102.02 1.25 0.003 0.044 
Q9UHG3 Prenylcysteine oxidase 1  121.58 1.25 0.001 0.025 
P16278 Beta-galactosidase  63.32 1.26 0.011 0.069 
Q9UM22 
Mammalian ependymin-related 
protein 1  30.04 1.26 0.000 0.007 
P10253 Lysosomal alpha-glucosidase  44.87 1.26 0.012 0.073 
P49748 
Very long-chain specific acyl-CoA 
dehydrogenase, mitochondrial  665.69 1.28 0.000 0.003 
O60749 Sorting nexin-2  67.33 1.29 0.005 0.048 
Q08AF3 Schlafen family member 5  42.15 1.32 0.030 0.109 
Q96CM8 
Acyl-CoA synthetase family member 2, 
mitochondrial  44.2 1.33 0.000 0.006 
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Q6PL18 
ATPase family AAA domain-containing 
protein 2  31.66 1.33 0.001 0.028 
Q9BQE5 Apolipoprotein L2  95.59 1.34 0.001 0.025 
Q8NBM8 Prenylcysteine oxidase-like  55.45 1.40 0.013 0.074 
Q9Y3B3 
Transmembrane emp24 domain-
containing protein 7  81.75 1.46 0.028 0.108 
Q9Y4F9 Protein FAM65B  47.04 1.46 0.042 0.126 
Q9Y6A5 
Transforming acidic coiled-coil-
containing protein 3  56.19 1.51 0.015 0.080 
Q15022 Polycomb protein SUZ12  39.03 1.51 0.005 0.048 
P31350; 
Q7LG56 
Ribonucleoside-diphosphate reductase 
subunit M2  437.12 1.59 0.000 0.003 
Q9UKR5 
Probable ergosterol biosynthetic 
protein 28  33.42 1.72 0.001 0.022 
 
 
a Accession number according to UniProt database. b Protein description with relative 
symbol. c Confidence score generated by Progenesis. * Proteins shared between 
both treatments (resveratrol and curcumin). Green reduction, red induction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.0 – 1.49   
1.5 – 1.99   
2 – 2.49   
2.5 – 2.99   
3 – 3.49   
3.5 +   
 
* Protein common between resveratrol and 
curcumin treatment. 
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Table 8.9 – Significantly modulated proteins in Jurkat T lymphocytes after 10μM 
curcumin identified by label-free LC-MS. 
 
Accessiona    Descriptionb Confidence 
scorec 
Fold 
change  
p-value q-value 
Q13257 
Mitotic spindle assembly checkpoint 
protein MAD2A  77.24 1.41 0.016 0.405 
Q9NQS7 Inner centromere protein  102.02 1.40 0.001 0.232 
Q9UG63 
ATP-binding cassette sub-family F 
member 2  93.35 1.39 0.015 0.405 
Q9UN37 
Vacuolar protein sorting-associated 
protein 4A  65.05 1.36 0.039 0.494 
Q14061 
Cytochrome c oxidase copper 
chaperone  78.49 1.35 0.004 0.353 
Q05086 Ubiquitin-protein ligase E3A  36.49 1.34 0.028 0.458 
Q9UIL1 Short coiled-coil protein  57.87 1.32 0.021 0.421 
Q9UIQ6 Leucyl-cystinyl aminopeptidase  50.35 1.30 0.007 0.353 
Q96I25 Splicing factor 45  58.17 1.29 0.001 0.232 
Q01581 
Hydroxymethylglutaryl-CoA synthase, 
cytoplasmic  137.6 1.27 0.001 0.232 
P31350; 
Q7LG56 
Ribonucleoside-diphosphate 
reductase subunit M2  437.12 1.26 0.002 0.257 
Q9Y697 Cysteine desulfurase, mitochondrial  33.68 1.25 0.035 0.494 
Q96BF6 
Nucleus accumbens-associated 
protein 2  47.73 1.25 0.024 0.433 
P34896 
Serine hydroxymethyltransferase, 
cytosolic  126.99 1.24 0.035 0.494 
Q9UEY8 Gamma-adducin  50.56 1.23 0.036 0.494 
Q8WW12 
PEST proteolytic signal-containing 
nuclear protein  39.68 1.23 0.031 0.471 
O14907 Tax1-binding protein 3  101.14 1.21 0.012 0.386 
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O95671 
N-acetylserotonin O-
methyltransferase-like protein  49.68 1.20 0.024 0.432 
P06132 Uroporphyrinogen decarboxylase  36.47 1.19 0.007 0.353 
P04818 Thymidylate synthase  295.42 1.19 0.007 0.353 
Q9ULR0 
Pre-mRNA-splicing factor ISY1 
homolog  97.96 1.19 0.038 0.494 
P98175 RNA-binding protein 10  123.1 1.19 0.043 0.517 
P25098; 
P35626 Beta-adrenergic receptor kinase 1  379.78 1.19 0.010 0.386 
O43660 Pleiotropic regulator 1  175.44 1.18 0.012 0.386 
Q6FI81 Anamorsin  145.83 1.18 0.012 0.386 
Q9NVI1 Fanconi anemia group I protein  103.5 1.17 0.003 0.335 
Q99848 
Probable rRNA-processing protein 
EBP2  46.52 1.17 0.048 0.534 
P51570 Galactokinase  56.25 1.16 0.047 0.530 
P29083 
General transcription factor IIE 
subunit 1  42.88 1.16 0.007 0.353 
Q9UHA4 Ragulator complex protein LAMTOR3  45.13 1.15 0.006 0.353 
Q16576 Histone-binding protein RBBP7  314.02 1.15 0.013 0.391 
Q8WU39 
Marginal zone B- and B1-cell-specific 
protein  301.22 1.15 0.014 0.398 
P14927 Cytochrome b-c1 complex subunit 7  70.82 1.15 0.025 0.433 
P18858 DNA ligase 1  134.39 1.15 0.007 0.353 
Q9UN86 
Ras GTPase-activating protein-binding 
protein 2  161.75 1.15 0.037 0.494 
Q96T60 
Bifunctional polynucleotide 
phosphatase/kinase  69.68 1.15 0.029 0.468 
Q13123 Protein Red  142.18 1.14 0.018 0.405 
Q96CT7 
Coiled-coil domain-containing protein 
198.22 1.14 0.027 0.453 
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O95347 
Structural maintenance of 
chromosomes protein 2  252.71 1.14 0.005 0.353 
Q6JBY9 CapZ-interacting protein  184.69 1.14 0.001 0.238 
P54886 
Delta-1-pyrroline-5-carboxylate 
synthase  306.09 1.13 0.001 0.238 
Q9UNN5 FAS-associated factor 1  111.24 1.13 0.049 0.541 
Q96PE3 
Type I inositol 3,4-bisphosphate 4-
phosphatase  119.89 1.13 0.011 0.386 
P09012 U1 small nuclear ribonucleoprotein A  272.05 1.13 0.022 0.428 
E9PAV3; 
Q9BZK3 
Nascent polypeptide-associated 
complex subunit alpha, muscle-
specific form  357.92 1.13 0.016 0.405 
P23921 
Ribonucleoside-diphosphate 
reductase large subunit  505.12 1.13 0.001 0.232 
P13798 Acylamino-acid-releasing enzyme  610.9 1.13 0.017 0.405 
Q8NCW5 NAD(P)H-hydrate epimerase  175.02 1.12 0.022 0.428 
P46013 Antigen KI-67  283.08 1.12 0.009 0.364 
Q16566 
Calcium/calmodulin-dependent 
protein kinase type IV  280.76 1.12 0.023 0.432 
Q7Z6Z7 E3 ubiquitin-protein ligase HUWE1  138.15 1.12 0.012 0.386 
P09497 Clathrin light chain B  134.83 1.12 0.003 0.335 
O15117 FYN-binding protein  194.45 1.12 0.046 0.530 
O75792 Ribonuclease H2 subunit A  122.68 1.12 0.018 0.405 
P30520 
Adenylosuccinate synthetase isozyme 
2  224.65 1.12 0.047 0.534 
P52888 Thimet oligopeptidase  224.72 1.12 0.009 0.364 
Q16531 DNA damage-binding protein 1  1055.93 1.12 0.001 0.232 
Q15287 
RNA-binding protein with serine-rich 
domain 1  104.21 1.11 0.028 0.460 
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P17480 Nucleolar transcription factor 1  206.05 1.11 0.039 0.494 
Q9UBX3 Mitochondrial dicarboxylate carrier  76.36 1.11 0.013 0.391 
P07311 Acylphosphatase-1  82.06 1.11 0.044 0.530 
O00410; 
O60518 Importin-5  919.06 1.11 0.025 0.433 
O00170 AH receptor-interacting protein  291.69 1.11 0.038 0.494 
O75368 
SH3 domain-binding glutamic acid-
rich-like protein  316.99 1.11 0.014 0.398 
Q13404 
Ubiquitin-conjugating enzyme E2 
variant 1  259.98 1.10 0.039 0.494 
P19174 
1-phosphatidylinositol 4,5-
bisphosphate phosphodiesterase 
gamma-1  356.21 1.10 0.032 0.487 
Q9NR30 Nucleolar RNA helicase 2  554.67 1.10 0.031 0.471 
O15067 
Phosphoribosylformylglycinamidine 
synthase  374.31 1.10 0.009 0.365 
P33316 
Deoxyuridine 5'-triphosphate 
nucleotidohydrolase, mitochondrial  588.33 1.10 0.012 0.386 
P33991; 
Q9UJA3 
DNA replication licensing factor 
MCM4  1496.23 1.10 0.007 0.353 
P42166 
Lamina-associated polypeptide 2, 
isoform alpha  1091.49 1.10 0.002 0.257 
Q9UK76 
Hematological and neurological 
expressed 1 protein  157.04 1.10 0.038 0.494 
Q969G3 
SWI/SNF-related matrix-associated 
actin-dependent regulator of 
chromatin subfamily E member 1  437.15 1.10 0.007 0.353 
O43768; 
P56211 Alpha-endosulfine  158.37 1.10 0.009 0.364 
P35611 Alpha-adducin  425.46 1.10 0.011 0.386 
P11388 DNA topoisomerase 2-alpha  2184.55 1.10 0.024 0.433 
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Q4G176 
Acyl-CoA synthetase family member 
3, mitochondrial  260.7 1.09 0.016 0.405 
P49915 
GMP synthase [glutamine-
hydrolyzing]  544.58 1.09 0.008 0.353 
P06493 Cyclin-dependent kinase 1  357.46 1.09 0.035 0.494 
Q9HCE1 Putative helicase MOV-10  425.86 1.09 0.009 0.364 
O94874 E3 UFM1-protein ligase 1  64.48 1.09 0.026 0.443 
P62310 
U6 snRNA-associated Sm-like protein 
LSm3  32.54 1.09 0.036 0.494 
P25685 DnaJ homolog subfamily B member 1  404.23 1.09 0.017 0.405 
P36639 
7,8-dihydro-8-oxoguanine 
triphosphatase  264.86 1.09 0.038 0.494 
Q9Y5Z4 Heme-binding protein 2  121.02 1.09 0.001 0.257 
P63208 S-phase kinase-associated protein 1  118.69 1.09 0.027 0.450 
Q9UJU2; 
P36402 Lymphoid enhancer-binding factor 1  125.22 1.09 0.040 0.494 
Q8IX12 
Cell division cycle and apoptosis 
regulator protein 1  63.87 1.09 0.038 0.494 
Q15691 
Q9UPY8 
Microtubule-associated protein RP/EB 
family member 1  453.96 1.09 0.047 0.534 
P13073 
Cytochrome c oxidase subunit 4 
isoform 1, mitochondrial  199.5 1.09 0.006 0.353 
P62495 
Eukaryotic peptide chain release 
factor subunit 1  431.99 1.08 0.005 0.353 
Q14980 Nuclear mitotic apparatus protein 1  2382.65 1.08 0.002 0.257 
P62269 40S ribosomal protein S18  492.85 1.08 0.016 0.405 
Q5TBB1 Ribonuclease H2 subunit B  155.52 1.08 0.041 0.505 
Q9H0D6 5'-3' exoribonuclease 2  429.62 1.08 0.049 0.541 
P33993 
DNA replication licensing factor 
MCM7  760.99 1.08 0.016 0.405 
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P15927 Replication protein A 32 kDa subunit  159.26 1.08 0.046 0.530 
Q9NVP2 Histone chaperone ASF1B  94.35 1.08 0.029 0.466 
P12004 Proliferating cell nuclear antigen  598.14 1.08 0.005 0.353 
P67809; 
P16989 
Nuclease-sensitive element-binding 
protein 1  786.89 1.08 0.018 0.405 
P45973 Chromobox protein homolog 5  378.89 1.08 0.046 0.530 
P55265 
Double-stranded RNA-specific 
adenosine deaminase  656.1 1.08 0.042 0.511 
Q99986 Serine/threonine-protein kinase VRK1  508.71 1.07 0.002 0.257 
O76071 
Probable cytosolic iron-sulfur protein 
assembly protein CIAO1  123.04 1.07 0.020 0.420 
Q86XP3 ATP-dependent RNA helicase DDX42  189.62 1.07 0.017 0.405 
Q09028 Histone-binding protein RBBP4  484.41 1.07 0.045 0.530 
Q14566 
DNA replication licensing factor 
MCM6  1269.25 1.07 0.005 0.353 
Q6P2E9 
Enhancer of mRNA-decapping protein 
4  640.32 1.07 0.023 0.432 
Q92900 Regulator of nonsense transcripts 1  555.69 1.07 0.008 0.353 
P17174 
Aspartate aminotransferase, 
cytoplasmic  388.1 1.06 0.020 0.418 
P13693 
Translationally-controlled tumor 
protein  238.44 1.06 0.049 0.541 
Q9UI08 Ena/VASP-like protein  736.92 1.06 0.025 0.433 
P23193; 
Q15560 
Transcription elongation factor A 
protein 1  461.31 1.06 0.036 0.494 
Q9NY27 
Serine/threonine-protein 
phosphatase 4 regulatory subunit 2  151.06 1.06 0.014 0.395 
P12268 
Inosine-5'-monophosphate 
dehydrogenase 2  912.86 1.06 0.022 0.428 
Q9GZS3 WD repeat-containing protein 61  255.78 1.06 0.030 0.471 
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Q8WXX5 DnaJ homolog subfamily C member 9  489.02 1.06 0.024 0.432 
Q15181 Inorganic pyrophosphatase  823.4 1.06 0.027 0.457 
Q9NQR4 Omega-amidase NIT2  357.97 1.06 0.012 0.386 
P17812; 
Q9NRF8 CTP synthase 1  695.16 1.06 0.048 0.538 
P30050 60S ribosomal protein L12  505.8 1.06 0.007 0.353 
P49736 
DNA replication licensing factor 
MCM2  1351.22 1.06 0.003 0.335 
P49321 Nuclear autoantigenic sperm protein  1018.75 1.05 0.048 0.536 
P18669; 
P15259; 
Q8N0Y7 Phosphoglycerate mutase 1  1120.25 1.05 0.046 0.531 
P55060 Exportin-2  1119.92 1.05 0.011 0.386 
P26373 60S ribosomal protein L13  440.18 1.05 0.039 0.494 
P52292 Importin subunit alpha-1  285.55 1.05 0.038 0.494 
P63244 
Guanine nucleotide-binding protein 
subunit beta-2-like 1  1251.87 1.05 0.031 0.475 
Q9NQG5 
Regulation of nuclear pre-mRNA 
domain-containing protein 1B  287.6 1.04 0.018 0.405 
P41091; 
Q2VIR3 
Eukaryotic translation initiation factor 
2 subunit 3  415.61 1.04 0.049 0.541 
Q15029 
116 kDa U5 small nuclear 
ribonucleoprotein component  1121.6 1.04 0.032 0.483 
P62318 
Small nuclear ribonucleoprotein Sm 
D3  396.06 1.04 0.013 0.391 
P18124 60S ribosomal protein L7  594.63 1.04 0.018 0.405 
P36578 60S ribosomal protein L4  881.37 1.04 0.009 0.365 
Q52LJ0 Protein FAM98B  289.38 1.03 0.043 0.517 
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P59998 
Actin-related protein 2/3 complex 
subunit 4  285.45 1.04 0.008 0.353 
O00571; 
O15523; 
Q9NQI0 ATP-dependent RNA helicase DDX3X  1006.7 1.04 0.039 0.494 
Q92556 Engulfment and cell motility protein 1  384.64 1.05 0.020 0.418 
Q13200 
26S proteasome non-ATPase 
regulatory subunit 2  891.94 1.05 0.032 0.483 
P40937 Replication factor C subunit 5  330.3 1.05 0.036 0.494 
P09211 Glutathione S-transferase P  829.47 1.05 0.018 0.405 
Q9NTJ5 
Phosphatidylinositide phosphatase 
SAC1  512.85 1.06 0.042 0.511 
P49588 Alanine--tRNA ligase, cytoplasmic  1261.62 1.06 0.026 0.443 
P27824 Calnexin  921.13 1.06 0.023 0.432 
Q04760 Lactoylglutathione lyase  242.54 1.06 0.037 0.494 
P21333 Filamin-A  5864.52 1.06 0.009 0.364 
P23368 
NAD-dependent malic enzyme, 
mitochondrial  495.38 1.07 0.030 0.470 
Q15008 
26S proteasome non-ATPase 
regulatory subunit 6  531.9 1.07 0.028 0.458 
P41250 Glycine--tRNA ligase  635.35 1.07 0.045 0.530 
Q99460 
26S proteasome non-ATPase 
regulatory subunit 1  964.51 1.08 0.006 0.353 
O43242 
26S proteasome non-ATPase 
regulatory subunit 3  669.32 1.08 0.022 0.432 
O43175 D-3-phosphoglycerate dehydrogenase  870.82 1.08 0.006 0.353 
P07339 Cathepsin D  708.95 1.08 0.017 0.405 
Q92685 
Dol-P-Man:Man(5)GlcNAc(2)-PP-Dol 
alpha-1,3-mannosyltransferase  93.69 1.09 0.028 0.457 
P68366 Tubulin alpha-4A chain  1313.56 1.09 0.041 0.503 
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O43670 Zinc finger protein 207  74.45 1.09 0.023 0.432 
Q06830 Peroxiredoxin-1  493.88 1.09 0.016 0.405 
P08195 4F2 cell-surface antigen heavy chain  533.29 1.10 0.019 0.415 
P30405 
Peptidyl-prolyl cis-trans isomerase F, 
mitochondrial  128.03 1.10 0.012 0.386 
O00487 
26S proteasome non-ATPase 
regulatory subunit 14  173.62 1.10 0.004 0.353 
P08754 
Guanine nucleotide-binding protein 
G(k) subunit alpha  504.6 1.11 0.023 0.432 
Q9UHG3 Prenylcysteine oxidase 1  121.58 1.11 0.012 0.386 
P61009 Signal peptidase complex subunit 3  105.12 1.11 0.020 0.418 
P53634 Dipeptidyl peptidase 1  305.95 1.11 0.006 0.353 
Q9Y617 Phosphoserine aminotransferase  379.25 1.13 0.017 0.405 
Q8N5M4 Tetratricopeptide repeat protein 9C  64.74 1.13 0.010 0.385 
Q9UM00 
Transmembrane and coiled-coil 
domain-containing protein 1  90.32 1.14 0.022 0.428 
O15173 
Membrane-associated progesterone 
receptor component 2  223.17 1.14 0.004 0.353 
Q01650; 
Q92536 
Large neutral amino acids transporter 
small subunit 1  142.25 1.14 0.005 0.353 
Q9BQE5 Apolipoprotein L2  95.59 1.14 0.045 0.530 
P50416 
Carnitine O-palmitoyltransferase 1, 
liver isoform  663.42 1.14 0.004 0.353 
P20645 
Cation-dependent mannose-6-
phosphate receptor  119.18 1.14 0.017 0.405 
P00390 Glutathione reductase, mitochondrial  591.49 1.15 0.000 0.232 
A6NDJ8 
Putative Rab-43-like protein 
ENSP00000330714  117.15 1.16 0.003 0.335 
Q9UJW0 Dynactin subunit 4  167.33 1.17 0.020 0.418 
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Q9NQT5 Exosome complex component RRP40  62.98 1.18 0.039 0.494 
Q969V3 Nicalin  71.9 1.19 0.055 0.558 
P55212 Caspase-6  73.75 1.20 0.007 0.353 
P07355; 
A6NMY6 Annexin A2  600.64 1.23 0.002 0.257 
Q7L0Y3 
Mitochondrial ribonuclease P protein 
1  70.74 1.24 0.033 0.493 
P02795; 
P04731; 
P04732 Metallothionein-2  92.55 1.25 0.019 0.415 
P00747 Plasminogen  200.49 1.25 0.014 0.395 
P78559 Microtubule-associated protein 1A  58.28 1.26 0.007 0.353 
Q9BT22 
Chitobiosyldiphosphodolichol beta-
mannosyltransferase  124.21 1.27 0.039 0.494 
Q9BT09 Protein canopy homolog 3  47.93 1.31 0.035 0.494 
O75569 
Interferon-inducible double-stranded 
RNA-dependent protein kinase 
activator A  199.26 1.38 0.036 0.494 
P12259 Coagulation factor V  77.83 1.44 0.030 0.471 
 
a Accession number according to UniProt database. b Protein description with relative 
symbol. c Confidence score generated by Progenesis. * Proteins shared between 
both treatments (resveratrol and curcumin). Green reduction, red induction. 
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* Protein common between resveratrol and 
curcumin treatment. 
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Table 8.10 – Significantly modulated proteins in Jurkat T lymphocytes after 1μM 
isorhamnetin identified by label-free LC-MS. 
 
Accessiona    Descriptionb Confidence 
scorec 
Fold 
change  
p-value q-value 
Q6UXB8 Peptidase inhibitor 16  31.35 1.27 0.036 0.987 
Q86TU7 
Histone-lysine N-methyltransferase 
setd3  34.83 1.25 0.021 
0.987 
Q5UIP0 Telomere-associated protein RIF1  30.91 1.25 0.039 0.987 
Q02218 
2-oxoglutarate dehydrogenase, 
mitochondrial 31.22 1.23 0.014 
0.987 
Q92552 
28S ribosomal protein S27, 
mitochondrial  44.06 1.23 0.015 
0.987 
Q9HC07 Transmembrane protein 165  45.58 1.21 0.011 0.987 
Q9NXJ5 Pyroglutamyl-peptidase 1  31.61 1.21 0.049 0.987 
Q9Y5Z4 Heme-binding protein 2  48.89 1.21 0.019 0.987 
O15305 Phosphomannomutase 2  33.42 1.20 0.023 0.987 
Q9ULR0 
Pre-mRNA-splicing factor ISY1 
homolog  94.69 1.19 0.024 
0.987 
P60602 Reactive oxygen species modulator 1  56.72 1.17 0.031 0.987 
O15160 
DNA-directed RNA polymerases I and 
III subunit RPAC1  37.84 1.17 0.028 
0.987 
Q8N5M4 Tetratricopeptide repeat protein 9C  39.27 1.16 0.009 0.987 
Q7Z4H7 HAUS augmin-like complex subunit 6  51.45 1.16 0.003 0.987 
Q96ER3 Protein SAAL1 84.76 1.15 0.038 0.987 
Q15392 Delta(24)-sterol reductase  136.11 1.15 0.013 0.987 
Q9UI12 V-type proton ATPase subunit H  40.45 1.15 0.009 0.987 
Q7L1Q6 
Basic leucine zipper and W2 domain-
containing protein 1  313.99 1.15 0.019 
0.987 
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Q8NFH3 Nucleoporin Nup43  223.78 1.15 0.024 0.987 
P43897 Elongation factor Ts, mitochondrial  149.55 1.14 0.012 0.987 
Q9UQ88 Cyclin-dependent kinase 11A  124.58 1.14 0.031 0.987 
Q08752 Peptidyl-prolyl cis-trans isomerase D  199.15 1.14 0.033 0.987 
O95379 
Tumor necrosis factor alpha-induced 
protein 8 161.61 1.13 0.035 
0.987 
Q9UBE0 SUMO-activating enzyme subunit 1  313.59 1.13 0.036 0.987 
Q9Y4W6 AFG3-like protein 2  61.2 1.12 0.041 0.987 
Q9UGP8 Translocation protein SEC63 homolog  162.48 1.12 0.040 0.987 
P63092; 
P38405 
Guanine nucleotide-binding protein 
G(s) subunit alpha isoforms short  254.28 1.12 0.017 
0.987 
O75396 Vesicle-trafficking protein SEC22b  364.6 1.11 0.005 0.987 
Q6L8Q7 2',5'-phosphodiesterase 12  96.55 1.11 0.035 0.987 
O95573 Long-chain-fatty-acid--CoA ligase 3  224.99 1.11 0.002 0.987 
Q9Y4P1 Cysteine protease ATG4B  148.92 1.11 0.023 0.987 
P00846 ATP synthase subunit a  44.36 1.10 0.037 0.987 
Q9UBX3 Mitochondrial dicarboxylate carrier  129.56 1.10 0.025 0.987 
Q16566 
Calcium/calmodulin-dependent 
protein kinase type IV  262.66 1.10 0.000 0.188 
P12236 ADP/ATP translocase 3  600.74 1.10 0.031 0.987 
Q15005 Signal peptidase complex subunit 2  215.12 1.10 0.016 0.987 
Q9H9B4; 
Q9BWM7 Sideroflexin-1  525.31 1.10 0.033 
0.987 
Q01581 
Hydroxymethylglutaryl-CoA synthase, 
cytoplasmic 168.58 1.10 0.039 
0.987 
P21266 Glutathione S-transferase Mu 3  274.29 1.10 0.050 0.987 
P60468 
Protein transport protein Sec61 
133.46 1.10 0.004 0.987 
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subunit beta  
P46781 40S ribosomal protein S9  367.26 1.09 0.004 0.987 
P48449 Lanosterol synthase  488.43 1.09 0.014 0.987 
Q9H7D7 WD repeat-containing protein 26  89.11 1.09 0.044 0.987 
Q92930 Ras-related protein Rab-8B  328.85 1.09 0.048 0.987 
P32969 60S ribosomal protein L9  383.76 1.09 0.046 0.987 
P50416 
Carnitine O-palmitoyltransferase 1, 
liver isoform 309.47 1.08 0.025 
0.987 
P28482; 
P09619; 
P27361 Mitogen-activated protein kinase 1  216.29 1.08 0.031 
0.987 
P56192 Methionine--tRNA ligase, cytoplasmic  571.26 1.08 0.015 0.987 
P56134 ATP synthase subunit f, mitochondrial  109.15 1.08 0.012 0.987 
Q9UQE7 
Structural maintenance of 
chromosomes protein 3  531.87 1.07 0.035 
0.987 
P06493 Cyclin-dependent kinase 1  349.99 1.07 0.038 0.987 
O14980 Exportin-1  608.63 1.07 0.018 0.987 
Q9NPQ8; 
Q9NVN3 Synembryn-A  218.4 1.07 0.018 
0.987 
Q15008 
26S proteasome non-ATPase 
regulatory subunit 6  274.56 1.06 0.005 
0.987 
P42166 
Lamina-associated polypeptide 2, 
isoform alpha  1157.24 1.05 0.039 
0.987 
P62826 GTP-binding nuclear protein Ran 374.58 1.04 0.010 0.987 
Q9BXS5; 
Q9Y6Q5 AP-1 complex subunit mu-1  95.16 1.06 0.049 
0.987 
Q8NEV1 Casein kinase II subunit alpha 3  214.01 1.06 0.008 0.987 
Q15006 
ER membrane protein complex 
185.43 1.06 0.041 0.987 
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subunit 2  
Q16881; 
Q9NNW7 Thioredoxin reductase 1, cytoplasmic  431.42 1.07 0.028 
0.987 
Q49A26 Putative oxidoreductase GLYR1  53.13 1.07 0.026 0.987 
Q99598 Translin-associated protein X  115.83 1.08 0.041 0.987 
Q96CW1 AP-2 complex subunit mu  197.07 1.09 0.040 0.987 
P49916 DNA ligase 3  240.06 1.09 0.011 0.987 
O75821 
Eukaryotic translation initiation factor 
3 subunit G  205.44 1.09 0.006 
0.987 
O75937 DnaJ homolog subfamily C member 8  100.29 1.09 0.035 0.987 
Q9UNZ2 NSFL1 cofactor p47  441.85 1.10 0.038 0.987 
P49006 MARCKS-related protein  308.67 1.10 0.044 0.987 
Q9UKK9 ADP-sugar pyrophosphatase  164.34 1.10 0.024 0.987 
Q9UNN5 FAS-associated factor 1  91.91 1.11 0.008 0.987 
O75431 Metaxin-2  79.14 1.12 0.034 0.987 
P62857 40S ribosomal protein S28  250.78 1.12 0.030 0.987 
Q86X76 Nitrilase homolog 1  130.09 1.14 0.027 0.987 
Q9BV44 THUMP domain-containing protein 3  85.19 1.15 0.002 0.987 
Q9HBU6 Ethanolamine kinase 1  94.98 1.15 0.024 0.987 
Q13330; 
Q9BTC8 Metastasis-associated protein MTA1  269.09 1.17 0.013 
0.987 
Q96F15 GTPase IMAP family member 5  68.51 1.23 0.002 0.987 
P13612 Integrin alpha-4 32.61 1.25 0.011 0.987 
P55081 Microfibrillar-associated protein 1  33.84 1.29 0.017 0.987 
Q9H0R4 
Haloacid dehalogenase-like hydrolase 
domain-containing protein 2  32.38 1.31 0.013 
0.987 
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Q8IY37 
Probable ATP-dependent RNA 
helicase DHX37  34.64 1.35 0.039 
0.987 
Q9Y2X7 ARF GTPase-activating protein GIT1  33.12 1.70 0.016 0.987 
P04264; 
P04259; 
P35908 Keratin, type II cytoskeletal 1  88.8 2.01 0.008 
0.987 
 
a Accession number according to UniProt database. b Protein description with relative 
symbol. c Confidence score generated by Progenesis. * Proteins shared between 
both treatments (resveratrol and curcumin). Green reduction, red induction. 
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* Protein common between resveratrol and 
curcumin treatment. 
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Table 8.11 – Significantly modulated proteins in Jurkat T lymphocytes after 30μM 
isorhamnetin identified by label-free LC-MS. 
 
Accessiona    Descriptionb Confidence 
scorec 
Fold 
change  
p-value q-value 
P06396 Gelsolin  33.62 2.64 0.001 0.038 
Q01581 
Hydroxymethylglutaryl-CoA synthase, 
cytoplasmic 168.58 1.91 0.000 0.000 
P37268 Squalene synthase  704.92 1.79 0.000 0.000 
Q8NBT2 Kinetochore protein Spc24  141.91 1.50 0.013 0.120 
Q92522 Histone H1x  401.69 1.42 0.001 0.043 
Q5MIZ7 
Serine/threonine-protein phosphatase 
4 regulatory subunit 3B  50.04 1.40 0.028 0.146 
Q9NXJ5 Pyroglutamyl-peptidase 1  31.61 1.31 0.005 0.077 
P02774 Vitamin D-binding protein  57.1 1.30 0.049 0.186 
Q9HBM1 Kinetochore protein Spc25  35.24 1.30 0.036 0.162 
Q14790 Caspase-8  29.02 1.30 0.032 0.154 
P48449 Lanosterol synthase  488.43 1.29 0.000 0.027 
Q9BZF1 
Oxysterol-binding protein-related 
protein 8 49.77 1.28 0.031 0.151 
P63092; 
P38405 
Guanine nucleotide-binding protein 
G(s) subunit alpha isoforms short  254.28 1.27 0.000 0.022 
P23921 
Ribonucleoside-diphosphate reductase 
large subunit  551.47 1.27 0.000 0.022 
P13674 Prolyl 4-hydroxylase subunit alpha-1  416.86 1.27 0.004 0.071 
Q15836 Vesicle-associated membrane protein 3  42.62 1.24 0.038 0.166 
Q9UBM7 7-dehydrocholesterol reductase 222.35 1.24 0.001 0.047 
O75152 
Zinc finger CCCH domain-containing 
protein 11A 86.12 1.24 0.035 0.160 
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Q8NFH3 Nucleoporin Nup43  223.78 1.24 0.001 0.039 
P53007 
Tricarboxylate transport protein, 
mitochondrial  227.59 1.23 0.015 0.125 
Q9NRX4 14 kDa phosphohistidine phosphatase  75.66 1.23 0.010 0.109 
P10515 
Dihydrolipoyllysine-residue 
acetyltransferase component of 
pyruvate dehydrogenase complex, 
mitochondrial  515.96 1.23 0.001 0.039 
Q9BZX2 Uridine-cytidine kinase 2  56.3 1.22 0.012 0.116 
Q15392 Delta(24)-sterol reductase 136.11 1.22 0.004 0.072 
P31350 
Ribonucleoside-diphosphate reductase 
subunit M2 146.64 1.22 0.018 0.125 
Q7L1Q6 
Basic leucine zipper and W2 domain-
containing protein 1  313.99 1.22 0.000 0.027 
P55212 Caspase-6  56.64 1.22 0.010 0.108 
O15305 Phosphomannomutase 2  33.42 1.22 0.005 0.080 
Q63HN8 E3 ubiquitin-protein ligase RNF213  94.06 1.21 0.048 0.185 
Q7Z4H7 HAUS augmin-like complex subunit 6  51.45 1.20 0.000 0.027 
Q9H4E7 
Differentially expressed in FDCP 6 
homolog  118 1.20 0.028 0.146 
Q9Y6G9 
Cytoplasmic dynein 1 light intermediate 
chain 1  53.87 1.20 0.002 0.059 
Q99943 
1-acyl-sn-glycerol-3-phosphate 
acyltransferase alpha 63.87 1.20 0.006 0.089 
Q86YV0 RAS protein activator like-3 122.95 1.20 0.033 0.158 
O15027 Protein transport protein Sec16A  109.7 1.20 0.037 0.165 
Q86TU7 
Histone-lysine N-methyltransferase 
setd3  34.83 1.20 0.048 0.184 
Q9NSE4 Isoleucine--tRNA ligase, mitochondrial  52.94 1.20 0.037 0.165 
P49327 Fatty acid synthase 879.28 1.19 0.004 0.071 
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P08134 Rho-related GTP-binding protein RhoC 203.16 1.19 0.003 0.063 
Q9P035 
Very-long-chain (3R)-3-hydroxyacyl-
[acyl-carrier protein] dehydratase 3  263.43 1.19 0.042 0.172 
P52292 Importin subunit alpha-1  449.61 1.19 0.019 0.129 
P10155 60 kDa SS-A/Ro ribonucleoprotein  49.1 1.19 0.050 0.186 
O00182; 
Q3B8N2 Galectin-9  161.13 1.19 0.043 0.173 
Q92665 
28S ribosomal protein S31, 
mitochondrial  50.73 1.19 0.011 0.112 
P50416 
Carnitine O-palmitoyltransferase 1, liver 
isoform 309.47 1.18 0.002 0.053 
Q9UNF1 Melanoma-associated antigen D2  48.74 1.18 0.004 0.071 
Q14558 
Phosphoribosyl pyrophosphate 
synthase-associated protein 1 153.92 1.18 0.000 0.033 
P53396 ATP-citrate synthase  2180.48 1.18 0.000 0.002 
P22830 Ferrochelatase, mitochondrial  136.1 1.18 0.030 0.148 
Q9H4M9 EH domain-containing protein 1  41.58 1.18 0.024 0.141 
P03905 
NADH-ubiquinone oxidoreductase 
chain 4  48.04 1.18 0.034 0.158 
Q9UQ88 Cyclin-dependent kinase 11A 124.58 1.18 0.009 0.106 
P60842 Eukaryotic initiation factor 4A-I  1242.37 1.17 0.002 0.055 
Q9P003 Protein cornichon homolog 4  49.21 1.17 0.017 0.125 
P12236 ADP/ATP translocase 3  600.74 1.16 0.003 0.071 
Q9Y6B6 GTP-binding protein SAR1b  152.12 1.16 0.014 0.121 
Q5JPE7 Nodal modulator 2  633.91 1.16 0.001 0.051 
P63218 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(O) subunit gamma-5  32.15 1.16 0.043 0.173 
O15258 Protein RER1  74.79 1.16 0.028 0.145 
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P50914 60S ribosomal protein L14  187.02 1.16 0.018 0.125 
Q15027 
Arf-GAP with coiled-coil, ANK repeat 
and PH domain-containing protein 1  379.54 1.16 0.017 0.125 
Q5T4S7 E3 ubiquitin-protein ligase UBR4  384.69 1.16 0.029 0.147 
P11310 
Medium-chain specific acyl-CoA 
dehydrogenase, mitochondrial  535.89 1.16 0.003 0.071 
Q9NS69 
Mitochondrial import receptor subunit 
TOM22 homolog  219.29 1.16 0.026 0.143 
Q96F07; 
Q7L576 Cytoplasmic FMR1-interacting protein 2  252.41 1.16 0.016 0.125 
P46781 40S ribosomal protein S9  367.26 1.16 0.001 0.038 
Q9NUU7; 
Q9UHL0; 
Q9UMR2 ATP-dependent RNA helicase DDX19A  259.82 1.15 0.002 0.052 
Q5SRE5 Nucleoporin NUP188 homolog  78.44 1.15 0.011 0.111 
P19404 
NADH dehydrogenase [ubiquinone] 
flavoprotein 2, mitochondrial  47.32 1.15 0.025 0.142 
Q16566 
Calcium/calmodulin-dependent protein 
kinase type IV  262.66 1.15 0.002 0.054 
O95573 Long-chain-fatty-acid--CoA ligase 3  224.99 1.15 0.016 0.125 
P78344 
Eukaryotic translation initiation factor 4 
gamma 2  269.3 1.15 0.018 0.125 
Q96CS3 FAS-associated factor 2  92.79 1.15 0.029 0.146 
Q9BTT0 
Acidic leucine-rich nuclear 
phosphoprotein 32 family member E 630.39 1.15 0.004 0.073 
P05771 Protein kinase C beta type  345.22 1.15 0.022 0.133 
O75832 
26S proteasome non-ATPase regulatory 
subunit 10 136.94 1.15 0.019 0.126 
Q96D05 Uncharacterized protein C10orf35  93.05 1.14 0.026 0.144 
Q86UX7 Fermitin family homolog 3 850.38 1.14 0.004 0.071 
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O95571 
Persulfide dioxygenase ETHE1, 
mitochondrial  248.41 1.14 0.006 0.086 
P07305 Histone H1.0  162.04 1.14 0.001 0.048 
Q8WU39 
Marginal zone B- and B1-cell-specific 
protein 296.2 1.14 0.002 0.052 
P62879 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-2  674.25 1.14 0.011 0.112 
P15153 
Ras-related C3 botulinum toxin 
substrate 2  232.08 1.14 0.009 0.106 
Q9H7D7 WD repeat-containing protein 26  89.11 1.14 0.010 0.108 
P19367; 
Q2TB90 Hexokinase-1  772.01 1.14 0.010 0.108 
Q8N752 Casein kinase I isoform alpha-like  48.66 1.14 0.046 0.182 
O94925 
Glutaminase kidney isoform, 
mitochondrial  233.6 1.14 0.003 0.063 
P19784 Casein kinase II subunit alpha'  208.38 1.14 0.042 0.173 
P10606 
Cytochrome c oxidase subunit 5B, 
mitochondrial  81.62 1.14 0.007 0.090 
Q92974 
Rho guanine nucleotide exchange 
factor 2  741.41 1.13 0.003 0.063 
P21266 Glutathione S-transferase Mu 3  274.29 1.13 0.015 0.125 
O75489 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 3, mitochondrial  264.83 1.13 0.008 0.098 
Q16563 Synaptophysin-like protein 1  61.13 1.13 0.044 0.176 
Q14157 Ubiquitin-associated protein 2-like  250.46 1.13 0.028 0.146 
P62280 40S ribosomal protein S11  278.08 1.13 0.029 0.146 
P62979; 
P0CG47 Ubiquitin-40S ribosomal protein S27a 359.63 1.13 0.010 0.107 
P56134 ATP synthase subunit f, mitochondrial  109.15 1.13 0.003 0.063 
P02786 Transferrin receptor protein 1  980.43 1.13 0.011 0.112 
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Q9BV86 
N-terminal Xaa-Pro-Lys N-
methyltransferase 1  131.96 1.13 0.002 0.058 
Q7L014 
Probable ATP-dependent RNA helicase 
DDX46  743.53 1.13 0.004 0.071 
Q9BSJ8 Extended synaptotagmin-1  927.4 1.13 0.015 0.125 
Q01813 6-phosphofructokinase type C  1504.46 1.13 0.000 0.022 
Q9H9B4; 
Q9BWM7 Sideroflexin-1  525.31 1.13 0.007 0.090 
Q13576 
Ras GTPase-activating-like protein 
IQGAP2  628.25 1.13 0.025 0.142 
Q16512 Serine/threonine-protein kinase N1  53.05 1.13 0.014 0.121 
Q96T76 
MMS19 nucleotide excision repair 
protein homolog  144.44 1.12 0.015 0.125 
Q13885 Tubulin beta-2A chain  1390.54 1.12 0.038 0.166 
P39023; 
Q92901 60S ribosomal protein L3 834.85 1.12 0.012 0.118 
Q00839 
Heterogeneous nuclear 
ribonucleoprotein U  1887.69 1.12 0.002 0.054 
Q9BVK6 
Transmembrane emp24 domain-
containing protein 9  210.62 1.12 0.030 0.149 
Q9BWD1 Acetyl-CoA acetyltransferase, cytosolic  468.41 1.12 0.006 0.089 
P14868 Aspartate--tRNA ligase, cytoplasmic  861.83 1.12 0.007 0.090 
O94874 E3 UFM1-protein ligase 1  157.26 1.11 0.047 0.184 
P00846 ATP synthase subunit a  44.36 1.11 0.004 0.072 
P51659 
Peroxisomal multifunctional enzyme 
type 2  804.27 1.11 0.010 0.110 
Q9Y5Y2 
Cytosolic Fe-S cluster assembly factor 
NUBP2  224.62 1.11 0.031 0.152 
P46782 40S ribosomal protein S5  651.39 1.11 0.032 0.153 
Q9Y4W6 AFG3-like protein 2  61.2 1.11 0.047 0.182 
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O00264 
Membrane-associated progesterone 
receptor component 1  258.59 1.11 0.045 0.180 
P47985; 
P0C7P4 
Cytochrome b-c1 complex subunit 
Rieske, mitochondrial  269.52 1.11 0.030 0.148 
O00217 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 8, mitochondrial  85.63 1.11 0.046 0.182 
Q96CN7 
Isochorismatase domain-containing 
protein 1  81.46 1.11 0.021 0.133 
O00571; 
O15523 ATP-dependent RNA helicase DDX3X  971.13 1.11 0.002 0.051 
Q9UBX3 Mitochondrial dicarboxylate carrier  129.56 1.11 0.011 0.111 
Q9NVI7; 
Q5T2N8; 
Q5T9A4 
ATPase family AAA domain-containing 
protein 3A  483.99 1.11 0.001 0.047 
P62266 40S ribosomal protein S23  349.48 1.11 0.002 0.058 
Q13011 
Delta(3,5)-Delta(2,4)-dienoyl-CoA 
isomerase, mitochondrial 660.24 1.11 0.040 0.170 
P46459 Vesicle-fusing ATPase  276.05 1.11 0.048 0.186 
Q6P2Q9 Pre-mRNA-processing-splicing factor 8 1795.45 1.11 0.022 0.136 
P48047 ATP synthase subunit O, mitochondrial 613.99 1.11 0.016 0.125 
P62753 40S ribosomal protein S6  492.29 1.11 0.003 0.192 
Q15185 Prostaglandin E synthase 3  519.64 1.10 0.005 0.079 
P40939 
Trifunctional enzyme subunit alpha, 
mitochondrial  1068.05 1.10 0.028 0.145 
Q13094 Lymphocyte cytosolic protein 2  75.38 1.10 0.031 0.192 
P00403 Cytochrome c oxidase subunit 2  203.18 1.10 0.001 0.038 
P62913 60S ribosomal protein L11  287.84 1.10 0.032 0.153 
P68371; Tubulin beta-4B chain  1935.29 1.10 0.048 0.184 
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Q3ZCM7 
P17252; 
P05129 Protein kinase C alpha type 561.07 1.10 0.018 0.125 
P51665 
26S proteasome non-ATPase regulatory 
subunit 7 310.19 1.10 0.020 0.132 
Q5JTV8 Torsin-1A-interacting protein 1  136.24 1.10 0.017 0.125 
P38117 
Electron transfer flavoprotein subunit 
beta  445.82 1.10 0.006 0.086 
A0AVT1 
Ubiquitin-like modifier-activating 
enzyme 6  308.59 1.10 0.020 0.129 
P13804 
Electron transfer flavoprotein subunit 
alpha, mitochondrial  679.66 1.10 0.013 0.118 
P36507 
Dual specificity mitogen-activated 
protein kinase kinase 2  372.26 1.10 0.050 0.186 
P01111; 
P01116 GTPase NRas  189.44 1.10 0.049 0.186 
P30085 UMP-CMP kinase  212.43 1.10 0.039 0.169 
P10809 
60 kDa heat shock protein, 
mitochondrial  2904.81 1.10 0.023 0.139 
O95881 
Thioredoxin domain-containing protein 
12  71.56 1.10 0.022 0.133 
Q9BQE3; 
A6NHL2; 
Q9H853 Tubulin alpha-1C chain 1765.34 1.10 0.035 0.160 
P62269 40S ribosomal protein S18  568.99 1.10 0.005 0.083 
Q00610; 
P53675 Clathrin heavy chain 1  3109.45 1.10 0.003 0.067 
P40763 
Signal transducer and activator of 
transcription 3  272.49 1.10 0.015 0.125 
P04818 Thymidylate synthase  320.63 1.10 0.023 0.139 
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P62241 40S ribosomal protein S8  496.38 1.09 0.003 0.071 
P35998 26S protease regulatory subunit 7 1000.15 1.09 0.043 0.173 
Q96DI7 
U5 small nuclear ribonucleoprotein 40 
kDa protein  287.22 1.09 0.011 0.112 
Q13151 
Heterogeneous nuclear 
ribonucleoprotein A0  607.45 1.09 0.014 0.121 
P36578 60S ribosomal protein L4  883.13 1.09 0.001 0.047 
Q02878 60S ribosomal protein L6  867.33 1.09 0.017 0.125 
P16615 
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2  1195.67 1.09 0.019 0.126 
P27824 Calnexin  1078.73 1.09 0.021 0.133 
Q9UBS4 DnaJ homolog subfamily B member 11  223.96 1.09 0.020 0.129 
Q15287 
RNA-binding protein with serine-rich 
domain 1  227.89 1.09 0.047 0.182 
O43837 
Isocitrate dehydrogenase [NAD] subunit 
beta, mitochondrial  420.5 1.09 0.009 0.106 
Q14498; 
Q86U06 RNA-binding protein 39  648.84 1.09 0.018 0.125 
P62888 60S ribosomal protein L30  460.88 1.09 0.014 0.120 
P50570; 
Q05193; 
Q9UQ16 Dynamin-2  462.5 1.09 0.011 0.111 
O43615 
Mitochondrial import inner membrane 
translocase subunit TIM44  290.5 1.09 0.028 0.146 
Q9NSD9 
Phenylalanine--tRNA ligase beta 
subunit  520.43 1.09 0.019 0.126 
O60831 PRA1 family protein 2  88.37 1.09 0.029 0.146 
P61604 
10 kDa heat shock protein, 
mitochondrial  472.98 1.09 0.016 0.125 
Q12769 Nuclear pore complex protein Nup160  159.72 1.09 0.035 0.160 
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P40429; 
Q6NVV1 60S ribosomal protein L13a  373.67 1.08 0.012 0.112 
Q07960 Rho GTPase-activating protein 1  241.38 1.08 0.040 0.169 
P22307 Non-specific lipid-transfer protein  493.33 1.08 0.005 0.080 
Q92973 Transportin-1  505.82 1.08 0.001 0.051 
P84095 Rho-related GTP-binding protein RhoG  535.95 1.08 0.041 0.171 
P48735 
Isocitrate dehydrogenase [NADP], 
mitochondrial 1330.31 1.08 0.022 0.133 
P31943 
Heterogeneous nuclear 
ribonucleoprotein H  980.42 1.08 0.014 0.120 
P30048 
Thioredoxin-dependent peroxide 
reductase, mitochondrial  428.51 1.08 0.037 0.165 
P56192 Methionine--tRNA ligase, cytoplasmic 571.26 1.08 0.013 0.118 
P60709; 
A5A3E0; 
P0CG38; 
P0CG39; 
Q562R1; 
Q6S8J3; 
Q9BYX7 Actin, cytoplasmic 1  2271.13 1.08 0.005 0.083 
Q07955 Serine/arginine-rich splicing factor 1  555.74 1.08 0.012 0.116 
P25398 40S ribosomal protein S12 390.6 1.08 0.025 0.192 
Q02543 60S ribosomal protein L18a  318.67 1.08 0.047 0.184 
Q08J23 
tRNA (cytosine(34)-C(5))-
methyltransferase  845.53 1.08 0.008 0.094 
Q8WYJ6 Septin-1  512.17 1.08 0.041 0.171 
Q13547; 
O15379 Histone deacetylase 1 520.45 1.08 0.005 0.083 
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P11717 
Cation-independent mannose-6-
phosphate receptor OS=Homo sapiens 
GN=IGF2R PE=1 SV=3 315.72 1.08 0.034 0.159 
P31942 
Heterogeneous nuclear 
ribonucleoprotein H3  687.57 1.08 0.027 0.145 
P46776 60S ribosomal protein L27a  184.8 1.08 0.013 0.120 
P42677; 
Q71UM5 40S ribosomal protein S27 187.14 1.08 0.023 0.138 
P18621 60S ribosomal protein L17  205.73 1.08 0.028 0.146 
P61313 60S ribosomal protein L15 261.41 1.08 0.001 0.051 
P61247 40S ribosomal protein S3a  793.01 1.08 0.019 0.128 
P62263 40S ribosomal protein S14  314.21 1.08 0.025 0.142 
P62244 40S ribosomal protein S15a  209.97 1.08 0.005 0.080 
P55209 Nucleosome assembly protein 1-like 1  576.82 1.08 0.025 0.142 
P22102 
Trifunctional purine biosynthetic 
protein adenosine-3  858.05 1.08 0.028 0.146 
P14625; 
Q58FF3 Endoplasmin  2119.46 1.08 0.008 0.094 
P60468 
Protein transport protein Sec61 subunit 
beta  133.46 1.08 0.034 0.158 
P23396 40S ribosomal protein S3  853.45 1.07 0.010 0.109 
P00367; 
P49448 
Glutamate dehydrogenase 1, 
mitochondrial  757.31 1.07 0.021 0.133 
Q9UHD8 Septin-9  454.96 1.07 0.020 0.129 
P62424 60S ribosomal protein L7a  690.58 1.07 0.050 0.186 
P51149 Ras-related protein Rab-7a 649.34 1.07 0.049 0.186 
P61353 60S ribosomal protein L27  244.37 1.07 0.022 0.136 
P63244 
Guanine nucleotide-binding protein 
subunit beta-2-like 1  1304.43 1.07 0.009 0.102 
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P63173 60S ribosomal protein L38  164.85 1.07 0.035 0.160 
P24539 
ATP synthase F(0) complex subunit B1, 
mitochondrial  236.1 1.07 0.035 0.160 
Q14204 Cytoplasmic dynein 1 heavy chain 1  2076.8 1.07 0.013 0.118 
P52272 
Heterogeneous nuclear 
ribonucleoprotein M  2073.74 1.07 0.018 0.125 
P83731 60S ribosomal protein L24  431.86 1.07 0.049 0.186 
Q16629 Serine/arginine-rich splicing factor 7  228.25 1.07 0.026 0.144 
Q9Y230 RuvB-like 2  616.83 1.07 0.032 0.153 
Q15365 Poly(rC)-binding protein 1  845.71 1.06 0.027 0.145 
P33992 DNA replication licensing factor MCM5 1066.36 1.06 0.017 0.125 
Q14566 DNA replication licensing factor MCM6  1629.88 1.06 0.022 0.133 
Q15008 
26S proteasome non-ATPase regulatory 
subunit 6 274.56 1.06 0.002 0.052 
P47897 Glutamine--tRNA ligase  721.93 1.06 0.001 0.051 
P14324 Farnesyl pyrophosphate synthase  332.03 1.06 0.001 0.051 
P07686 Beta-hexosaminidase subunit beta  143.46 1.06 0.035 0.160 
P39656 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase 48 kDa 
subunit  484.81 1.06 0.025 0.142 
Q15366; 
P57721 Poly(rC)-binding protein 2  606.4 1.06 0.037 0.165 
P11021; 
O95399 78 kDa glucose-regulated protein  2044.95 1.06 0.033 0.155 
P12268 
Inosine-5'-monophosphate 
dehydrogenase 2  1214.57 1.05 0.038 0.167 
Q92841 
Probable ATP-dependent RNA helicase 
DDX17 1329.48 1.05 0.018 0.125 
Q9P258 Protein RCC2  670.33 1.04 0.018 0.125 
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P11413 Glucose-6-phosphate 1-dehydrogenase  654.38 1.06 0.012 0.117 
O43765 
Small glutamine-rich tetratricopeptide 
repeat-containing protein alpha  279.15 1.06 0.043 0.173 
P62826 GTP-binding nuclear protein Ran 374.58 1.06 0.023 0.137 
Q9Y2W1 
Thyroid hormone receptor-associated 
protein 3  426.09 1.06 0.014 0.121 
P26196 
Probable ATP-dependent RNA helicase 
DDX6 491.27 1.06 0.040 0.169 
P22234 Multifunctional protein ADE2  1389.4 1.06 0.041 0.171 
P29144 Tripeptidyl-peptidase 2  249.74 1.07 0.045 0.179 
O43175 D-3-phosphoglycerate dehydrogenase  822.26 1.07 0.027 0.144 
O43776 Asparagine--tRNA ligase, cytoplasmic  514.13 1.07 0.022 0.133 
P49588 Alanine--tRNA ligase, cytoplasmic  1396.95 1.07 0.018 0.125 
Q16531 DNA damage-binding protein 1  755.41 1.07 0.007 0.090 
Q04837 
Single-stranded DNA-binding protein, 
mitochondrial  294.31 1.07 0.017 0.125 
Q9BT78 COP9 signalosome complex subunit 4  302.1 1.07 0.024 0.140 
Q13428 Treacle protein  504.02 1.07 0.039 0.169 
P55072 
Transitional endoplasmic reticulum 
ATPase  2044.99 1.07 0.007 0.090 
P63010 AP-2 complex subunit beta 420.33 1.07 0.036 0.162 
P06733 Alpha-enolase  2107.6 1.08 0.009 0.106 
P26639 Threonine--tRNA ligase, cytoplasmic  592.55 1.08 0.008 0.097 
Q06830 Peroxiredoxin-1 515.18 1.08 0.041 0.171 
Q96CW1 AP-2 complex subunit mu  197.07 1.08 0.027 0.144 
P00558 Phosphoglycerate kinase 1  1975.91 1.08 0.045 0.179 
O43488; 
O95154; 
Aflatoxin B1 aldehyde reductase 
member 2  324.91 1.08 0.018 0.125 
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Q8NHP1 
Q9GZL7 Ribosome biogenesis protein WDR12 224.38 1.08 0.019 0.126 
Q9Y266 Nuclear migration protein nudC  509.24 1.08 0.024 0.141 
Q9NQC3 Reticulon-4 240.28 1.08 0.004 0.076 
P62993 
Growth factor receptor-bound protein 
2 289.01 1.08 0.033 0.158 
Q9UK76 
Hematological and neurological 
expressed 1 protein  235.51 1.08 0.035 0.160 
Q13435 Splicing factor 3B subunit 2  500.01 1.08 0.018 0.125 
P08575 
Receptor-type tyrosine-protein 
phosphatase C 1149.04 1.08 0.018 0.125 
P54578 
Ubiquitin carboxyl-terminal hydrolase 
14  999.86 1.08 0.002 0.061 
P54577 Tyrosine--tRNA ligase, cytoplasmic  793.47 1.08 0.015 0.125 
P34932 Heat shock 70 kDa protein 4  1847.08 1.09 0.021 0.133 
O60880 SH2 domain-containing protein 1A  210.08 1.09 0.041 0.171 
P78406 mRNA export factor  220.12 1.09 0.018 0.125 
Q9NZL4 Hsp70-binding protein 1  226.91 1.09 0.018 0.125 
Q16543 Hsp90 co-chaperone Cdc37  268.35 1.09 0.027 0.145 
P19623 Spermidine synthase  278.54 1.09 0.039 0.168 
O14818; 
Q8TAA3 Proteasome subunit alpha type-7  603.55 1.09 0.049 0.186 
Q15459 Splicing factor 3A subunit 1 445.91 1.09 0.030 0.149 
Q13617 Cullin-2  96.42 1.09 0.043 0.174 
P09429; 
B2RPK0; 
P23497 High mobility group protein B1  487.64 1.09 0.016 0.125 
P12814; Alpha-actinin-1  1332.6 1.10 0.035 0.160 
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P35609; 
Q08043 
Q13283 
Ras GTPase-activating protein-binding 
protein 1  188.15 1.10 0.031 0.153 
Q13177; 
O75914; 
Q13153 Serine/threonine-protein kinase PAK 2  671.02 1.10 0.027 0.145 
P63104 14-3-3 protein zeta/delta  1109.71 1.10 0.026 0.143 
P11233; 
P11234 Ras-related protein Ral-A  155.23 1.10 0.024 0.140 
O96019; 
O94805 Actin-like protein 6A  253.02 1.10 0.026 0.144 
P14550; 
Q96JD6 Alcohol dehydrogenase [NADP(+)]  322.65 1.10 0.042 0.173 
P39687; 
O43423; 
O95626 
Acidic leucine-rich nuclear 
phosphoprotein 32 family member A 556.07 1.10 0.021 0.133 
Q04760 Lactoylglutathione lyase  249.58 1.10 0.050 0.186 
P32119 Peroxiredoxin-2 450.78 1.10 0.024 0.140 
Q9Y4Z0 
U6 snRNA-associated Sm-like protein 
LSm4  148.09 1.10 0.033 0.158 
P33316 
Deoxyuridine 5'-triphosphate 
nucleotidohydrolase, mitochondrial  413.27 1.10 0.016 0.125 
O75940 
Survival of motor neuron-related-
splicing factor 30  67.51 1.11 0.025 0.142 
P61964 WD repeat-containing protein 5  204.38 1.11 0.014 0.120 
P16949; 
H7BZ55; 
Q93045; Stathmin  704.09 1.11 0.019 0.127 
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Q9H169 
P30041 Peroxiredoxin-6  617.68 1.11 0.009 0.102 
P28066 Proteasome subunit alpha type-5  295.16 1.11 0.018 0.125 
Q8NEV1 Casein kinase II subunit alpha 3  214.01 1.11 0.002 0.058 
Q93084 
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 3 884.11 1.11 0.018 0.125 
Q13838 Spliceosome RNA helicase DDX39B  1077.99 1.11 0.014 0.120 
P52209 
6-phosphogluconate dehydrogenase, 
decarboxylating  995.07 1.11 0.016 0.125 
Q9UI30 tRNA methyltransferase 112 homolog 209.5 1.11 0.026 0.144 
Q9UJU2; 
P36402 Lymphoid enhancer-binding factor 1 138.29 1.11 0.007 0.090 
P54727 
UV excision repair protein RAD23 
homolog B 265.22 1.11 0.035 0.160 
Q9BXS5; 
Q9Y6Q5 AP-1 complex subunit mu-1  95.16 1.12 0.025 0.142 
P09012 U1 small nuclear ribonucleoprotein A  173.95 1.12 0.007 0.090 
P07737 Profilin-1  782.27 1.12 0.011 0.112 
P62328 Thymosin beta-4  110.74 1.12 0.017 0.125 
P62820; 
A6NDJ8; 
P51153; 
P59190 Ras-related protein Rab-1A  508.76 1.12 0.004 0.071 
Q04323 UBX domain-containing protein 1 270.27 1.12 0.041 0.171 
P09211 Glutathione S-transferase P  928.54 1.12 0.042 0.172 
P25788 Proteasome subunit alpha type-3  351.31 1.12 0.020 0.129 
Q9UQ35 
Serine/arginine repetitive matrix 
protein 2  370.91 1.12 0.041 0.171 
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O75347 Tubulin-specific chaperone A 348.71 1.12 0.006 0.089 
P83916 Chromobox protein homolog 1  235.4 1.13 0.029 0.146 
P00491 Purine nucleoside phosphorylase  891.19 1.13 0.039 0.169 
P29218 Inositol monophosphatase 1  158.94 1.13 0.030 0.148 
Q06203 Amidophosphoribosyltransferase  126.8 1.13 0.044 0.178 
Q06323 
Proteasome activator complex subunit 
1  479.26 1.13 0.038 0.167 
P40925 Malate dehydrogenase, cytoplasmic  629.68 1.13 0.018 0.125 
P26368 Splicing factor U2AF 65 kDa subunit  314.83 1.13 0.036 0.162 
P61225; 
P10114 Ras-related protein Rap-2b  96.37 1.13 0.022 0.133 
P62942 
Peptidyl-prolyl cis-trans isomerase 
FKBP1A 174.86 1.13 0.029 0.147 
P99999 Cytochrome c  256.19 1.13 0.029 0.146 
Q92945 
Far upstream element-binding protein 
2  1093.26 1.13 0.001 0.051 
P27695 
DNA-(apurinic or apyrimidinic site) 
lyase 636.27 1.13 0.006 0.085 
Q01082; 
O15020; 
P11277 Spectrin beta chain, non-erythrocytic 1  4279.5 1.13 0.001 0.051 
Q14978 
Nucleolar and coiled-body 
phosphoprotein 1  357.76 1.14 0.007 0.090 
Q13813 Spectrin alpha chain, non-erythrocytic 1 4310.16 1.14 0.002 0.054 
Q12906; 
Q96SI9 Interleukin enhancer-binding factor 3 745.67 1.14 0.000 0.008 
Q13330; 
Q9BTC8 Metastasis-associated protein MTA1 269.09 1.14 0.010 0.108 
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P04439; 
P16188; 
P30512 
HLA class I histocompatibility antigen, 
A-3 alpha chain  198.82 1.14 0.039 0.168 
P28072 Proteasome subunit beta type-6  126.69 1.14 0.004 0.071 
Q96KP4 Cytosolic non-specific dipeptidase  422.74 1.14 0.017 0.125 
O43813 LanC-like protein 1  108.5 1.14 0.025 0.142 
Q9UKV3 
Apoptotic chromatin condensation 
inducer in the nucleus  307.98 1.14 0.009 0.106 
Q5T280 Uncharacterized protein C9orf114  30.72 1.14 0.048 0.185 
P61923 Coatomer subunit zeta-1  108.72 1.14 0.011 0.111 
O95777 
N-alpha-acetyltransferase 38, NatC 
auxiliary subunit  179.95 1.15 0.041 0.172 
O43670 Zinc finger protein 207  111.06 1.15 0.004 0.077 
Q9UI08 
Ena/VASP-like protein OS=Homo 
sapiens GN=EVL PE=1 SV=2 601.46 1.15 0.014 0.121 
P28074 Proteasome subunit beta type-5  157.85 1.15 0.001 0.051 
P30626 Sorcin 167.9 1.15 0.026 0.143 
Q99497 Protein DJ-1 658.95 1.15 0.005 0.081 
O43399 Tumor protein D54  275.09 1.15 0.035 0.160 
P48444 Coatomer subunit delta  304.57 1.15 0.013 0.118 
Q92769 Histone deacetylase 2  246.03 1.15 0.001 0.051 
P49589 Cysteine--tRNA ligase, cytoplasmic  182.97 1.15 0.046 0.182 
P23526 Adenosylhomocysteinase  617.03 1.15 0.008 0.094 
P28070 Proteasome subunit beta type-4  314.75 1.15 0.027 0.144 
Q04917 14-3-3 protein eta  479.74 1.16 0.042 0.172 
P61289 
Proteasome activator complex subunit 
3  170.47 1.16 0.039 0.168 
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P21333 Filamin-A  4586.31 1.16 0.001 0.051 
P10599 Thioredoxin  198.56 1.16 0.004 0.071 
Q01105 Protein SET  423.03 1.16 0.041 0.172 
P69905; 
P02008 Hemoglobin subunit alpha  290.61 1.17 0.007 0.090 
Q9Y490; 
Q9Y4G6 Talin-1  3475.69 1.17 0.001 0.038 
O75431 Metaxin-2  79.14 1.17 0.017 0.125 
Q9UKK9 ADP-sugar pyrophosphatase 164.34 1.17 0.005 0.077 
Q14019 Coactosin-like protein  305.64 1.17 0.005 0.083 
O43598 
2'-deoxynucleoside 5'-phosphate N-
hydrolase 1  68.34 1.17 0.014 0.120 
P37837 Transaldolase  520.1 1.17 0.007 0.090 
P07195 L-lactate dehydrogenase B chain  1251.65 1.18 0.029 0.146 
O75937 DnaJ homolog subfamily C member 8  100.29 1.18 0.001 0.039 
Q86X76 Nitrilase homolog 1  130.09 1.18 0.013 0.118 
Q15424; 
Q14151 Scaffold attachment factor B1  592.66 1.18 0.002 0.058 
P49006 MARCKS-related protein  308.67 1.18 0.006 0.089 
Q00534 Cyclin-dependent kinase 6  537.66 1.18 0.000 0.027 
P51858 Hepatoma-derived growth factor  239.73 1.18 0.017 0.125 
Q9Y6H1; 
Q5T1J5 
Coiled-coil-helix-coiled-coil-helix 
domain-containing protein 2, 
mitochondrial  119.59 1.18 0.004 0.071 
Q9UFW8 CGG triplet repeat-binding protein 1  30.44 1.18 0.000 0.033 
P41250 Glycine--tRNA ligase  713.6 1.19 0.006 0.086 
P30086 
Phosphatidylethanolamine-binding 
511.76 1.19 0.016 0.125 
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protein 1  
Q9H6Z4 Ran-binding protein 3 91.88 1.19 0.023 0.138 
Q13112 Chromatin assembly factor 1 subunit B  38.55 1.19 0.014 0.152 
Q9Y237 
Peptidyl-prolyl cis-trans isomerase 
NIMA-interacting 4  61.92 1.19 0.028 0.145 
Q6P1J9 Parafibromin  84.57 1.19 0.011 0.112 
O43768; 
P56211 Alpha-endosulfine  82.49 1.19 0.032 0.155 
P52888 Thimet oligopeptidase 30.92 1.19 0.004 0.071 
P15121; 
C9JRZ8 Aldose reductase  312.17 1.20 0.007 0.090 
Q9BXV9 Uncharacterized protein C14orf142  47.76 1.20 0.020 0.132 
P55327 Tumor protein D52  239.84 1.20 0.003 0.067 
Q9BQ52 Zinc phosphodiesterase ELAC protein 2 39.99 1.21 0.009 0.106 
Q16881; 
Q9NNW7 Thioredoxin reductase 1, cytoplasmic  431.42 1.21 0.000 0.022 
Q99808 Equilibrative nucleoside transporter 1  92.77 1.21 0.049 0.186 
P05556 Integrin beta-1  53.3 1.22 0.046 0.182 
P00390 Glutathione reductase, mitochondrial  354.49 1.22 0.001 0.043 
Q9NWH9 SAFB-like transcription modulator  83.1 1.22 0.044 0.176 
P61086 Ubiquitin-conjugating enzyme E2 K  175.11 1.22 0.004 0.071 
P61077 Ubiquitin-conjugating enzyme E2 D3 90.67 1.23 0.019 0.126 
P39210 Protein Mpv17 69.15 1.23 0.027 0.144 
P08195 4F2 cell-surface antigen heavy chain  643.73 1.23 0.000 0.016 
Q9BZZ5 Apoptosis inhibitor 5  185.11 1.24 0.002 0.061 
O75995 
SAM and SH3 domain-containing 
protein 3  103.89 1.25 0.000 0.038 
358 
 
 
 
Q8TDQ7 Glucosamine-6-phosphate isomerase 2  30.53 1.26 0.007 0.090 
P52655 
Transcription initiation factor IIA 
subunit 1 56.2 1.26 0.006 0.088 
Q9NYB0 
Telomeric repeat-binding factor 2-
interacting protein 1  41.98 1.27 0.000 0.029 
Q15257 
Serine/threonine-protein phosphatase 
2A activator  74.73 1.28 0.021 0.133 
Q9HB07 UPF0160 protein MYG1, mitochondrial  88.83 1.28 0.049 0.186 
Q96F15 GTPase IMAP family member 5  68.51 1.28 0.006 0.088 
P15374 
Ubiquitin carboxyl-terminal hydrolase 
isozyme L3  72.94 1.28 0.034 0.159 
P28062 Proteasome subunit beta type-8  131.73 1.28 0.002 0.052 
P50897 Palmitoyl-protein thioesterase 1  71.64 1.29 0.038 0.167 
Q01650 
Large neutral amino acids transporter 
small subunit 1  134.83 1.30 0.002 0.056 
Q9HCG8 
Pre-mRNA-splicing factor CWC22 
homolog  53.8 1.30 0.011 0.111 
Q9Y617 Phosphoserine aminotransferase 279.9 1.30 0.000 0.018 
Q8IYS1 
Peptidase M20 domain-containing 
protein 2  42.47 1.31 0.001 0.051 
Q9NWV4 UPF0587 protein C1orf123 46.85 1.34 0.032 0.153 
Q9NTZ6 RNA-binding protein 12  113.39 1.42 0.026 0.144 
Q5BKY9 Protein FAM133B  37.97 1.46 0.018 0.125 
Q9H0R4 
Haloacid dehalogenase-like hydrolase 
domain-containing protein 2  32.38 1.48 0.004 0.071 
P82650 
28S ribosomal protein S22, 
mitochondrial  108.96 1.56 0.010 0.110 
P08243 
Asparagine synthetase [glutamine-
hydrolyzing]  31.56 1.60 0.013 0.118 
Q9H1E3 
Nuclear ubiquitous casein and cyclin-
dependent kinase substrate 1  121.62 1.78 0.000 0.001 
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a Accession number according to UniProt database. b Protein description with relative 
symbol. c Confidence score generated by Progenesis. * Proteins shared between 
both treatments (resveratrol and curcumin). Green reduction, red induction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.0 – 1.49   
1.5 – 1.99   
2 – 2.49   
2.5 – 2.99   
3 – 3.49   
3.5 +   
 
* Protein common between resveratrol and 
curcumin treatment. 
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8.5    Appendix 5 
 
Functional classification of induced vs repressed proteins observed with 
polyphenol treatments, 
 
As the dose of the polyphenols increased the number of proteins modified 
also increased. There seemed to be a difference in the number of repressed and 
induced proteins with dose. The greatest number of dose dependent protein 
modulations was observed with the isorhamnetin treatment, with 35 proteins in 
common between the 1 and 30μM. Isorhamnetin was used to investigate the 
differences in repressed and induced proteins with the different doses. Fig 8.17, 
shows all data from 1 and 30µM treatments split into functional categories. These 
functional categories were identified using Reactome. There was an approx. 9 fold 
increase from the 1µM treatment to the 30µM treatment. 
 
When examining these functional classes, to see whether induced and 
repressed patterns were maintained when the dose increased, at least 4 of the 
categories had notable differences between 1 and 30µM (fig. 8.18), in particular with 
protein classified under ‘ metabolism’ and ‘metabolism of proteins’. It was noted 
that the number of repressed proteins increased with the 30µM dose. Other changes 
were observed with the proteins classified under ‘cell cycle’ & ‘DNA repair’, ‘cellular 
stress response’ and ‘gene expression’. Isorhamnetin had no significant effect on the 
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viability of the Jurkat cells, showing that the changes to cell cycle and repair proteins 
are not affecting the ability of the cells to replicate. This is contrary to previous 
research investigating isorhamnetin and cell proliferation, where 50µM significantly 
decreased cell viability in gastric cancer cells after 48h and 72h treatment286. 
Concentrations as low as 2.5µM significantly lowered cell proliferation in a human 
lung cancer cell line, following 24h treatment287. Since the Jurkat cell line is also a 
cancer cell line, it is unusual that the same effect on cell viability and apoptosis was 
not seen in these cells. 
 
 
Figure 8.17 – Proteomics data from Isorhamnetin both doses (1 and 30µM) split 
into function categories. Reactome was used to categorise protein functions 
((http://www.reactome.org/) accessed 15/12/14)  
0
20
40
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100
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Figure 8.5 – Proteomics data characterised into function categories, Isorhamnetin 1 
µM (bottom) and 30µM (top), each category is split into induced (green) and 
repressed (blue) proteins . Those highlighted in red are those were the 
induced/repressed trend is altered by dose. Reactome was used to categorise 
proteins functions (accessed 15/12/14) 
 
 
  
Proteins classified under ‘Metabolism and metabolism of proteins’ were of 
particular interest showing the biggest difference in the number of repressed 
proteins. This category included translation, protein folding, post-translational 
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protein modifications and unfolded protein response and correlated with the 
decrease in the number of ribosomal proteins observed with all the treatments.  
 
 
Figure 8.19 - Key for Ingenuity network analysis pathways. 
 
 
A relationship with and X over it indicates that the interaction does not occur. These 
relationships are only in Disease pathways to indicate an interaction that would 
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normally happen in the absence of the disease, but does not happen in the disease 
context. 
 
An arrow pointing from A to B signifies different actions for different circumstances, 
as described below: 
 
For signalling pathways: 
An arrow pointing from A to B signifies that A causes B to activated (includes any 
direct interaction: eg binding, phosphorylation, dephosphorylation, etc). 
 
For metabolic pathways: 
An arrow pointing from A to B signifies that B is produced from A. 
 
For ligand/receptors: 
An arrow pointing from a ligand to a receptor signifies that the ligand binds the 
receptor and subsequently leads to activation of the receptor. The binding event 
does not necessarily directly activate the receptor; activation of the receptor could 
be caused by events secondary to the ligand/receptor binding event. 
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Figure 8.20 – Enlarged version of Ingenuity network analysis for 10µM curcumin 
data set identified Nrf2 signalling as a modified pathway, (original figure 4.4, page 
167). 
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Figure 8.21 – Enlarged version of Ingenuity network analysis for 30µM 
isorhamnetin data set identified Nrf2 signalling as a modified pathway, (original 
figure 4.6, page 171). 
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8.6 Appendix 6 
 
Outcomes 
Conference attendance: 
 2015 – Healthy Ageing: From Molecules to Organisms (Wellcome Trust, 
Cambridge).  Poster presentation. 
 2014 – Proteomics bioinformatics workshop held by the Wellcome trust, EBI 
in Cambridge. Poster presentation. 
 2014 – Experimental Biology (San Diego).  Oral and poster presentation. 
 2013 – 10th International Medical Postgraduate Conference (Czech Republic). 
Oral presentations. 
 2013/14 - BBSRC PhD Studentship day at Unilever. Poster presentation. 
 2012/13/14/15 – BBSRC DRINC (Diet and health research industry club) 
conference. Bristol (2012), Nottingham (2013), Chester (2014), and Oxford 
(2015). Poster presentation  
 
Publications:  
 May 2016 - Identification of (poly)phenol treatments that modulate the 
release of pro-inflammatory cytokines by human lymphocytes. British Journal 
of Nutrition. 
 Draft paper - Effects of polyphenols of glutathione metabolism in Jurkat T 
lymphocytes. 
 Abstracts - Cytokine release by Jurkat T-lymphocytes is modulated following 
treatment with polyphenols or Lactobacillus rhamnosus probiotic extracts 
(1044.10) The FASEB Journal (April, 2014) and Dietary phenolic compounds 
modify glutathione redox homeostasis and cytokine release in human T 
lymphocytes (134.1) The FASEB Journal (April, 2014).  
 
Certificates/awards: 
 2015 – Healthy Ageing: From Molecules to Organisms (Wellcome Trust, 
Cambridge). Awarded a bursary to cover 50% of the cost of the conference. 
 2014 – Experimental Biology (San Diego).  Posters accepted into two poster 
competitions by the American society of nutrition. 
 2014 – University of Liverpool. Awarded 2nd place at the poster day online 
event.  
 
Industrial Placement: 
This study was part-funded by industry which allowed me a 6 months placement 
based in the strategic science group at Unilever (Bedford). Whilst on my placement I 
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continued my work in the lab, using a different cell line and exploring the redox 
related biology. I also took advantages of some of the software and expertise 
available on site. This placement gave me a feel for working in industry, to observe 
areas of process development and pilot plant scale of products. This experience 
allowed me to become more independent with my research, gaining experience in 
new techniques and successfully continuing my research in a new and unfamiliar 
environment, whilst also understanding the rules and regulations associated with 
industry related work.  
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